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Abstract
The effectiveness of interventions to treat severe acute 
malnutrition in young children: a systematic review
J Picot,1 D Hartwell,1 P Harris,1 D Mendes,1 AJ Clegg1* and A Takeda1,2
1Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK
2Centre for Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, 
London, UK
*Corresponding author
Background: Severe acute malnutrition (SAM) arises as a consequence of a sudden period 
of food shortage and is associated with loss of a person’s body fat and wasting of their 
skeletal muscle. Many of those affected are already undernourished and are often 
susceptible to disease. Infants and young children are the most vulnerable as they require 
extra nutrition for growth and development, have comparatively limited energy reserves 
and depend on others. Undernutrition can have drastic and wide-ranging consequences 
for the child’s development and survival in the short and long term. Despite efforts made to 
treat SAM through different interventions and programmes, it continues to cause 
unacceptably high levels of mortality and morbidity. Uncertainty remains as to the most 
effective methods to treat severe acute malnutrition in young children.
Objectives: To evaluate the effectiveness of interventions to treat infants and children aged 
< 5 years who have SAM.
Data sources: Eight databases (MEDLINE, EMBASE, MEDLINE In-Process & Other Non-
Indexed Citations, CAB Abstracts Ovid, Bioline, Centre for Reviews and Dissemination, 
EconLit EBSCO and The Cochrane Library) were searched to 2010. Bibliographies of 
included articles and grey literature sources were also searched. The project expert 
advisory group was asked to identify additional published and unpublished references.
Review methods: Prior to the systematic review, a Delphi process involving international 
experts prioritised the research questions. Searches were conducted and two reviewers 
independently screened titles and abstracts for eligibility. Inclusion criteria were applied to 
the full texts of retrieved papers by one reviewer and checked independently by a second. 
Included studies were mapped to the research questions. Data extraction and quality 
assessment were undertaken by one reviewer and checked by a second reviewer. 
Differences in opinion were resolved through discussion at each stage. Studies were 
synthesised through a narrative review with tabulation of the results.
Results: A total of 8954 records were screened, 224 full-text articles were retrieved, and 74 
articles (describing 68 studies) met the inclusion criteria and were mapped. No evidence 
focused on treatment of children with SAM who were human immunodeficiency virus sero-
positive, and no good-quality or adequately reported studies assessed treatments for SAM 
among infants < 6 months old. One randomised controlled trial investigated fluid 
resuscitation solutions for shock, with none adequately treating shock. Children with acute 
diarrhoea benefited from the use of hypo-osmolar oral rehydration solution (H-ORS) 
compared with the standard World Health Organization-oral rehydration solution (WHO-
ORS). WHO-ORS was not significantly different from rehydration solution for malnutrition iv Abstract
(ReSoMal), but the safety of ReSoMal was uncertain. A rice-based ORS was more 
beneficial than glucose-based ORSs, and provision of zinc plus a WHO-ORS had a 
favourable impact on diarrhoea and need for ORS. Comparisons of different diets in 
children with persistent diarrhoea produced conflicting findings. For treating infection, 
comparison of amoxicillin with ceftriaxone during inpatient therapy, and routine provision of 
antibiotics for 7 days versus no antibiotics during outpatient therapy of uncomplicated 
SAM, found that neither had a significant effect on recovery at the end of follow-up. No 
evidence mapped to the next three questions on factors that affect sustainability of 
programmes, long-term survival and readmission rates, the clinical effectiveness of 
management strategies for treating children with comorbidities such as tuberculosis and 
Helicobacter pylori infection and the factors that limit the full implementation of treatment 
programmes. Comparison of treatment for SAM in different settings showed that children 
receiving inpatient care appear to do as well as those in ambulatory or home settings on 
anthropometric measures and response time to treatment. Longer-term follow-up showed 
limited differences between the different settings. The majority of evidence on methods for 
correcting micronutrient deficiencies considered zinc supplements; however, trials were 
heterogeneous and a firm conclusion about zinc was not reached. There was limited 
evidence on either supplementary potassium or nicotinic acid (each produced some 
benefits), and nucleotides (not associated with benefits). Evidence was identified for four of 
the five remaining questions, but not assessed because of resource limitation.
Limitations: The systematic review focused on key questions prioritised through a Delphi 
study and, as a consequence, did not encompass all elements in the management of SAM. 
In focusing on evidence from controlled studies with the most rigorous designs that were 
published in the English language, the systematic review may have excluded other forms of 
evidence. The systematic review identified several limitations in the evidence base for 
assessing the effectiveness of interventions for treating young children with severe acute 
malnutrition, including a lack of studies assessing the different interventions; limited details 
of study methods used; short follow-up post intervention or discharge; and heterogeneity 
in participants, interventions, settings, and outcome measures affecting generalisability.
Conclusions: For many of the most highly ranked questions evidence was lacking or 
inconclusive. More research is needed on a range of topic areas concerning the treatment 
of infants and children with SAM. Further research is required on most aspects of the 
management of SAM in children < 5 years, including intravenous resuscitation regimens for 
shock, management of subgroups (e.g. infants < 6 months old, infants and children with 
SAM who are human immunodeficiency virus sero-positive) and on the use of antibiotics. 
Funding: The National Institute for Health Research Technology Assessment programme.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Executive summary
Background
Undernutrition (referred to here as malnutrition) makes a major contribution to the global 
disease burden, accounting for more than one-third of child deaths worldwide. Acute 
malnutrition arises as a consequence of a sudden/sharp period of food shortage and is associated 
with loss of body fat and wasting of skeletal muscle. Malnutrition can be classified as mild, 
moderate or severe based on anthropometry (measurement of the size, weight and proportions 
of the human body), biochemistry and clinical assessment. The focus of this report is on severe 
acute malnutrition (SAM). A defining feature of SAM is severe wasting. In developing countries, 
some 19 million children < 5 years old are severely wasted. In 2004, approximately 310,000 deaths 
among these children in Africa, Asia and Latin America were attributed to severe wasting. Forms 
of SAM include kwashiorkor, marasmus and marasmic kwashiorkor.
Standard and accepted methods for defining and/or classifying SAM in children < 5 years of 
age have been established by organisations such as the World Health Organization (WHO) and 
the United Nations, although a variety of definitions exist, differing in the specific criteria and 
thresholds used. In addition, differences in treatment practices have been found to be a key factor 
in the large variation in mortality rates of severely malnourished children during treatment. To 
try and improve identification and treatment of SAM, WHO introduced guidance in 1999 that 
provided a 10-step ordered approach through three treatment phases. In the first phase of initial 
treatment, the focus is on stabilising the child’s condition. The second phase of rehabilitation 
involves increasing the energy content and volume of the feeds to recover lost weight. The third 
phase begins after discharge and focuses on following up the child and his or her family at home, 
and providing support in order to prevent relapse and ensure the continued development of the 
child. However, implementation of this guidance in the 20 countries that are home to 80% of the 
world’s undernourished children is variable. As a result of this, and many other factors, mortality 
from SAM remains unacceptably high.
Objectives
The objective of this report was to systematically review the evidence assessing interventions, 
programmes and/or guidelines to treat infants and children aged < 5 years of age who have SAM. 
The effects that factors such as the setting (e.g. hospital, community, emergency) or different 
comorbidities [e.g. human immunodeficiency virus (HIV) infection] have on their effectiveness 
have also been examined.
Methods
Data sources
A sensitive search strategy was designed and applied to eight electronic bibliographic databases, 
including MEDLINE (1950 onwards), EMBASE (1980 onwards) and The Cochrane Library (from 
inception to November/December 2010). Bibliographies of included articles and grey literature 
sources were searched, and the project expert advisory group was contacted to identify additional 
published and unpublished references.x Executive summary
Study selection
Titles and abstracts were screened independently by two reviewers. Inclusion criteria were 
defined a priori and applied to the full text of retrieved papers by one reviewer and checked 
independently by a second. The inclusion criteria were as follows.
  ■ Study design: randomised controlled trials (RCTs), controlled clinical trials (CCTs), cohort 
studies (with control group) and case–control studies were eligible for inclusion. Evidence 
from studies with the most rigorous designs was prioritised based on the hierarchy evidence. 
Studies without a comparator group or those with a comparator group that did not have 
SAM (e.g. healthy individuals) were excluded.
  ■ Interventions: any intervention for treating SAM (either an entire treatment plan or any 
individual treatment step).
  ■ Comparators: any alternative treatment strategy (including no intervention and placebo).
  ■ Population: infants and children < 5 years of age with SAM. The set of criteria for the 
definition/classification of SAM were agreed following consultation with the expert 
advisory group and included WHO’s and the United Nations Children’s Fund’s reference 
standards, the Wellcome working party’s, Gómez and colleagues’ and the Indian Academy 
of Paediatrics’ classifications, mid-upper arm circumference < 115 mm, clinical oedema and 
diagnoses of marasmus, kwashiorkor or marasmic kwashiorkor.
  ■ Outcomes: studies were included providing they reported on measures of mortality or 
weight change.
Delphi process and map of the evidence base
A Delphi process was used in order to gain an understanding of the priority order of the research 
questions relating to the WHO 10-step plan. A ‘map’ of the evidence base was created, as each 
study was mapped to the prioritised research question(s) it primarily addressed by one reviewer. 
The decision was checked by a second reviewer. After the available evidence had been mapped, 
the final decision on how many questions would be addressed by the systematic review was 
taken, based on the extent of the evidence and the resources available for the research.
Data extraction and assessment of validity
Data were extracted and study quality was assessed by one reviewer and checked by a second. 
Discrepancies were resolved by discussion, with involvement of a third reviewer when necessary. 
Included studies that mapped to questions that could not be assessed in the systematic review, 
and studies that did not map to any question were not data extracted or quality assessed.
Data synthesis
Studies were synthesised through a narrative review with tabulation of results of included studies.
Results
Quantity and quality of studies
A total of 8954 records were identified. Seventy-four references describing 68 studies met the 
general review inclusion criteria. The available evidence mapped against 9 of the 15 questions 
prioritised in the Delphi process. For one other question, very limited evidence was available in 
two studies. No evidence was found to inform the remaining five questions. Project resources 
were available to review the evidence for the first six questions for which any evidence was 
available. Only the best available evidence was reviewed and, for all but one question, this meant 
that only RCTs and CCTs were included.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Summary of benefits and risks
What methods are effective for treating severe acute malnutrition 
among infants < 6 months old?
No research focused on treating SAM in infants < 6 months old. Two cohort studies included this 
age group within their study populations. However, baseline data were not reported separately for 
this subgroup and only a very limited quantity of separate outcome information was provided. 
No formal quality assessment was undertaken.
Which form of intravenous fluid administration is most effective for 
treating shock?
One RCT of moderate methodological quality compared the efficacy of three fluid resuscitation 
solutions for treating hypovolaemic shock in children with SAM. The principal comparison was 
between Ringer’s lactate isotonic fluid (RL) and the WHO hypotonic fluid solution [half-strength 
Darrow’s in 5% dextrose (HSD/5D)] because few participants received 4.5% human albumin 
solution (HAS). Hypotonic HSD/5D was given according to the WHO recommendation, whereas 
similar volumes and rates of the isotonic RL and HAS solutions were administered to a different 
schedule. Other aspects of management in all groups followed WHO guidelines. The study found 
that neither the standard WHO hypotonic HSD/5D nor the RL isotonic resuscitation fluids were 
effective in reducing mortality or adequately treating shock after 48 hours of treatment. However, 
it should be noted that the study was prematurely terminated because of high overall mortality 
and inadequate correction of shock in all study arms.
What are the best treatments for children with severe acute malnutrition who 
have diarrhoea?
Five RCTs of strong or moderate methodological quality focused on children with acute 
diarrhoea and three RCTs of strong or weak methodological quality focused on children with 
persistent diarrhoea.
Acute diarrhoea
Four of the five RCTs compared oral rehydration solutions (ORSs). The fifth RCT investigated 
standard WHO-ORS alongside a zinc-containing syrup compared with WHO-ORS and placebo. 
Children with acute diarrhoea benefited from the use of hypo-osmolar oral rehydration solution 
compared with the standard WHO-ORS on measures of frequency, duration and recovery from 
diarrhoea and consumption of ORS. In contrast, weight gain was significantly higher in those 
receiving WHO-ORS (one study). WHO-ORS was not significantly different from rehydration 
solution for malnutrition (ReSoMaL) for mortality or adequacy of hydration, although ReSoMal 
may pose safety concerns. A rice-based ORS was more beneficial at 72 hours in promoting weight 
gain and reducing diarrhoeal output than glucose-based ORSs, whereas the provision of zinc and 
a WHO-ORS had a favourable impact on diarrhoeal outcomes and reduced the need for ORS.
Persistent diarrhoea
These studies compared different diets and had conflicting findings. Although a comparison 
in one study of an elemental diet with a skimmed milk and soy-based diet showed significant 
benefits on anthropometric measures for the elemental diet, two other studies either 
showed no difference between an elemental diet, soy-based diet and a chicken-based diet on 
mortality, weight gain, frequency of diarrhoea and recovery, or showed a significant benefit on 
anthropometric measures and ORS consumption from a soy-based diet compared with a khitchri 
and yoghurt-based diet.xii Executive summary
What methods are effective in treating infection?
Two studies of moderate methodological quality (one RCT and one retrospective cohort analysis) 
investigated the use of antibiotic therapy in children with SAM, but neither focused on treating 
diagnosed infection. The retrospective observational evidence indicates that the systematic 
addition of a broad-spectrum antibiotic to home-based treatment with ready-to-use therapeutic 
food has a statistically significant detrimental effect on the initial recovery (4 weeks) of children 
with SAM, although later (12 weeks) the proportion recovered was similar and no effect was 
shown on mortality. The RCT comparing administration of intramuscular ceftriaxone with orally 
administered amoxicillin showed no difference in effects on outcomes, apart from ceftriaxone 
being associated with fewer adverse events.
What is the clinical effectiveness of interventions in different settings 
(e.g. hospital, community, emergency)?
Four included studies, of moderate or weak methodological quality, investigated the clinical 
effectiveness of SAM treatment in different settings. There were numerous differences between 
these trials and, although the inpatient hospital setting was included in all trials, the type of 
inpatient care provided varied. It appears that children receiving inpatient care do as well as, 
if not better than, those receiving care in the ambulatory or home setting on anthropometric 
measures and response time to treatment. Longer-term follow-up showed limited differences 
between the different settings.
Which methods for correcting micronutrient deficiencies are 
effective?
Thirteen studies evaluated the effect of supplements to correct micronutrient deficiencies. Of 
these, 10 RCTs focused on the provision of zinc supplements, whereas the remaining three 
investigated potassium, nicotinic acid or nucleotides (NTs). Although the methodological quality 
of studies varied, > 80% were either moderate (n = 3) or weak (n = 8).
Zinc
The provision of zinc varied in a number of aspects (e.g. when supplementation began, dose 
or duration of supplementation). In seven trials, the comparator was no zinc/placebo, whereas 
three compared different doses/duration of zinc. Although studies assessing the effects of 
supplementary zinc were heterogeneous, those considered of a higher methodological quality 
showed no significant benefit from the addition of zinc supplementation. If there is a benefit to 
be obtained from zinc supplementation, the included evidence is insufficient to determine which 
dose of zinc might represent the optimal balance between maximising benefits and minimising 
any harms.
Other supplements
Evidence on other micronutrients was limited, with significant benefits from the addition of 
potassium (i.e. reducing late deaths, sepsis, skin ulcers) and nicotinic acid (i.e. weight gain), but 
no benefit from the addition of NTs.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Conclusions
Evidence for the first six prioritised questions for which any evidence was available was 
often lacking or not always conclusive. In addition, the diversity of the interventions made 
comparisons between studies difficult. No good-quality evidence or adequately reported studies 
assessed treatments for SAM in infants < 6 months old and neither of the studies evaluating 
antibiotic therapy focused on treating diagnosed infection. Neither of the resuscitation fluids was 
effective in treating children with hypovolaemic shock, and no clear benefit was evident from 
the addition of zinc supplementation in correcting micronutrient deficiencies. Inpatient care 
was found to be beneficial, or at least comparable, to the ambulatory or home setting for treating 
children with SAM, whereas trials of children with both acute and persistent diarrhoea found 
conflicting results.
Recommendations for further research
  ■ Treatments for SAM in infants < 6 months old was one of the highest ranked questions in the 
Delphi study and, therefore, more research is needed to fill this gap in the evidence base.
  ■ The high priority given to the question of intravenous (i.v.) fluid administration for treating 
shock, coupled with the potential to significantly improve survival, indicates that further 
prospective RCTs of alternative i.v. resuscitation regimens for shock are needed. Any 
RCT should be informed by an initial pilot study and should include measures of cardiac 
dysfunction and haemodynamic response to fluid expansion.
  ■ More research in treating diagnosed infections in children with SAM is needed because this 
topic was also ranked highly, and yet little research was found that met the inclusion criteria 
of the review.
  ■ Additional research could be conducted on many other aspects of the management of SAM 
in children < 5 years of age, including areas which were also prioritised in the Delphi study 
but for which little or no research was identified, e.g. use of multivitamin supplements, 
optimum dose of vitamin A, management strategies for children with HIV infection, 
tuberculosis or other comorbidities.
  ■ Future trials should include children identified using the current WHO criteria and ideally 
should involve more than one centre to generate results with better generalisability to other 
locations and to aid comparison between different trials.
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Chapter 1  
Background
Description of underlying health problem
The World Health Organization (WHO) describes nutrition as ‘the intake of food, considered in 
relation to the body’s dietary needs’ and good nutrition is a key determinant of health.1 When 
food intake is not in balance with the body’s dietary needs, malnutrition occurs. The term 
malnutrition encompasses both undernutrition and overnutrition (obesity) and is, therefore, an 
ambiguous term if the direction of the dietary imbalance is not clarified. In this report, we have 
not sought to alter the terms used in the published literature, much of which uses ‘malnutrition’ 
rather than ‘undernutrition’. Therefore, the reader should note that in this report, whenever 
the term malnutrition is used, it is always to describe undernutrition and never overnutrition 
(obesity).
Undernutrition makes a major contribution to the global disease burden and more than 
one-third of child deaths worldwide are attributed to undernutrition.2 Common causes of 
undernutrition are as follows.3,4
  ■ Inadequate quantity of food: food shortages may be acute (sudden/sharp) or chronic 
(long-lasting) and arise as a result of poverty, natural disaster (e.g. flood or drought) or 
conflicts, which may lead to the displacement of people from their homes and disruption of 
food supplies.
  ■ Inadequate quality of food: people may not have access to the variety of foods that 
will provide all the necessary vitamins and minerals in their diet. People may also lack 
the knowledge needed to make sound choices about the food they eat or provide to 
their children.
  ■ Infections: these may reduce appetite, increase energy and nutrient utilisation (e.g. to 
fight infection) and limit the ability to absorb or retain nutrients (e.g. as a consequence of 
diarrhoea and/or intestinal parasites).
Consequences of undernutrition
Different terms are used in the literature to reflect the different causes of undernutrition and/
or clinical characteristics. When undernutrition is due to the absence of a specific nutrient 
(micronutrient deficiency), the consequence may be a particular nutritional disorder (e.g. goitre 
due to a lack of iodine, scurvy due to lack of vitamin C, xerophthalmia due to a lack of vitamin 
A or anaemia due to a lack of iron).3 When both protein and energy are lacking from the diet, 
the term protein–energy malnutrition (PEM) has been commonly applied (but this ‘causal name’ 
now tends to be avoided because protein and energy deficits are likely to be accompanied by 
deficiencies of other nutrients). Malnutrition in children is described as chronic when it lasts 
for a long time (i.e. at least months) and this is strongly associated with shorter adult height 
(stunting), less schooling, reduced economic activity and, for women, lower birth weight in the 
next generation.5 In contrast, the term acute malnutrition is applied to describe the consequences 
of a sudden/sharp period of food shortage, and this is associated with loss of body fat and 
wasting of skeletal muscle.4 A lack of dietary energy and one or more micronutrient deficiencies 
frequently occur concurrently within the same individual.2 Background
Undernutrition/malnutrition can be classified as mild, moderate or severe based on 
anthropometry (measurement of the size, weight and proportions of the human body), 
biochemistry and clinical assessment (described in Severe acute malnutrition – classifications 
and definitions). The focus of this report is on severe acute malnutrition (SAM) in infants and 
children. Forms of SAM include kwashiorkor [characteristics include oedema which may be mild 
(bipedal) or severe (generalised), often associated with skin desquamation and hair changes6,7], 
marasmus (characteristics include emaciated appearance) and marasmic kwashiorkor (which has 
a combination of features).
The consequences of SAM have been most evident when emergency situations are widely 
portrayed in the media and responded to by international aid efforts. It should be remembered, 
however, that such high-profile emergency situations focusing on those with SAM represent 
only a fraction of the problem. Although food shortages may affect several sections of society, 
the majority of the undernourished often go unnoticed because they are the most destitute, 
vulnerable and marginalised people.8 ‘Endemic’ undernutrition is common, however, throughout 
much of Africa and parts of Asia, where exposure to pathogens and recurrent cycles of infection 
compound the problems of nutritional and food security. It is also now known that all degrees of 
underweight, even in the mild-to-moderate range, carry an increased risk of mortality.3,9
Infants and children and undernutrition
Although the consequences of undernutrition can be felt by all people, those in the early stages 
of life (including during the fetal period) are particularly affected. Infants and children are 
most vulnerable to the effects of undernutrition during the period of their most rapid physical 
growth and development, which predominantly takes place during the first 2 years of life. They 
are particularly vulnerable at this time because of the extra nutritional requirements for growth 
and development. In addition, infants and children have smaller bodily reserves than an adult so 
undernutrition has a more rapid effect. Infants and children are additionally vulnerable because 
they are dependent on others to provide and prepare foods, and even to be fed. Inadequate 
nutrition may lead to impairment of both body function (e.g. of organs) and structure (e.g. brain 
development). Interventions implemented from pregnancy to 2 years of age can counteract 
the effects of undernutrition. However, if undernutrition is not halted in the first 2 years of 
life, irreversible damage may be caused.5 Children suffering from SAM often have a history of 
undernutrition and social deprivation and, if they survive, face long-term consequences for their 
future health and economic well-being.10
The initial consequences of a deficit in energy obtained from food in mild-to-moderate 
undernutrition place a child on a continuum of risk leading to a lack of activity (energy 
conservation) and a decrease in growth rate (weight and height). An energy deficit is often 
combined with specific nutrient deficiencies, for example of protein, iron or zinc, and this 
combined deficiency also limits growth. Children who are undernourished are less able 
to withstand infections, and repeated infections also contribute to reduced growth. When 
undernutrition becomes severe, the consequences are more drastic and wide-ranging. A range of 
physical and metabolic changes occur as the body tries to conserve energy and preserve essential 
functions for as long as possible in a process known as reductive adaptation.11
Severe acute malnutrition – classifications and definitions
Severe acute malnutrition in children has been defined and/or classified in several ways. 
Although ‘standard and accepted’ methods have been established by United Nations agencies, 
particularly WHO, the Food and Agriculture Organization and the United Nations Children’s 
Fund (UNICEF),12 developments have continued and alternative approaches have emerged to 
address specific limitations or new evidence. Despite common elements, many of the definitions 
and classifications differ in the specific criteria and thresholds used. As a result, differing groups © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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of children may be identified as having SAM depending on which of the various definitions 
and classifications is used, influencing any assessment of interventions to treat SAM. To allow 
an appropriate comparison of different interventions, it is important to have an understanding 
of the terminology, definitions and classifications used by studies and, as a consequence, 
the people treated. This section provides a brief outline of some of the main definitions and 
classifications that have been used to identify SAM in infants and children aged < 5 years. It is 
not a comprehensive listing and does not endeavour to provide a complete history or critical 
assessment of all the different definitions and classifications. It will focus on, and outline, those 
that are used in the primary studies that are included in the subsequent systematic review of 
interventions to treat severely malnourished children.
Currently, WHO and UNICEF recommend three key criteria for diagnosing SAM among 
children aged from 6 months to 5 years. First, a child’s weight relative to his or her height, known 
as weight-for-height (W/H), is considered to be an important measure of nutritional status and 
useful in identifying SAM. Using the WHO child growth standards published in 2006,13,14 a 
cut-off of < 3 standard deviations (SDs) from the median value (also described as a z-score of 
≤ −3) is thought to provide an appropriate threshold for diagnosing marasmus among children 
aged from 6 months to 5 years. This acute form of severe malnutrition is characterised by severe 
wasting and an elevated risk of death, but therapeutic diets with limited known risks or negative 
consequences are effective.12,15 Second, WHO and UNICEF have recommended the use of the 
mid-upper arm circumference (MUAC) as an independent indicator of severe wasting and 
SAM. It is a useful measure within community settings or during emergency situations, when 
measuring the weight and height of children may prove difficult. MUAC is easy and inexpensive 
to measure and does not require a chart to calculate. Importantly, it has been shown to perform 
at least as well as measures of W/H for identifying children with SAM.16 Children aged from 
6 months to 5 years are considered to have SAM if they have a MUAC of < 115 mm. Third, the 
presence of clinical signs of bilateral oedema of nutritional origin provides evidence of SAM 
(i.e. oedematous malnutrition or kwashiorkor),15 despite the possibility of other weight-related 
measures remaining above specified thresholds. The three criteria have been endorsed by several 
other international organisations (e.g. the International Union of Nutritional Sciences and 
the International Pediatric Association) and adopted by over 90 countries.12 For infants aged 
< 6 months of age, WHO currently recommends the use of the same W/H threshold compared 
with the WHO child growth standards for that age group and the presence of clinical signs of 
bilateral oedema of nutritional origin. It does not recommend the use of the MUAC.17
Although the three criteria recommended by WHO and UNICEF are recognised internationally 
for defining SAM in children aged from 6 months to 5 years, other growth references, thresholds 
and approaches have been used. The current WHO growth standards were published in 2006,13 
replacing the growth reference developed by the US National Center for Health Statistics (NCHS) 
and employed from 1977.18,19 Although the NCHS growth reference has been criticised,20 it has 
been used extensively as part of national programmes and for research.21 The thresholds for 
severe wasting using W/H and MUAC measurements have also changed. Previously, severe 
wasting was defined for a child aged from 6 months to 5 years as a W/H < 70% of the median 
on the NCHS growth reference or a MUAC < 110 mm. The change from the use of the NCHS 
growth reference to the WHO growth standards and the different thresholds used have resulted 
in an increase in the sensitivity of the measures for identifying cases of SAM while maintaining 
specificity. As a consequence, the number of children identified as having SAM has increased 
markedly, with developing countries noting a two- to fourfold increase in cases.12,22
The use of W/H as a measure for diagnosing SAM has increasingly replaced the use of earlier 
measures based on a child’s weight-for-age (W/A), which is now seen as an inappropriate 
measure. The W/A measurement does not differentiate children who are wasted from those 4 Background
who have reduced linear growth (i.e. stunted) and, as a result, is unable to distinguish past 
nutritional history from current nutritional status.15,23 As a consequence, the W/A measurement 
is more appropriate for identifying chronic malnutrition and W/H acute malnutrition. Measures 
based on age-related standards also incur the difficulty that in many communities a child’s age 
is often unknown.24 Despite this, different thresholds have been adopted by the various earlier 
classifications measuring W/A, affecting the population included.23,25
Several different classifications have developed during the last 50 years, which have used the 
different anthropometric measures and clinical characteristics to help identify children with acute 
malnutrition and to diagnose the type and severity of the condition. Although many are similar 
to those currently adopted by the WHO and UNICEF, differences are evident in the specific 
criteria and thresholds used. Gómez and colleagues26 developed a classification (the Gómez 
classification) which identifies three degrees of malnutrition based on W/A according to the 
Boston (or Harvard) reference for the weight of a normal child (i.e. 50th percentile or median) 
(Table 1).25 Children < 60% W/A were classified as having grade III or severe malnutrition (i.e. 
children with marasmus).
Classifications have incorporated clinical features to identify different types of severe 
malnutrition. The Gómez classification was adapted to incorporate the presence of oedema, 
such that all children with oedema were classified as having third-degree malnutrition or severe 
malnutrition irrespective of their weight (i.e. kwashiorkor or marasmic kwashiorkor).23,27 The 
Wellcome working party23,28 developed a very similar classification (the Wellcome classification) 
based on the child’s W/A and the presence of oedema (Table 2). It identifies four groups with 
malnutrition. Children with a W/A < 60% of the Boston reference were diagnosed as having 
marasmus if oedema was absent and marasmic kwashiorkor if oedema was present. Children 
with a W/A between 60% and 80% of the Boston reference and oedema were diagnosed as having 
kwashiorkor. The fourth group with a W/A between 60% and 80% of the Boston reference but 
no oedema were classified as being undernourished. Children identified as having marasmus, 
marasmic kwashiorkor or kwashiorkor are considered as having SAM.
Waterlow and colleagues29 suggested that it would be beneficial to consider both W/H and 
height-for-age (H/A) as a basis for assessing the occurrence of SAM (Table 3). Children 
TABLE 1  The Gómez classification of malnutrition
Per cent of reference W/A (%) Interpretation
90–110 Normal
75–89 Grade I: mild malnutrition
60–74 Grade II: moderate malnutrition
< 60 Grade III: severe malnutrition
A child’s weight is compared with that of a normal child (50th percentile) of the same age.
Per cent of reference W/A = (patient weight/weight of normal child of same age) × 100.
TABLE 2  The Wellcome working party classification of PEM
W/A (% of referencea)
Oedema
Present Absent
60–80 Kwashiorkor Undernourished
< 60 Marasmic kwashiorkor Marasmus
a  Reference is the Boston reference weight (median, 50th percentile) for a normal child of the same age.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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with severe malnutrition were characterised by a W/H of < 70% or a H/A of < 85% of the 
reference standard.
The Indian Academy of Pediatrics (IAP) developed a classification of PEM based on a child’s 
W/A compared with the Boston reference for a normal child. Children with a W/A from 51% 
to 60% and < 50% of that expected were classified as having grades III and IV malnutrition, 
respectively. Both groups were considered to have severe malnutrition. In 2007, the IAP revised 
their classification and now recommends a W/H/weight-for-length (W/L) < 70% or < 3 SDs of the 
NCHS median and/or visible severe wasting and/or bipedal oedema. Also, it suggests that MUAC 
criteria may also be used for identifying severe wasting.30
Different terminology has developed to refer to infants and children with severe wasting and 
oedema, including kwashiorkor and marasmus, protein deficiency, PEM, severe malnutrition 
and SAM. In this report we predominantly use the term SAM in infants and young children. 
However, when describing individual studies we have not altered the terms used by the authors of 
those studies.
Epidemiology
Malnutrition (severe or otherwise) is a preventable cause of considerable morbidity and mortality 
among children. It is a significant contributing factor in approximately half of the 10 million 
deaths seen annually in children aged < 5 years worldwide.31,32 Malnutrition is highly prevalent 
in low-income and middle-income countries – predominantly in Africa and Asia, and to a 
lesser degree, Latin America – with only 1% of deaths in children < 5 years occurring outside 
these regions.3
Severe wasting (W/H z-score < −3), a defining feature of severe malnutrition, is thought to affect 
around 3.5% of the world’s children (Table 4).3 Estimates suggest that in developing countries 
some 19 million children < 5 years old are severely wasted.3 In 2004, there were approximately 
310,000 deaths attributed to severe wasting among children < 5 years old in Africa, Asia and Latin 
America.3 The prevalence of severe wasting among children aged < 5 years appears highest in the 
areas of south-central Asia (5.7%; 10.3 million children) and in middle Africa (5.0%; 1 million 
children) (see Table 4). Data from 19 surveys carried out in south Asia, Africa and Latin America 
between 1998 and 2005 by the Demographic and Health Surveys Programme show that the 
prevalence of severe wasting was higher at younger ages and declined by 24 months of age.33 
This trend may be linked to the initiation of weaning in infants, whereby breastfeeding no longer 
supplies all the nutritional and energy requirements and there is a lack of suitable or accessible 
complementary (weaning) foods.
TABLE 3  The Waterlow et al.29 classification of malnutrition
Classification of malnutrition Per cent W/H (wasting) Per cent H/A (stunting)
Normal > 90 > 95
Mild 80–90 90–95
Moderate 70–80 85–90
Severe < 70 < 85
Per cent W/H = (weight of patient/weight of a normal child of same height) × 100.
Per cent H/A = (height of patient/height of a normal child of same age) × 100; normal = child with the median value on the reference population.6 Background
TABLE 4  Childhood severe wasting estimates and numbers affected in 2005: data by United Nations regions and 
subregions based on the WHO child growth standards3
Regions Percentage severely wasted (95% CI) Number severely wasted in millions (95% CI)
Africa 3.9 (2.2 to 5.7) 5.6 (3.0 to 8.0)
Eastern 3.6 (1.5 to 8.4) 1.8 (0.7 to 4.1)
Middle 5.0 (2.0 to 12.0) 1.0 (0.4 to 2.4)
Northern 3.3 (1.2 to 8.9) 0.7 (0.3 to 2.0)
Southern 2.7 (1.0 to 6.8) 0.2 (0.06 to 0.4)
Western 4.3 (1.8 to 9.6) 1.9 (0.8 to 4.3)
Asia 3.7 (1.2 to 6.2) 13.3 (4.4 to 22.3)
Eastern 0.7 (0.3 to 1.6) 0.7 (0.3 to 1.6)
South-central 5.7 (2.4 to 12.8) 10.3 (4.4 to 23.3)
South-eastern 3.6 (1.4 to 8.8) 2.0 (0.8 to 4.9)
Western 1.6 (0.4 to 5.8) 0.4 (0.1 to 1.5)
Latin America 0.6 (0.2 to 1.0) 0.3 (0.1 to 1.5)
Caribbean 1.0 (0.4 to 2.5) 0.03 (0.01 to 0.9)
Central America 0.6 (0.2 to 1.7) 0.1 (0.04 to 0.3)
South America 0.6 (0.2 to 1.6) 0.2 (0.07 to 0.6)
All developing countries 3.5 (1.8 to 5.1) 19.3 (10.0 to 28.6)
CI, confidence interval.
Severe wasting = W/L or W/H < −3 SD.
Human immunodeficiency virus infection and severe acute malnutrition
An estimated 2.1 million children in the world are living with the human immunodeficiency 
virus (HIV) and 90% of them live in sub-Saharan Africa.34 The nutritional status of these children 
can be impaired by HIV infection from early in life.35 A systematic review and meta-analysis of 
HIV prevalence and mortality among children treated for SAM in sub-Saharan Africa included 
17 studies (4891 children), and found that the average prevalence of HIV infection was 29.2%.36 
Children with HIV and SAM were significantly more likely to die than those children who were 
HIV sero-negative (HIV–ve).36
Current service provision
Management of disease
The development of SAM can occur rapidly, and is observed commonly in emergency situations, 
especially if children are already experiencing mild or moderate undernutrition. Many parts 
of the developing world that are vulnerable to undernutrition also have a high prevalence of 
diarrhoeal diseases, pneumonia and HIV infection. Therefore, SAM often occurs in association 
with other underlying problems (e.g. infection, dehydration), which in combination can 
result in differences in clinical presentation that complicate diagnosis and management. Early 
identification and treatment is needed, but the urgency of the situation may not always be 
recognised, and failure to take notice of SAM in a sick child may result in management that 
reduces the likelihood of survival.
In the 1990s, one in four severely malnourished children died during treatment; however, 
mortality rates varied between centres from 5% to 50%, a variation that was mainly due to 
differences in treatment practices.37 The centres where mortality was low followed a basic set of © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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principles that implemented treatment in stages and addressed clinical problems in a considered 
order.37 To try and improve identification and treatment of SAM, WHO introduced guidance 
in 1999 that provided a 10-step ordered approach through three phases.10 The guideline takes 
into account the profound physiological and metabolic changes (reductive adaptation) that have 
taken place in severely malnourished children, which means that they have to be fed, rehydrated 
and managed differently from well nourished children.37 If intensive feeding is started too soon, 
before metabolic and electrolyte imbalances have been corrected, the child may deteriorate and 
die (refeeding or recovery syndrome). The WHO 1999 guidelines have been further developed 
in subsequent WHO publications for the management and inpatient treatment of children 
with malnutrition.37,38
The WHO 10-step approach10 to the management of SAM is presented in Table 5. There are three 
phases to treatment: initial treatment, rehabilitation and follow-up. In the first phase, initial 
treatment, the focus is on stabilising the child’s condition by careful refeeding and identifying 
and treating any life-threatening problems (steps 1–7: treating/preventing hypoglycaemia, 
hypothermia and dehydration, correcting electrolyte imbalance, treating infection, correcting 
micronutrient deficiencies and giving small frequent feeds of F75 formula, by nasogastric tube if 
necessary). This first phase usually takes place in a hospital or residential care facility and in most 
cases will last from 2 to 7 days, by which point the child’s appetite should have improved.
The second phase (rehabilitation phase) involves increasing the energy and nutrient content 
of the feeds (transition from F75 formula to F100 formula) to recover lost weight. Most older 
children (e.g. those > 2 years of age) can start to receive solid food in this phase. In these 
guidelines, the use of ready-to-use therapeutic food (RUTF) is not discussed; only local foods are 
mentioned. At the same time, play interventions to stimulate the child’s emotional and physical 
development are implemented; these can include different types of play with children individually 
and in small groups. At this time the child’s carer should also receive training so that he or she 
understands what causes undernutrition and to prevent a recurrence. Carers should also know 
how to treat or obtain treatment for common ailments (e.g. diarrhoea, intestinal parasites). The 
1999 manual10 and the 2005 guidelines37 indicate that a child can be considered for discharge 
once his or her W/H has reached −1 SD (90%) of the median WHO reference values, but early 
TABLE 5  The 10-step plan for the management of severe malnutrition, WHO 1999.10 This table has been reproduced 
with permission from WHO
Activity
Initial treatment Rehabilitation Follow-up
Days 1–2 Days 3–7 Weeks 2–6 Weeks 7–26
Treat or prevent
1. Hypoglycaemia
2. Hypothermia
3. Dehydration
4. Correct electrolyte imbalance
5. Treat infection
6. Correct micronutrient deficiencies Without iron With iron
7. Begin feeding
8. Increase feeding to recover lost weight (‘catch-up growth’)
9. Stimulate emotional and sensorial development
10. Prepare for discharge8 Background
discharge can be considered if a carer is able and willing to look after the child and, if possible, 
a health worker is available to make a visit to the family home (see below). The more recent 
(2009) statement12 recommends that discharge is based on a percentage weight gain (after loss 
of oedema) of 15% in most instances, but this can be adjusted up to 20% weight gain depending 
on the local situation. The third phase begins after discharge and focuses on following up the 
child and their family at home, and providing support in order to prevent relapse and ensure the 
continued physical, mental and emotional development of the child.
Treatment of SAM during the rehabilitation phase (steps 8–10) in those aged > 6 months and 
without medical complications can take place at home within the community, instead of as an 
inpatient as described above. Other alternatives to inpatient care include residential rehabilitation 
centres for children and their carers and day-stay rehabilitation centres.39 Community-based 
management of SAM is increasingly used in emergency settings and the same approach can 
be used in non-emergency situations, in which children can be initially assessed and carers 
counselled. Treatment involves using RUTF, which is a complete food source, nutritionally 
equivalent to F100 formula, high in energy and protein, containing the appropriate levels of 
electrolytes, vitamins, minerals and other nutrients.40 RUTFs are not water based and require no 
preparation by the child’s carer. It has been suggested that about 80% of children with SAM (i.e. 
those who do not have medical complications41) who are actively identified in the community 
could be treated at home using RUTF supported by health workers.40 Community-based care 
with RUTF and home-based therapy with locally developed and produced therapeutic diets 
have, on occasions, resulted in recovery rates of > 90%.42 However, the evidence to support this 
community approach, in both the non-emergency setting and during the rehabilitation phase 
after hospitalisation, has not been fully established.
It is recognised that case fatality rates are likely to vary between countries and hospitals. Effective 
implementation of the WHOs guidance should reduce mortality from SAM to < 5%, a case 
fatality rate that is considered good in the 2003 guidelines for the inpatient treatment of severely 
malnourished children.37 Case fatality rates of 5–10% are considered moderate. However, 
implementation of the WHO guidance in the 20 countries which are home to 80% of the world’s 
undernourished children is variable. Five countries (25%) report that they have implemented 
it nationwide, eight countries (40%) report they have implemented it in selected districts only, 
data are not reported for two countries (10%) and the remaining five countries (25%) have 
not implemented the WHO guidelines.43 Less than half of the 20 countries include the WHO 
guidance in their national nutrition strategies (Figure 1). As a result of this, and many other 
factors, mortality from SAM in many areas remains unacceptably high.
Overall aims and objectives of assessment
The project will evaluate the effectiveness of interventions to treat infants and children aged 
< 5 years who have SAM. It aims to systematically review the evidence assessing the effectiveness 
of programmes and/or guidelines that have been developed and implemented, as well as the 
individual components or steps that have been used to treat or manage severely malnourished 
children. In doing so, it will aim to examine the context in which the interventions are provided 
to assess the effects of factors such as the setting (e.g. hospital, community, emergency) or 
different comorbidities (e.g. HIV infection) on their effectiveness. Possible constraints to 
implementation of the interventions for treating severely malnourished children will be 
discussed. Finally, it will identify any recommendations for future research.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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FIGURE 1  Use of the WHO guidelines around the world.43. aCountry reports that they have implemented WHO 
guidelines nationwide. Key: Africa: DRC, Democratic Republic of Congo; ETH, Ethiopia; KEN, Kenya; MAD, 
Madagascar; NIG, Nigeria; SAF, South Africa; SUD, Sudan; UGA, Uganda; TAN, Tanzania. The Middle East: EGY, Egypt; 
YEM, Yemen. Asia: AFG, Afghanistan; BAN, Bangladesh; INDIA, India; MYA, Myanmar; NEP, Nepal; PAK, Pakistan. 
Western Pacific: IND, Indonesia; PHL, Philippines; VTN, Vietnam.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 2  
Methods for the Delphi process and 
systematic review of clinical effectiveness
T
he a priori methods for conducting the Delphi process and for systematically reviewing the 
evidence of clinical effectiveness are described in the research protocol (see Appendix 1), 
which was subject to peer review and sent to our expert advisory group for comments. None of 
the comments we received identified specific problems with the methods of the review, which 
has been undertaken following the general principles recommended in the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) statement (see Appendix 2). The 
methods outlined in the protocol are briefly summarised below.
Delphi process
The initial scope of this project had a series of possible research questions relating to the WHO’s 
10-step plan, with additional questions being suggested by experts who reviewed the protocol. 
A Delphi process was used to ensure that appropriate questions were identified and in order 
to gain an understanding of the priority order of the research questions. The Delphi method 
is an anonymised, iterative consensus method which follows a series of rounds as described 
in Figure 2.
Identification of studies
The search strategies, which were designed to identify studies reporting clinical effectiveness, 
were developed and tested by an experienced information specialist.
The following databases were searched for published studies to November/December 2010, 
unless otherwise stated: MEDLINE (1950 onwards), MEDLINE In-Process & Other Non-
Indexed Citations (MEIP), EMBASE (1980 onwards), CAB Abstracts Ovid (this contains a 
specific database: Nutrition Abstracts and Reviews, searched to December 2009, subscription 
subsequently withdrawn), Bioline, Centre for Reviews and Dissemination (CRD) [Database of 
Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) database and 
NHS Economic Evaluation Database (NHS EED)], The Cochrane Library [Cochrane Reviews, 
Cochrane Other Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), 
Cochrane Technology Assessment] and EconLit EBSCO. To identify ongoing research, the 
following databases were searched to December 2010: UK Clinical Research Network (UKCRN), 
Current Controlled trials.com, WHO International Clinical Trials Registry Platform (ICTRP), 
clinicaltrials.gov, Australian New Zealand Clinical Trials Register (ANZCTR), Clinical Trials 
Registry – India (CTRI). Although searches were not restricted by language, only full texts 
of English-language articles were retrieved for the study selection process. Bibliographies of 
included articles and grey literature sources were also searched. Our expert advisory group was 
asked to identify additional published and unpublished references. Further details, including 
search dates for each database, grey literature sources and an example search strategy, can be 
found in Appendix 3.12 Methods for the Delphi process and systematic review of clinical effectiveness
Round 1 
Draft list of research questions sent to suitable experts, who score the
questions on a Likert scale (1–7) and suggest possible additional
questions
Researcher collates scores, identifies median and IQR and uses this
to identify the top 15 questions.  New questions considered and suitable
questions with support from more than one panel member added to
the question sheet for round 2
Top 15 questions and up to five new questions sent to panel on an 
individually tailored score sheet, with a note of the median score and 
the panel member’s individual score from round 1 for each question  
Participants rescore questions, with the opportunity to change their 
original score in view of the group’s response
Researcher collates scores, identifies median and IQR and uses this 
to identify top 15 questions for round 3
Top 15 questions sent to panel on an individually tailored score sheet 
as for round 2.  Participants rescore questions, with the opportunity to 
change their original score in view of the group’s response
Researcher collates scores, identifies median and IQR and uses this
to rank the top 15 questions
Prioritised list of research questions finalised, with the resulting list
and scores sent to panel for their information
Round 2 
Round 3 
Feedback round 
FIGURE 2  Flow chart of Delphi process for severe malnutrition project. IQR, interquartile range.
Inclusion and exclusion criteria and process for screening studies
Study design
  ■ Randomised controlled trials (RCTs), controlled clinical trials (CCTs), cohort with control 
(prospective and retrospective studies) and case–control studies were eligible for inclusion. 
Following consultation with the expert advisory group, studies published before 1970 
were excluded. It was felt that changes in the diagnostic criteria used to identify SAM and 
developments in the interventions assessed, rendered any evidence published before 1970 of 
limited relevance to current and future practice.
  ■ Where evidence from different types of study design was identified, only those with the most 
rigorous designs based on the hierarchy of evidence were included.
  ■ Studies without a comparator group (e.g. before-and-after studies) or those with a 
comparator group that was not defined in the same way as the experimental group (e.g. a 
control group of healthy individuals or moderately malnourished children) were excluded.
Intervention(s)
  ■ Any intervention for treating SAM (either an entire treatment plan or any individual 
treatment step).
Comparator(s)
  ■ Any alternative treatment strategy.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Comparators could include no intervention and placebos.
Population
  ■ Infants and children < 5 years old with SAM.
With several different definitions and classifications of SAM having been developed and used, 
it was considered important to use those in the systematic review that were considered to be 
either ‘standard and accepted’, key for use within different geographical regions, population 
groups or settings, or that were thought to incorporate important developments. In doing so, it 
was important to select those that limited the possible variation in the children studied, allowing 
appropriate comparison of the interventions assessed. Following consultation with the expert 
advisory group, the following set of criteria were selected for use in the systematic review.
  ■ The WHO and UNICEF criteria of a W/H < −3 SDs from the median value using the WHO 
growth standards published in 200613,14 or < −3 SDs or < 70% of the median value using the 
NCHS child growth reference standards published in 1977.18,19
  ■ A MUAC measurement of < 115 mm.
  ■ Diagnosis of severe malnutrition with clinical signs of oedema of nutritional origin.
  ■ Diagnosis of kwashiorkor or marasmic kwashiorkor or where anthropometric measures 
and/or clinical characteristics have been stated to allow their diagnosis against recognised 
classifications, specifically:
  – The Wellcome classification with children defined as having kwashiorkor (60–80% 
expected body weight plus oedema) and marasmic kwashiorkor (< 60% expected body 
weight with oedema present),23,28 and
  – The Save the Children criteria44 for case definition of kwashiorkor (bilateral oedema of 
nutritional origin and a W/H ≤ –2 SDs from the median value using the WHO growth 
standard) and marasmic kwashiorkor (bilateral oedema of nutritional origin and a W/H 
< –2 SDs from the median value using the WHO growth standard).
  ■ Diagnosis of marasmus where anthropometric measures have been stated to allow their 
diagnosis against other recognised classifications (i.e. in addition to the WHO and UNICEF 
criteria), specifically:
  – The Wellcome classification with children defined as having marasmus (< 60% expected 
body weight with no oedema present).
  – The Gómez classification,25,26 which defines severe or third-degree malnutrition as a 
percentage expected W/A of < 60%.
  – The IAP 1972 definition45 of grade III (51–60% expected W/A) or grade IV PEM (≤ 50% 
expected W/A).
Outcomes
  ■ Studies were included providing they reported on the primary outcome measures for this 
review of mortality or weight gain (these outcomes did not have to be the primary outcomes 
of the study). Other outcomes reported by studies could also be included, providing 
mortality or weight gain was reported.
  ■ Outcome measures obtained after any length of follow-up were eligible for inclusion.
Studies were selected for inclusion in the systematic review of clinical effectiveness using a 
two-stage process. Literature search results (titles and abstracts) were screened independently by 
two reviewers to identify all the citations that might meet the inclusion criteria. Full manuscripts 
of selected citations were then retrieved and assessed by one reviewer against the inclusion/
exclusion criteria and checked independently by a second reviewer. Discrepancies were resolved 
by discussion, with the involvement of a third reviewer when necessary.14 Methods for the Delphi process and systematic review of clinical effectiveness
Mapping the evidence to the prioritised research questions
A ‘map’ of the evidence base was created by categorising each study according to which one 
of the research questions, prioritised by the Delphi process, it primarily addressed. Inevitably, 
some of the studies mapped to the questions identified in the Delphi study examined specific 
sub-questions. These were grouped together within the systematic review under broader topics, 
allowing comparison of common themes. Each study was mapped to the prioritised research 
questions by one reviewer and the decision was checked independently by a second reviewer. 
After the available evidence had been mapped against each research question, the final decision 
on how many questions would be addressed by the systematic review was taken, based on the 
extent of the evidence and the resources available for the research.
Data extraction strategy
Data were extracted from the included studies that mapped to prioritised research questions 
included in the systematic review. Data were extracted by one reviewer using a standardised form 
and checked for accuracy by a second reviewer. Discrepancies in the extracted data were resolved 
by discussion, with involvement of a third reviewer when necessary. Data were not extracted 
from included studies that mapped to questions that were not assessed in the systematic review 
or from studies that did not map to any question.
Quality assessment strategy
It was anticipated that the evidence base would include studies of different methodological 
designs. Therefore, a quality assessment tool was chosen which could be used to assess the 
methodological quality of a range of study types.46 Details of the tool and scoring system are 
presented in Appendix 4. Study quality was assessed by one reviewer using a standardised form 
and checked by a second reviewer. Disagreements were resolved by discussion and, if necessary, 
by arbitration involving a third reviewer. Included studies that mapped to questions that were 
not assessed in the systematic review and studies that did not map to any question were not 
quality assessed.
Method of data synthesis
The methods of data synthesis were determined by the nature of the studies identified through 
searches and included in the review. Studies were synthesised through a narrative review 
with tabulation of results of included studies. Meta-analysis was not possible because of the 
heterogeneous nature of studies identified, including differences in the interventions (e.g. dose 
and duration of treatment) and the outcomes (e.g. units, time points and measures) assessed.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Chapter 3  
Results of the Delphi process
L
eading international experts in the field of malnutrition were identified during the time the 
protocol was being developed for this review. Invitations to participate in the Delphi process 
were sent to 28 individuals, with a view to balancing input from academics, people working 
in the field (i.e. in institutions or treatment centres closely linked with the population group), 
governmental departments, charities and non-governmental organisations (NGOs) and WHO. 
Table 6 shows the number of people in each area who responded at each stage of the process. 
Given the nature of this work, some people could be classified as working in two or more areas 
(e.g. academics who also worked in the field on training courses).
Round 1
For round 1 of the Delphi study, 14 people who had expressed an interest in contributing to 
the project were sent the question sheet described in Appendix 5. Of these, 11 people returned 
completed question sheets, seven of whom also contributed additional questions to be considered 
for inclusion in round 2. The original 18 questions were ranked according to median score, 
followed by the upper and the lower interquartile range (IQR) limits. The top 15 questions were 
retained and the three questions which received the lowest scores were removed. The ranked list 
is shown in Appendix 5.
Development of question sheet and scoring in round 2 and round 3
The 15 retained questions from round 1 were refined either by rewording or by adding sub-
questions, and four new questions were added in response to comments received by the Delphi 
panel members. Full details of the questions presented to the panel in round 2 are available 
in Appendix 5.
The question sheet for round 2 was sent to 16 people, 14 of whom replied. In this round, each 
question sheet was individually tailored to show each panel member his or her own scores from 
round 1 and the overall median score for each question. Participants rescored the questions and 
TABLE 6  Composition of the Delphi panel
Stage
Area(s) of work of panel membersa
Total number of 
individuals Academic Field Government NGO or charity WHO
Initial invite 10 5 4 7 5 28
Agreed to participate 6 4 1 3 2 16b
Completed round 1 4 3 1 3 2 11
Completed round 2 6 4 1 3 2 14
Completed round 3 6 4 1 2 2 13
a  Some panel members were counted in more than one category, therefore numbers in the rows of this section may not match the number of 
people contacted.
b  When round 1 took place, 14 participants had agreed to participate.16 Results of the Delphi process
were able to take the opportunity to change their score in view of the overall median score from 
the Delphi group. Once again, the results were used to rank the questions according to median 
score, followed by the upper and lower IQR limits, and the top 15 questions were retained. Full 
details, including an additional analysis to assess whether or not rankings were affected by the 
responses from two people who had not taken part in round 1, are provided in Appendix 5.
For round 3, the same score sheet used for round 2 was sent to 16 people. Thirteen people 
returned a completed score sheet, one of whom had not returned a score sheet for rounds 2 or 1. 
The median and IQR limits calculated for all 13 respondents’ scores, and an additional analysis to 
assess the impact of the scores received from the person who had not contributed to the previous 
rounds, are provided in Appendix 5.
The final prioritised list of research questions resulting from the Delphi process is shown in 
Table 7. This list of questions formed the basis for the systematic review.
TABLE 7  Ranking of questions after round 3 (n = 13 respondents)
Rank:  
round 3
Question 
number Question
1 =  19 What methods are effective for treating SAM among infants < 6 months old?
1 =  20 How should management of HIV-infected children with SAM differ from those who are severely malnourished 
but HIV–ve?
1 =  21 Which form of i.v. fluid administration is most effective for treating shock?
1 =  22 What are the best treatments for children with SAM who have diarrhoea?
5 =  7 What methods are effective in treating infection?
5 =  18 What factors affect sustainability of programmes, long-term survival and readmission rates?
7 =  15 What is the clinical effectiveness of management strategies for treating children with comorbidities such as 
tuberculosis and Helicobacter pylori? (other than HIV and diarrhoea, which are considered in Q20 and Q22)
7 =  17 What factors limit full implementation of treatment programmes?
9 14 What is the clinical effectiveness of interventions in different settings (e.g. hospital, community, emergency)?
10 8 Which methods for correcting micronutrient deficiencies are effective?
11 1 What is the overall effectiveness of current programmes/guidance (e.g. the WHO 10-step plan)? 
12 =  5 What methods for treating dehydration are effective?
12 =  9 What are the most effective methods for feeding during the initial stages of treatment?
12 =  10 Which methods are effective in the rehabilitation phase?
15 11 What is the effectiveness of different methods for increasing appetite and food intake to recover lost weight and 
aid catch-up growth?
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Chapter 4  
Assessment of clinical effectiveness
T
itles and, where available, abstracts of a total of 8954 records were screened and full copies of 
the 224 references were retrieved (because of resource limitations only references in English 
were selected for retrieval). After inspection of the retrieved references, 150 were excluded (see 
Appendix 6): 81 because they did not focus on the patient group of interest, two because the 
intervention was not relevant, 12 because they did not report the necessary outcomes, 62 were 
because of their design and four because they were abstracts containing insufficient information 
to judge study quality, methodology and results (references could be excluded for more than one 
reason). Seventy-four retrieved references/full papers describing 68 studies met the inclusion 
criteria of the review. The total number of records assessed at each stage of the systematic review 
screening process is shown in the flow chart of Figure 3.
As set out in the protocol for this review, the prioritised list of research questions that resulted 
from the Delphi process formed the basis for this systematic review. Each of the 68 studies that 
met the general review inclusion criteria was therefore mapped against the list of prioritised 
questions to provide an overview of the extent of the available evidence (Table 8).
11,279 records identified through
database searching 
31 additional records identified
through other sourcesa
8954 records after duplicates removed
8954 records screened 8728 records excluded
224 full-text articles
assessed for eligibility
74 articles describing 68
studies were mapped to
research questions
150 full-text articles
excluded
Reasons:
Patient group (n = 81)
Intervention  (n = 2)
Outcome(s) (n = 12)
Design (n = 62)
Abstract (n = 4)
Studies could be
excluded for multiple
reasons, therefore
numbers sum to more
than 150 
65 studies (70 articles)
mapped to a question
Three studies (four articles)
mapped to a question that
had not been prioritised or
to no question 
Two full-text articles
unobtainable
FIGURE 3  Reference retrieval flow chart.  
a, For example, bibliographies of included studies and grey literature identified by the advisory group.18 Assessment of clinical effectiveness
The available evidence mapped against 9 of the 15 prioritised questions. For one other question 
(Q19), no studies focused on the topic of interest; however, very limited evidence was available in 
two other studies. These 10 questions in which evidence was included were as follows:
  ■ What methods are effective for treating SAM among infants < 6 months old? (Q19, limited 
information only)
  ■ Which form of intravenous (i.v.) fluid administration is the most effective for treating shock? 
(Q21)
  ■ What are the best treatments for children with SAM who have diarrhoea? (Q22)
  ■ What methods are effective in treating infection? (Q7)
  ■ What is the clinical effectiveness of interventions in different settings (e.g. hospital, 
community, emergency)? (Q14)
  ■ Which methods for correcting micronutrient deficiencies are effective? (Q8)
  ■ What is the overall effectiveness of current programmes/guidance (e.g. the WHO 10-step 
plan)? (Q1)
  ■ What methods for treating dehydration are effective? (Q5)
  ■ What are the most effective methods for feeding during the initial stages of treatment? (Q9)
  ■ Which methods are effective in the rehabilitation phase? (Q10)
No evidence was found to inform the remaining five questions:
  ■ How should management of HIV-infected children with SAM differ from those who are 
severely malnourished but HIV–ve? (Q20)
  ■ What factors affect sustainability of programmes, long-term survival and readmission rates? 
(Q18)
  ■ What is the clinical effectiveness of management strategies for treating children with 
comorbidities such as tuberculosis (TB) and Helicobacter pylori? (other than HIV infection 
and diarrhoea, which are considered in Q20 and Q22) (Q15)
  ■ What factors limit full implementation of treatment programmes (e.g. insufficient training, 
cultural difficulties and funding limitations)? (Q17)
  ■ What is the effectiveness of different methods for increasing appetite and food intake to 
recover lost weight and aid catch-up growth? (Q11)
After the available evidence had been mapped against each research question, the final decision 
on how many questions would be addressed was taken, based on the extent of the evidence and 
the resources available for the research. It was decided that project resources were available to 
review the evidence for the first six questions for which any evidence was available.
  ■ What methods are effective for treating SAM among infants < 6 months old? (limited 
information only)
  ■ Which form of i.v. fluid administration is most effective for treating shock?
  ■ What are the best treatments for children with SAM who have diarrhoea?
  ■ What methods are effective in treating infection?
  ■ What is the clinical effectiveness of interventions in different settings (e.g. hospital, 
community, emergency)?
  ■ Which methods for correcting micronutrient deficiencies are effective?
For each question, evidence was included from studies with the most rigorous designs based on 
the hierarchy of evidence. For all but one question, this meant that only RCTs and CCTs were 
included. The exception was Q7 (What methods are effective in treating infection?), where a © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
19   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
TABLE 8  Evidence available for each of the research questions prioritised in the Delphi process
Question (rank) RCT CCT PCA + C PCA + HC RetroCA + C
Case-
control Other Unclear
What methods are effective for treating SAM 
among infants < 6 months old? ( = first)a
How should management of HIV-infected children 
with SAM differ from those who are severely 
malnourished but HIV–ve? ( = first)
Which form of i.v. fluid administration is the most 
effective for treating shock? ( = first)
1
What are the best treatments for children with 
SAM who have diarrhoea? ( = first)
8
What methods are effective in treating infection? 
( = fifth)
1 1
What factors affect sustainability of programmes, 
long-term survival and readmission rates? 
( = fifth)
What is the clinical effectiveness of management 
strategies for treating children with comorbidities 
such as TB and H. pylori? ( = seventh)
What factors limit full implementation of treatment 
programmes? ( = seventh)
What is the clinical effectiveness of interventions 
in different settings? (ninth)
4 1 1
Which methods for correcting micronutrient 
deficiencies are effective? (10th)
3 10 1
What is the overall effectiveness of current 
programmes/guidance? (11th)b
1 4
What methods for treating dehydration are 
effective? ( = 12th)b
1
What are the most effective methods for feeding 
during the initial stages of treatment? ( = 12th)b
1 1 1
Which methods are effective in the rehabilitation 
phase? ( = 12th)b
8 13 1 1 2 1
What is the effectiveness of different methods for 
increasing appetite and food intake to recover lost 
weight and aid catch-up growth? (15th)b
PCA + C, prospective cohort analysis with concurrent comparison group; PCA + HC, prospective cohort analysis with historic comparison group; 
RetroCA + C, retrospective cohort analysis with comparison group.
a  No studies focused on this question, so none have been mapped to it. However, very limited evidence was available from one prospective 
cohort study and one retrospective cohort study, which is commented in in What methods are effective for treating severe acute malnutrition 
among infants < 6 months old? (Q19, rank 1).
b  Study publications mapping to the bottom five ranked questions have not been data extracted or quality assessed. If these studies were quality 
assessed, some that are described as RCTs might be judged to be CCTs.
The number of studies categorised above sum to 66 (rather than the 65 expected) because one study mapped to Q5 was also included under 
Q22 and is therefore counted twice. Three studies mapped to a question not prioritised (n = 2) or did not map to any question (n = 1). 
RCT and a retrospective cohort study with control were the only two studies that addressed this 
question, but each one focused on a different aspect of this topic.
The evidence is presented in the remainder of this chapter with each of the six questions reviewed 
being considered in a separate section. The evidence is presented in the remainder of the chapter, 
with each of the six questions reviewed.20 Assessment of clinical effectiveness
What methods are effective for treating severe acute malnutrition 
among infants < 6 months old? (Q19, rank 1 = )
No research focusing on treating SAM of infants < 6 months old was identified. The majority 
of studies excluded this age group, and most of those which allowed for the inclusion of this 
age group did not report on outcomes for this subgroup. Two studies47,48 were identified that 
did include infants < 6 months of age within their study populations and provided some 
outcome information for this subgroup; however, the information available was very limited 
(see Appendix 7). Although data were extracted, no formal quality assessment was undertaken. 
The findings are presented to illustrate the nature of the studies and should be interpreted 
with caution.
Nu Shwe’s retrospective cohort study with control47 described outcomes at a children’s hospital 
in Myanmar before and after the introduction of the WHO’s guidelines for SAM. In the year 
before the introduction of the WHO guidelines (1999), 11.4% of children were < 6 months 
of age, but this proportion fell in subsequent years to 10.7% in 2000 and to 6.4% in 2001. No 
baseline data were presented for the group of children < 6 months of age; thus, the comparability 
of the cohorts in each year is unknown. The only outcome reported for the group of interest is 
proportional mortality (the number of deaths for each age group expressed as a percentage of all 
the deaths), but a statistical comparison between the control year, 1999, and the years 2000 and 
2001, when the WHO guidelines were in use, is not reported (control year 1999: cases 11.4%, 
proportional mortality 12%; WHO year 2000: cases 10.7%, proportional mortality 9.1%; WHO 
year 2001: cases 6.5%, proportional mortality 12.5%). The author comments that the introduction 
of exclusive breast feeding programmes may have reduced SAM in children < 6 months of age 
and may also have contributed to the lower proportional mortality in the < 12 months age group 
in comparison with other age groups. Nu Shwe47 states that, comparatively, the proportional 
mortality in the age groups < 6 months and 6–12 months (9–24%) was lower than in the 
13–24 months and > 24 months age groups (20–50%).
Hossain and colleagues48 described a prospective cohort study with concurrent control in 
Bangladesh, which compared a locally adapted protocol for treatment of SAM with the WHO 
protocol. They included children in the age range 2–59 months, but the number of children 
enrolled who were aged < 6 months is not reported and no baseline characteristics are provided 
for this subgroup of children; therefore, the comparability of the groups with regard to children 
aged < 6 months is unknown. The only outcome reported for the group of interest is weight 
gain. There was no statistically significant difference in weight gain for the < 6 months age group 
between the treatment arms [mean ± SD weight gain: Institute of Child and Mother Health 
(ICMH) protocol 17.5 ± 7.5 g/kg/day vs the WHO protocol 11.6 ± 6.8 g/kg/day; p = 0.21]. The 
mortality rate overall in each group was 6.7%, but mortality was not reported on separately for 
children aged < 6 months.
Which form of intravenous fluid administration is most effective 
for treating shock? (Q21, rank 1 = )
Quantity and quality of research available: shock
One RCT was included that investigated the efficacy of fluid resuscitation solutions for treating 
hypovolaemic shock in children with SAM.49 The key characteristics of the trial can be seen 
in Table 9, with further details in Appendix 8. The trial was a phase II safety and efficacy RCT 
conducted in a district hospital in Kenya, and funded by a global charity.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Severe acute malnutrition was defined in this RCT as any of W/H z-score < −3 or W/H < 70% 
of reference median, a MUAC measurement of < 11.0 cm, or oedema involving at least both feet 
(kwashiorkor). Participants were also required to have evidence of shock and were categorised 
as having either severe dehydration/shock (shock and severe dehydrating diarrhoea defined 
as ≥ 6 watery stools/day) or presumptive septic shock (non-diarrhoeal shock). The trial 
predominantly evaluated Ringer’s lactate isotonic fluid (RL) compared with a standard WHO 
hypotonic fluid solution [half-strength Darrow’s in 5% dextrose (HSD/5D)]. Children with severe 
dehydrating diarrhoea/shock randomly received RL or HSD/5D, whereas those with presumptive 
septic shock were randomised to RL, HSD/5D or 4.5% human albumin solution (HAS); although 
limited data were subsequently reported for the HAS group, owing to small study numbers 
(n = 6). HSD/5D was given according to the WHO recommendation in a maximum of two 
boluses of 15 ml/kg over 2 hours, whereas the RL group received 10 ml/kg over 30 minutes (up to 
a maximum of 40 ml/kg where necessary). HAS was administered in the same dosage as for RL. 
Follow-up was at 8 and 24 hours for the primary outcome, although the children were followed 
up intensively for up to 48 hours and thereafter for in-hospital mortality.
Other interventions that all participants received included standard WHO management of 
SAM comprising treatment of hypoglycaemia, antibiotics and oral rehydration solution (ORS) 
[rehydration solution for malnutrition (ReSoMal)] for those with dehydrating diarrhoea, and 
maintenance i.v. dextrose fluids up until tolerance of oral feeds was established.
The trial49 was relatively small with 61 participants, although with few data reported on the six 
children receiving HAS, this number was reduced to 55 for reported baseline characteristics 
and most outcomes. Children allocated to the RL and HSD/5D treatment groups were around 
15 months of age (though it is not clear from the publication whether this is the mean or 
median), with a slightly higher proportion being boys (58–59%). The mean W/H z-score at 
baseline ranged from −3.4 to −3.9 and the mean MUAC was approximately 10 cm. Approximately 
two-thirds of participants had severe wasting, about 40% were HIV sero-positive (HIV+ve) and 
around 75% fulfilled the strict WHO definition of advanced shock for severely malnourished 
children. Of the total included population, approximately twice as many children had severe 
dehydration/shock as had presumptive septic shock, although within the RL and HSD/5D 
treatment groups there were approximately an even number of children with each type of shock.
The study was limited to children > 6 months of age with SAM and evidence of shock. The 
clinical shock criteria were defined and included measures such as a capillary refill time (CRT) 
> 2 seconds, weak pulse volume and deep ‘acidotic’ breathing, among others (see Appendix 8). 
Children were excluded if they had known congenital heart disease, severe anaemia, clinical 
features of pulmonary oedema or raised intracranial pressure. The primary outcome was 
stipulated as resolution of features of shock, defined as the absence of all of severe tachycardia 
(heart rate > 160 beats/minute), CRT > 2 seconds or oliguria (urine output < 1 ml/kg/hour) at 
8 and 24 hours post treatment. Secondary outcomes included the incidence of adverse events 
and mortality. Improvements in the W/H z-score or other measures of weight gain were not 
reported outcomes.
Summary of quality assessment
The methodological rigour of the trial by Akech and colleagues49 was rated moderate overall 
(Table 10). The trial was potentially at risk of selection bias, because not all of the eligible 
children who were selected actually participated in the trial either for clinical reasons or because 
consent was declined. The study was a RCT and an adequate method (use of sealed envelopes) 
was used for randomisation to treatment groups, resulting in a strong rating for study design. 
Baseline characteristics and disease severity indices were reported to be balanced across the 
three fluid intervention arms (although data were not presented for the HAS arm because 22 Assessment of clinical effectiveness
of small numbers), also leading to a strong rating. However, neither the participants nor the 
care providers were blinded to treatment and no details were reported regarding the outcome 
assessors, leading to a higher risk of detection bias and thus a weak rating. For data collection 
methods, the trial was rated as moderate as it used valid criteria for measuring shock, but it 
was not possible to judge whether or not these criteria were reliable. There were no dropouts or 
withdrawals from the trial, only losses because of deaths, and all surviving children completed 
the study, indicating a low risk of attrition bias. The intervention integrity of the trial was strong 
as all the participants were deemed likely to have received his or her allocated intervention 
without any cross-contamination. Appropriate statistical methods were employed in the data 
analysis and the authors report that all analyses were performed using the intention-to-treat 
(ITT) principle, although outcomes were presented for all survivors (those who died were not 
included), rather than for all those randomised. However, the area under curves (AUCs) were 
calculated in order to compensate for the confounding effect of mortality and, hence, missing 
observations, leading to biases in the highest risk group and resulting imbalance within the 
survivors. It should also be noted that the trial was prematurely terminated because of the high 
overall mortality and inadequate correction of shock in all study arms after an interim review 
of safety data and consultation with the external safety monitors. As a result, the study did not 
recruit the required sample size and was therefore underpowered.
Assessment of effectiveness: shock
Mortality
Overall mortality was high, with 51% (31/61) of children not surviving. Of these deaths, 39% 
(12/31) occurred within 24 hours of recruitment,49 whereas 52% (16/31) of fatalities occurred 
within 48 hours of enrolment (Professor Kathryn Maitland, Imperial College London, 2011, 
personal communication). There was no statistically significant difference in mortality rates 
between the three treatment groups (p = 0.62), nor between children who received RL versus 
HSD/5D (p = 0.34) (Table 11). On Kaplan–Meier survival analysis, there was no significant 
difference in time to death when any of the intervention fluids were used for resuscitation (log-
rank test combined, p = 0.42).
Mortality rates within a number of subgroups were also reported by Akech and colleagues,49 
although not all were presented as comparisons between fluid resuscitation treatment groups. 
TABLE 9  Characteristics of the included RCT of children with shock
Study details and target population Intervention Comparator
Akech et al. 201049
Design: phase II RCT
Location: Kenya
Length of follow-up: 24 hours’ follow-up for primary outcome; 
up to 48 hours and thereafter for in-hospital survival
No. enrolled: 61
Target population: children aged > 6 months with any of: 
W/H z-score < −3 or W/H < 70%,c MUAC < 11.0 cm, or 
oedema involving at least both feet (kwashiorkor) and with 
hypovolaemic shock
RLa WHO fluid resuscitation regimen 
(HSD/5D)
Ageb (IQR): 16 (6) months
Sex F : M, %: 41 : 59
Mean W/H z-score ± SD: −3.9 ± 1.0
Mean MUAC ± SD: 10.0 ± 1.9 cm
W/A: NR
Met WHO SAM shock criteria,%: 79
Severe dehydrating shock,%: 72
Presumptive septic shock,%: 28
Ageb (IQR): 15 (14) months
Sex F : M, %: 42 : 58
Mean W/H z-score ± SD: −3.4 ± 1.3
Mean MUAC ± SD: 10.4 ± 1.4 cm
W/A: NR
Met WHO SAM shock criteria,%: 69
Severe dehydrating shock,%: 73
Presumptive septic shock,%: 27
NR, not reported.
a  A third treatment arm with only six participants (some of those with non-diarrhoeal shock) received 4.5% HAS, but no baseline characteristics 
were reported for this group.
b  Reporting of baseline age is unclear. Original paper does not indicate whether or not the value reported is the median or mean; states IQR is 
given, but there is only a single value, not a range.
c  Not explicitly stated, but appears that W/H compared against the WHO child growth standards, 2006.13,14© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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624 Assessment of clinical effectiveness
In those with severe diarrhoeal shock, mortality was higher in the standard HSD/5D group 
than in the RL group {13/19 (68%) vs 9/22 (43%), respectively; p = 0.11 [note: there is a possible 
error reported in the publication, RL should be 9/21 (43%)]}, although the opposite trend 
was observed for those with presumptive (non-diarrhoeal) shock [2/7 (29%) vs 4/8 (50%), 
respectively; p = 0.61 (note: there is a possible error reported in the publication for presumptive 
shock for HSD/5D)], but neither difference reached statistical significance. Children who fulfilled 
the WHO malnutrition shock definition at admission were at a statistically significant increased 
risk of death [risk ratio (RR) 2.0, 95% confidence interval (CI) 0.92 to 4.36; p = 0.05] compared 
with those who did not fulfil this definition, irrespective of allocated intervention. Similarly, 
kwashiorkor was associated with an increased risk of death irrespective of treatment arm [odds 
ratio (OR) 2.2, 95% CI 0.7 to 10.1; p = 0.14], though this was not statistically significant. Mortality 
in children who were HIV+ve was similar to those that among who were HIV–ve (42% vs 45%, 
respectively; p-value not reported) and infection with HIV did not significantly increase the risk 
of death (OR 1.18, 95% CI 0.38 to 3.72; p = 0.76).
Weight gain and anthropometry
Weight gain and anthropometry outcomes were not reported by the Akech and colleagues’ trial49 
because of the focus of the study (i.e. the trial was designed to look at emergency management of 
shock rather than nutritional rehabilitation).
Resolution of shock
The proportion of children in whom shock persisted after fluid resuscitation treatment was 
considerable, but was not significantly different between RL and HSD/5D at either 8 or 24 hours 
(Table 12). The authors report that a larger decline in the proportion with shock was observed 
in children who received RL than in those who received HSD/5D, particularly in the diarrhoeal 
group, but the differences were not significant at any time point (data not shown).
Oliguria
Adequate urinary output was used as a gold standard for successful fluid resuscitation, with 
oliguria (the production of an abnormally small volume of urine) being a marker of persistent, 
severe shock. The incidence of oliguria was significantly higher in children receiving the standard 
WHO HSD/5D solution than in those receiving RL at 8 hours (reported by the authors as p = 0.02 
in the table, but p = 0.05 in the text). This trend was also evident at 24 hours, but was no longer 
statistically significant (p = 0.16) (Table 13).
In an additional analysis, the median AUC for the hourly urine output was significantly lower in 
HSD/5D participants (51 ml/kg/hour, IQR 36–116) than in RL participants (101 ml/kg/hour, IQR 
63–141; Kruskal–Wallis chi-squared = 4.6; p = 0.03) (data not shown).
Tachycardia
Persistent tachycardia is an index of unresolved shock and was defined as a heart rate of 
> 160 beats/minute. Children who received the standard WHO HSD/5D solution had a higher 
TABLE 11  Mortality in children with shock
Study Treatment arms p-value
Akech et al. 201049 RL (n = 29) HSD/5D (n = 26) 4.5% albumin (HAS) (n = 6)
In-hospital mortality, n/N (%) 13/29 (45) 15/26 (58) 3/6 (50) 0.62a
0.34b
a  Comparison of three groups.
b  HSD/5D vs RL.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 12  Persistence of shock in children with shock
Study Treatment arms p-value
Akech et al. 201049 RL (n = 29) HSD/5D (n = 26)
Number with shock, n/N (%):
  8 hours 14/25 (56) 15/22 (68) 0.39
  24 hours 14/25 (56)a 14/18 (78) 0.14
a  Shown to be approximately 60% at 24 hours in figure 2 AUC line graph in the publication49 (estimated by reviewer).
TABLE 13  Oliguria in children with shock
Study Treatment arms p-value
Akech et al. 201049 RL (n = 29) HSD/5D (n = 26)
Oliguria (< 1 ml/kg/hour), n/N (%):
  8 hours 3/25 (12)a 9/22 (41)b 0.02c
  24 hours 6/25 (24)d 8/18 (44)e 0.16
a  Shown to be approximately 21% in figure 3 AUC line graph in the publication49 (all estimated by reviewer).
b  Shown to be approximately 46% in figure 3 AUC line graph in the publication49 (all estimated by reviewer).
c  p = 0.05 in text.
d  Shown to be approximately 38% in figure 3 AUC line graph in the publication49 (all estimated by reviewer).
e  Shown to be approximately 54% in figure 3 AUC line graph in the publication49 (all estimated by reviewer).
incidence of tachycardia (and hence unresolved shock) compared with those who received the RL 
solution, becoming statistically significant at 24 hours (p = 0.04) (Table 14).
In the additional analysis, median AUC of heart rates were similar for both treatments (Kruskal–
Wallis chi-squared = 0.3; p = 0.59).
Adverse events
Although the incidence of adverse events was not presented, Akech and colleagues49 did 
report that no child developed clinical features of pulmonary oedema or allergic reaction 
(to HAS) during the course of study observation. In addition, no diuretics were required or 
prescribed during the trial and there were no differences in the mean sodium concentration at 
admission (133 ± 11 mmol/l vs 134 ± 10 mmol/l, respectively; p = 0.81), 8 hours (134 ± 10 mmol/l 
vs 139 ± 10 mmol/l, respectively; p = 0.09) or 24 hours (138 ± 9 mmol/l vs 140 ± 9 mmol/l, 
respectively; p = 0.47) between those who received HSD/5D and RL implying that children did 
not exhibit the problem of either water or sodium retention.
Other outcomes
Additional outcomes such as severe tachypnoea (rapid breathing of > 60 breaths/minute), 
creatinine levels and resolution of base deficit (acidosis) were also reported in the trial 
publication, but have not been presented here. Further details are available in the data extraction 
forms in Appendix 8.
Summary
  ■ Only one trial49 was identified that evaluated the efficacy of fluid resuscitation solutions for 
the treatment of children with SAM and hypovolaemic shock. The trial was relatively small 
and was rated as having a moderate methodological quality overall. It should be noted that 
the study was underpowered because of premature termination of the trial because of safety 
issues (i.e. high overall mortality and inadequate correction of shock in both arms) and the 
results should therefore be interpreted with caution.26 Assessment of clinical effectiveness
  ■ The overall mortality rate in the trial was high (> 45%), with no statistically significant 
differences between treatment groups nor any difference in the time to death between 
treatment arms. There was an inadequate correction of shock that persisted after fluid 
resuscitation treatment in both the standard WHO HSD/5D hypotonic solution and the 
isotonic RL solution groups (> 50%).
  ■ The incidence of oliguria (used as a marker of persistent, severe shock) was higher in 
children receiving HSD/5D hypotonic solution than in those receiving RL, being significant 
at 8 hours, but not at 24 hours. Similarly, children who received the HSD/5D solution had 
a higher incidence of tachycardia (denoting unresolved shock) than those in the RL group, 
becoming statistically significant at 24 hours.
  ■ The isotonic RL solution was found to be as safe as the currently recommended WHO 
HSD/5D hypotonic solution with no adverse events reported. However, it should be noted 
that all the fluid solutions were deemed inadequate by the authors in the correction of shock.
What are the best treatments for children with severe acute 
malnutrition who have diarrhoea? (Q22, rank 1 = )
Eight trials50–57 were included that investigated the efficacy of treatments for children with SAM 
who also had diarrhoea. Within this section, similar trials have been grouped together for ease 
of comparison between studies. The groupings consist of those with acute diarrhoea and treated 
with ORS (n = 5,50,51,54,55,57 see Quantity and quality of research available: acute diarrhoea and 
Assessment of effectiveness: acute diarrhoea) and those with persistent diarrhoea and treated with 
formula and/or solid diets (n = 3,52,53,56 see Quantity and quality of research available: persistent 
diarrhoea and Assessment of effectiveness: persistent diarrhoea).
Quantity and quality of research available: acute diarrhoea
Five trials50,51,54,55,57 were included that investigated children with acute diarrhoea, defined as 
diarrhoea lasting < 2, < 3, < 4 or ≤ 10 days. The key characteristics of these RCTs can be seen in 
Table 15, with further details of the trials in Appendix 9. All the trials were single-centre RCTs 
carried out in India51,54,55 or Bangladesh.50,57 One study50 received funding from WHO and one57 
was funded jointly by a commercial organisation and an international health research institution. 
For three studies51,54,55 the primary source of financial support was not stated, although Alam and 
colleagues51 received funding for materials from a local medical college/university.
Severe acute malnutrition was defined similarly in three trials, being W/H < 70% of the NCHS 
median,51 and either W/L < 70% of the NCHS median or with bilateral pedal oedema.50,57 Dutta 
and colleagues54 defined SAM as being < 60% of the Harvard standard W/A without oedema. In 
the fifth trial, Dutta and colleagues55 included different grades of malnourished children and used 
the IAP 1972 classification system.45 They did not specifically define SAM.
TABLE 14  Tachycardia in children with shock
Study Treatment arms p-value
Akech et al. 201049 RL (n = 29) HSD/5D (n = 26)
Tachycardia, n/N (%):
  8 hours 4/25 (16) 6/22 (27) 0.34
  24 hours 4/25 (16) 8/14 (57)a 0.04
a  Note: there is a possible error reported in the publication for presumptive shock for HSD/5D.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Two trials51,54 evaluated a hypo-osmolar oral rehydration solution (H-ORS) (containing 
lower concentrations of sodium, chlorine and glucose), and one trial50 evaluated a modified 
ORS, termed ReSoMal (containing lower concentrations of sodium, chlorine and citrate, and 
higher concentrations of potassium and glucose, as well as including other selected minerals). 
The comparator in these three studies was a standard WHO-ORS. In the fourth trial,55 all 
participants received a standard WHO-ORS initially with either a zinc-supplemented syrup 
or a placebo syrup [this study is included in this section rather than in Which methods for 
correcting micronutrient deficiencies are effective? (Q8, rank 10) because the focus of the study 
was on treatment of diarrhoea]. The fifth trial57 evaluated three types of ORS, which differed 
only by the addition of glucose, glucose plus amylase-resistant starch (ARS) or rice powder. 
In four trials,51,54,55,57 the ORS was given over a period of 4–6 hours, whereas in the ReSoMal 
trial50 the ORS was given more slowly, over a period of 12–14 hours, with all continuing to 
receive the ORS thereafter, if necessary, until diarrhoea stopped. None of the studies specifically 
stated the intended total duration of ORS treatment, although it appeared to be until diarrhoea 
ceased,50,51,54,55,57 with two studies suggesting that if diarrhoea had not ceased treatment continued 
for up to 5 days.54,55 The additional treatment with zinc or placebo syrup in the Dutta and 
colleagues trial55 was continued after discharge until the bottle was finished. None of the studies 
reported any follow-up beyond the treatment period with the exception of Dutta and colleagues55 
who reported outcome data at a follow-up of 30 days.
The trials varied in the other interventions that were offered to participants. Three trials51,55,57 gave 
i.v. rehydration to participants, where needed, in addition to the ORS. Three trials50,51,57 treated 
infections with antibiotics, one study54 specifically stated that no drug therapy was given and 
one55 did not report either way. Most of the studies51,54,55,57 permitted breastfeeding and children 
were also given solid food where appropriate, with children in the Dutta and colleagues trial54 
also given water ad libitum and formula or animal milk. Two trials reported that all children 
received the standardised treatment for SAM according to either WHO50 or International Centre 
for Diarrhoeal Disease Research (ICDDR)57 guidelines. It is not clear whether or not this is the 
case in the other trials, although it is possible that the two H-ORS studies51,54 used the WHO-ORS 
as their control intervention.
All the trials took place in an inpatient setting, recruiting children from diarrhoea treatment 
centres50,51,57 or hospital.54,55 The studies were relatively small, ranging from 64 participants in 
the Dutta and colleagues trial54 to 175 participants in the Alam and colleagues trial.57 Although 
the Alam and colleagues trial51 included 170 children in total, only 81 of these had SAM, with 
results reported separately for this group. This trial reported baseline characteristics for the whole 
study population, with only age and W/A reported in the subgroup with SAM. The five trials 
included children aged from 3 months to 5 years, although most were toddlers, with the average 
age being around 1–2 years. In one study,57 around half the participants were boys, in another50 
approximately two-thirds were boys, whereas in both trials by Dutta and colleagues54,55 all the 
included children were boys (for the purposes of ease of collection of urine and stools separately). 
The last study51 did not report the proportions of males and females.
For three trials,50,51,57 the mean W/A (as a percentage of the NCHS median) at admission ranged 
from 50% to 59%, for one trial54 about 95% of children were < 60% Harvard standard W/A and 
for the fifth trial55 around 85% of participants were < 70% Harvard standard W/A. Two studies50,57 
reported baseline z-scores, with a mean W/A z-score ranging from −4.3 to −4.7 and a mean 
W/L z-score ranging from −2.8 to −3.6. The mean duration of diarrhoea before admission was 
very different in the four trials that reported it, ranging from a mean of around 13 hours57 to 
75 hours.50 Dutta and colleagues54 reported a mean of 22 days despite an inclusion criterion of 
acute diarrhoea for ≤ 72 hours. In three trials, some50,51 or all57 of the children had diarrhoea 
with cholera.28 Assessment of clinical effectiveness
TABLE 15  Characteristics of the included studies of children with acute diarrhoea
Study details and target population Intervention Comparator
Alam et al. 200051
Design: double-blind RCT
Location: India
Length of follow-up: until recovery and 
discharge
n enrolled: 81 SAM (170 total study population)
Target population: children with SAM (W/H 
< 70% of NCHS) and acute diarrhoea (< 4 days 
duration) with dehydration, and either with non-
cholera diarrhoea (3 months –5 years) or with 
clinical suspicion of cholera (aged > 3 months)
H-ORS Standard WHO-ORS
Mean age ± SD: 25.29 ± 2.09 months
Sex F : M: NR
W/H: NR
MUAC: NR
Mean W/A ± SD, %: 52.4 ± 1.64
Duration of diarrhoea: NR
Frequency of diarrhoea: NR
Dehydration status: NR
Mean age ± SD: 24.17 ± 2.23 months
Sex F : M: NR
W/H: NR
MUAC: NR
Mean W/A ± SD, %: 58.6 ± 1.12
Duration of diarrhoea: NR
Frequency of diarrhoea: NR
Dehydration status: NR
Alam et al. 200350
Design: double-blind RCT
Location: Bangladesh
Length of follow-up: until diarrhoea resolved
No. enrolled: 130
Target population: children aged 3–36 months 
with SAM (W/H < 70% of NCHS median or with 
bilateral pedal oedema) and a history of watery 
diarrhoea for ≤ 10 days
ReSoMal (ORS for malnourished children) Standard WHO-ORS
Mean age ± SD: 15 ± 7 months
Sex F : M, %: 60 : 40
Mean % expected W/L ± SD: 66 ± 4
Mean W/L z-score ± SD: −3.6 ± 0.6
MUAC: NR
Mean % expected W/A ± SD: 50 ± 7
Mean W/A z-score ± SD: −4.7 ± 1
Mean duration of diarrhoea ± SD: 77 ± 62 hours
Mean frequency of diarrhoea ± SD: 12.5 ± 5 
stools/24 hours
Dehydration status,a % ‘none’/’some’: 32/68
Mean age ± SD: 15 ± 6 months
Sex F : M, %: 65 : 35
Mean % expected W/L ± SD: 66 ± 3
Mean W/L z-score ± SD: −3.5 ± 0.5
MUAC: NR
Mean % expected W/A ± SD: 51 ± 7
Mean W/A z-score ± SD: −4.6 ± 0.7
Mean duration of diarrhoea ± SD: 
74 ± 59 hours
Mean frequency of diarrhoea ± SD: 14 ± 9 
stools/24 hours
Dehydration status,a % ‘none’/’some’: 35/65 
Alam et al. 200957
Design: RCT
Location: Bangladesh
Length of follow-up: ORS until cessation of 
diarrhoea; standard treatment until 80% W/L 
reached
No. enrolled: 175
Target population: children aged 6–60 months 
with SAM (< 70% of NCHS median or with 
bipedal oedema) and acute, watery diarrhoea 
(< 48 hours duration) and cholera
Glucose-ORS Glucose-ORS + ARS Rice-ORS
Mean age ± SD: 
27.17 ± 12.36 months
Sex F : M, %: 45 : 55
Mean % expected W/L ± SD: 
68.99 ± 4.92
Mean W/L z-score ± SD: 
−3.14 ± 1.88
Mean MUAC ± SD: 
112.7 ± 9.9 mm
Mean % expected W/A ± SD: 
54.51 ± 9.50
Mean W/A z-score ± SD: 
−4.38 ± 68b
Mean duration of 
diarrhoea ± SD: 
12.59 ± 8.27 hours
Mean frequency of 
diarrhoea ± SD: 14.36 ± 6.00 
stools/24 hours
Dehydration status of ‘severe’, 
n (%): 48 (84)
Mean age ± SD: 
28.36 ± 13.42 months
Sex F : M, %: 58 : 42
Mean % expected W/L ± SD: 
69.01 ± 5.27
Mean W/L z-score ± SD: 
−2.76 ± 46b
Mean MUAC ± SD: 
113.6 ± 9.7 mm
Mean % expected W/A ± SD: 
53.42 ± 6.86
Mean W/A z-score ± SD: 
−4.31 ± 0.63
Mean duration of 
diarrhoea ± SD: 
13.07 ± 9.11 hours
Mean frequency of 
diarrhoea ± SD: 14.02 ± 6.09 
stools/24 hours
Dehydration status of 
‘severe’, n (%): 49 (83)
Mean age ± SD: 
27.33 ± 11.97 months
Sex F : M, %: 55 : 45
Mean % expected W/L ± SD: 
67.54 ± 6.19
Mean W/L z-score ± SD: 
−3.38 ± 0.60
Mean MUAC ± SD: 
111.9 ± 10.8 mm
Mean % expected W/A ± SD: 
53.16 ± 7.94
Mean W/A z-score ± SD: 
−4.39 ± 0.71
Mean duration of 
diarrhoea ± SD: 
10.98 ± 5.73 hours
Mean frequency of 
diarrhoea ± SD: 14.55 ± 7.16 
stools/24 hours
Dehydration status of 
‘severe’, n (%): 49 (84)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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All five studies had similar inclusion criteria with children required to have SAM, acute, 
watery diarrhoea for < 48 hours,57 ≤ 72 hours,54,55 < 4 days51 or ≤ 10 days,50 and be within the 
age range > 3 months and < 5 years. Four trials either required children to have some degree of 
dehydration51,54,55 or such children were eligible for inclusion.57 Alam and colleagues51 stipulated 
that children should be included if aged between 3 months and 5 years with non-cholera 
diarrhoea or if aged > 3 months with a clinical suspicion of cholera. The two trials by Dutta 
and colleagues54,55 included only males (for the reasons reported above). Children with severe 
infections were excluded from all five trials. In addition, some trials also excluded those with 
invasive,51 bloody50,57or a previous episode54 of diarrhoea. Other reasons for exclusion included 
having chronic underlying disease,55 receipt of i.v. fluids50 or antibiotics,54,55 convulsions,51 being 
exclusively breastfed54,55 or having signs of kwashiorkor.54
Only two trials specified their primary outcomes. Alam and colleagues57 specified stool output, 
whereas Alam and colleagues50 specified the proportion of children developing overhydration 
and with correction of basal hypokalaemia. The other three trials did not specifically report what 
their primary outcomes were, but the main outcomes presented were similar and included weight 
gain, duration and volume of diarrhoea, ORS intake and electrolyte concentrations in addition 
to fluid54,57 or energy intake,51 time to recovery,51,54,55,57 urine output51,57 and requirement for i.v. 
fluids.51,57 None of the trials reported W/H or W/A z-scores. Further details on all the outcomes 
reported in the trials can be seen in the data extractions in Appendix 9.
Study details and target population Intervention Comparator
Dutta et al. 200055
Design: double-blind RCT
Location: India
Length of follow-up: treatment until diarrhoea 
ceased or up to day 5; 30-day follow-up
No. enrolled: 80
Target population: male children aged 
3–24 months with acute watery diarrhoea for 
≤ 72 hours, clinical signs and symptoms of 
‘some’ dehydration, and W/A < 80% Harvard 
standard
Elemental zinc 40 mg/day, (as syrup of zinc 
sulphate, 177 mg/day) administered in three 
divided doses + standard ORS
Placebo syrup + standard ORS
Mean age ± SD: 10.4 ± 5.4 months
Sex F : M, %: 0 : 100
W/H: NR
Mean MUAC ± SD: 10.3 ± 1.3
W/A < 70% expected, n (%): 38 (87)
Mean duration of diarrhoea ± SD: 
33.4 ± 11.5 hours
Mean frequency of diarrhoea ± SD: 13.8 ± 3.8 
per 24 hours
Dehydration status of ‘some’, %: 100
Mean age ± SD: 11.0 ± 4.9 months
Sex F : M, %: 0 : 100
W/H: NR
Mean MUAC ± SD: 10.5 ± 1.0
W/A < 70% expected, n (%): 30 (83)
Mean duration of diarrhoea ± SD: 
38.3 ± 10.3 hours
Mean frequency of diarrhoea ± SD: 
13.3 ± 3.9 per 24 hours
Dehydration status of ‘some’, %: 100
Dutta et al. 200154
Design: double-blind RCT
Location: India
Length of follow-up: until diarrhoea ceased or 
for up to 5 days
No. enrolled: 64
Target population: male children aged 
6–48 months with SAM (< 60% of Harvard 
standard W/A without oedema), marasmic, 
history of watery diarrhoea for ≤ 72 hours 
and clinical signs and symptoms of ‘some’ 
dehydration
Hypo-osmolar ORS Standard WHO/UNICEF-ORS
Mean age ± SD: 17.3 ± 9.7 months
Sex F : M, %: 0 : 100
W/H: NR
MUAC: NR
W/A < 60% expected, n (%): 30 (94)
Mean duration of diarrhoea ± SD: 
21.3 ± 8.2 days
Mean frequency of diarrhoea ± SD: 15 ± 3 
stools/day
Dehydration status of ‘some’, %: 100
Mean age ± SD: 22.5 ± 15.6 months
Sex F : M, %: 0 : 100
W/H: NR
MUAC: NR
W/A < 60% expected, n (%): 31 (97)
Mean duration of diarrhoea ± SD: 
22 ± 8.0 days
Mean frequency of diarrhoea ± SD: 13 ± 4 
stools/day
Dehydration status of ‘some’, %: 100
NR, not reported.
a  Percentage calculated by the reviewer.
b  Possible error reported in paper.
TABLE 15  Characteristics of the included studies of children with acute diarrhoea (continued)30 Assessment of clinical effectiveness
Summary of quality assessment
The methodological quality and the quality of reporting of the five included trials did not 
vary greatly. Two trials50,51 were rated strong overall, with the other three trials being rated 
moderate54,55,57 (Table 16).
Selection bias varied between the studies, with three trials50,54,55 being at potential risk of selection 
bias. For all of these trials, it was unclear what proportion of selected individuals agreed to 
participate in the trials before they were randomised. In addition, the included children in both 
trials by Dutta and colleagues54,55 were considered to be only somewhat likely to be representative 
of the target population, leading to a higher risk of selection bias. Conversely, the study design 
of all five trials was strong, with all being RCTs and using an adequate method to generate 
random allocations. Hence, trial arms within all the studies were balanced with respect to 
baseline characteristics and confounders, leading to a strong rating. All but one57 trial employed 
a double-blind method, reporting that the interventions looked identical to participants. Alam 
and colleagues57 reported that treatments could not be blinded to those involved in the study 
because of visible differences in the three ORS solutions. Furthermore, neither study by Alam 
and colleagues51,57 reported sufficient details on the blinding of outcome assessors and they were 
therefore rated as moderate51 and weak57 as this could lead to detection bias. For data collection 
methods, all five trials were rated as moderate as they included valid data collection tools, but it 
was not possible to judge if these tools were reliable.
Sources of attrition bias in clinical trials include losses of participants to follow-up, unequal 
dropout rates between interventions, selective reporting of outcomes (missing outcomes) and 
failure to explain why participants are missing (e.g. whether or not they are missing at random). 
All five trials were rated as strong for withdrawals and dropouts, though they varied in their level 
of reporting. One trial50 provided both the number and reasons for any losses and had 80–100% 
of participants completing the study, indicating a low risk of attrition bias. Three trials51,54,57 either 
did not report any information on dropouts or only reported numbers (without reasons), but 
had most or all the participants completing the study. Consequently, these were rated as strong 
as the outcomes can be considered to be reasonably reliable and reflect the study population. In 
the trial by Dutta and colleagues,55 two contrasting ratings were allocated because all participants 
completed the acute phase of the study up to the point of recovery (rated strong), but over half 
the participants were not included in the 30-day follow-up assessments and neither the number 
nor reasons for the dropouts were reported by the authors (rated weak). The intervention 
integrity of all five trials was strong, as all the participants were deemed likely to have received 
their allocated intervention without any cross-contamination. All five trials used appropriate 
statistical methods in their analysis, although two51,57 did not perform an ITT analysis. For Alam 
and colleagues,51 this was presumably because the children with SAM were only a subgroup of the 
total study population. It should be pointed out that all five studies excluded children with severe 
infections, and as this is not uncommon in hospitalised children with SAM (Professor Kathryn 
Maitland, Imperial College, London, 2011, personal communication), the results of the studies 
may not be generalisable to most children with SAM and acute diarrhoea.
Assessment of effectiveness: acute diarrhoea
Mortality
The two studies by Alam and colleagues50,57 were the only trials to report mortality, with no 
deaths in any treatment group (Table 17). The other trials did not report this outcome, although 
in the third Alam and colleagues trial51 it is assumed there were no deaths as the children who 
were not discharged (after having recovered) were accounted for as dropouts. In both trials by 
Dutta and colleagues,54,55 it remains unclear whether the few children who did not recover within 
the 5 days of hospitalisation were lost to follow-up or died as no details were reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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:32 Assessment of clinical effectiveness
Weight gain
Most of the trials51,54,55,57 reported weight gain as an outcome measure, with two finding 
significant differences between treatment groups (Table 18). Dutta and colleagues54 found that 
children receiving the standard WHO/UNICEF-ORS had at discharge gained significantly more 
weight (p = 0.001) than those receiving the H-ORS (or on day 5 if they did not recover during this 
period). However, in the Alam and colleagues trial51 weight gain was similar in the H-ORS and 
WHO-ORS treatment groups. Alam and colleagues57 reported that children receiving the rice-
ORS had significantly greater weight gain at 72 hours than those receiving either of the glucose-
ORS treatments (p = 0.05). There was no statistically significant benefit on weight gain from a 
zinc supplement compared with placebo either at the time of recovery or at 30 days follow-up in 
the trial by Dutta and colleagues.55 Alam and colleagues50 did not provide any numerical data on 
weight gain, but stated that weight gain before discharge was similar between the groups.
Duration of diarrhoea
The length of time that diarrhoea persisted in treated children was reported in four51,54,55,57 of 
the five trials and can be seen in Table 19. The two trials51,54 evaluating a hypo-osmolar-ORS 
found similar results. The duration of diarrhoea was statistically significantly shorter in children 
who received the H-ORS than in those who received the standard WHO/UNICEF-ORS (41.5 
vs 66.4 hours, respectively; p = 0.001).54 In the Alam and colleagues trial,51 the duration of 
diarrhoea was reported separately for a rehydration phase and maintenance phase (as well 
as overall duration), though the timescale for these phases was not defined. The difference 
between treatment groups followed the same pattern and was statistically significant during 
the maintenance phase in favour of H-ORS (95% CI 0.46 to 0.88; p = 0.007), but was no longer 
significant when the phases were combined as overall duration. Supplementation with zinc 
was favourable compared with placebo with a mean difference in duration of diarrhoea of 
approximately 30 hours (p = 0.0001),55 whereas in another study,57 although the median duration 
of diarrhoea was lower in the rice-ORS group than in the glucose-ORS or glucose-ORS + ARS 
groups, this did not reach statistical significance.
Frequency of diarrhoea
The frequency of diarrhoea was reported by three trials,51,54,57 although differences in the way this 
outcome was reported make direct comparisons between trials difficult. Alam and colleagues51 
reported the number of stools in a 4-hour period, whereas the other two trials54,57 reported 
stool output (g/kg and ml/kg, respectively) in several 24-hour periods and also at recovery54 
(Table 20). Despite differences in the reporting, for both studies evaluating H-ORS,51,54 the mean 
frequency of stool output was significantly less in the children receiving H-ORS than in those 
receiving standard WHO-ORS at all time points. For the third trial, by Alam and colleagues,57 the 
cumulative mean stool output of children receiving rice-ORS was statistically significantly lower 
than among children receiving glucose-ORS at 24 hours (32% mean reduction, 95% CI 44% to 
174%; p = 0.004), and this statistical difference was maintained at 48 and 72 hours. Compared 
with the study by Dutta and colleagues,54 data for stool output per kg of body weight were 
markedly higher in the trial by Alam and colleagues,57 but the reason for this is unclear.
TABLE 17  Mortality in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200350 ReSoMal (n = 65) WHO-ORS (n = 65)
Deaths, n 0 0 NR
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Deaths, n 0 0 0 NR
NR, not reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Recovery
Two54,55 of the five trials specifically reported recovery (proportion of children who recovered 
within 5 days) as an outcome (Table 21), with one of these54 also reporting median survival 
time to recovery. Recovery was defined as the passage of a normal stool or no stool for the last 
18 hours,55 or was assumed to be when diarrhoea had ceased (two formed stools passed or no 
stool for 12 hours).54 A further two trials50,57 reported outcomes that inferred recovery in the 
children. Alam and colleagues57 reported the time taken to attain an oedema-free W/L of 80% of 
the NCHS median, whereas Alam and colleagues50 reported the number of children who were 
adequately rehydrated at 12 hours.
Dutta and colleagues55 found a small but significant (p = 0.04) difference between treatment 
groups with all children supplemented with zinc recovering within 5 days of hospitalisation, 
TABLE 18  Weight gain in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200051 H-ORS (n = 41) WHO-ORS (n = 40)
Mean percentage weight gain ± SDa 4.54 ± 1.79 4.45 ± 2.18 NS
Dutta et al. 200154 H-ORS (n = 32) WHO/UNICEF-ORS (n = 32)
Mean percentage weight gain ± SDb  4.3 ± 1.2 5.4 ± 1.3 0.001
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Mean percentage weight gain at 72 hours 11 9.7 13 0.05
Dutta et al. 200055 Zinc + ORS (n = 44) Placebo + ORS (n = 36) 
Mean percentage weight gain ± SDb 3.9 ± 4.1 3.2 ± 2.9 0.41
Mean percentage weight gain ± SD on 30th dayc 2.6 ± 3.3 (n = 18) 2.9 ± 3.7 (n = 16) 0.88
NS, not statistically significant.
a  Time point unclear.
b  At discharge/recovery or on day 5 if not recovered.
c  Per cent of recovery weight.
TABLE 19  Duration of diarrhoea in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200051 H-ORS (n = 41) WHO-ORS (n = 40)
Mean duration of diarrhoea ± SD, hours
Rehydration phase 10.95 ± 2.23 11.72 ± 2.26 NS
Maintenance phasea 10.45 ± 2.09 16.36 ± 2.01 0.007 (95% CI 
0.46 to 0.88)
Overall 24.35 ± 1.57 30.12 ± 1.69 NS
Dutta et al. 200154 H-ORS (n = 32) WHO/UNICEF-ORS (n = 32)
Mean duration of diarrhoea ± SD, hours 41.5 ± 25.1 66.4 ± 32.3 0.001
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Median duration of diarrhoea (95% CI), 
hours
72 (62 to 82) 60 (50 to 70) 54 (44 to 54) 0.530
Dutta et al. 200055 Zinc + ORS (n = 44) Placebo + ORS (n = 36) 
Mean duration of diarrhoea ± SD, hours 70.4 ± 10.0 103.4 ± 17.1 0.0001
NS, not statistically significant.
a  n = 22 H-ORS, n = 19 WHO-ORS.34 Assessment of clinical effectiveness
TABLE 20  Frequency of diarrhoea in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200051 H-ORS (n = 41) WHO-ORS (n = 40)
Mean frequency of diarrhoea ± SD, stools/4 hours
  Rehydration phase 4.27 ± 2.029 5.86 ± 1.73 0.32a (95% CI 0.55 to 0.97)
  Maintenance phaseb 1.72 ± 1.92 2.45 ± 2.17 0.035 (95% CI 0.51 to 0.97)
 Overall 3.39 ± 1.80 4.70 ± 1.68 0.011 (95% CI 0.56 to 0.93)
Dutta et al. 200154 H-ORS (n = 32) WHO/UNICEF-ORS (n = 32)
Mean frequency of stool output ± SD, g/kg
  0–24 hours 73.4 ± 23.1 105.9 ± 44.6 0.001
  24–48 hours 34.9 ± 13.5 87.5 ± 66.5 0.001
  48–72 hours 28.4 ± 18.0 90.4 ± 67.7 0.01
  At recovery 52.3 ± 21.3 96.6 ± 42.8 0.0001
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Stool output, ml/kgc,d
  At 24 hours 355 309 236 0.004, difference 109 (95% CI 
44 to 174), 32% reductione
  At 48 hours 600 518 382 0.007, difference 213 (95% CI 
79 to 346), 37% reductione
  At 72 hours  735 645 475 0.018, difference 242 (95% CI 
73 to 412), 36% reductione
a  Reported as p = 0.32, but as this is not significant it is assumed to be an error and should probably read p = 0.032.
b  n = 22 H-ORS, n = 19 WHO-ORS.
c Alam  et al.57 state that 1 g is considered equivalent to 1 ml.
d  Data estimated by reviewer from bar charts.
e  Rice-ORS vs glucose-ORS group.
TABLE 21  Recovery in children with acute diarrhoea
Study Treatment arms p-value
Dutta et al. 200055 Zinc + ORS (n = 44) Placebo + ORS (n = 36) 
Recovered within 5 days, n (%) 44 (100) 32 (89) 0.04
Dutta et al. 200154 H-ORS (n = 32) WHO/UNICEF-ORS (n = 32)
Recovered within 5 days, n (%) 32 (100) 29 (91) > 0.05
Median survival time to recovery, 
hours
36 53 0.001
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Mean days to attain 80% of 
median W/L ± SD
7.14 ± 2.26 7.12 ± 2.2 7.2 ± 3.78 0.99
Alam et al. 200350 ReSoMal (n = 65) WHO-ORS (n = 65)
Adequately rehydrated at 
12 hours, n/N (%)
45/59 (76) 51/63 (81) 0.68; OR 0.16 
(95% CI 0.29 to 1.96) 
compared with 89% of children receiving placebo. Dutta and colleagues54 also reported a high 
recovery rate, with all but three children (all in WHO-ORS group) having recovered within 
5 days of treatment, but the difference between treatment groups was not significant. However, 
children treated with H-ORS recovered significantly quicker than those treated with the WHO-
ORS (36 vs 53 hours, respectively; p = 0.001).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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In the Alam and colleagues57 trial, it took around 7 days for children to attain an oedema-free 
W/L of 80%, being similar regardless of the type of ORS (p = 0.99).
In the Alam and colleagues trial,50 most of the children in both treatment arms were adequately 
rehydrated at 12 hours, with no statistically significant differences between groups.
Consumption of oral rehydration solution
Most of the trials51,54,55,57 measured how much ORS was consumed by the children, either as the 
total amount consumed (litres)51,55 or as ml/kg of body weight54,57 (Table 22). In two trials,51,54 
children receiving H-ORS needed to consume less rehydration solution than those receiving 
the standard WHO-ORS, although this reached statistical significance in only one of the 
trials (p = 0.0001).54 The other two studies also found significant differences in favour of the 
intervention groups. Dutta and colleagues55 reported a lower ORS consumption in children 
supplemented with zinc than in those supplemented with placebo (p = 0.0001). Alam and 
colleagues57 found that children receiving rice-ORS had a significantly lower ORS intake at 
18 hours compared with those receiving glucose-ORS (see Appendix 9). This difference was 
maintained at each 6-hourly interval thereafter until 72 hours, when there was a 38% reduction 
in intake (p = 0.012).
Adverse effects
Adverse effects were not reported in any detail by the included studies. Two trials51,55 did not 
report any safety issues, whereas two trials54,57 reported that no children developed symptoms 
of overhydration. Alam and colleagues50 report that prevention of overhydration is the primary 
theoretical advantage of ReSoMal. Overhydration was defined as a weight gain > 5% after 
correction of dehydration at any time during the study period with any of the following signs: 
periorbital oedema/puffy face, increased heart rate (> 160/minute) or increased respiration 
TABLE 22  Consumption of ORS in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200051 H-ORS (n = 41) WHO-ORS (n = 40)
Mean ORS consumed ± SD, l
  Rehydration phase 1.45 ± 0.002 1.55 ± 0.002 NS
  Maintenance phasea 0.69 ± 0.005 0.74 ± 0.01 NS
 Overall 2.74 ± 0.0017 3.32 ± 0.0017 NS
Dutta et al. 200154 H-ORS (n = 32) WHO/UNICEF-ORS (n = 32)
Mean ORS intake ± SD, ml/kg
  0–24 hours 109.7 ± 32.2 184.5 ± 53.7 0.0001
  24–48 hours 73.4 ± 22.7 151.2 ± 81.3 0.0001
  48–72 hours 54.9 ± 28.3 151.5 ± 65.0 0.001
Mean ORS intake at recovery ± SD, 
g/kg/day
111.5 ± 39.4 168.9 ± 52.4 0.0001
Alam et al. 200957 Glucose-ORS (n = 58) Glucose-ORS + ARS (n = 59) Rice-ORS (n = 58)
Mean ORS intake at 72 hours,b ml/kg 710 620 450 0.012, 38% 
reductionc
Dutta et al. 200055 Zinc + ORS (n = 44) Placebo + ORS (n = 36) 
Mean ORS consumed ± SD, l 2.5 ± 1.0 3.6 ± 0.8 0.0001
NS, not statistically significant.
a n = 22 H-ORS, n = 19 WHO-ORS.
b Data estimated by reviewer from bar charts.
c Rice-ORS vs glucose-ORS.36 Assessment of clinical effectiveness
(> 60/minute). Although there appeared to be a lower occurrence of over-rehydration in those 
children who received ReSoMal than in those receiving WHO-ORS, numbers were small and this 
was not supported statistically (Table 23). Alam and colleagues50 also looked in detail at serum 
electrolytes and, thus, the incidence of hypo- and hyperkalaemia and hypo- and hypernatraemia 
(these outcomes have not been reported here as they are not main outcomes of interest to this 
review, but data are available in Appendix 9). However, it is worth noting that three children in 
the ReSoMal group developed severe hyponatraemia (low serum sodium) by 24 hours, with one 
child having a resulting convulsion, which the authors highlight as a safety concern that may 
limit the use of ReSoMal in its current formulation.
Other outcomes
Additional outcomes, such as caloric or fluid (water, milk) intake, other fluid losses (e.g. urine, 
vomit) and correction of hypokalaemia, were also reported by some studies, but have not been 
presented here. Further details are available in the data extraction forms in Appendix 9.
Summary
  ■ Five trials evaluated the treatment of children with acute diarrhoea with various types of 
ORS, including a H-ORS,51,54 a modified WHO-ORS (ReSoMal),50 an ORS containing either 
glucose, glucose plus ARS or rice powder,57 and supplementation with zinc.55 The trials were 
all of strong or moderate methodological quality.
  ■ There were no deaths in the two trials that reported mortality,50,57 and it is assumed that 
there were no deaths in a third trial,51 as all children who did not recover were accounted for 
as dropouts.
  ■ Compared with the standard WHO-ORS, children receiving the H-ORS had a significantly 
shorter duration and lower frequency of diarrhoea, consumed less ORS and had a quicker 
time to recovery (one trial54).
  ■ There appeared to be no benefit from H-ORS with respect to weight gain compared with 
WHO-ORS.
  ■ Supplementation with 40 mg elemental zinc (as zinc syrup) in addition to a standard WHO-
ORS resulted in a significantly shorter duration of diarrhoea, a better recovery rate and a 
lower ORS intake, but no difference compared with placebo in terms of weight gain.55
  ■ Rice-ORS appeared to be more favourable than glucose-ORS in treating children with 
cholera diarrhoea. The rice-ORS groups had significantly better weight gain, a lower 
frequency and duration of diarrhoea and consumed less ORS.57
  ■ ReSoMal did not appear to show any advantage over a standard WHO-ORS in rehydrating 
severely malnourished children with acute diarrhoea, although it was beneficial in correcting 
potassium depletion.
  ■ Adverse effects were not generally reported by the trials, although ReSoMal50 may result in 
symptomatic severe hyponatraemia and seizures in some patients.
Quantity and quality of research available: persistent diarrhoea
Three included trials, reported in four publications,52,53,56,58 pertained to children with persistent 
diarrhoea. Persistent diarrhoea was defined as diarrhoea lasting ≥ 14 days (Table 24).
TABLE 23  Adverse effects in children with acute diarrhoea
Study Treatment arms p-value
Alam et al. 200350 ReSoMal (n = 65) WHO-ORS (n = 65)
Overhydration, n/N (%) 3/65 (5) 8/65 (12) 0.20; OR 0.3 (95% CI 0.1 to 1.5)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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TABLE 24  Characteristics of the included studies of children with persistent diarrhoea
Study details and target 
population Intervention Comparator
Amadi et al. 2005,52 Amadi 200258
Design: RCT
Location: Zambia
Length of follow-up: 4 weeks
No. enrolled: 200
Target population: children aged 
6–24 months with malnutrition and 
persistent diarrhoea (≥ 14 days 
duration) meeting the Wellcome 
classification for malnutrition (W/A 
and H/A)
54% of the population are HIV+ve
Neocate amino acid-based elemental infant 
formula (and components of the WHO guidelines 
for management of persistent diarrhoea and 
malnutrition)
Skimmed milk diet, followed by soy-based porridge 
from week 2 (plus components of the WHO 
guidelines for management of persistent diarrhoea 
and malnutrition)
Selected baseline characteristics
Mean age (range): 17 (14–20) months
Sex F : M, %: 51 : 49
W/H: NR
Median MUAC (IQR): 11 (10–12.2) cm
Median W/A z-score (IQR): −4.0 (−4.6 to −3.4)
Duration of diarrhoea: ≥ 14 days
Frequency of diarrhoea: NR
Degree dehydration: NR
Selected baseline characteristics
Mean age (range): 18 (13–22) months
Sex F : M, %: 55 : 45
W/H: NR
Median MUAC (IQR): 11 (10–12) cm
Median W/A z-score (IQR): −4.1 (−4.8 to −3.6)
Duration of diarrhoea: ≥ 14 days
Frequency of diarrhoea: NR
Degree dehydration: NR
Bhutta et al. 199453
Design: RCT
Location: Pakistan
Length of follow-up: presumed to be 
14 days
No. enrolled: 51
Target population: male children 
aged 6–36 months with persistent 
diarrhoea (≥ 2 weeks) and with 
severe PEM, i.e. W/A ≤ 80th centile 
of the median NCHS standard (i.e. 
Gómez grade II and III malnutrition)
Full-strength soy formulation (given orally or by 
nasogastric tube if necessary)
Half-strength buffalo milk with KY (given orally or 
by nasogastric tube if necessary)
Selected baseline characteristics
Mean age ± SD: 16 ± 8.6 months
Sex F : M, %: 0 : 100a
Mean % expected W/L ± SD: 88.4 ± 4.3
Mean MUACb ± SD: 9.9 ± 1.3 cm
Mean W/A z-score ± SD: −4.41 ± 0.6
Mean duration of diarrhoea ± SD: 75.0 ± 77.0 days
Mean frequency of diarrhoea ± SD: 
8.2 ± 2.7 stools/day
Degree dehydration: NR
Selected baseline characteristics
Mean age ± SD: 13.8 ± 5.8 months
Sex F : M, %: 0 : 100a
Mean % expected W/L ± SD: 89.5 ± 4.3
Mean MUACb ± SD: 10.6 ± 1.7 cm
Mean W/A z-score ± SD: −3.91 ± 0.9
Mean duration of diarrhoea ± SD: 
150.0 ± 117.0 days
Mean frequency of diarrhoea ± SD: 8.1 ± 2.7 
stools/day
Degree dehydration: NR
Nurko et al. 199756
Design: RCT
Location: Mexico
Length of follow-up: until full 
concentration of diet achieved 
(9 days if no intolerance) plus an 
additional 7 days
No. enrolled: 60 (56 randomised)
Target population: children aged 
3–36 months with third-degree 
malnutrition of the marasmic type 
defined by the Gómez criteria (W/A 
< 60% of the NCHS 50th percentile) 
and persistent diarrhoea (≥ 3 loose 
stools for ≥ 14 days)
Intervention 1: local chicken-
based diet
Intervention 2: soy-based diet 
(Nursoy) (both in gradually 
increasing amounts)
Elemental diet: standard Vivonex (in 
gradually increasing amounts)
Selected baseline 
characteristics
Mean age ± SD: 6.7 ± 3.7 months
Sex F : M, %: 47 : 53a
W/H: NR
MUAC: NR
Mean % expected W/A ± SD: 
50.8 ± 7.4
Mean W/A z-score ± SD: 
−4.2 ± 1.0
Mean duration of diarrhoea ± SD: 
36.6 ± 3.9 days
Frequency of diarrhoea 
output first 24 hours ± SD: 
41.6 ± 12.1 ml/kg/day
Dehydration status of severe, n 
(%): 4 (21.1)
Selected baseline 
characteristics
Mean age ± SD: 
5.6 ± 4.0 months
Sex F : M, %: 42 : 58a
W/H: NR
MUAC: NR
Mean % expected W/A ± SD: 
51.0 ± 7.5
Mean W/A z-score ± SD: 
−3.9 ± 0.7
Mean duration of 
diarrhoea ± SD: 
48.7 ± 5.1 days
Frequency of diarrhoea 
output first 24 hours ± SD: 
45.8 ± 13.6 ml/kg/day
Dehydration status of severe, 
n (%): 5 (26.3)
Selected baseline characteristics
Mean age ± SD: 6.9 ± 5.3 months
Sex F : M, %: 50 : 50a
W/H: NR
MUAC: NR
Mean % expected W/A ± SD: 
52.9 ± 7.5
Mean W/A z-score ± SD: 
−4.0 ± 1.0
Mean duration of diarrhoea ± SD: 
41.8 ± 4.0 days
Frequency of diarrhoea 
output first 24 hours ± SD: 
52.3 ± 19.6 ml/kg/day
Dehydration status of severe, n (%): 
6 (33.3)
NR, not reported.
a  Percentage calculated by the reviewer.
b  Measure described as mid-arm circumference and presumed to be MUAC.38 Assessment of clinical effectiveness
All three trials were single-centre RCTs, of which one was a single-blind52,58 and one a double-
blind trial.56 The third trial provided no details about blinding.53 The trials were set in Mexico,56 
Pakistan53 and Zambia,52,58 and all received external funding. One trial was funded by a grant 
from a commercial organisation, with one of the authors also receiving support from a global 
charity.52,58 Of the two remaining trials, one was part-funded56 and one fully-funded53 by a US 
academic institution, by means of a cooperative agreement with a US Government department. 
The part-funded trial received a further grant from another US Government department.56
All three trials evaluated varying diets, including soy as either an intervention53,56 or as a 
comparator (milk followed by a soy porridge).52,58 Bhutta and colleagues53 evaluated a full-
strength soy diet against a half-strength buffalo milk diet with khitchri (rice-lentils) and yoghurt 
(KY), with diets given in gradually increasing amounts over 14 days. The trial by Nurko and 
colleagues56 compared three intervention strategies – a local chicken-based diet, a soy-based 
(Nursoy®; Wyeth Laboratories, Philadelphia, PA, USA) diet and an elemental diet (Vivonex® 
standard; Norwich Eaton Ltd, Surrey, UK) – all provided at gradually increasing concentrations 
by nasogastric tube for around 16 days if the diet was tolerated. The third trial by Amadi and 
colleagues,52,58 compared an amino acid-based infant formula (Neocate®, SHS International Ltd, 
Liverpool, UK), without cow’s milk, soy and cereal antigen, with a standard skimmed milk diet 
(followed by soy-based porridge from week 2) for 4 weeks. One of the trials followed the WHO 
guidelines for the treatment of persistent diarrhoea and malnutrition52,58 and one the WHO/
UNICEF guidelines for hydration (standard glucose–electrolyte i.v. solution).56 In addition, 
two of the trials provided antibiotic treatment as needed52,56,58 and one provided micronutrient 
supplements.52,58
All trials took place in the hospital inpatient setting. Sample sizes were small for two of the trials, 
5153 and 5656 children, whereas the third RCT included 200 children.52,58 The age of children 
included ranged from 3 to 36 months. Two of the trials had fairly similar ratios of boys and girls 
in their trial arms,52,56,58 whereas the remaining trial consisted of boys only (to facilitate separate 
quantitative collections of urine and faeces).53
Definitions for SAM varied, with Amadi and colleagues52,58 using the Wellcome classification 
for severe malnutrition (W/A and H/A). The remaining two trials used the NCHS growth 
reference, with W/A ≤ 80th centile of the median NCHS standard (i.e. Gómez grades II and 
III malnutrition) described as severe PEM,53 and W/A < 60% of the NCHS 50th percentile for 
W/A described as third-degree malnutrition of the marasmic type by the Gómez criteria.56 One 
trial reported W/Ls at baseline.53 W/A z-scores were similar across the three trials, ranging 
from −3.953,56 to −4.41.53 All three trials excluded exclusively breastfed children.52,53,56,58 Other 
exclusion criteria were chronic illnesses,56 neurological or serious systemic disorders52,58 and 
children with kwashiorkor and the presence of intercurrent infections.53 The children in the 
Amadi and colleagues52,58 trial had a high prevalence of intestinal infection, and around half were 
HIV+ve. In the trial by Nurko and colleagues,56 64% of the sample had associated conditions (e.g. 
pneumonia, sepsis, infections) on admission.
There were large differences in the baseline duration of diarrhoea between the trials, reported as 
around 36.6–48.7 days in one trial,56 an average of 75–150 days in another trial,53 but as ≥ 14 days 
in the remaining trial.52,58
Trials assessed outcomes of weight gain and some measures of diarrhoea, but only one trial 
specified these as primary outcomes in addition to mortality.52,58 Other outcomes included 
treatment success/failure, nutritional recovery and nitrogen balance,56 as well as developmental 
milestones achieved, activity and play, and laboratory indicators of severity of illness.52,58 For 
further details on reported outcome measures see Appendix 9.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Summary of quality assessment
Two of the included trials were rated overall as ‘weak’ for their methodological quality and 
quality of reporting (Table 25),52,53,58 with the third being rated overall as ‘strong’.56
Trials were rated as moderate,52,58 weak53 or strong56 for selection bias. A moderate rating 
indicates that the selected individuals are at least somewhat likely to be representative of the 
target population and at least 60% of selected individuals participated in the trial. A weak rating 
indicates that participants may not be representative of the target population, or that the selection 
method and/or levels of participation were not described. The two trials with moderate and weak 
ratings were at potential risk of selection bias.52,53,58 All three trials were rated as strong for their 
study design (RCTs).
There were no important differences in baseline characteristics between the trial arms, and 
without potentially confounding variables all three trials were rated as strong. For blinding, 
only one trial employed a double-blind method and was therefore rated as strong.56 Of the other 
two trials, both were rated as weak, with one employing a single-blind method52,58 and the other 
reporting no details.53 It is recognised that blinding of children is not always possible because of 
the nature of the intervention. This could lead to bias in either the care provided (performance 
bias) or how the outcomes were assessed (measurement or detection bias), or both. Not blinding 
children/parents to the research question could lead to reporting bias. Although it may be 
problematic in some circumstances to blind children/parents to the intervention, the potential 
bias it can introduce needs to be kept in mind when interpreting the results.
For data collection methods, two trials were rated as moderate.53,56 Although both trials included 
valid data collection tools, it was not possible to judge if these tools were reliably employed. The 
remaining trial was rated as weak, as it was not possible to assess if the data collection tools were 
either valid or shown to be reliable.52,58 One trial52,58 provided both numbers and reasons for 
withdrawals and dropouts, and with a follow-up rate of ≥ 80% received a strong rating. Of the 
remaining two trials,53,56 both had lower follow-up rates (60–79%) and one provided inadequate 
information by giving reasons for withdrawal, but not numbers for each group.53 There was 
a possible risk of attrition bias in both these trials and they both received an overall rating of 
moderate for withdrawals and dropouts. For the section of the tool capturing intervention 
integrity, two trials52,56,58 reported that > 80% of the participants received the intervention, and in 
the third53 60–79% received the intervention. The consistency of the intervention was measured 
by all three trials, using weight gain as the measure, and there appeared to be no contamination 
of the interventions (i.e. all children received the allocated diet only). All trials used patients as 
the unit of allocation and analysis for statistical analysis of the results, and were judged to use 
appropriate methods of statistical analysis for the research question. Two of the trials did not 
perform an ITT analysis,52,56,58 and it was not possible to determine how missing data were dealt 
with in the analysis in the third trial.53
Assessment of effectiveness: persistent diarrhoea
Mortality
Only Amadi and colleagues52,58 reported mortality as an outcome (Table 26). Although mortality 
was highest in the Neocate group (22/100), the difference was not statistically significant (see 
Table 26). The highest number of deaths for the combined treatment groups (43%) occurred 
in the second treatment week (week 1 = 31%, week 3 = 26% and week 4 = 10%). Irrespective of 
treatment arm, death was more likely to occur in children with marasmic kwashiorkor (34.9%; 
p = 0.004), or cryptosporidiosis (no data reported) and in children identified as HIV+ve (24% 
compared with 11% of HIV–ve children; p = 0.04). Although mortality was not formally identified 
as an outcome in the trial by Nurko and colleagues,56 the authors reported that five children 
died during the trial and how many deaths occurred in each group (see Table 26). However, the 40 Assessment of clinical effectiveness
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causes of death, intestinal pneumatosis (n = 2), central line-associated sepsis (n = 2) or bacterial 
sepsis (n = 1), were reported only for the whole trial population and not by group. Bhutta and 
colleagues53 also did not specify mortality as an outcome; however, it can be assumed that there 
were no deaths, because all children either completed the treatment or were accounted for 
as dropouts.
Weight gain
Measures of weight gain were employed by all three trials; however, only one trial reported 
weight gain relative to initial weight (the benefit of relative weight gain measures is that any 
effects because of starting differences in body weight are removed). In the trial by Amadi and 
colleagues,52,58 feeding with Neocate was associated with a 41% better gain in weight from nadir 
compared with the skimmed milk/soy-based diet, and the difference was statistically significant 
(p = 0.002) (Table 27). In the trial by Bhutta and colleagues,53 weight gain was higher for the 
intervention diet of soy than for KY milk, but reached statistical significance only at the end of 
treatment (i.e. week 2; p < 0.02). Conversely, mean daily weight gain was higher in the KY milk 
group, but the difference between groups was not statistically significant. It should be noted that 
there was also a reported weight loss in two children in the soy group (10%) and seven (37%) in 
the KY milk group (p = not statistically significant). Nurko and colleagues56 reported statistically 
significant weight gains for all three diets used in their trial for their comparison of weight change 
from admission versus at the end of the protocol and from admission versus discharge. However, 
no statistically significant differences between the three treatment arms were reported.
Anthropometry
Two of the studies reported anthropometry outcomes as well as weight gain. Amadi and 
colleagues52,58 reported that increases in z-scores of W/A and W/H were statistically significantly 
higher from admission (W/A, p = 0.018; W/H, p < 0.001) and from nadir (W/A, p = 0.002; 
W/H, p < 0.001) for the Neocate group, with results mirrored in HIV+ve (W/A, p = 0.007; W/H, 
p < 0.001) and HIV–ve (W/A, p = 0.01; W/H, p = 0.009) subgroups (Table 28). In the trial by 
Bhutta and colleagues,53 increases in W/A z-score during the study were significantly greater 
in the soy group (p < 0.001) than in the KY milk group (p = not statistically significant), but no 
statistical comparison between the groups was reported. Bhutta and colleagues53 did report a 
statistical comparison between the groups for improvement in mid-arm circumference, which 
was significantly higher in the soy intervention group (1.0 cm vs 0.1 cm; p < 0.001).
Diarrhoea
Diarrhoea output was quantified either by collecting urine separately from stools (using adhesive 
urine bags and pre-weighed nappies/diapers)53 or by the use of metabolic beds/cots for separation 
of stool from urine.56 There were no statistically significant differences in any of the measures of 
diarrhoea between treatment arms in the two trials53,56 that reported these outcomes (Table 29). 
In addition, Amadi and colleagues,52,58 who presented no numerical data, stated that there were 
no differences in either stool number or frequency.
TABLE 26  Mortality in children with persistent diarrhoea
Study Treatment arms p-value
Amadi et al. 2005,52, Amadi et al. 200258 Neocate (n = 100) Standard skimmed milk/soy-based diet (n = 100)
Deaths over 4 weeks, n (%) 22 (22) 17 (17) 0.48
Nurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Death, n 2 1 2 NR
NR, not reported.42 Assessment of clinical effectiveness
TABLE 27  Weight gain in children with persistent diarrhoea
Study Treatment arms p-value
Amadi et al. 2005,52, Amadi et al. 200258 Neocate Standard skimmed milk/soy-based diet 
Median weight gain (IQR), kg n = 79 n = 78
  From admission 1.10 (0.55–1.55) 0.75 (0.2–1.3) 0.006
  From nadir 1.7 (1.2–2.0) 1.2 (0.6–1.7) 0.002
Bhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Mean weight change ± SD, g/kg/daya
  Week 1 7.1 ± 11.3 3.1 ± 12.1 NS
  Week 2 11.6 ± 10.0 4.3 ± 7.2 < 0.02
Mean weight change ± SD, g/kg/day 3.7 ± 5.9 7.9 ± 9.7 NS
Percentage (n/N) of participants who lost weight 10 (2/21) 37 (7/19) NS
Nurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Mean weight ± SD, g
  At admission 3572 ± 823 3270 ± 1167 3764 ± 1575 NR
  At end of protocol 3736 ± 870b 3495 ± 1172b  3940 ± 1599b
  At time of discharge 4133 ± 1160c 3797 ± 1128c 4225 ± 1706c
NR, not reported; NS, not statistically significant.
a  Not explicitly stated, but data presumed to be mean ± SD.
b  p < 0.05 admission vs end of protocol.
c  p < 0.05 admission vs discharge.
TABLE 28  Anthropometric outcomes in children with persistent diarrhoea
Study Treatment arms p-value
Amadi et al. 2005,52, Amadi et al. 200258 Neocate  Standard skimmed milk/soy-based diet 
Median increase in W/A z-score (IQR)a n = 79 n = 78
  From admission 0.83 (0.35–1.22) 0.43 (0–0.9) 0.018
  From nadir 1.23 (0.89–1.57) 0.87 (0.47–1.25) 0.002
Median increase in W/H z-score (IQR)a n = 79 n = 78
  From admission 1.28 (0.52–1.88) 0.56 (0–1.15) < 0.001
  From nadir 1.77 (1.30–2.26)a 1.23 (0.59–1.70) < 0.001
Median increase in z-score (IQR) from nadir in HIV+ve 
childrena
n = 38 n = 40
 W/A 1.2 (0.8–1.5) 0.70 (0.4–1.2) 0.007
 W/H 1.8 (1.1–2.3) 0.8 (0.4–1.6) < 0.001
Median increase in z-score (IQR) from nadir in HIV–ve 
childrena
n = 41 n = 38
 W/A 1.29 (0.98–1.57) 0.95 (0.5–1.45) 0.01
 W/H 1.82 (1.47–2.38) 1.43 (0.81–1.86) 0.009
Bhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Mean improvement in W/A z-score ± SDb From −4.4 ± 0.6 to 
−3.6 ± 0.6; p < 0.001
From −3.9 ± 0.9 to −3.6 ± 1.0; p = NS NR
Mean improvement in MUACc ± SD, cmb 1.0 ± 0.1 0.1 ± 0.05 < 0.001
NR, not reported; NS, not statistically significant.
a  IQR reported as 130 in paper, which is assumed to be an error and taken to be 1.30 instead.
b  Not explicitly stated, but data presumed to be mean ± SD.
c  Measure described as mid-arm circumference and presumed to be MUAC.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Oral rehydration solution intake
Only Bhutta and colleagues53 reported ORS intake, which was significantly reduced by week 2 in 
the soy intervention arm compared with the KY milk diet (p < 0.05); however, differences in time 
to recovery were not statistically significant between the two diets (Table 30).
Calorie intake
Surprisingly, Amadi and colleagues52,58 reported that intake of calories (per kg per day) as liquid 
feeds, was statistically significantly higher at all time points for the control group (p < 0.0001). 
However, it should be noted that in addition to the liquid feed based on skimmed milk, the 
control group also received soy-based porridge from the beginning of the second week. In 
contrast, Bhutta and colleagues53 found caloric intake (per kg per day) to be only significantly 
higher for the soy-based intervention arm than for the KY milk arm at the end of week 1 
(p < 0.02), and although this remained higher, it was no longer statistically significant at the 
end of week 2. Caloric intake in the trial by Nurko and colleagues56 was similar in all three 
diet groups (Table 31).
Treatment success/failure
Although clinical failure appeared to be lower in the soy-based diet arm than in the KY milk 
arm (no p-value reported), Bhutta and colleagues53 reported no statistical difference between 
TABLE 29  Diarrhoea volume and frequency in children with persistent diarrhoea
Study Treatment arms p-value
Bhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Mean stool volume ± SD, g/kg/daya
  Week 1 68.8 ± 43.1 60.9 ± 40.6 NS
  Week 2 36.2 ± 23.2 63.9 ± 61.8 NS
 Overall 58 ± 33 62 ± 49 NS
Mean stool frequency ± SD, n/daya
  Week 1 7.0 ± 3.1 6.6 ± 4.4 NS
  Week 2 4.0 ± 2.4 5.5 ± 3.8 NS
 Overall 6 ± 3 6 ± 4 NS
Nurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Diarrhoea status
  Mean total stool output/kg/day ± SD 19.1 ± 7.5 18.5 ± 6.6 18.8 ± 9.2 NS
  Mean stools/kg/day ± SD 3.2 ± 1.2 2.5 ± 0.7 3.4 ± 1.3 NR
  Mean day of cessation ± SD 6.9 ± 4.7 3.9 ± 3 8 ± 5.1 NS
NR, not reported; NS, not statistically significant.
a  Not explicitly stated, but data presumed to be mean ± SD.
TABLE 30  Oral rehydration solution intake in children with persistent diarrhoea
Study Treatment arms p-value
Bhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Mean ORS intake ± SD, ml/kg/daya
  Week 1 33.9 ± 41.0 37.9 ± 46.2 NS
  Week 2 1.7 ± 3.6 29.2 ± 58.1 < 0.05
Mean time to recovery ± SD, days 6 ± 4 5 ± 3 NS
NS, not statistically significant.
a  Not explicitly stated, but data presumed to be mean ± SD.44 Assessment of clinical effectiveness
treatment arms. Nurko and colleagues56 reported that there was no statistically significant 
differences between the three diets in terms of successful outcome (Table 32), with nutritional 
recovery and treatment failures appearing similar between the groups (p-values not reported). 
However, across the whole trial population (i.e. analysis not per treatment group), significant 
differences between treatment success and failure (p < 0.05) were associated with albumin and 
sodium concentration at admission, as well as the incidence of associated infections. Treatment 
failures were associated with formula intolerance (Table 33). Of the 15 treatment failures 
that occurred (see Table 32), 10 were successfully managed. One of the failures in the Nursoy 
group was because of allergy to the formula. The other five children who failed treatment died 
(see Table 26).
Safety outcomes
Only the study by Nurko and colleagues56 reported on safety, but there was no statistically 
significant difference in formula intolerance between the treatment arms (see Table 33). Of 
those children with formula intolerance, 15 were treatment failures (see Table 32) and four had 
intestinal pneumatosis (two of those with intestinal pneumatosis died; see Table 26).
Additional outcomes
Additional reported outcomes, such as protein ingested after full diet tolerance or time from diet 
start to failure, were reported in some studies, but have not been presented here. Further details 
can be seen in the data extraction forms in Appendix 9.
Summary
  ■ Three trials52,53,56,58 evaluated the treatment of children with persistent diarrhoea, with each 
trial comparing different diets. The overall methodological quality was rated as weak for two 
trials52,53,58 and strong for one trial.56
  ■ Although all three trials employed a hospital inpatient setting, making diet intake easier to 
control and regulate, all three trials were judged to be open to a potential risk of bias in a 
number of areas and results should therefore be treated with caution.
TABLE 31  Caloric intake in children with persistent diarrhoea
Study Treatment arms p-value
Amadi et al. 2005,52, Amadi et al. 200258 Neocate (n = 100) Standard skimmed milk/soy 
diet (n = 100)
Median (IQR)a intake, kcal/kg/day
  Week 1 116 (86–143), n = 95 167 (130–214), n = 97 < 0.0001
  Week 2 168 (135–203), n = 85 258 (210–301), n = 93 < 0.0001
  Week 3 184 (166–206), n = 75 283 (229–337), n = 85 < 0.0001
  Week 4 187 (163–210), n = 70 269 (214–305), n = 79 < 0.0001
Bhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Mean caloric intake ± SD, kcal/kg/dayb
  Week 1 140.1 ± 33.4 115.1 ± 25.1 < 0.02
  Week 2 157.1 ± 72.3 151.6 ± 32.3 NS
 Overall 154.2 ± 36.8 132.8 ± 27.6 NS
Nurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Mean number of total calories, /kg/day ± SD 
after full diet tolerated
116.0 ± 9.6 111.3 ± 9.1 115.2 ± 8.3 NS
NS, not statistically significant.
a  Not explicitly stated, but data presumed to be median (IQR).
b  Not explicitly stated, but data presumed to be mean ± SD.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
45   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
  ■ There were no significant differences in mortality rates between the diets employed in the 
two trials reporting mortality.52,56,58
  ■ None of the diets in the three included trials52,53,56,58 pertaining to children with persistent 
diarrhoea produced statistically significant improvements in measures of diarrhoea.
  ■ The majority of diets appeared to be effective in increasing weight, with two out of three trials 
reporting better results for the diet used in the intervention arm. In the trial by Amadi and 
colleagues,52,58 Neocate produced greater weight gain over a 4-week period than the standard 
skimmed milk/soy-based diet, which was reflected by increases in W/A and W/H z-scores, 
as well as weight increases in both HIV+ve and HIV–ve subgroups. The full-strength soy diet 
in the trial by Bhutta and colleagues53 also produced better weight gain over a 2-week period 
than the half-strength buffalo milk diet with rice-lentils and yoghurt given to the control 
group. This was again reflected by increases in W/A z-scores. In contrast, the three diets of 
chicken, Nursoy and Vivonex (control) employed by Nurko and colleagues56 were found to 
be equally effective for weight gain.
What methods are effective in treating infection? (Q7, rank 5 = )
The overarching question for this section included within it broader issues regarding antibiotic 
therapy (examples of these are available in Appendix 5). No study addressed the overarching 
question directly, but two studies59,60 were included that investigated different aspects of antibiotic 
therapy in children with severe malnutrition. As these addressed different questions they are 
presented in separate sections. Dubray and colleagues59 studied the relative effectiveness of 
two broad-spectrum antibiotics prescribed systematically to all participants (regardless of 
confirmation of infection) (see Quantity and quality of research available: different antibiotics 
in the inpatient setting), whereas Trehan and colleagues60 sought to determine whether or not 
including amoxicillin in the home-based treatment of uncomplicated severe malnutrition with 
RUTF led to better recovery rates than treatment with RUTF alone (see Quantity and quality of 
research available: antibiotic use in the outpatient setting).
TABLE 32  Treatment success/failure in children with persistent diarrhoea
Study Treatment arms p-value
aBhutta et al. 199453 Soy (n = 21) KY milk (n = 19)
Clinical failures, n 2 7 NR
aNurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Successful outcome, n (%) 15 (78.9) 13 (68.4) 13 (72.2) NS
Nutritional recovery, n (%) 13 (86.6) 12 (85) 10 (77) NR
Treatment failure, n 4 6 5 NR
NR, not reported; NS, not statistically significant.
a  Study definitions of treatment failure and success are recorded in the data extraction forms (see Appendix 9).
TABLE 33  Safety outcomes in children with persistent diarrhoea
Study Treatment arms p-value
Nurko et al. 199756 Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13)
Some formula intolerance, n (%) 9 (47.4) 11 (57.9) 14 (77.8) NS
Intestinal pneumatosis, n 1 1 2 NR
NR, not reported; NS, not statistically significant.46 Assessment of clinical effectiveness
Quantity and quality of research available: different antibiotics in the 
inpatient setting
This question was addressed by one RCT59 that met the inclusion criteria for this review. The 
key characteristics of this RCT are presented in Table 34, and the full data extraction form in 
Appendix 10 provides further details.
Dubray and colleagues59 conducted a randomised, unblinded superiority controlled trial to 
compare two antibiotic regimens in a therapeutic feeding centre (TFC) in Sudan. This was a 
single-centre trial funded by an international humanitarian medical aid organisation. Systemic 
broad-spectrum antibiotic therapy was provided on admission to all participants (with or 
without any signs of clinical infection), with the aim of improving the outcomes of SAM (reduce 
mortality and improve nutritional response to feeding). Four hundred and sixty children with 
SAM were randomly allocated to either ceftriaxone (the intervention, n = 230) or amoxicillin 
(the comparator, n = 230). Children were eligible to participate if they presented with a W/H 
< 70% of the reference median [NCHS/Center for Disease Control (CDC) 1977 growth reference 
curves18] and/or bilateral oedema and/or MUAC < 110 mm. In addition, eligible children had to 
weigh at least 5 kg and have a height within the range of > 65 cm to ≤ 109.9 cm. Children whose 
parents refused permission to participate were excluded from the study, as were children who 
had undertaken treatment with any of the study drugs or had been admitted to any health facility 
for SAM in the 7 days before admission, children with known hypersensitivity to amoxicillin or 
ceftriaxone, children whom the physician decided to treat using a different antimicrobial drug 
on admission and children with acute otitis media (AOM) or severe complications diagnosed 
on admission.
All participants received the same nutritional rehabilitation and care (further details in 
Appendix 10). The intervention group received a once-daily intramuscular (i.m.) injection 
of ceftriaxone at a dose of 75 mg/kg/day for 2 days, whereas the comparator group was given 
oral amoxicillin (80 mg/kg/day) twice daily over 5 days. When necessary, a second antibiotic 
(ceftriaxone, chloramphenicol, cotrimoxazole, amoxicillin or metronidazole) was administered as 
per the TFC protocol.
Dubray and colleagues59 reported that baseline characteristics did not differ significantly between 
groups. The mean age of the participants was approximately 17 months and just over half of the 
trial participants were male. More than 70% of the participants had W/H < 70% of the median, 
15% had a MUAC measurement of < 110 mm and at least 10% had bilateral oedema. Though 
there was no diagnostic confirmation of infection, approximately 30% of the participants had 
fever (≥ 37.5 °C), 1–2% tested positive for malaria, more than 17% presented with an abnormal 
respiratory rate and at least 10% were moderately dehydrated.
The reported primary outcome was the proportion of children with a weight gain increase of 
at least 10 g/kg/day calculated over a 14-day period starting on the first day of weight gain after 
admission. Additionally, the authors considered secondary outcomes such as the recovery rate of 
discharged children, overall case fatality ratios (CFRs), defaulter rate, referral (to another medical 
facility) rate and the occurrence of adverse events.
Summary of quality assessment
Although 230 participants were randomly allocated to the ceftriaxone group, two of these were 
secondarily excluded; thus, only 228 were included in the analyses. The authors state that an ITT 
analysis was conducted, given that all children who had received at least one dose of the study 
drug were included. However, because of the post-randomisation exclusion of two participants, 
this was judged not to be a full ITT analysis during quality assessment.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Dubray and colleagues’ study59 was rated moderate in terms of its overall methodological quality, 
as shown in Table 35. More than 80% of the selected individuals, who are very likely to be 
representative of the target population, participated in the RCT. The use of a computer-generated 
block randomisation method and sealed envelopes for allocation was appropriate. Additionally, 
there were no important baseline differences between groups and the number and reasons for 
withdrawals and dropouts were reported per group. Therefore, this study was considered strong 
regarding the selection bias, study design, confounders and the withdrawals and dropouts 
components of quality assessment. Despite using valid data collection tools, the reliability of 
the tools is not reported, and, hence, the study strength on data collection methods was rated 
moderate. For the blinding component, the study was judged to have weak methodological 
strength because neither outcome assessors nor participants were blinded. Considering that 
the consistency of the intervention was measured, that 60–79% of the participants received the 
allocated intervention and that they are not likely to have received an unintended intervention, 
the intervention integrity is considered to have been ensured. Furthermore, the analysis 
performed was found to be appropriate for the study design, despite the shortcomings of the 
ITT analysis.
Assessment of effectiveness: different antibiotics in the inpatient setting
Mortality
Dubray and colleagues59 reported several mortality-related secondary outcomes, based on an 
analysis that excluded two participants who had been randomised, but who did not receive any 
treatment. As can be seen in Table 36, fewer deaths occurred in the ceftriaxone group, not only 
within 14 days after admission but also during the whole follow-up period to discharge from the 
TFC. However, the difference in total deaths during follow-up was not statistically significant 
(p = 0.62) and no p-value was reported for the former. The 13 deaths that occurred during the 
first 14 days were because of septic shock (n = 5), lower respiratory tract infections (n = 3), fluid 
overload (n = 4) and severe dehydration (n = 1).
Weight gain
Table 37 presents the primary outcomes on weight gain from the Dubray and colleagues59 study, 
which were success rate and mean overall weight gain, as well as a secondary outcome of weight 
gain at exit from TFC. The reported success rate is defined as a weight gain ≥ 10 g/kg/day by day 
TABLE 34  Characteristics of the included RCT of different antibiotics in the inpatient setting
Study details and target population Intervention Comparator
Dubray et al. 200859
Design: RCT
Location: TFC in Sudan
Length of follow-up: not clearly stated, but 
appears to be until exit from TFC
No. enrolled: 460
Target population: severely malnourished 
children with weight ≥ 5 kg and height 
> 65 cm and ≤ 109.9 cm (usually 
corresponding to age 6–59 months); 
displaced population
Ceftriaxone (75 mg/kg/day) administered via 
i.m. injection once daily for 2 days 
Amoxicillin (80 mg/kg/day) administered orally 
twice daily over 5 days
Selected baseline characteristics
Mean age ± SD: 17 ± 7 months
Sex F : M, %: 48 : 52
W/H < 70% of median,a n (%): 169 (74.1)
MUAC < 110 mm,b n (%): 36 (15.8)
W/A: NR
Fever (≥ 37.5ºC), n (%): 70 (30.7)
Moderate dehydration, n (%): 33 (14.5)
Paracheck positive,c n (%): 4 (1.9)
Selected baseline characteristics
Mean age ± SD: 18 ± 8 months
Sex F : M, %: 45 : 55
W/H < 70% of median,a n (%): 166 (72.1)
MUAC < 110 mm,b n (%): 36 (15.7)
W/A: NR
Fever (≥ 37.5ºC), n (%): 67 (29.1)
Moderate dehydration, n (%): 23 (10.1)
Paracheck positive,c n (%): 2 (0.9)
NR, not reported.
a  No bilateral oedema, W/H compared with the NHCS 1977 growth reference curves.61
b  No bilateral oedema and W/H ≥ 70%.
c  No other specific infection was diagnosed.48 Assessment of clinical effectiveness
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14 or discharge before 14 days of weight gain because the TFC exit criteria were met (maintained 
W/H ≥ 85% for 7 consecutive days). Mean overall weight gain was calculated 14 days after the 
first weight gain. The groups showed similar results and no statistically significant differences 
were found between groups for any of the outcomes.
Length of stay and reasons for exit from the therapeutic feeding centre
As shown in Table 38, the authors reported a slightly shorter length of stay for the ceftriaxone 
group, but the difference from the amoxicillin control group was not statistically significant. No 
statistically significant differences were found on the reasons for exit either.
Infection-related deaths and adverse events
Dubray and colleagues59 reported the number of infection-related deaths per type of infection 
and adverse effects attributed to antibiotics (Table 39). A statistically significant lower rate of 
adverse events was found in the ceftriaxone group (p = 0.05).
Summary
  ■ One RCT59 that compared ceftriaxone (i.m.) with oral amoxicillin met the inclusion criteria 
of the review for this question. The RCT’s methodological quality was summarised as 
moderate, mainly owing to the fact that blinding of the outcome assessors or the participants 
was not carried out.
  ■ Mortality was a secondary outcome of the RCT. Dubray and colleagues59 did not find a 
statistically significant difference in mortality between the ceftriaxone and amoxicillin 
groups. Similarly, no statistically significant differences in the number of recovered patients, 
weight gain, length of stay or reasons for exit from the TFC were found either.
  ■ A statistically significant lower rate of adverse events was found in participants receiving 
ceftriaxone (p = 0.05) than in those receiving amoxicillin.
  ■ No data on resolution of existing infections, development of new infections, relapse or 
development of antibiotic resistance outcomes were reported.
TABLE 36  Mortality in children receiving different antibiotics in the inpatient setting
Study Treatment arms p-value
Dubray et al. 200859 Ceftriaxone (n = 228) Amoxicillin (n = 230)
Deaths within 14 days after admission,a n (%) 5 (2.2) 8 (3.5) NR
Total deaths during follow-up,b n (%) 7 (3.1) 9 (3.9)  0.62
Overall CFR 3.5% (16 deaths in 458 participants)
NR, not reported.
a  Percentage calculated by the reviewer.
b  Total deaths during follow-up includes the deaths within 14 days of admission.
TABLE 37  Weight gain in children receiving different antibiotics in the inpatient setting
Study Treatment arms p-value
Dubray et al. 200859 Ceftriaxone (n = 228) Amoxicillin (n = 230)
Success rate, n (%)  127 (55.7) 123 (53.5)  0.63, difference: 
2.2% (95% CI 
−6.9% to 11.3%) 
Mean overall weight gain (95% CI), g/kg/day 11.4 (10.5 to 12.2) 11.2 (10.2 to 11.9) 0.69
Mean weight gain at exit from TFC (95% CI), g/kg/day 10.2 (9.7 to 10.7) 10.2 (9.4 to 11.0) 0.5050 Assessment of clinical effectiveness
TABLE 38  Length of stay and reasons for exit from the TFC in children receiving different antibiotics in the 
inpatient setting
Study Treatment arms p-value
Dubray et al. 200859 Ceftriaxone (n = 228) Amoxicillin (n = 230)
Mean length of stay (95% CI), days 31.4 (29.4 to 33.3) 33.5 (31.5 to 35.5) 0.07
Reasons for exit from TFC, n (%)
 Recovered 170 (74.6) 161 (70) 0.27
 Defaulted 43 (18.9) 39 (17.0) 0.59
 Referred 2 (0.9) 4 (1.7) 0.68
TABLE 39  Infection-related deaths and adverse events in children receiving different antibiotics in the inpatient setting
Study Treatment arms p-value
Dubray et al. 200859 Ceftriaxone (n = 228) Amoxicillin (n = 230)
Infection-related deaths after 14 days from admission, n (day after admission)a
  Meningoencephalitis syndrome  1 (26th) 0 NR
  Severe respiratory infection 0 1 (30th) NR
  Pulmonary TB 1 (50th) 0 NR
Adverse events, n (%)b 2 (0.88) 8 (3.5)  0.05
 Vomiting 1 1 NR
 Diarrhoea 1 6 NR
  Facial oedema (allergic reaction) 0 1 NR
NR, not reported.
a  The three deaths which occurred after 14 days from admission are included in the reporting of total deaths during follow-up.
b  Percentage calculated by the reviewer.
  ■ The criteria used to define SAM were broadly in line with current WHO criteria, hence, 
results are likely to be generalisable to the SAM populations identified by WHO criteria. 
However, the generalisability to settings where HIV prevalence is high and where children 
may be receiving long-term cotrimoxazole prophylaxis is uncertain.
  ■ More than 25% of children in each group received a second antimicrobial treatment 
(ceftriaxone, chloramphenicol, cotrimoxazole, amoxicillin or metronidazole, in accordance 
with TFC treatment protocols), which may have reduced the evidence of difference 
between groups.
  ■ The study site was chosen because the working conditions were satisfactory, the centre 
adhered to international standards of nutritional rehabilitation programmes and the political 
situation was stable. Centres with poorer operational conditions might not be able to reach 
the same level of care, which might adversely affect outcomes.
Quantity and quality of research available: antibiotic use in the outpatient setting
The key characteristics of the single retrospective cohort study investigating this question are 
presented in Table 40, and the full data extraction form in Appendix 10 provides further details.
Trehan and colleagues60 conducted a retrospective analysis of outcomes from two cohorts of 
children in Malawi to determine whether or not including amoxicillin in the home-based 
treatment of uncomplicated SAM with RUTF led to better recovery rates than treatment with 
RUTF alone. The study was funded by a US government department. The data were obtained for 
the same time period from two different feeding projects, one operating in one district of Malawi, 
the other operating in two other districts of Malawi (the number of feeding centres in each © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
51   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
district was not reported). Data from anonymised records of 2453 children who had qualified 
for outpatient treatment of SAM were included: 1955 children in one cohort had received RUTF 
alone and 498 children in the second cohort received amoxicillin in addition to RUTF. SAM 
was defined as W/H z-score ≤ −3 and/or the presence of bilateral pitting oedema. To be eligible 
for outpatient treatment, children in both cohorts needed to have uncomplicated SAM and 
a good appetite. Children with poor appetite, altered mental status, compromised perfusion 
or respiratory distress or who were being transferred from inpatient to outpatient therapy 
were excluded.
The intervention cohort received a 7-day supply of amoxicillin, equivalent to approximately 
60 mg/kg/day, and RUTF to provide 175 kcal/kg/day. Children in the comparison cohort (who 
met the same criteria for outpatient treatment described above), received the same RUTF 
provision, but did not receive any antibiotics. In both cohorts RUTF was given until children 
reached a W/H z-score ≥ −2 with no peripheral oedema for a minimum of 4 weeks and a 
maximum of 12 weeks. Caregivers of the children in both cohorts were educated about the 
child’s illness and instructed on optimal feeding practices. They were also referred to local health 
providers with any concerns about other acute illnesses.
The primary outcome was the nutritional recovery rate, with recovery defined as W/H z-score 
≥ −2 and no peripheral oedema. Secondary outcomes were survival, W/H z-scores, W/A z-scores, 
H/A z-scores and presence of oedema.
Summary of quality assessment
Trehan and colleagues’ retrospective analysis of two cohorts60 was rated moderate in terms of its 
overall methodological quality (Table 41). The study was judged to be at a low risk of selection 
bias (rated strong for selection bias), but because this was a cohort with control study a moderate 
rating was applied for study design. Although there were some important differences between 
the cohorts prior to the intervention, the study authors indicated that these were taken into 
account in the analysis, which enabled the confounders section of the quality assessment to be 
judged strong. Although study participants were not aware of the research question, the outcome 
assessors knew what treatment participants had received, which led to a moderate rating for the 
blinding section. The data collection methods were rated weak because tools were not reported 
to be either valid or reliable. The final section contributing to the global rating, withdrawals and 
dropouts, was rated strong because 80–100% of participants completed the study, so the risk 
of bias owing to missing data was considered to be low. The intervention integrity is difficult to 
determine because the consistency of the intervention did not appear to have been measured, 
and it was not possible to tell whether or not any unintended intervention could have occurred in 
either cohort. There was also some uncertainty regarding the analysis of the data. The study was 
powered to detect a difference of at least 5% in the recovery rate.
Assessment of effectiveness: antibiotic use in the outpatient setting
Mortality
Mortality was one of the secondary outcomes of the Trehan and colleagues study.60 The total 
number of deaths was reported at 4 weeks and at 12 weeks for the overall number of participants 
in each cohort, but also reported separately for those with and without oedema at baseline 
(Table 42). The rates of death at both time points were described as similar for each group.
Recovery
Recovery was defined as a W/H z-score ≥ −2 and no peripheral oedema (Table 43). Those 
who remained alive but did not meet the criteria for recovery were classed as remaining 
malnourished, and those who missed two follow-up visits were categorised as defaulters. At 
the 4-week follow-up, a greater proportion of children in the RUTF-only cohort had recovered 52 Assessment of clinical effectiveness
TABLE 40  Characteristics of the included cohort study of antibiotic use in the outpatient setting
Study details and Target population Intervention cohort  Comparator cohort
Trehan et al. 201060
Design: retrospective cohort with control
Location: home-based treatment in Malawi
Length of follow-up: between 4 and 12 weeks
No. enrolled: 2453
Target population: severely malnourished 
children aged 6–59 months with W/H z-score 
≤ −3 and/or the presence of bilateral pitting 
oedema (WHO 1999)10
Amoxicillin (60 mg/kg/day) for 7 days + RUTF 
(175 kcal/kg/day)
RUTF (175 kcal/kg/day)
Selected baseline characteristics
Mean age ± SD: 25.5 ± 11.7 months
Sex F : M, %: 49.4 : 50.6
Mean W/H z-score ± SD: −1.99 ± 1.26
MUAC: NR
Mean W/A z-score ± SD: −3.51 ± 1.20
Selected baseline characteristics
Mean age ± SD: 22.3 ± 10.6 months
Sex F : M, %: 50.4 : 49.6
Mean W/H z-score ± SD: −1.91 ± 1.45
MUAC: NR
Mean W/A z-score ± SD: −3.05 ± 1.36
NR, not reported.
in comparison with the cohort receiving amoxicillin and RUTF (70.8% vs 39.8%; no p-value 
reported). A statistically significant difference (p < 0.001) in favour of the RUTF-only cohort was 
reported for the subgroups of children with and without oedema at baseline. In the subgroup 
of children who recovered after 4 weeks, the W/H z-score was significantly higher in the RUTF 
cohort than in the RUTF plus amoxicillin cohort (−0.37 vs −0.75; p < 0.0001).
At the 12-week follow-up, the overall proportion who had recovered in each cohort was 
described as similar (no p-value reported). Rates of defaulting were described as similar in the 
two cohorts at 4 and 12 weeks (no p-values reported). Therefore, the proportions of children 
classed as remaining malnourished were as expected, with a greater proportion remaining 
malnourished at the 4-week follow-up in the intervention cohort receiving amoxicillin, but more 
similar proportions from each cohort were malnourished by the 12-week follow-up (no p-values 
reported for the between group comparison at either time point).
Other outcomes
A regression analysis was conducted to compare recovery rates, while controlling for differences 
in baseline characteristics between the cohorts. The model based on outcomes at 4 weeks showed 
that age (older children) and W/H z-score (higher W/H z-score) at baseline were predictive 
of recovery (p < 0.001 for both), whereas receipt of amoxicillin was correlated with failure to 
recover at 4 weeks (OR 0.22; p < 0.001). However, the 12-week follow-up regression analysis 
demonstrated that none of the baseline factors considered were predictive of recovery. The W/A 
z-score, H/A z-score and presence of oedema were not correlated with recovery in either the 4- or 
12-week analysis. Full results are available in Appendix 10.
Summary
  ■ One cohort study60 of moderate methodological quality compared amoxicillin plus RUTF 
with RUTF only for the treatment of uncomplicated SAM in children.
  ■ Mortality rates were < 5% and similar in both cohorts.
  ■ The primary outcome of the study was recovery rate (W/H z-score ≥ −2 and no peripheral 
oedema), which appeared substantially greater at 4 weeks in the cohort of children who did 
not receive amoxicillin. However, by 12 weeks the proportion of children in each cohort who 
had recovered was described as similar.
  ■ The provision of a 7-day course of amoxicillin did not improve recovery rates from 
uncomplicated SAM in children in Malawi in this cohort when compared with the outcomes 
of a cohort who did not receive amoxicillin.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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654 Assessment of clinical effectiveness
What is the clinical effectiveness of interventions in different 
settings (e.g. hospital, community, emergency)? (Q14, rank 9)
Quantity and quality of research available: settings
Four trials62–65 that investigated the clinical effectiveness of interventions in different settings 
were included. All the studies were CCTs. The key characteristics of these CCTs are presented in 
Table 44 and Appendix 11 provides further details. These trials were conducted in Niger62 (100 
participants), Malawi63 (1178 participants overall, 645 as subgroup with SAM), Jamaica64 (81 
participants) and Bangladesh65 (573 participants). Two trials were single-centre64,65 and two were 
multicentre trials.62,63 Heikens and colleagues64 received funding from the government of the 
Netherlands, Chapko and colleagues62 were partially funded by a US governmental education 
fellowship, Khanum and colleagues65 were supported by a UK charity and the UK government 
and Ciliberto and colleagues63 received funding from the United Nations, a US charity and 
hospital foundation, a UK humanitarian organisation and the US government.
TABLE 42  Mortality in the cohort study of antibiotic use in the outpatient setting
Study Cohorts p-value
Trehan et al. 201060 Amoxicillin + RUTF (n = 498) RUTF (n = 1955)
Deaths at 4 weeks follow-up, n (%)
 Overall 10 (2.0) 26 (1.3) NR
  With oedema 8 (2.1) 16 (1.0) NR
  Without oedema 2 (1.8) 10 (2.6) NR
Deaths at 12 weeks follow-up, n (%)
 Overall 13 (2.6) 34 (1.7) NR
  With oedema 10 (2.6) 19 (1.2) NR
  Without oedema 3 (2.7) 15 (3.9) NR
NR, not reported.
TABLE 43  Recovery in the cohort study of antibiotic use in the outpatient setting
Study Cohorts (4-week follow-up) p-value Cohorts (12-week follow-up) p-value
Trehan et al. 201060 Amoxicillin +  
RUTF (n = 498)
RUTF 
(n = 1955)
Amoxicillin +  
RUTF (n = 498)
RUTF (n = 1955)
Recovered, n (%)
 Overall 198 (39.8) 1385 (70.8) NR 417 (83.7) 1673 (85.6) NR
  With oedema 170 (43.8) 1206 (76.6) p < 0.001 336 (86.6) 1385 (88.0) NR
  Without oedema 28 (25.5) 179 (47.0) p < 0.001 81 (73.6) 288 (75.6) NR
Remained malnourished, n (%)
 Overall 264 (53.0) 423 (21.6) NR 29 (5.8) 66 (3.4) NR
  With oedema 191 (49.2) 254 (16.1) NR 13 (3.4) 36 (2.3) NR
  Without oedema 73 (66.4) 169 (44.4) NR 16 (14.5) 30 (7.9) NR
Defaulted, n (%)
 Overall 26 (5.2) 121 (6.2) NR 39 (7.8) 182 (9.3) NR
  With oedema 19 (4.9) 98 (6.2) NR 29 (7.5) 134 (8.5) NR
  Without oedema 7 (6.4) 23 (6.0) NR 10 (9.1) 48 (12.6) NR
NR, not reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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TABLE 44  Characteristics of the included studies of interventions in different settings
Study details and target population Intervention Comparator
Chapko et al. 199462
Design: CCTa
Location: Niger
Length of follow-up: 6 months
No. enrolled: 100
Target population: malnourished 
children ready for discharge after 
treatment for acute conditions with 
W/H < −2 SD of NCHS median or a 
diagnosis of kwashiorkor
Ambulatory rehabilitation 
Total Study Population
Mean age: NR
Age range: 5–28 months
Sex F : M, %: 46 : 54
Median W/H z-score: −3.16
W/H z-score < −3, %: 59
MUAC: NR
W/A: NR
Hospital rehabilitation
Ciliberto et al. 200563
Design: CCT
Location: Malawi
Length of follow-up: 6 months
No. enrolled: 1178 (with 645 in the 
SAM subgroup)
Target population: children aged 
10–60 months with malnutrition 
(W/H < −2 SD of NCHS median, mild 
oedema, or both) and presenting a 
good appetite. Separate outcomes for 
the subgroup with SAM (W/H < −3 SD 
or oedema)
Home rehabilitation with a 2-week supply of 
RUFT
Hospital rehabilitation or at home using additional 
cereal–legume supplement
Total trial population
Mean age ± SD: 23 ± 10 months
Sex F : M, %: 47 :53
Mean W/H z-score ± SD: −2.2 ± 0.8
Mean MUAC ± SD: 11.6 ± 1.4 cm
Mean W/A z-score ± SD: −3.5 ± 1.0
For the SAM subgroup (n = 532) mean W/H 
z-score ± SD: −2.5 ± 1.0b
Total trial population
Mean age ± SD: 24 ± 12 months
Sex F : M, %: 47 : 53
Mean W/H z-score ± SD: −2.5 ± 0.9
Mean MUAC ± SD: 11.6 ± 1.5 cm
Mean W/A z-score ± SD: −3.7 ± 1.0
For the SAM subgroup (n = 113): mean W/H 
z-score ± SD: −2.5 1.1b
Heikens et al. 199464
Design: CCTa
Location: Jamaica
Length of follow-up: 36 months post-
admission
No. enrolled: 81
Target population: children aged 
3–36 months judged to require 
hospital admission based on W/A 
< 80% of NCHS median, oedema, 
anorexia, dermatosis or hair condition 
symptomatic of kwashiorkor and the 
need for parenteral antibiotic therapy
Home rehabilitation supported by CHAs 
(following initial short stay in hospital) with 
weekly supply of high-energy supplement and 
standard care for 3 months + standard care 
only for a further 3 months
Hospital rehabilitation (long stay) with high-energy diet 
until discharge followed by standard care at home for 
6 months
Mean age ± SE: 10.8 ± 1.1 months
Sex F : M: NR
Mean % expected (NCHS) W/H ± SE: 81.6 ± 1.5
MUAC: NR
Mean % expected (NCHS) W/A ± SE: 57.9 ± 1.7
Mean age ± SE: 11.7 ± 0.9 months
Sex F : M: NR
Mean % expected (NCHS) W/H ± SE: 80.6 ± 1.7
MUAC: NR
Mean % expected (NCHS) W/A ± SE: 60.3 ± 1.7
Khanum et al. 199465
Design: CCT
Location: Bangladesh
Length of follow-up: to attainment of 
80% W/H, plus a further 12 months 
for those reaching 80% W/H
No. enrolled: 573
Target population: children aged from 
12–60 months with W/H < 60% of 
NCHS median, and/or oedema
Home rehabilitation (following first 
7 days in day-care facility) – visited 
weekly for 1 month and twice 
monthly from then on until reaching 
80% W/H
Ambulatory rehabilitation – 
children attended day-care 
facility with their mothers every 
day except Friday until 80% W/H 
reached
Hospital rehabilitation – 
children admitted with their 
mothers and resident until 
reaching 80% W/H
Mean age ± SD: 28 ± 13 months
Sex F : M: NR
Mean % expected (NCHS including 
oedema) W/H ± SD: 70 ± 7
MUAC: NR
Mean % expected (NCHS including 
oedema) W/A ± SD: 51 ± 9
Mean age ± SD: 26 ± 13 months
Sex F : M: NR
Mean % expected (NCHS 
including oedema) W/H ± SD: 
70 ± 8
MUAC: NR
Mean % expected (NCHS 
including oedema) W/A ± SD: 
50 ± 10
Mean age ± SD: 
25 ± 13 months
Sex F : M: NR
Mean % expected (NCHS 
including oedema) 
W/H ± SD: 67 ± 7
MUAC: NR
Mean % expected (NCHS 
including oedema) 
W/A ± SD: 48 ± 9
NR, not reported; SE standard error.
a  Described as RCT but judged to be CCT during quality assessment.
b  Approximately 80% of the subgroup had oedema (see Appendix 11). It is presumed that this is the reason why the average W/H z-score for 
this subgroup is not < −3.56 Assessment of clinical effectiveness
Chapko and colleagues62 compared inpatient with daily ambulatory rehabilitation, and two of the 
trials63,64 investigated hospital- and home-based rehabilitation (differing, however, in the level of 
support provided). These three trials62–64 evaluated alternative settings for the rehabilitation phase 
of treatment for malnourished children, after an initial phase of hospital care common to both 
treatment arms. In contrast, the fourth trial, by Khanum and colleagues,65 had three trial arms 
to compare inpatient care with daily ambulatory care for both the initial and the rehabilitation 
phases of treatment for children with SAM, and with home rehabilitation (after daily ambulatory 
care during the initial phase of treatment).
Although hospital care was one of the investigated settings in all of the included trials, the 
inpatient care provided differed among the trials, for instance not only were different diet 
formulas and number of meals administered, but staff teams also varied in their composition. 
Similarly, the home-based care involved in the three trials63–65 that investigated home-based 
rehabilitation also differed. Ciliberto and colleagues63 studied home-based care provided by 
caretakers and involved two weekly clinic visits at which RUTF supplies were given, whereas 
Heikens and colleagues’64 home-based treatment was supported by community health aides 
(CHAs) who were trained to offer standard health-service care. The frequency of care provided by 
CHAs, reported in an earlier publication that did not meet the inclusion criteria for this review,66 
was unclear. Khanum and colleagues65 studied home-based care with no food supplements, and 
trained home visitors made home visits weekly for 1 month, then fortnightly. Trials also differed 
in the duration of the interventions and the length of follow-up.
Two studies62,63 included both moderately and severely malnourished children using similar 
criteria. Chapko and colleagues62 included children with a W/H z-score < −2 SD or kwashiorkor 
(not further defined) and Ciliberto and colleagues63 included children with a W/H z-score < −2 
SD or mild oedema (< 0.5 cm of pitting oedema on the dorsum of the foot). However, both 
these studies were eligible for inclusion in this review. In the study by Chapko and colleagues,62 
this was because the median W/H z-score was −3.38, with 70% of children having a z-score 
< −3, whereas in the study by Ciliberto and colleagues63 separate outcome data were presented 
for a subgroup of children with SAM (W/H z-score < −3 or presence of oedema). Heikens and 
colleagues64 also included both moderately and severely malnourished children judged to require 
hospital admission using the admission criteria of W/A < 80% of the NCHS median, oedema, 
anorexia, dermatosis or hair condition symptomatic of kwashiorkor and the need for treatment 
with parenteral antibiotics. Baseline status was described according to the Gómez,26 Wellcome67 
and Waterlow classifications,29 which enabled the study to be included because the mean baseline 
W/A was ≤ 60% of the NCHS median. Khanum and colleagues65 included only children with 
SAM and used W/H < 60% of NCHS median and/or oedema as their admission criterion.
Reporting of exclusion criteria varied, with Chapko and colleagues62 not reporting exclusion 
criteria at all. Ciliberto and colleagues63 excluded children < 10 months of age and/or with 
severe oedema, systemic infection or anorexia. Heikens and colleagues64 excluded children with 
congenital abnormalities and/or siblings in the present study or in the authors’ community 
study. Khanum and colleagues’65 reasons for excluding children from entry to the study were 
conditions that might require > 7 days of medical supervision (see Appendix 11), age < 12 months 
or > 60 months and children having TB or a congenital or metabolic disorder, children whose 
homes were > 10 km from the unit were also excluded.
Chapko and colleagues,62 Khanum and colleagues65 and Heikens and colleagues64 did not 
specifically identify their primary outcomes, but their main outcomes included mortality,62,65 
utilisation62 (in terms of hospital and ambulatory days), days to reach oedema-free 80% W/H65 © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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and time to discharge,64 W/H,62,64 W/A,62,64 H/A64 treatment completion65 and weight gain.65 
Ciliberto and colleagues63 stated that their primary outcomes were successful recovery (W/H > −2 
SD while remaining free of oedema), relapse or death.
Summary of quality assessment
As summarised in Table 45, the overall methodological quality for two of the trials62,63 was found 
to be moderate, while for the remaining two trials it was found to be weak.64,65
All four trials were judged to be at moderate risk of selection bias because, although 80–100% 
of the selected individuals participated in each of the four trials, their selected participants were 
judged as only somewhat likely to be representative of the target population. Two of the trials62,64 
stated that children were randomly allocated to groups; however, during quality assessment 
they were judged to be CCTs (in accordance with the instructions on the use of the quality 
assessment tool, see Appendix 4) because the method of randomisation was not described. 
Nevertheless, the quality assessment tool still led to the trials being rated strong in terms of study 
design. Ciliberto and colleagues’ study,63 was the only trial with important differences between 
groups at baseline (including differences in W/H, details in Appendix 11), but as 80–100% of the 
relevant confounders were controlled for in the analysis, all trials were rated strong with respect 
to confounders.
All trials showed weak methodological quality on blinding, as the outcome assessor was not 
blinded in three of the studies62,64,65 (Ciliberto and colleagues63 is unclear on this matter) nor were 
the participants blinded in any of them. The studies by Chapko and colleagues62 and Ciliberto 
and colleagues63 were found to be moderate regarding data collection methods, as their tools were 
valid, but their reliability was not reported. The Heikens and colleagues64 study was rated weak 
for data collection methods because information on the validity and reliability of the methods 
used was not reported. Khanum and colleagues65 used valid and reliable methods for the second 
follow-up after an additional 12 months, and hence, their study was rated as strong; however, 
the validity of the tools of the initial study could not be determined and their reliability was not 
reported, so this initial study was classified as weak. Three of the studies had 80–100% of their 
participants completing the study; hence, they were rated strong on withdrawals and dropouts, in 
spite of the fact that only Heikens and colleagues64 reported on both the numbers and reasons for 
missing data.
Studies vary widely in terms of the integrity of intervention. Chapko and colleagues62 reported 
that some children did not receive the assigned care; in particular, 11% of those assigned to 
ambulatory treatment received hospital rehabilitation at the insistence of their mothers, but it was 
not clear whether or not any of the children assigned to hospital care did not attend. Khanum 
and colleagues65 reported that 60–79% of their participants received their allocated intervention, 
and the other two trials63,64 reported 80–100%. Consistency was reported to have been measured 
by one trial65 and not measured by two trials;62,63 one trial was not clear on the matter.64 
Contamination or co-intervention was likely to have occurred in Chapko and colleagues62 trial, 
whereas the other three studies63–65 are not clear on this aspect.
The infant/child was the unit of allocation in three trials,62,64,65 whereas allocation was established 
per rehabilitation centre by Ciliberto and colleagues,63 whose trial had a stepped-wedge design. 
The unit of analysis in all four included trials was the infant/child. Overall, statistical methods 
were found to be appropriate for the design of two of the included studies,62,64 but it was unclear 
if they were appropriate for the other two studies.63,65 Out of the four studies, only Ciliberto and 
colleagues63 conducted an ITT analysis.58 Assessment of clinical effectiveness
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Assessment of effectiveness: settings
Mortality
Although mortality was a primary outcome of the Chapko and colleagues62 study and the 
Ciliberto and colleagues63 study, Khanum and colleagues65 reported it as a secondary outcome. 
None of the studies reported statistically significant differences in mortality between the different 
settings (Table 46). Chapko and colleagues62 reported a higher proportion of deaths in children 
in hospital than in the ambulatory setting. Ciliberto and colleagues63 reported only a 2.5% (95% 
CI −0.8% to 6.8%) difference in mortality between the groups, whereas Khanum and colleagues65 
reported that mortality was low and did not differ between the groups (no p-value reported). 
Heikens and colleagues64 did not specify mortality as an outcome, but reported deaths among 
data on children lost to follow-up, and consequently no p-value was reported.
The authors of the included studies63–65 accounted for the number of deaths that occurred in 
both the initial and the rehabilitation phases, apart from Chapko and colleagues,62 who reported 
deaths in the rehabilitation period only. This study had the highest proportion of deaths.
Weight gain
One study, that by Chapko and colleagues,62 did not include weight gain as an outcome. Khanum 
and colleagues65 reported the mean weight gain from admission to 80% W/H as a primary 
outcome and weight gain after an additional 12 months’ follow-up as a secondary outcome 
(Table 47). A statistically significant difference in the primary outcome was found (p < 0.001), 
with inpatient care resulting in a greater daily mean weight gain from admission to the point 
at which participants reached 80% W/H than either home care or day care. However, after an 
additional 12 months of follow-up for all participants who reached 80% W/H, no significant 
differences in weight gain were apparent. Heikens and colleagues64 stated either that the rates 
of weight gain were similar or that there was no difference between the groups at the different 
treatment stages, but it is not clear whether or not any formal statistical testing was conducted 
and no p-values were reported. The exception was the average final rate of weight gain before 
discharge of 6–7 g/kg/day. The authors stated that this was maintained over a longer period 
for the long-stay group, but presented no data. Ciliberto and colleagues63 reported a non-
statistically significant difference in the rate of weight gain for children at home compared with 
hospital during the first 4 weeks of the study. However, Ciliberto and colleagues63 performed a 
multivariate regression analysis, which showed that the overall rate of weight gain was 1.4 (95% 
CI 1.1 to 1.7) times as great among the severely malnourished children in those subject to home-
based therapy than in those who received standard therapy at the rehabilitation unit.
Anthropometry
Chapko and colleagues62 reported W/H data in line graphs separately for those who died and 
for those who survived. Within both groups, there was no significant difference between the 
ambulatory-based and hospital-based groups (no p-value reported). Heikens and colleagues64 
reported measures of W/H, W/A and H/A at discharge, after 6 months’ home care (end of 
intervention) and then at 6-month intervals to 36 months post admission (groups altered in 
size at later time points; see Appendix 11). At discharge, the hospital (long-stay) group had a 
better W/H z-score than the home (short-stay) group and the difference between the groups 
was statistically significant [mean z-score ± standard error (SE): long-stay group −0.49 ± 0.11 vs 
−1.17 ± 0.16 in the short-stay group; p = 0.001]64 (Table 48). However, 6 and 12 months later, the 
difference between the groups was no longer statistically significant (p-values 0.105 and < 0.1, 
respectively), and the difference between the groups narrowed further at 18 months and at later 
time points (no p-values reported). Ciliberto and colleagues63 found a statistically significantly 
higher proportion of patients with W/H > −2 SD after 8 weeks of treatment in the group under 
home-based therapy than in the inpatient group.60 Assessment of clinical effectiveness
Weight-for-age and H/A outcomes were reported only by Heikens and colleagues.64 Statistically 
significantly higher z-scores were reported for the long-stay group up to 24 months (W/A) or 
30 months (H/A), but not thereafter (see Table 48 and Appendix 11).
Only Ciliberto and colleagues63 reported MUAC gain, finding a statistically significantly higher 
rate of MUAC gain during the first 4 weeks in the group under home-based therapy compared 
with the inpatient group.
TABLE 46  Mortality in studies of interventions in different settings
Study Treatment arms  p-value
Chapko et al. 199462 Ambulatory (n = 47) Hospital (n = 53)
Deaths,a % 33  41 0.172
Ciliberto et al. 200563 (SAM subgroup) Home (n = 532) Hospital (n = 113)
Difference  
(95% CI)
Deaths, n (%) 20 (3.7) 7 (6.2) 2.5% 
(−0.8% to 6.8%)
Heikens et al. 199464
Home with support  
(short stay) (n = 39)
Hospital  
(long stay) (n = 40) p-value
Deaths, n (%)b 2 (5.1) 1 (2.5) NR
Khanum et al. 199465 Home (n = 173)  Ambulatory (n = 200) Hospital (n = 200) p-value
Mortality at initial study,c n (%) 6 (3.5) 10 (5.0) 7 (3.5) NR
Mortality at 12 months further follow-up, n/N (%)d 2/130 (1.5) 2/134 (1.5) 6/173 (3.4) NR
NR, not reported.
a  Excluding dropouts.
b  Percentage calculated by reviewer.
c  Initial study followed children until they attained 80% W/H.
d  n calculated by reviewer based on the number of participants who entered the 12 months further follow-up of those who attained 80% W/H 
(hospital inpatients N = 173, ambulatory N = 134 and home N = 130).
TABLE 47  Weight gain in studies of interventions in different settings
Study Treatment arms  p-value
Ciliberto et al. 2005,63 (SAM subgroup) Home (n = 532) Hospital (n = 113) Difference (95% CI)
Mean rate of weight gain during first 
4 weeks ± SD, g/kg/day
3.7 ± 4.3 3.0 ± 8.8 0.7 (−0.4 to 1.8) 
Heikens et al. 199464
Home with support (short stay) 
(n = 39)
Hospital (long stay)  
(n = 40) p-value
Rate of weight gain, g/kg/day NR
  Range on first 14 days −8 to 24a −8 to 24a
  Third and fourth weeks 12.1 10.4 NR
  Fifth week onwards 6 to 7 6 to 7 NR
  3-months post discharge (range) 1.05 (−4 to 7) 1.13 (−4 to 7) NR
  6-months post discharge ~ 0.85 ~ 0.85 NR
Khanum et al. 199465 Home (n = 173)  Ambulatory (n = 200) Hospital (n = 200) p-value
Mean weight gain from admission to 80% 
W/H, g/kg/day
4 6 11 < 0.001
Mean weight gain ± SD at 12 months of 
follow-up, kg
2.47 ± 1.13 (n = 106) 2.39 ± 0.98 (n = 111) 2.15 ± 1.12 (n = 118) NS
NR, not reported; NS, not statistically significant.
a  These data represent the total study population, not a specific subgroup.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Completion of treatment
Khanum and colleagues65 reported a significantly longer period of time to achieve 80% W/H in 
the group treated at home than in the group receiving hospital or ambulatory care (Table 49). 
The hospital (long-stay) group in the Heikens and colleagues64 study was considered to have 
completed treatment and was discharged when 95–100% W/H was reached (a mean ± SE of 
39.45 ± 2.35 days post admission), but these data were not presented for the group that received 
care at home.
Relapse
Ciliberto and colleagues63 presented the composite outcome of children who relapsed or died 
(Table 50). It is presumed (although not explicitly stated) that this outcome incorporates the 
deaths already reported in Table 46, indicating, therefore, that 12 children (10.6%) in the hospital 
group relapsed, in comparison with 33 (6.2%) in the home group. A multivariate regression 
analysis was conducted to control for a range of covariates, and this indicated a statistically 
significantly lower probability of relapse or death [0.5 times (95% CI 0.3 times to 0.7 times)] in 
the subgroup of SAM children who received home-based therapy with RUTF compared with 
those receiving standard care at hospital. Khanum and colleagues65 reported on those who were 
readmitted during the 12-month follow-up. Children were readmitted if they relapsed (became 
oedematous or were < 60% W/H) or because of medical emergencies. Overall, there were eight 
readmissions (1.8% of the 437 children followed up), of which 0.6% occurred because of relapse. 
Data were not presented separately for relapse in each group, but Khanum and colleagues65 stated 
that relapse did not differ among the groups.
Additional outcomes
Other outcomes such as height gain, oedema loss and prevalence of fever, cough or diarrhoea 
were reported by some studies, but details have not been presented here. Full details are available 
in the data extraction forms in Appendix 11.
Summary
  ■ One moderate-quality CCT was found comparing ambulatory care with hospital care.62 Two 
other included CCTs involved home- and hospital-based therapy (one of them was graded 
moderate,63 whereas the other CCT’s methodological quality was considered weak64), and 
another methodologically weak CCT65 compared the three settings.
  ■ Only one trial63 undertook an ITT analysis. There is the possibility, therefore, that the results 
of the remaining trials62,64,65 are at a higher risk of bias and, consequently, the intervention 
effect may not have been accurately captured.
  ■ None of the included studies reported a significant difference in mortality between groups.
  ■ Conflicting results were obtained for weight gain. No significant differences in weight 
gain during the first 4 weeks,63 at 12 months of follow-up65 or in the different stages up to 
6 months after discharge64 were found between settings. However, a separate multivariate 
regression analysis in one trial found that overall rate of weight gain was greater among 
children in the home-based group than in those receiving standard therapy at the 
rehabilitation unit.63 In contrast, two studies of weaker quality64,65 reported that inpatient 
care presented a statistically significantly higher mean weight gain to 80% W/H than home 
or ambulatory care,65 and the final average rate of weight gain was maintained over a longer 
period in the inpatient group than in the home-care group.64
  ■ There was no significant difference during a 6-month follow-up period in W/H between 
the ambulatory and hospital-based groups in one study.62 However, two studies63,64 showed 
conflicting results for the comparison of hospital and home care. According to Heikens and 
colleagues,64 the inpatient group showed statistically significant improvement in W/H at 
discharge compared with the home-based group (supported by CHAs). In contrast, Ciliberto 
and colleagues’63 home-based group (visiting the rehabilitation centre fortnightly) included 62 Assessment of clinical effectiveness
TABLE 48  Anthropometric outcomes in studies of interventions in different settings
Study Treatment arms  p-value
Ciliberto et al. 200563 (SAM subgroup) Home (n = 532) Hospital (n = 113) Difference (95% CI)
W/H > −2 SD after 8 weeks, n (%) 382 (72) 55 (49) 21% (10% to 32%)
Mean rate of MUAC gain during first 
4 weeks ± SD, mm/day
0.42 ± 0.71 0.28 ± 0.44  0.14 (0.04 to 0.24)
Heikens et al. 199464
Home with support (short stay) 
(n = 39) Hospital (long stay) (n = 40) p-value
NCHS z-scores, mean ± SE
W/H
 Dischargea −1.17 ± 0.16 −0.49 ± 0.11 0.001
  6 months −0.80 ± 0.16 −0.46 ± 0.14 0.105
  12 monthsb −1.00 ± 0.40 −0.60 ± 0.30 < 0.1
  18 monthsb −0.95 ± 0.30 −0.75 ± 0.30 NR
  24 monthsb −0.95 ± 0.35 −0.75 ± 0.30 NR
  30 monthsb −0.70 ± 0.30 −0.80 ± 0.30 NR
  36 monthsb −0.65 ± 0.35 −0.55 ± 0.30 NR
W/A
 Dischargea −3.38 ± 0.16 −2.49 ± 0.12 0.001
  6 months −2.45 ± 0.15 −1.81 ± 0.16 0.006
  12 monthsb −2.3 ± 0.45 −1.55 ± 0.30 < 0.001
  18 monthsb −2.05 ± 0.40 −1.40 ± 0.30 < 0.001
  24 monthsb −1.90 ± 0.35 −1.20 ± 0.30 < 0.01
  30 monthsb −1.45 ± 0.30 −1.20 ± 0.30 NS
  36 monthsb −1.30 ± 0.25 −1.25 ± 0.45 NS
H/A
 Dischargea −3.52 ± 0.22 −3.02 ± 0.18 0.086
  6 months −2.82 ± 0.18 −2.38 ± 0.17 0.059
  12 monthsb −2.60 ± 0.60 −1.80 ± 0.35 < 0.05
  18 monthsb −2.20 ± 0.45 −1.10 ± 0.40 < 0.001
  24 monthsb −1.85 ± 0.50 −0.95 ± 0.40 < 0.01
  30 monthsb −1.40 ± 0.40 −0.80 ± 0.40 < 0.05
  36 monthsb −1.20 ± 0.40 −0.95 ± 0.40 NR
NR, not reported; NS, not statistically significant.
a  Discharge was a mean ± SE of 17.99 ± 1.43 days post admission in the home (short-stay) group and 39.45 ± 2.35 days post admission in the 
hospital (long-stay) group (p = 0.001).
b  Data estimated to the nearest 0.05 from bar charts.
TABLE 49  Completion of treatment in studies of interventions in different settings
Study Treatment arms 
Khanum et al. 199465 Home (n = 173)  Ambulatory (n = 200) Hospital (n = 200) p-value
Median number of days to achieve 80% oedema-free W/H 35a 23 18 < 0.001
a  Significantly longer than the other two groups.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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a statistically significantly higher proportion of patients with W/H > −2 SD after 8 weeks of 
treatment than in the inpatient group.
  ■ Statistically significantly higher W/A and H/A z-scores were found after hospital-based 
treatment than after home care with support of CHAs.64 In contrast, another trial reported 
a statistically significantly higher rate of MUAC gain during the first 4 weeks in the group 
under home-based therapy than in the inpatient group.63
  ■ Most studies defined SAM with criteria similar to those currently used by the WHO 
or analysed a subgroup that met them.62,63,65 It is not clear, however, whether or not the 
participants in Heikens and colleagues’ study64 would meet current WHO criteria.
  ■ Studies varied in the care provided, even if the same setting is considered. For instance, 
studies on home rehabilitation63–65 involved different diets, time and frequency of contact 
with nutritional rehabilitation centres/staff. Additionally, Chapko and colleagues62 point out 
that nutritional rehabilitation differed between ambulatory centres, and between the hospital 
and the ambulatory centres. Ciliberto and colleagues63 provide no indication regarding 
similarities or differences between centres.
Which methods for correcting micronutrient deficiencies are 
effective? (Q8, rank 10)
Thirteen trials68–82 were included that investigated the efficacy of treatments for correcting 
micronutrient deficiencies in children with SAM. Any supplements or combinations of 
supplements were eligible for inclusion, providing other review inclusion criteria (e.g. reported 
outcomes) were met. Within this section, 10 trials68–79 (12 publications) investigating zinc 
supplements have been grouped together for ease of comparison between studies (see Quantity 
and quality of research available: zinc and Assessment of effectiveness: zinc). The remaining three 
trials,80–82 each focus on different interventions: potassium,80 nicotinic acid81 and nucleotides 
(NTs)82 (see Quantity and quality of research available: other supplements and Assessment of 
effectiveness: other supplements).
Quantity and quality of research available: zinc
A summary of the key characteristics of the 10 trials68–79 can be seen in Table 51, with further 
details of the trials in Appendix 12. Three trials took place in Bangladesh,68,69,73,77 two in India,72,78 
and one trial each in Pakistan,79 Kenya,70 Jamaica,71 South Africa74,75 and Chile.76 Two studies were 
RCTs,68,69,79 the remaining eight were CCTs70–78 and all were conducted at a single centre. Three 
studies did not report on how the study was funded,72,73,78 one study was funded by a commercial 
TABLE 50  Relapse after treatment in studies of interventions in different settings
Study Treatment arms 
Ciliberto et al. 2005,63 (SAM subgroup) Home (n = 532) Hospital (n = 113) Difference (95% CI)
Children relapsed or died, n (%) 53 (10) 19 (16.8) 6.8% (0.3% to 24.7%)
Khanum et al. 199465 Home (n = 173)  Ambulatory (n = 200) Hospital (n = 200) p-value
Readmitted to unit at the 12-month  
follow-up, n/N (%)a
3/130 (2.3) 2/134 (1.5) 3/173 (1.7) NR
NR, not reported.
a  n calculated by reviewer based on the number of participants who entered the 12 months further follow-up of those who attained 80% W/H 
(home n = 130, ambulatory n = 134 and hospital inpatients n = 173).64 Assessment of clinical effectiveness
TABLE 51  Characteristics of the included studies providing zinc as a supplement
Study details and target 
population Study arms
Doherty et al. 199868,69
Design: RCT
Location: Bangladesh
Length of follow-up: 90 days
No. enrolled: 141
Target population: children aged 
6–36 months and with W/A 
< 60% of NCHS median, with 
nutritional oedema or both
Elemental zinc (as zinc sulphate in 
suspension) 1.5 mg/kg body weight 
administered by syringe for 15 days 
followed by placebo for 15 days
Elemental zinc (as zinc sulphate in 
suspension) 6.0 mg/kg body weight 
administered by syringe for 15 days 
followed by placebo for 15 days
Elemental zinc (as zinc sulphate 
in suspension) 6.0 mg/kg body 
weight administered by syringe 
for 30 days
Mean age ± SD: 15.5 ± 8.7 months
Sex F : M: NR
Mean W/H z-score ± SD: 
−2.56 ± 0.97
MUAC: NR
Mean W/A z-score ± SD: 
−4.47 ± 0.91
Baseline zinc: NR
Mean age ± SD: 15.0 ± 9.0 months
Sex F : M: NR
Mean W/H z-score ± SD: 
−2.73 ± 0.90
MUAC: NR
Mean W/A z-score ± SD: 
−4.56 ± 0.98
Baseline zinc: NR
Mean age ± SD: 
16.3 ± 8.6 months
Sex F : M: NR
Mean W/H z-score ± SD: 
−2.71 ± 0.93
MUAC: NR
Mean W/A z-score ± SD: 
−4.66 ± 0.86
Baseline zinc: NR
Gatheru et al. 198870
Design: CCT
Location: Kenya
Length of follow-up: 10 days
No. enrolled: 82
Target population: children aged 
1–3 years with kwashiorkor 
(Wellcome classification)
Elemental zinc (as zinc sulphate solution) 5 mg/kg body 
weight per day given in three divided doses for the 
duration of treatment
No zinc supplement
Mean age: NR
Sex F : M, %: 52 : 48a
W/H: NR
MUAC: NR
W/A: NR
Mean age: NR
Sex F : M, %: 42 : 58a
W/H: NR
MUAC: NR
W/A: NR
Mean baseline serum zinc (range) reported for the whole study population: 6.4 (4.0–12.9) μmol/l
Golden et al. 199271
Design: CCT
Location: Jamaica and West 
Indies
Length of follow-up: 6 weeks
No. enrolled: 11
Target population: severely 
wasted boys (Wellcome 
classification) aged 
6–31 months
High: 10 mg (153 μmol) zinc per kg 
feed (as zinc acetate) + basic diet
Moderate: 5 mg (76 μmol) zinc per 
kg feed (as zinc acetate) + basic 
diet
Low: basic diet alone [3.5 mg 
(54 μmol) zinc per kg feed] with 
no zinc supplement
Mean age ± SE: 13 ± 4 months
Sex F : M, %: 0 : 100
Mean % expected W/L ± SEM: 
61 ± 2
MUAC: NR
W/A: NR
Mean baseline plasma zinc ± SE: 
9.9 ± 1.3 μmol
Mean age ± SE: 15 ± 2 months
Sex F : M, %: 0 : 100
Mean% expected W/L ± SEM: 
60 ± 4
MUAC: NR
W/A: NR
Mean baseline plasma zinc ± SE: 
11.1 ± 1.4 μmol
Mean age ± SE: 18 ± 4 months
Sex F : M, %: 0 : 100
Mean % expected W/L ± SEM: 
63 ± 2
MUAC: NR
W/A: NR
Mean baseline plasma zinc ± SE: 
9.6 ± 1.9 μmol
Hemalatha et al. 199372
Design: CCTb
Location: India
Length of follow-up: 1 month
No. enrolled: 33
Target population: children aged 
1–5 years with W/A < 60% of 
that expected compared with 
the NCHS
Elemental zinc, 40 mg each day in capsule form (as zinc 
sulphate) estimated to be about 6 mg/kg body weight per 
day for 21 days
Placebo capsule
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Mean baseline plasma zinc ± SE: 80.4 ± 9.972 μg/dl
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Mean baseline plasma zinc ± SE:  
83.6 ± 10.363 μg/dl© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
65   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
Study details and target 
population Study arms
Khanum et al. 198873
Design: CCT
Location: Bangladesh
Length of follow-up: 36 days
No. enrolled: 60
Target population: children aged 
from 5 months to 5 years with 
oedema and/or with ≤ 60% W/H 
as a percentage of the Harvard 
reference
Zinc at 10 mg/kg/day (as zinc sulphate) if body weight 
< 6 kg, 50 mg per day for those > 6 kg; provided on days 
15–36, mode of delivery not specified
No zinc supplement
Mean age: 29 months
Sex F : M: states equally represented, but numbers NR
Mean % expected W/H ± SEM: 70 ± 1.3
MUAC: NR
Mean % expected W/A ± SEM: 50.3 ± 1.61
Mean baseline plasma zinc ± SE: 8.23 ± 0.7 mmol/l
Mean age: 29 months
Sex F : M: states equally represented, but numbers 
NR
Mean % expected W/H ± SEM: 67 ± 1.3
MUAC: NR
Mean % expected W/A ± SEM: 47.6 ± 1.60
Mean baseline plasma zinc ± SE: 
7.90 ± 0.7 mmol/l
Makonnen et al. 200374,75
Design: CCTb
Location: South Africa
Length of follow-up: 90 days 
(post-discharge)
No. enrolled: 300
Target population: children 
aged 6–60 months with PEM 
(Wellcome classification) 
or > 80% of expected W/A 
with signs and symptoms of 
kwashiorkor
Zinc 10 mg/day (as zinc sulphate suspension) 
administered in drop form from admission to 90 days 
post-discharge
Placebo suspension
Mean age: NR
Sex F : M, %: 51 : 49
W/H: NR
Mean MUAC ± SD: 11.8 ± 1.6 cm
W/A: mean value NR
Mean baseline serum zinc ± SD: 6.23 ± 1.83 μmol/l
Mean age: NR
Sex F : M, %: 49 : 51
W/H: NR
Mean MUAC ± SD: 11.9 ± 1.8 cm
W/A: mean value NR
Mean baseline serum zinc ± SD: 
6.25 ± 1.74 μmol/l
Schlesinger et al. 199276
Design: CCT
Location: Chile
Length of follow-up: 105 days
No. enrolled: 39
Target population: marasmic 
infants < 1 year of age
Zinc (as zinc chloride) at a concentration of 15 mg/l in 
infant formula for 105 days
Infant formula containing 3.2 mg/l zinc
Mean age ± SD: 7.05 ± 2.0 months
Sex F : M, %: 47 : 53a
Mean W/H z-score ± SD: −0.83 ± 0.6
MUAC: NR
Mean W/A z-score ± SD: −3.13 ± 0.71
Mean baseline serum zinc ± SD: 19.4 ± 5.5 μmol/l
Mean age ± SD: 8.1 ± 3.0 months
Sex F : M, %: 50 : 50a
Mean W/H z-score ± SD: −1.18 ± 0.81
MUAC: NR
Mean W/A z-score ± SD: −3.21 ± 0.87
Mean baseline serum zinc ± SD: 23.4 ± 8.4 μmol/l
Simmer et al. 198877
Design: CCT
Location: Bangladesh
Length of follow-up: 2 weeks
No. enrolled: 25
Target population: children 
aged 1–7 years with nutritional 
oedema or W/A < 60% and 
W/H < 70% of local standards 
(< 42% and < 63% respectively 
of Western standards)
Zinc at 10 mg/kg/day (as zinc sulphate) if weight < 5 kg, 
50 mg per day for those > 5 kg; for 2 weeks starting at 
least 3 days after admission (usually after 7 days), mode 
of delivery not specified
No zinc supplement
Mean age ± SE: 35.3 ± 5 months
Sex F : M: NR
Mean % expected W/H c ± SE: 70% ± 2
MUAC: NR
Mean % expected W/A c ± SE: 46% ± 3
Mean plasma zinc at study entry ± SE: 10.8 ± 0.8 μmol/l
Mean age ± SE: 42.8 ± 7.8 months
Sex F : M: NR
Mean % expected W/H c ± SE: 66% ± 2
MUAC: NR
Mean % expected W/A c ± SE: 48% ± 3
Mean plasma zinc at study entry ± SE: 
8.6 ± 0.8 μmol/l
continued
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Study details and target 
population Study arms
Vasudevan et al. 199778
Design: CCT
Location: India
Length of follow-up: 3 months
No. enrolled: 72
Target population: children aged 
8–24 months with PEM grades 
III and IV (IAP 1972 criteria45)
Elemental zinc 6.6 mg in capsule form (equivalent to 
20 mg of zinc sulphate) once per day for 3 months
Placebo capsule
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Meand baseline serum zinc reported for the whole study population: 98.4 ± 26.1 μg/dl
Bhutta et al. 199979
Design: RCT
Location: Pakistan
Length of follow-up: 28 days
No. enrolled: 87
Target population: children aged 
6–36 months with persistent 
diarrhoea and malnutrition (W/A 
z-score ≤ 2)e
Elemental zinc 3 mg/kg /day (as zinc sulphate) in a single 
daily dose for 28 days, mode of delivery not specified
Placebo for 28 days
Mean age ± SD: 11.6 ± 5.6 months
Sex F : M, %: 16 : 27
Mean W/H z-score ± SD: −3.02 ± 0.90
Mean MUAC ± SD: 11.1 ± 1.5 cm
Mean W/A z-score ± SD: −3.47 ± 0.97
Mean baseline serum zinc ± SD: 78.0 ± 32.2 μg/dl
Mean age ± SD: 13.1 ± 6.2 months
Sex F : M, %: 18 : 26
Mean W/H z-score ± SD: −3.13 ± 1.19
Mean MUAC ± SD: 11.6 ± 1.9 cm
Mean W/A z-score ± SD: −3.27 ± 1.33
Mean baseline serum zinc ± SD: 70.3 ± 19.0 μg/dl
NR, not reported; SEM, standard error of the mean.
a  Percentage calculated by the reviewer.
b  Described as RCT, but judged to be CCT during quality assessment.
c  Presume W/H and W/A are with respect to local standard.
d  Not known whether this is mean ± SD or mean ± SEM.
e  Standard for W/A comparison is not stated.
TABLE 51  Characteristics of the included studies providing zinc as a supplement (continued)
research grant programme76 and another study funded from a US academic source.79 The 
remaining five studies received funding from a combination of a commercial and an academic 
source (two studies68,69,74,75 with academic sources either in the UK68,69 or in South Africa74,75), or 
an academic source and a government department (both in Kenya),70 or an academic source and 
a charity (both based in the UK).71,77
The age range of the children enrolled in each study varied. In three studies,70,72,77 children ranged 
in age from a minimum of 1 year to a maximum of either 3 years,70 5 years72 or 7 years77 (this 
study could be included because the mean age of participants was < 5 years of age). Six studies 
allowed for the inclusion of children under 1 year in age, with ages ranging from 6 months to 
about 2.5 years in one study,71 6 months to 3 years in two studies,68,69,79 and in three studies from 
either 6 months to 5 years,74,75 5 months to 5 years73 or 8 months to 2 years.78 Only one study 
focused on children aged < 1 year.76 The total number of children enrolled and reported on in the 
trials ranged from 1171 to 30074,75 with most studies reporting on fewer than 100 participants.
Four studies enrolled approximately equal numbers of male and female children,70,73–76 in one 
study the population contained more male than female children,79 and one study enrolled only 
male children.71 In the remaining four studies, the ratio of male to female children was not 
reported.68,69,72,77,78
The criteria for identifying SAM included a W/A assessment in 8 of the 10 studies,68–72,74,75,77–79 
although only three68,69,79 reported baseline W/A for each intervention arm. In three studies,72,78,79 
this was the only criterion used. Hemalatha and colleagues72 included children with a W/A < 60% © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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of that expected in comparison with the NCHS reference median using the Gómez criteria,26 
whereas Vasudevan and colleagues78 included children with 51–60% expected W/A (PEM grade 
III) and ≤ 50% W/A (PEM grade IV), based on the Harvard standard according to the IAP 1972 
classification of PEM.45 The third study, by Bhutta and colleagues,79 was the only one to focus 
on children with persistent diarrhoea in combination with evidence of malnutrition, defined as 
a W/A z-score ≤ 2. This study was included in this section, rather than in Quantity and quality 
of research available: persistent diarrhoea and Assessment of effectiveness: persistent diarrhoea, 
because the primary outcome was weight gain (whereas diarrhoea-related outcomes were 
secondary outcomes), and plasma zinc levels were checked before and after supplementation. 
The Wellcome classification67 was employed by three studies.70,71,74,75 This categorises W/A as 
either < 60% or 60–80% of that expected based on the Harvard standard, and combines this with 
an assessment of whether oedema is present or absent to identify children with kwashiorkor, 
marasmic kwashiorkor or marasmus (children in the fourth category, undernourished, were not 
included). One of the studies, that by Makonnen and colleagues,74,75 also included children with 
W/A > 80% if they had signs and symptoms of kwashiorkor. Two other studies also included an 
assessment of nutritional oedema in their criteria for assessing SAM. Doherty and colleagues68,69 
included children with nutritional oedema, or with W/A < 60% of the NCHS median, or 
both. Simmer and colleagues77 included children with nutritional oedema, or W/A < 60% 
and W/H < 70% of local standards (< 42% and < 63% respectively of Western standards, not 
further defined).
Two studies did not use W/A in their assessment of SAM. Khanum and colleagues73 included 
children with oedema and/or with ≤ 60% of the W/H expected in comparison with the Harvard 
reference. Schlesinger and colleagues76 described all the infants in their study as marasmic.
Although the 10 trials68–79 investigating zinc supplements have been grouped together for ease 
of comparison, the interventions varied in many aspects: when zinc supplementation began, the 
daily dose, the mode used to administer this and the duration it was provided for. In addition to 
the summary information presented in Table 51, further details of zinc supplementation can be 
found in Table 52.
The comparator in four trials was a placebo;72,74,75,78,79 three trials did not provide a placebo to the 
comparator group,70,73,77 and three trials varied dose and/or duration of treatment between the 
groups.68,69,71,76
Only 2 of the 10 studies specified what their primary outcome measures were.74,75,79 Mortality was 
reported by two studies,68,69,74,75 weight or weight gain was an outcome in seven studies70–73,77–79 and 
anthropometric measures were reported by five studies68,69,73–76,79 (including the three that did not 
report on weight). Eight studies reported on zinc levels,70,72–79 four reported on symptoms70,72,74,75,79 
(e.g. diarrhoea, oedema) and seven reported one or more other outcomes (e.g. results of 
biochemical tests, length of hospital stay).68,69,71,72,74–77,79
Summary of quality assessment
The trials were assessed against a number of criteria to obtain an overview of their 
methodological quality. The global rating for methodological quality varied: two trials68,69,79 
were rated strong overall, two trials74–76 were rated moderate and six trials were rated 
weak70–73,77,78 (Table 53).
The assessment of selection bias required a judgement about how likely it was that participants 
selected to take part in the study were representative of the target population and information 
about the percentage of selected individuals who did participate. In general, this information 
was not well reported. Consequently, only two studies74,75,79 were rated ‘strong’ (at low risk of 68 Assessment of clinical effectiveness
selection bias). Of the remaining studies, four had a moderate rating68,69,73,77,78 and four had a weak 
rating70–72,76 (the latter judged to be at a high risk of selection bias).
The study design of all 10 trials was strong, with two being RCTs68,69,79 and the remaining eight 
being CCTs70–78 (in two of these,72,74,75 there was a suggestion of randomisation but no information 
was provided about the method, hence they were judged to be CCTs). Both of the RCTs68,69,79 
and four of the CCTs71,73,76,77 were judged to have trial arms that were balanced with respect to 
baseline characteristics and confounders, leading to a strong rating. Reporting in the remaining 
four CCTs70,72,74,75,78 was either insufficient or unclear, so it was not possible to be certain whether 
or not the trial arms were balanced, which led to a weak rating. Six trials68,69,72,74–76,78,79 were 
described as double-blind; of these, five used a placebo and were judged strong with respect to 
blinding.68,69,72,74,75,78,79 One trial76 was judged moderate because it was not clear whether or not 
TABLE 52  Details of zinc supplementation provided
Study
zinc given 
where Supplement start Variable zinc dose
Constant zinc 
dose Comparison
zinc content of 
dietary therapy
Doherty et al. 
199868,69
Inpatient 
(15 days) and 
after discharge
Within a week (i) 1.5 mg/kg/day for 15 days 
(ii) 6 mg/kg/day for 15 days 
(iii) 6 mg/kg/day for 30 days
Compared 
doses and 
durations
Inpatient: 
0.3 mg zinc per 
100 ml liquid 
dietb
Gatheru et al. 
198870
Inpatient Not stateda 5 mg/kg/day for the duration 
of treatment
No 
supplement
NR
Golden et al. 
199271
Inpatient When free of 
oedema and 
infection. Able to 
start high-energy 
feeds
High: 10 mg/kg feed + basic 
diet
Moderate: 5 mg/kg 
feed + basic diet
Low: basic diet (3.5 mg)
For duration of treatment
Compared 
doses
3.5 mg/kg feed
Hemalatha et 
al. 199372
Inpatient From patient 
admission
Estimated as equivalent to 
6 mg/kg/day
40 mg/day for 
21 days
Placebo Mean ± SE: 
7.3 ± 0.49 mg 
zinc per day
Khanum et al. 
198873
Inpatient Day 15 10 mg/kg/day for 22 days in 
participants weighing < 6 kg
50 mg/day 
for 22 days in 
participants 
weighing > 6 kg
No 
supplement
zinc in individual 
food items 
ranged from 1.5 
to 7 p.p.m.
Makonnen et 
al. 200374,75
Inpatient and 
after discharge
From patient 
admission
10 mg/day for 
90 days
Placebo NRb
Schlesinger et 
al. 199276
Inpatient Not stateda 15 mg/l of feed for 105 days Feed with 
zinc content 
3.2 mg/l 
No other 
dietary therapy 
(participants 
infants)
Simmer et al. 
198877
Inpatient A minimum of 
3 days (usually 
7 days) after 
admission and 
start of treatment
10 mg/kg/day for 14 days in 
participants weighing < 5 kg
50 mg/day 
for 14 days in 
participants 
weighing > 5 kg
No 
supplement
Mean 3.7 mg zinc 
per day, range 
2.4–5.3 mg
Vasudevan et 
al. 199778
Outpatient From enrolment 6.6 mg for 
3 months
Placebo NRb
Bhutta et al. 
199979
Inpatient and 
after discharge
After 24 hours 
stabilisation phase
3 mg/kg/day for 28 days Placebo Inpatient: 
< 2.5 mg zinc per 
100 g of foodb
NR, not reported; p.p.m., parts per million.
a  Not stated, but likely to be from admission.
b  Zinc content of diet for participants treated as outpatients and those continuing to receive zinc supplements after discharge likely to be 
variable as dependent on the food received within the home.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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the outcome assessor was blinded to the intervention status of the participants. Four trials,70,71,73,77 
that did not use a placebo were all judged weak with respect to blinding.
When judging the methodological quality of data collection methods, the judgement could 
differ depending on the outcome measure. Therefore, the data collection method judgements 
reported here are for the primary outcomes of this systematic review (see Appendix 12). In five 
trials,71–73,77,78 the data collection tool was not described and, therefore, could not be judged as 
valid or reliable. The remaining trials all used valid data collection tools, but only two trials68,69,76 
provided information indicating that the tools were reliable, which allowed data collection to be 
judged strong. The other three trials,70,74,75,79 were rated as moderate because no information about 
the reliability of the tools was reported. Most of the studies were rated as methodologically strong 
for the item on reporting of withdrawals and dropouts, even though six studies70–73,76,78 did not 
report the number and reasons for withdrawals and dropouts. The strong rating could be applied 
because the proportion of participants completing these studies lay between 80% and 100%. Only 
two studies did not gain a strong rating: one70 was judged moderate and one72 was judged weak 
because < 60% of participants completed the study.
The final two elements of the quality assessment tool, ‘intervention integrity’ and ‘analysis 
appropriate to question’, did not contribute to the global rating, but nevertheless provided 
important information about each study. In all studies, 80–100% of participants received their 
allocated intervention, in six trials the consistency of the intervention was measured,71,73,76–79 
and in eight trials70–73,76–79 it was judged unlikely that any unintended intervention had been 
implemented. All studies allocated individual infants/children to trial arms and in only one 
study72 was there insufficient detail to determine whether or not appropriate statistical methods 
had been used. Three studies71,76,79 performed an ITT analysis.
Assessment of effectiveness: zinc
Mortality
Mortality was reported by only two of the studies68,69,74,75 investigating zinc as a supplement 
(Table 54). Doherty and colleagues68,69 conducted a planned interim analysis of the first 100 
participants. Data from the two groups receiving 6 mg/kg zinc were combined and, when 
compared with the group receiving 1.5 mg/kg zinc, the risk of death in the 90-day study period 
was significantly greater for those receiving 6 mg/kg (Yates’-corrected chi-squared value of risk 
of death 4.52, 95% CI for relative risk of 1.09 to 18.8; p = 0.03). This led to the suspension of 
enrolment to the trial, by which point 141 participants had been recruited. Of the 19 deaths 
that occurred overall (all three groups combined), 13 occurred during the inpatient phase and 
11 of these occurred in one of the two 6 mg/kg zinc groups. The six deaths in the outpatient 
phase all occurred in children who had received 6 mg/kg zinc as inpatients (intervention group 
two who subsequently received placebo in the outpatient phase) or were still receiving 6 mg/kg 
zinc (intervention group 3). The clinician’s impression was that sepsis was the cause of death in 
most cases. Doherty and colleagues68,69 conducted an analysis of a range of predictive/prognostic 
factors, but found that none of these factors in conjunction with the higher dose of zinc was 
predictive for death.
Makonnen and colleagues74,75 also recorded the majority of deaths during the initial period of 
hospitalisation. However, in this trial the authors state that there were significantly more deaths 
in the control group, who did not receive a zinc supplement, than in the group that did receive a 
zinc supplement [17.3% mortality in the control vs 4.7% in the zinc group; no p-value given, but 
a 95% CI of 5.5% to 19.5% was reported (although not clear in the paper, it appears that this is 
likely to be the 95% CI for the difference between the groups)]. In each group, some participants 
had to be readmitted after discharge. In the zinc group, two participants were readmitted, one 
5 days after discharge, who was subsequently discharged, and a second identified at the 30-day 70 Assessment of clinical effectiveness
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follow-up who subsequently died. In the control group, four participants were readmitted, three 
after initial discharge, of whom one subsequently died; the fourth was identified at the 30-day 
follow-up and also subsequently died.
Weight gain
Seven studies reported weight gain as an outcome, although the reported measures varied: 
overall weight gain, daily or weekly weight gain, grams of weight gained per kg body weight per 
day and proportion meeting a threshold value of weight gain (Table 55). All the studies except 
that by Gatheru and colleagues70 reported weight gain relative to initial weight or reported the 
proportion of participants meeting a threshold that was a measure of relative weight gain. These 
measures help remove differences due to starting differences in body weight. Three studies,70,73,77 
reported at least one statistically significant difference in a weight gain outcome between the 
groups in favour of zinc supplementation, but four studies71,72,78,79 found no evidence for a 
statistically significant difference between groups. A meta-analysis was not carried out because 
it was considered to be inappropriate because of heterogeneity in the dose(s) of zinc provided, 
differences in the reported outcome measures [units and time point(s) of measurement] and 
other limitations of the data (missing measure of variance).
Gatheru and colleagues70 reported a significantly greater total weight gain in the zinc-
supplemented group than in the control group (mean ± SD, 531 ± 277 g vs 338 ± 235 g; p < 0.05). 
However as noted above, the measures used in this study do not take into account starting 
differences in body weight. Approximately one-quarter of each group did not complete the study, 
but the reasons for this are not provided and it is not clear whether or not this had any impact 
on the outcome. Mean daily weight gain was greater in the zinc-supplemented group (67 g/day) 
than in the control group (47.3 g/day), but no p-value for a statistical comparison of these values 
was reported.
Khanum and colleagues73 found that during the first 2 weeks of rehabilitation (which was before 
zinc supplementation began), the rate of weight gain was not significantly different between 
the groups (see Appendix 12). However, at the start of the third week the intervention group 
started to receive a zinc supplement and Khanum and colleagues73 found that by the end of that 
week the group receiving the zinc supplement had gained significantly more weight than the 
TABLE 54  Mortality in children receiving zinc supplements
Study Treatment arms p-value
Doherty et al. 
199868,69
Zinc 1.5 mg/kg 15 days, 
then placebo 15 days 
(n = 49)
Zinc 6 mg/kg 15 days, 
then placebo 15 days 
(n = 49)
Zinc 6 mg/kg 
30 days (n = 43)
Inpatient deaths, n 2 5 6 Combined zinc 6 mg/kg groups 
vs zinc 1.5 mg/kg; 95% CI for 
relative risk of death 1.09 to 18.8, 
p = 0.03
Outpatient deaths, n 0 3 3
Makonnen et al. 
200374,75
Zinc 10 mg/day until 90 days post 
discharge (n = 150)
Placebo (n = 150) 95% CI for difference
Deaths during 
hospitalisation, n (%)
7 (4.7) 26 (17.3) 95% CI 5.5 to 19.5
Deaths after 
readmission, n
1 2 NR
Total deaths, n (%)a 8 (5.3) 28 (18.7) NR
NR, not reported.
a  Percentage calculated by reviewer.72 Assessment of clinical effectiveness
non-supplemented group (mean ± SE: zinc group 580 ± 67.6 g/week, control group 342 ± 86.5 g/
week; p < 0.05). This statistically significant effect was maintained in the following week, but 
by the fifth week of the study (after 3 weeks of zinc supplementation), the difference in weekly 
weight gain was no longer statistically significant. Khanum and colleagues73 also report that the 
percentage of participants in the zinc-supplemented group who achieved a mean daily weight 
gain of > 10 g/kg was statistically significantly greater than in the control group (66% vs 33%; 
p < 0.02). It is not clear for what time period the mean daily weight gain was calculated.
Simmer and colleagues77 also reported that the percentage of participants in the zinc-
supplemented group who achieved a mean daily weight gain of > 10 g/kg was statistically 
significantly greater than in the control group (42% vs 9%; p < 0.001). However, in this study, 
although the zinc group gained more weight each week than the control group, statistically 
significant differences between the groups for mean daily weight gain and mean daily weight gain 
per kg body weight could not be demonstrated in either week 1 (see Appendix 12) or week 2 (see 
Table 55).
All four of the studies71,72,78,79 that did not find evidence for a statistically significant difference 
between groups reported on the rate of weight gain in terms of g/kg/day (the benefit of a 
relative measure such as g/kg/day is that any effects due to starting differences in body weight 
are removed). Golden and colleagues71 reported mean weight gain during the first 6 weeks 
of recovery. Although children in the moderate- and high-zinc groups gained weight more 
rapidly, the difference between the groups was not significant. Hemalatha and colleagues72 
reported on this outcome separately for weeks 1, 2 and 3 (see Appendix 12) where gains appeared 
similar between groups, and for week 4 (see Table 55) when the difference in outcome was 
described as not statistically significant (mean ± SE: 22.6 ± 5.100 g/kg/day in the zinc group 
vs 24.5 ± 5.035 g/kg/day in the control group; no p-value reported). Bhutta and colleagues79 
reported g/kg/day weight gained separately for the 14 days of inpatient and for the following 
14 days of home-based supplementation. In both cases, although the zinc-supplemented group 
gained a little more weight than the control group and the differences were not found to be 
statistically significant (see Table 55; no p-value reported). Bhutta and colleagues also reported 
the total weight of children at baseline, on day 7 (see Appendix 12) and on day 14 of inpatient 
therapy, but again there was no significant difference between the groups (mean weight on day 
14 in the supplemented group 6.67 ± 1.43 kg vs 7.13 ± 1.42 kg in the placebo group; p = 0.27). 
Finally, Vasudevan and colleagues78 reported a rate of weight gain in terms of g/kg/day, which 
was much lower than that of the other studies (zinc-supplemented group 1.4 g/kg/day vs 0.98 g/
kg/day in the control group; p > 0.1). This lower value may be because the authors appear to have 
based their calculation on the initial weight and a single further weight measurement taken after 
3 months.
Anthropometry
Five studies reported anthropometry outcomes (Table 56).68,69,73–76,79 Two of these studies also 
reported weight gain as a separate measure,73,79 but anthropometry outcomes were the only 
measures capturing weight gain for the other three studies.68,69,74–76 One study73 reported a 
statistically significant difference in anthropometry outcomes between the groups in favour of 
zinc supplementation, two studies reported mixed results74–76 and two studies found no evidence 
for a statistically significant difference between groups.68,69,79 It was considered inappropriate 
to carry out a meta-analysis of these outcomes because of heterogeneity in the dose(s) of zinc 
provided and differences in the reported outcome measures.
Khanum and colleagues73 reported statistically significant differences in favour of zinc 
supplementation in measures of W/H, W/A and the percentage of patients reaching or exceeding 
90% W/H by discharge. There were no significant differences in W/H and W/A at admission © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 55  Weight gain in children receiving zinc supplements
Study Treatment arms p-value
Gatheru et al. 198870 Zinc 5 mg/kg/day during treatment (n = 42) Control (n = 40)
Mean total weight gain ± SD, g n = 31, 531 ± 277 n = 27, 338a ± 235 < 0.05
Mean weight gain/day, g 67 47.3 NR
Golden et al. 199271 Zinc 10 mg/kg feed + basic 
diet (n = 3)
Zinc 5 mg/kg 
feed + basic diet (n = 4)
Zinc 3.5 mg/kg feed 
(basic diet only) (n = 4)
Mean weight gain ± SE during 
first 6 weeks of recovery, 
g/kg/day
11.67 ± 1.41 11.60 ± 0.95 10.10 ± 0.22 NS
Hemalatha et al. 199372 Zinc 40 mg/day for 21 days (n = 16) Placebo (n = 17)
Mean weight gain ± SE in 
week 4, g/kg body weight/day
n = 12, 22.6 ± 5.100 n = 15, 24.5 ± 5.035 NS
Khanum et al. 198873 Zinc 10 mg/kg /day or 50 mg/day if body 
weight > 6 kg, on days 15–36 (n = 30)
Control (n = 30)
Mean weekly weight gain ± SE 
during supplementation,b g/week
Week 1: 580 ± 67.6 Week 1: 342 ± 86.5 < 0.05
Week 2: 403 ± 41.6 Week 2: 269 ± 47.1 < 0.05
Week 3: 462 ± 42.4 Week 3: 374 ± 48.9 NR
Participants with mean weight 
gain rate > 10 g/kg/day, %
66 33 0.02
Simmer et al. 198877 Zinc 10 mg/kg/day or 50 mg/day if weight 
> 5 kg, for 2 weeks (n = 12)
Control (n = 11)
Mean weight gain ± SE week 2, 
g/day
70 ± 20 40 ± 10 NR
Mean weight gain ± SE week 2, 
g/kg/day 
8.83 ± 1.56 5.09 ± 1.62 NR; 95% CI 
0.88 to – 8.36
Achieved an optimal rate of 
weight gain (> 10 g/kg/day), %
42 9 < 0.001
Vasudevan et al. 199778 Zinc 6.6 mg/day for 3 months (n = 31) Placebo (n = 31)
Meanc rate of weight gain, 
g/kg/day
1.4 0.98 > 0.1
Bhutta et al. 199979 Zinc 3 mg/kg/day for 28 days (n = 43) Placebo (n = 44)
Mean weight gain during 14 days 
of inpatient care ± SD,d g/kg/day
10.3 ± 5.7 8.7 ± 6.5 NS
Mean weight on day 14 of 
inpatient care ± SD,d kg 
6.67 ± 1.43 7.13 ± 1.42 0.27e
Mean weight gain during 
14 days of home-based 
supplementation ± SD,d g/kg/day
9.2 ± 46 7.6 ± 5.7 NS
ANOVA, analysis of variance; NR, not reported; NS, not statistically significant.
a  Mean weight gain was reported differently in text (338 g) and table (383 g). It is not clear which value is the correct value.
b  Week 1 of supplementation is week 3 of nutritional rehabilitation. The authors also report that weight gain was the same in both sexes.
c  Presumed to be mean gain, but not explicitly stated.
d  Presumed to be SD, but not explicitly stated.
e  p-values are for the repeated measures ANOVA, which evaluated the interaction of time trend and therapy effect for both groups during 
14 days of therapy. All differences were non-significant. Text indicates that rate of weight gain was slow in children with evidence of systemic 
infection requiring antibiotics, but numerical data are not presented. These patients were distributed equally between the two groups.74 Assessment of clinical effectiveness
(see Appendix 12), but a significant difference in favour of the zinc group was present in W/H 
by the beginning of the first week (eighth day) and in W/A by the beginning of the second week 
of nutritional therapy (15th day). As zinc supplementation only began on day 15, it is not clear 
what led to the differences emerging at this stage. The differences were then maintained for each 
of the following weeks during zinc supplementation (see Appendix 12) until discharge on day 36 
(at discharge W/H in the zinc group 95 ± 1.2, control 86 ± 1.2, p < 0.001; W/A in the zinc group 
68.1 ± 1.58, control 59.7 ± 1.77, p < 0.001). Over 75% of participants were discharged with a W/H 
of ≥ 90% of that expected in the zinc-supplemented group, whereas < 25% of the control group 
reached W/H of ≥ 90% of that expected at discharge.
Makonnen and colleagues74,75 found that at discharge from inpatient care (after a mean length of 
stay of approximately 11 days), there were no significant differences in anthropometry between 
the groups. However, the zinc group continued to receive supplements until 90 days after 
discharge, and at the 90-day follow-up the proportion of children with W/A < 60% was described 
as significantly lower in the zinc group than that of the control group (3.6% vs 13.8%, 95% CI 
for difference −17.2% to −3.1%; no p-value reported), and the proportion with W/A > 80% and 
no oedema was greater (58.7% vs 28.4%; no 95% CI for difference or p-value reported). The 
proportion of zinc-supplemented participants whose MUAC remained below the fifth percentile 
was also lower than those children in the control group (54.1% vs 77.9%, 95% CI for difference 
−35.2% to −11.5%; no p-value reported).
Schlesinger and colleagues76 reported outcomes after 105 days of supplementation, but this was 
the only study in which the participants were all < 1 year of age and so received liquid formula 
only. No significant difference between the groups was apparent when z-scores for H/A, W/A and 
W/H were analysed (see Table 56 and Appendix 12). However, there was a statistically significant 
difference in the proportion of infants in the zinc-supplemented group whose percentile H/A 
score increased after 30 and 45 days of nutritional rehabilitation, indicating that the zinc group 
began to grow earlier than the control group [58% (at 30 days) and 79% (at 45 days) of the 
15 mg/l zinc group had an increase in their H/A percentile score in relation to their admission 
score in comparison with only 20% (at 30 days) and 45% (at 45 days) in the 3.2 mg/l zinc group; 
p < 0.002 and p < 0.03, respectively]. When these data were analysed by sex, the authors found 
that the effect held for males, but not for females (see Appendix 12). This difference was no longer 
significant after 60 days of nutritional rehabilitation (see Table 56).
Doherty and colleagues68,69 reported on the changes in W/A, W/H and H/A z-scores and MUAC 
(see Table 56), as well as knemometry and skinfold thickness (see Appendix 12). There were three 
groups in this study and two comparisons were made, the first between the 1.5 mg/kg and the 
6 mg/kg zinc dose for 15 days and the second between the 6 mg/kg zinc dose for 15 days or for 
30 days. The results reported after 90 days of follow-up indicated that no significant differences 
were reported for either comparison for any of the anthropometric measures reported. Doherty 
and colleagues68,69 did find that, overall, good catch-up growth was achieved over 90 days, with 
the average intragroup W/H z-score improved from 1.54 to 1.67 units, and the H/A z-score 
improved from 0.44 to 0.49 units.
Finally, Bhutta and colleagues79 reported on just the anthropometric measure of MUAC, finding 
no significant differences in this measure after 14 days of inpatient therapy (mean MUAC: zinc 
group 12.0 ± 1.4 cm vs 12.4 ± 1.8 cm in the placebo group; p = 0.66), and no significant differences 
emerged after a further 14 days of home-based supplementation (see Table 56).
Comorbidities
The effect of zinc supplementation on comorbidities was an outcome reported by five 
studies.70,72,74–76,79 In three studies,70,72,79 at least some of these comorbidities had been present © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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at baseline and the study authors report on the effect of the intervention in resolving these. In 
the study76 in which comorbidities were recorded daily for 105 days and the study74,75 reporting 
outcomes at 90-day follow-up, it is likely that new incidences of comorbidities are captured.
Three studies70,72,74,75 reported oedema as an outcome (Table 57). Gatheru and colleagues70 
reported that the duration of oedema ranged between 2 and 18 days for both groups. However, 
a greater proportion of participants in the zinc group had lost their oedema by day 7 (77% vs 
55%), and the mean number of days taken to lose oedema was statistically significantly lower 
in the zinc group (mean ± SD: zinc group 6.3 ± 4.6 days vs control group 8.1 ± 4.4 days; p < 0.05). 
In contrast, Hemalatha and colleagues72 found no statistically significant difference in the mean 
number of days taken to lose oedema (mean ± SE: zinc group 9.0 ± 2.0 days vs control group 
15.7 ± 2.7 days). In the final study to report oedema, Makonnen and colleagues74,75 found a 
trend for the zinc group to recover more quickly during the first 3 weeks of hospitalisation, but 
the difference between the groups was not statistically significant (see Appendix 12) and by the 
90-day follow-up no patient in either group had any oedema.
Diarrhoea was reported by four studies70,74–76,79 and the results were mixed, with two studies70,74,75 
finding statistically significant differences in favour of zinc supplementation, one study76 finding a 
statistically significant difference in favour of the control group, and one79 finding no statistically 
significant differences between the groups. Gatheru and colleagues70 reported that the duration 
of diarrhoea was statistically significantly lower in the zinc group than in the control group 
(zinc group 3.62 ± 2.78 days vs control group 10.8 ± 3.4 days; p < 0.001). It is not clear whether 
the participants contributing data to this outcome all had diarrhoea at baseline or whether 
new episodes of diarrhoea arising during treatment are included. Makonnen and colleagues74,75 
also found in favour of zinc supplementation when reporting on the proportion of participants 
with diarrhoea at the 90-day follow-up. A statistically significant difference was observed, with 
fewer participants having diarrhoea in the zinc-supplemented group than in the placebo group 
(zinc group 2.9% vs placebo group 36.7%, 95% CI for difference −32% to −15%). In contrast, 
Schlesinger and colleagues,76 who analysed infectious episodes using three indices (mean 
episodes/infant, mean duration of each episode and mean percentage days infected during the 
105 days of rehabilitation), found a statistically significant difference in the average number of 
acute diarrhoeal episodes that favoured the formula with low zinc content (zinc 15 mg/l formula 
two episodes vs zinc 3.2 mg/l zero episodes; p-value not reported). Schlesinger and colleagues76 
stated that each episode lasted 1–2 days and had no impact on nutritional rehabilitation. Finally, 
Bhutta and colleagues,79 who focused their study on the treatment of children with diarrhoea at 
baseline, recorded two measures for the 14-day inpatient phase of their study: stool frequency 
and stool volume. No statistically significant differences were found between the groups for either 
measure (see Table 57).
The remaining morbidity outcomes reported by the studies (see Table 57) provide mixed results. 
Two studies70,74,75 reported statistically significant differences in favour of the zinc-supplemented 
group: Gatheru and colleagues70 for duration of anorexia and time taken for skin lesions to heal 
and Makonnen and colleagues74,75 for the proportion of participants with vomiting, fever, acute 
respiratory infections, skin infections or pallor at the 90-day follow-up. One study76 reported 
that the mean number of otitis media episodes came close to reaching a statistically significant 
difference between the groups in favour of the group receiving a higher concentration of zinc 
(zinc 15 mg/l formula 0.73 ± 0.9 vs zinc 3.2 formula 1.85 ± 2.3; p-value between 0.05 and 0.1), but 
the same authors stated that for number or duration of upper and lower respiratory infection, 
purulent conjunctivitis, and skin and mucous candidiasis, no differences were observed between 
groups (see Appendix 12). Finally, for the outcome duration of morbidity because of infections, 
Hemalatha and colleagues72 state that the groups were comparable, but no p-value is reported.76 Assessment of clinical effectiveness
TABLE 56  Anthropometric outcomes in children receiving zinc supplements
Study Treatment arms p-value
Doherty et al. 199868,69
Intervention 1 (I1):zinc 
1.5 mg/kg for 15 days, 
then placebo for 
15 days (n = 43)
Intervention 2 (I2): zinc 
6 mg/kg for 15 days, 
then placebo for 15 days 
(n = 38)
Intervention 3 (I3): 
zinc 6 mg/kg for 
30 days (n = 25)
95% CI for mean 
difference
Mean change in W/A 
z-score ± SD at 90 days
1.35 ± 0.69 1.51 ± 0.65 1.45 ± 0.66 I2–I1: (−0.27 to 0.52)
I3–I2: (−0.47 to 0.38)
Mean change in W/H 
z-score ± SD at 90 days
1.54 ± 0.93 1.67 ± 0.78 1.62 ± 0.86 I2–I1: (−0.14 to 0.46)
I3–I2: (−0.39 to 0.27)
Mean change in H/A 
z-score ± SD at 90 days
0.44 ± 0.32 0.48 ± 0.38 0.49 ± 0.27 I2–I1: (−0.11 to 0.2)
I3–I2: (−0.17 to 0.18)
Mean change in MUAC ± SD at 
90 days, cm
1.66 ± 1.40 1.98 ± 1.17 1.9 ± 1.38 I2–I1: (−0.26 to 0.89)
I3–I2: (−0.72 to 0.57)
Khanum et al. 198873
Zinc 10 mg/kg/day or 50 mg/day if 
body weight > 6 kg on days 15–36 
(n = 30) Control (n = 30) p-value
Mean W/Ha ± SE
  Day 8 76 ± 1.4 72 ± 1.0 < 0.05
  Day 15 (zinc started) 80 ± 1.4 75 ± 1.1 < 0.05
  Day 36 (discharged) 95 ± 1.2 86 ± 1.2 < 0.001
Mean W/Aa ± SE
  Day 8 52.5 ± 1.44 (n = 29) 49.9 ± 1.44 (n = 28) NR
  Day 15 (zinc started) 58.1 ± 1.53 (n = 29) 52.3 ± 1.60 (n = 28) < 0.05
  Day 36 (discharged) 68.1 ± 1.58 (n = 29) 59.7 ± 1.77 (n = 28) < 0.001
Discharge W/H, n (%)
  < 80%  0 (0) 5 (16.7) NR
 80–90% 7 (23.3) 18 (60.0) NR
  ≥ 90% 23 (76.6) 7 (23.3) < 0.001
Makonnen et al. 200374,75
Zinc 10 mg/day to 90 days post 
discharge (n = 150) Placebo (n = 150) 95% CI for difference
Discharge W/A, n (%) n = 139 n = 120
  < 60% 44 (31.7) 30 (25)  −4.4 to 17.4
 60–80% 78 (56.1) 74 (61.7) NR
  > 80% without oedemab 17 (12.2) 16 (13.3) NR
Discharge MUAC less than fifth 
percentile, n (%)
92 (92.9) 82 (85.4) −1.3 to 16.1
90-day follow-up W/A, n (%) n = 138 n = 116
  < 60% 5 (3.6%) 16 (13.8%) −17.2 to −3.1
 60–80% 52 (37.7%) 67 (57.8%) NR
  > 80% without oedema 81 (58.7%) 33 (28.4%) NRc
90-day follow-up MUAC less 
than fifth percentile, n (%)
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Adverse effects
Oral exposure to large doses of supplemental zinc is associated with some known adverse 
events, such as gastrointestinal effects (e.g. nausea) and copper deficiency.83 Two studies 
specifically checked for the adverse effects of zinc on plasma copper levels.72,79 Hemalatha and 
colleagues72 reported that, although plasma copper levels rose significantly in both groups, the 
zinc supplementation did not adversely affect plasma copper levels. In contrast, Bhutta and 
colleagues79 found that serum copper levels fell during zinc supplementation, whereas in the 
placebo group serum copper levels significantly increased. Both Simmer and colleagues77 and 
Vasudevan and colleagues78 reported that no adverse effects were noted in the zinc-supplemented 
groups. Simmer and colleagues77 reported that tube feeding was required for one patient in 
each group and two patients in each group received a blood transfusion. This study additionally 
reported on anorexia, which can develop because of zinc deficiency and might have been 
expected to affect the control group, but there was no difference in calorie or protein intakes 
between the groups. Two trials68,69,76 reported on comorbidity events which have already been 
noted in the sections above. Doherty and colleagues68,69 had to suspend enrolment to their trial 
when the groups receiving 6 mg/kg zinc supplements were found to be at a significantly greater 
risk of death than the group receiving 1.5 mg/kg zinc supplements. Schlesinger and colleagues76 
found that infants receiving formula with a zinc content of 15 mg/l had on average two acute 
Study Treatment arms p-value
Schlesinger et al. 199276
Zinc 15 mg/l in infant formula for 
105 days (n = 19)
Zinc 3.2 mg/l in infant formula for 
105 days (n = 20) p-value
Mean H/A z-score ± SD at 
105 days
−2.64 (0.86) −2.56 (0.84) NS
Mean W/A z-score ± SD at 
105 days
−1.66 (0.64) −1.59 (0.88) NS
Mean W/L z-score ± SD at 
105 days
0.42 (0.81) 0.32 (1.22) NS
Proportion with increase in H/A percentile score from admission, n/N (%)
  30 days 11/19 (58) 4/20 (20) < 0.002
  45 days 15/19 (79) 9/20 (45) < 0.03
  60 days 13/19 (68) 11/20 (55) NS
Bhutta et al. 199979 Zinc 3 mg/kg/day for 28 days (n = 43) Placebo (n = 44) p-value
Mean MUAC ± SDd on day 14 of 
inpatient care, cm
12.0 ± 1.4 12.4 ± 1.8 0.66e
Mean increment in MUAC ± SDd 
during 14 days of inpatient 
care, cm
0.3 ± 0.3 0.4 ± 0.3 NS
Mean increment in MUAC ± SDd 
after 14 days of home-based 
supplementation, cm
0.13 ± 0.28 0.19 ± 0.40 NR
ANOVA, analysis of variance; NR, not reported; NS, not statistically significant.
a  As a percentage of the Harvard reference.
b  Most children likely to have been discharged based on progressive weight gain of > 5 g/kg/day (rather than having W/A > 80%), as proportion 
with W/A > 80% on discharge is relatively small.
c  Reports in text that this difference is statistically significant, but no p-value or CI is provided.
d  Presumed to be SD, but not explicitly stated.
e  p-values are for the repeated measures ANOVA, which evaluated the interaction of time trend and therapy effect for both groups during 
14 days of therapy. All differences are non-significant.
TABLE 56  Anthropometric outcomes in children receiving zinc supplements (continued)78 Assessment of clinical effectiveness
TABLE 57  Comorbidities in children receiving zinc supplements
Study Treatment arms p-value
Gatheru et al. 198870
Zinc 5 mg/kg/day during treatment 
(n = 42) Control (n = 40)
Oedema duration, range in days 2–18 (n = 31) 2–18 (n = 26) NR
Oedema lost by end of day 7, % 77 (n = 31) 55 (n = 26) NR
Mean days taken to lose oedema ± SD 6.3 ± 4.6 (n = 31) 8.1 ± 4.4 (n = 26) < 0.05
Mean diarrhoeaa duration ± SD, days 3.62 ± 2.78 (n = 17) 10.8 ± 3.4 (n = 22) < 0.001
Mean anorexiaa duration ± SD, days 6 ± 3.16 (n = 26) 10.3 ± 5.01 (n = 22) < 0.01
Mean days taken for skin lesionsa to 
heal ± SD
7.9 ± 3.1 (n = 10) 11.1 ± 2.1 (n = 9) < 0.03
Hemalatha et al. 199372 Zinc 40 mg/day for 21 days 
(n = 16)
Placebo (n = 17)
Mean days for oedema to disappear ± SE 9.0 ± 2.035 15.7 ± 2.7 NS
Mean duration of morbidity because of 
infections ± SE, days
6.3 ± 0.959 7.7 ± 1.040 NRb
Makonnen et al. 200374,75
Zinc 10 mg/day until 90 days post 
discharge (n = 150) Placebo (n = 150) 95% CI for difference
Morbidity on follow-up (90 days), n (%) n = 138, 85–95 days c n = 116, 83–95 daysc
 Oedema 0 (0) 0 (0) −2.0 to 1.2
 Diarrhoea  4 (2.9) 31 (36.7) −32.0 to −15.0
 Vomiting 1 (0.7) 8 (6.9) −11.2 to −1.2
  Skin infection 1 (0.7) 8 (6.9) −11.2 to −1.2
 Fever 4 (2.9) 12 (10.3) −13.8 to −1.1
 ARI 4 (2.9) 45 (38.8) −44.7 to −26.2
 Pallor 32 (23.2) 62 (53.4) −41.3 to −18.4
Schlesinger et al. 199276
Zinc 15 mg/l in infant formula for 
105 days (n = 19)
Zinc 3.2 mg/l in infant formula 
for 105 days (n = 20)
Otitis media episodes (mean ± SD) 
during the 105 days rehabilitation
0.73 ± 0.9 1.85 ± 2.3 0.05 > p < 0.1, Student’s 
t-test
Average number of acute diarrhoeal 
episodes
2 0 Statistically significant 
difference, p-value NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
79   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
diarrhoeal episodes, whereas infants receiving 3.2 mg/l zinc formula had no such episodes. 
However, this statistically significant difference in diarrhoeal episodes had no impact on 
nutritional rehabilitation. The remaining studies did not report adverse events.70,71,73–75
Zinc status
Eight70,72–79 of the 10 studies reported on zinc status, and the results are briefly summarised here, 
with details provided in Appendix 12. It should be noted, however, that although serum or plasma 
zinc may be the best available biomarker at a population level to reflect dietary zinc intake, and 
although it changes in response to zinc supplementation, it does not necessarily reflect individual 
zinc status.84 Five studies70,73–75,78,79 found a statistically significant difference in serum zinc 
concentrations between the groups, with serum zinc being higher following supplementation 
than it was in the non-supplemented group. One study found a statistically significant difference 
in the proportion of participants defined as having a low plasma zinc, which was in favour of 
the zinc-supplemented group.76 Two studies72,77 did not report differences between groups, but 
did report statistically significant increases in plasma zinc in comparison with baseline values in 
either the zinc group or both study groups. Three studies72,76,77 also reported the difference from 
baseline in leucocyte zinc. One study72 found that leucocyte zinc was statistically significantly 
increased from baseline in both groups, one77 reported a statistically significant difference for the 
zinc-supplemented group only, and one76 found no significant differences in either group.
Other outcomes
Additional outcomes, such as duration of hospital stay, calorie intake, nitrogen intake and results 
of biochemical assays, were also reported by some studies, but have not been presented here. 
Further details are available in the data extraction forms in Appendix 12.
Study Treatment arms p-value
Bhutta et al. 199979
Zinc 3 mg/kg/day for 28 days 
(n = 43) Placebo (n = 44)
Mean stool frequency ± SDd (n/day)
  Day 1 10.2 ± 6.4 11.8 ± 7.8
  Day 7 5.9 ± 5.6 5.2 ± 3.7
  Day 14 2.9 ± 1.6 3.0 ± 2.2 0.52e
Decrease in stool frequency (n/day) 7.4 ± 7.4 8.1 ± 8.8 NS
Stool volume (g/kg/day) (males)
  Day 1 116.8 ± 103.7 141.9 ± 171.6
  Day 7 66.7 ± 68.1 43.9 ± 40.1
  Day 14 24.9 ± 16.2 27.8 ± 31.4 0.42e
Decrease in stool volume (g/kg/day) 91.1 ± 103.6 98.0 ± 187.9 NS
ANOVA, analysis of variance; ARI, acute respiratory infection; NR, not reported; NS, not statistically significant.
a  The number of participants contributing data to these outcomes varied, and it is not known how many participants had diarrhoea, anorexia or 
skin lesions at baseline.
b  States groups were comparable, but no p-value reported.
c  Time elapsed from discharge to third follow-up. Data were presented for morbidities during the first 3 weeks of hospitalisation (no morbidity, 
poor appetite, oedema, diarrhoea, vomiting, cough, fever, weight loss and oral lesions). The paper reports a general trend for the zinc-
supplemented group to recover more rapidly, though it is not true for all symptoms nor were there any statistically significant differences over 
the first 3 weeks.
d  Presumed to be SD, but not explicitly stated.
e  p-values are for the repeated measures ANOVA, which evaluated the interaction of time trend and therapy effect for both groups during 
14 days of therapy. All differences are non-significant.
TABLE 57  Comorbidities in children receiving zinc supplements (continued)80 Assessment of clinical effectiveness
Summary
  ■ Ten trials investigated zinc supplements as part of a treatment regimen for SAM.68–79 The 
trials took place in seven countries, and employed different criteria for identifying SAM; 
in addition, the age range of enrolled children differed and most reported on fewer than 
100 participants. One study focused on participants who also had persistent diarrhoea.79 
The interventions also varied in many aspects. More than half of the studies were of weak 
methodological quality,70–73,77,78 two were of moderate quality74–76 and only two were judged to 
have strong methodological quality.68,69,79 Only three trials conducted an ITT analysis of the 
data.71,76,79
  ■ Only two studies68,69,74,75 reported mortality as an outcome. One study68,69 of children aged 
from 6 to 36 months suspended enrolment to the trial after an interim analysis found a 
significant risk of death for participants receiving 6 mg/kg/day zinc in comparison with those 
receiving 1.5 mg/kg/day zinc. In contrast, in the other study74,75 that enrolled children aged 
from 6 to 60 months, significantly more deaths were reported in the group receiving placebo 
than in the group receiving a zinc dose of 10 mg/day. One study provided zinc according 
to body weight68,69 and the other as a fixed dose,74,75 and although neither study reports on 
the weight of participants, the 10 mg/day dose is likely to be one of the lowest provided 
whereas the 6 mg/kg/day dose is likely to be one of the highest. It is difficult to know how 
similar the participants were because the studies do not report on the same anthropometric 
characteristics at baseline, although the criteria for defining SAM were comparable.
  ■ Intervention effects on weight were reported directly by seven studies70–73,77–79 (e.g. as absolute 
gains in weight or rate of weight gain) or as anthropometric measures by five studies68,69,73–76,79 
(e.g. W/H, W/A), with two of these studies reporting weight both directly and by 
anthropometry. The results for weight and anthropometry outcomes are conflicting, with 
three studies70,73,77 reporting statistically significant effects in favour of zinc supplementation, 
two studies reporting mixed results74–76 (in favour of zinc or no significant differences 
between the groups) and five studies68,69,71,72,78,79 finding no significant differences between 
the groups. None of the studies reported a statistically significant effect in favour of the 
comparator/control group for a weight-related outcome.
  ■ Five studies70,72,74–76,79 reported the effect of zinc supplementation on comorbidities, either 
those present at baseline or also including new incidences of comorbidities. Again, the results 
present a mixed picture. One study70 found that zinc significantly reduced the duration of 
four comorbidities present at baseline, whereas another study74,75 reported a statistically 
significant beneficial effect of zinc at the 90-day follow-up for six of the seven comorbidities 
assessed. In contrast, two other studies found no statistically significant effects on diarrhoea 
(one study79) or oedema (one study72), and a third study76 stated that there was a statistically 
significant difference in the average number of acute episodes of diarrhoea that favoured the 
control group (i.e. lower dose zinc).
  ■ Four studies70,71,73–75 did not report on adverse events and two77,78 reported that no adverse 
events occurred because of zinc supplementation. Two studies specifically reported the 
impact of zinc supplementation on plasma copper because exposure to large doses of 
supplemental zinc is known to cause copper deficiency. In one study72 plasma copper levels 
rose in both groups, whereas in the other study79 copper levels significantly increased in the 
placebo group but fell in the group receiving zinc, and the study authors suggest that it may 
be more appropriate to provide a mix of micronutrients as a supplement rather than zinc 
alone. As already noted above, statistically significant differences in mortality were reported 
by one study67,68 in which more deaths occurred in the 6 mg/kg/day zinc-supplemented 
group, and in another study more episodes of acute diarrhoea75 occurred in the zinc group, 
although in this latter case this was stated not to have affected nutritional rehabilitation.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quantity and quality of research available: other supplements
There were three trials examining supplements other than zinc: one evaluating potassium,80 one 
evaluating nicotinic acid81 and one evaluating NTs82 (Table 58). All three trials were conducted 
in single centres. One trial was a double-blind RCT,82 whereas the other two trials were judged to 
be CCTs during quality assessment (see Table 59).80,81 The trials were set in India,81 Malawi80 and 
Mexico,82 with none reporting any external funding.
There was no consistency in the type of supplement compared by the three trials. Manary and 
Brewster80 evaluated a high dose of potassium (total dose 7.7 mmol/kg/day) versus a standard 
dose (total dose 4.7 mmol/kg/day) for the first 7 days of therapy. Philip and colleagues81 compared 
the addition of three doses of nicotinic acid per day (25 mg/kg /day) versus none for 1 month. 
Vásquez-Garibay and colleagues82 compared a milk-based formula with added NTs versus a 
formula of the same energy density, but without the addition of NTs. All trials took place in the 
hospital inpatient setting.
The sample sizes were small, varying from 2582 to 116 children.80 Mean age ranged from 7.6 to 
8.1 months in one trial82 and from 27.9 to 29.3 months in another.80 However, both these trials 
reported baseline characteristics for children completing the trial only. Philip and colleagues81 did 
not provide any baseline characteristics, but included children aged from 0 to 4 years. Sex was 
reported by only one trial,82 with almost double the number of boys as girls.
Only one trial, by Vásquez-Garibay and colleagues,82 provided a definition for severe 
malnutrition, this being W/A or W/H of < −3 SD from the median NCHS reference. Manary and 
Brewster80 included children with kwashiorkor, all of whom had oedema, whereas Philip and 
colleagues81 included children fulfilling what they called ‘the standard criteria’ for marasmus.
Baseline mean W/H z-scores suggested a greater severity of malnutrition in the children in the 
trial by Vásquez-Garibay and colleagues82 than in those in the trial by Manary and Brewster.80 
However, it appears that the W/H z-scores in the latter study were calculated before loss of 
oedema (z-scores would be expected to be lower, indicating more severe malnutrition after 
loss of oedema). Also, in the trial by Vásquez-Garibay and colleagues,82 mean baseline arm 
circumference (assumed to be MUAC) appears to be very low, falling well below the threshold 
for SAM. Without baseline characteristics, it is unclear if the severity of malnutrition was 
comparable with the population in the trial by Philip and colleagues with that in the other 
two trials.81
Summary of quality assessment
Two of the included trials were rated overall as weak for their methodological quality and quality 
of reporting (Table 59),81,82 with the third being rated overall as moderate.80
For selection bias, two trials were rated as strong,80,82 whereas the study of Philip and colleagues81 
was rated as weak and therefore at potential risk of selection bias. A strong rating indicates that 
the selected individuals are likely to be representative of the target population and ≥ 80% of 
selected individuals participated in the trial. A weak rating indicates that participants may not be 
representative of the target population, or that the selection method and/or levels of participation 
were unclear/not described. All three trials were rated as strong for their study design. Two of the 
trials were described as RCTs80,82 and one as a CCT;81 however, the trial by Manary and Brewster80 
was judged to be a CCT, as it provided no details of the randomisation method/procedure.
Only one trial had no important differences in baseline characteristics between the trial arms, 
and without potentially confounding variables was rated as strong.80 The remaining two trials81,82 
were rated as weak. Philip and colleagues81 only reported age for baseline characteristics and 82 Assessment of clinical effectiveness
TABLE 58  Characteristics of the included studies providing other supplements
Study details and target population Study arms
Manary and Brewster 199780
Design: CCTa
Location: Malawi
Length of follow-up: unclear
No. enrolled: 116
Target population: children aged 
< 3 years with kwashiorkor (all had 
oedema)
High potassium: 3 mmol/kg potassium 
above the standard. Total potassium dose of 
7.7 mmol/kg/day for the first 7 days of therapy
Standard potassium: 3.2 mmol/kg/day of potassium. 
Total potassium dose of 4.7 mmol/kg/day for the 
first 7 days of therapy
Selected baseline characteristicsb
Mean age ± SD: 29.3 ± 14 months
Sex F : M: NR
Mean W/H z-score ± SD: −2.04 ± 1.20
MUAC: NR
W/A: NR
Baseline potassium: NR
Selected baseline characteristicsb
Mean age ± SD: 27.9 ± 15 months
Sex F : M: NR
Mean W/H z-score ± SD: −2.40 ± 1.13
MUAC: NR
W/A: NR
Baseline potassium: NR
Philip et al. 198281
Design: CCT
Location: India
Length of follow-up: 1 month
No. enrolled: 80
Target population: children aged 
0–4 years with marasmus
Nicotinic acid, 25 mg/kg/day (three divided doses) 
for 1 month
No nicotinic acid supplement
Selected baseline characteristics
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Baseline nicotinic acid: NR
Selected baseline characteristics
Mean age: NR
Sex F : M: NR
W/H: NR
MUAC: NR
W/A: NR
Baseline nicotinic acid: NR
Vásquez-Garibay et al. 200582
Design: RCT
Location: Mexico
Length of follow-up: 4 weeks
No. enrolled: 25
Target population: children aged 
3–18 months W/A or W/H < −3 SD 
from the median NCHS/WHO 1996 
standard
Milk-based formula with NT Formula of the same energy density, but no NTs
Selected baseline characteristicsb
Mean age ± SD: 7.6 ± 4.6 months
Sex F : M, %: 27 : 73c
Mean W/H z-score ± SD: −2.80 ± 0.73
Mean MUACd ± SD: 7.9 ± 1.1 cm
W/A: NR
Selected baseline characteristicsb
Mean age ± SD: 8.1 ± 3.2 months
Sex F : M, %: 44 : 56c
Mean W/H z-score ± SD: −2.99 ± 0.74
Mean MUACd ± SD: 7.6 ± 1.0 cm
W/A: NR
NR, not reported.
a  Trial described as a RCT; however, during quality assessment it was judged to be a CCT (in accordance with the methods for use of the quality 
assessment tool) because no information was provided about the method of randomisation.
b  Baseline characteristics reported only for participants completing the study. The standard that W/H was compared with was not stated.
c  Percentage calculated by the reviewer.
d  Reports arm circumference, assumed to be MUAC.
it is, therefore, unclear if there were any confounding variables, whereas Vásquez-Garibay and 
colleagues82 acknowledged some differences between the treatment arms. It is unclear if these 
differences were between or within treatment arms. For blinding, only one trial employed a 
double-blind method and was therefore rated as strong.80 The two remaining trials provided 
no details and were therefore rated as weak.81,82 Both trials could therefore be at risk of bias in 
either the care provided (performance bias) or how the outcomes were assessed (measurement 
or detection bias) or both. Not blinding children/parents to the research question could lead to 
reporting bias. It may not always be possible to blind children/parents to the intervention, but the 
potential bias needs to be kept in mind when interpreting the results.
Two trials were rated as weak80,81 and one as moderate82 for their data collection methods. Only 
the trial by Vásquez-Garibay and colleagues82 used valid data collection tools, but it was not 
possible to judge if these tools were reliably employed. For the trials rated as weak, it was not © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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.84 Assessment of clinical effectiveness
possible to assess if either the data collection tools were valid or reliable.80,81 All three trials 
were rated as strong for withdrawals and dropouts, providing both numbers and reasons, as 
well as having ≥ 80% of participants completing the study. For intervention integrity, there 
was no information in one trial on either the percentage of participants who had received 
the intervention or if the consistency of the intervention had been measured.81 In the other 
two trials,80,82 ≥ 80% of participants received the allocated intervention, but only one of these 
measured the consistency of the intervention.82 There appeared to be no contamination of 
the interventions (i.e. all children received the allocated intervention only) in any of the three 
trials. All trials used the infant/child as the unit of allocation and for statistical analysis of the 
results, and were judged to use appropriate methods of statistical analysis for the research 
question. However, only one of the trials reported on how missing data were dealt with in the 
analysis (i.e. ITT).81
Assessment of effectiveness: other supplements
Mortality
Only Manary and Brewster80 reported mortality as an outcome (Table 60). There were a total 
of 34 (34%) deaths in hospital during the trial, 14 out of 48 deaths in the high-dose potassium 
intervention group compared with 20 out of 51 in the standard potassium control group. 
However, although the case fatality rate reduced by 33% in the intervention group, the difference 
between the groups was not statistically significant (p = 0.40). Twenty-one of the 34 deaths 
were early deaths (within 5 days) and 13 were late deaths (after 5 days). However, 11 children 
(intervention n = 3, control n = 8) were taken from hospital after completing the 7-day trial before 
discharge, resolution of oedema and clinical improvement. Only the percentage of late deaths 
was statistically significant after adjusting it to include three children (all from the control group) 
who had left hospital and who were not expected to have survived at home, with a lower number 
of deaths in the high-dose potassium intervention group (8%) than in the standard potassium 
control group (32%; p = 0.02) [OR 5.3 (95% CI 1.2 to 31.0)]. The five children whose deaths 
between days 9 and 13 were classified as unexpected all had persisting diarrhoea.
Weight gain
Two out of the three trials reported weight gain, but only one trial81 reported weight gain relative 
to initial weight (thus removing effects owing to the starting differences in body weight).81,82 The 
TABLE 60  Mortality in children receiving other supplements 
Study Treatment arms p-value
Manary and Brewster 199780 High potassium (n = 48) Standard potassium (n = 51)
Deaths in hospital, n/N (%) 14/48 (29.2) 20/51 (39.2)  0.40
Deaths during first 48 hours, n 6 6 NR
Death during days 3–5, n 5 4 NR
Late deaths, n 3 10 NR
Adjusted late deaths,a n/N (%) 3/37 (8.1) 13/41 (31.7)b  0.02
Causes of late death
Sepsis, n 3 3 NR
Anaemia, n 2 NR
Unexpected,c n 5 NR 
NR, not reported.
a  Denominators reported in the published paper excluded 21 early deaths (intervention n = 11, control n = 10).
b  Includes death of three seriously ill children, who were unlikely to have survived at home according to a blinded chart assessment.
c  Deaths classified as unexpected if there was no clinical indication of a life-threatening complication.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 61  Weight gain in children receiving other supplements 
Study Treatment arms p-value
Philip et al. 198281 Nicotinic acid (n = 40) Standard diet (n = 40)
Mean weight gain in 1 month ± SD, g/kg 231.05 ± 20.05 171.81 ± 22.01 0.001a
Vásquez-Garibay et al. 200582 Added NT (n = 11) No added NT (n = 9)
Mean weight gain ± SD, g/day 67 ± 15 69 ± 12 NR
NR, not reported.
a  Assumed Student’s t-test, as reported as t = 13.05.
trial by Manary and Brewster80 only reported weight loss, although it is not particularly clear if 
this was because of resolution of oedema.
Philip and colleagues81 calculated separately for each week, with both groups showing maximum 
gain during week 2, followed by week 3, with the lowest gain in weeks 1 and 4 (no data reported). 
For both groups, the rate of weight gain was slightly higher in those children with a greater 
initial weight deficit. Mean weight gain in 1 month was statistically significantly higher in the 
intervention group with added nicotinic acid (p = 0.001; Table 61). In the trial by Vásquez-
Garibay and colleagues,82 mean weight gain per day was similar between groups regardless of the 
addition of NT (no p-value reported). Typical weight gain was said to be five times higher than 
that of normal infants aged around 8 months.
Anthropometric measures
Only Vásquez-Garibay and colleagues82 reported on this outcome. The authors state that there 
was a significant improvement in W/A in both groups from the first week regardless of the 
addition of NTs, but presented no data. The same trend was reported for W/L (Table 62), but only 
p-values for within-group differences were reported. The pace of linear growth was said to be 
double that of normal infants aged around 8 months.
Vásquez-Garibay and colleagues82 also included total upper-arm area, upper-arm muscle area, 
upper-arm fat area and the arm fat index as outcomes, but differences were not significant 
between groups at week 4 regardless of the addition of NTs, although there were statistically 
significant within-group differences (see Appendix 12).
Additional outcomes
Manary and Brewster80 reported weight loss as one of their clinical outcomes (although not 
explicitly stated, this is presumed to be reported as an indication of the resolution of oedema 
following the start of treatment). There were no statistically significant differences between the 
treatment arms by day 7 (p = 0.36) or after discharge (p = 0.61) regardless of the added potassium 
(Table 63), nor were there any significant differences between treatment arms in the number 
of days children stayed in hospital (p = 0.21). However, the high-potassium intervention group 
suffered significantly fewer presumed septic episodes (3 vs 18) [OR 8.9 (95% CI 2.2 to 50.9)], 
respiratory symptoms and new skin ulcerations than the standard-potassium control group, as 
illustrated in Table 64.
Mean urea concentration and mean alkaline phosphatase were statistically significantly lower for 
the intervention with added NTs (p = 0.009 and p = 0.041, respectively).82 Treatment arms were 
combined for initial versus final outcome comparisons of white blood cell count, creatinine, 
glucose, calcium and phosphorus levels, with all showing significant improvements for the 86 Assessment of clinical effectiveness
TABLE 62  Anthropometric outcomes in children receiving other supplements
Study Treatment arms p-value
Vásquez-Garibay et al. 200582 Added NTs (n = 11) No added NTs (n = 9) a
Mean W/L z-score ± SD
  Week 1 −2.80 ± 0.73 −2.99 ± 0.74
  Week 4 −0.64 ± 0.66b −0.94 ± 0.47b
Mean initial BMI ± SD  11.0 ± 0.9  10.6 ± 1.0 0.33
Mean fourth week BMI ± SD 15.1 ± 1.0 14.5 ± 1.0 0.23
Mean skin fold ± SD, mm
 Triceps,b initial week 3.8 ± 1.0 2.8 ± 0.6 0.031
  Triceps, fourth week 9.2 ± 2.6 8.5 ± 1.6 0.517
 Subscapular,c initial week 2.9 ± 0.7 2.4 ± 0.6 0.076
  Subscapular, fourth week  8.1 ± 2.7 6.4 ± 1.1 0.112
 Subcostal,c initial week 2.3 ± 0.5 1.8 ± 0.3 0.045
  Subcosta, fourth week  5.5 ± 1.9 4.0 ± 0.6 0.004
 Suprailiac,c initial week 2.2 ± 0.5 1.7 ± 0.3 0.020 
  Suprailiac, fourth week  5.7 ± 2.5 4.2 ± 0.6 0.114 
BMI, body mass index.
a Some  p-values are differences between groups. Because of the absence of further notations, it is uncertain which p-values are for within-
group and which for between-group differences.
b  Increase in W/L z-score from initial to week 4 was significant within groups (added NTs p < 0.001, no added NTs p = 0.001).
c Denotes  p < 0.001; initial vs fourth week within each group.
TABLE 63  Additional outcomes in children receiving other supplements
Study Treatment arms p-value
Manary and Brewster 199780 High potassium (n = 37)a Standard potassium (n = 41)a
Mean percentage weight loss by day 7 ± SD 5.6 ± 8.0 4.0 ± 7.2 0.36
Mean percentage weight loss by discharge ± SD 4.9 ± 9.1 3.8 ± 10.3 0.61
Mean length of hospital stay ± SD, days 11.6 ± 0.9 13.2 ± 4.9 0.21
Left before discharge (after day 7), n/N (%) 3/37 (8) 8/41 (19.5) 0.15
a  Excluding 21 early deaths.
whole group apart from changes in white blood cell count.85 Philip and colleagues81 included 
an outcome for calories consumed for 1 g gain in weight. Although this was lower in the 
intervention group (14.2 vs 19.3), which had the added nicotinic acid; no p-value was reported.
Summary
  ■ Three trials investigated supplements other than zinc as part of a treatment regimen for 
SAM. Each trial examined a different supplement either potassium,80 nicotinic acid81 or 
NTs.82 The trials took place in different countries and enrolled participants meeting different 
criteria. Two of the studies81,82 were of weak methodological quality; the third80 was of 
moderate quality. Only one trial81 conducted an ITT analysis of the data.
  ■ Only the study80 providing high-dose potassium to the intervention group reported mortality 
as an outcome. This trial found no difference in early deaths, but found a statistically 
significant benefit for the intervention group receiving high-dose potassium for late deaths, 
which meant that there was a 33% reduction in the case fatality rate overall in this group.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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  ■ Intervention effects on weight were reported directly by two studies as mean weight gained 
per kg of body weight81 or mean weight gained per day.82 One of these studies82 also reported 
weight gain in terms of body mass index (BMI), alongside other anthropometric measures. 
Participants receiving nicotinic acid supplementation81 gained statistically significantly more 
weight per kg in 1 month than participants on the standard diet. In the other study,82 there 
was no difference in daily weight gain between groups receiving milk-based formula either 
with or without added NTs, and reporting of anthropometry outcomes was unclear so it 
was not possible to determine which (if any) p-values indicated a statistically significant 
difference between the groups.
  ■ One study80 reported on comorbidities, finding that the high-potassium intervention group 
suffered significantly fewer presumed septic episodes, respiratory symptoms and new skin 
ulcerations, whereas there was no statistical difference between the groups for irritability, 
diarrhoea and oedema.
Ongoing studies
The search for ongoing studies identified 41 records. Of these, 10 appear (from the limited details 
available) to meet the inclusion criteria for the review. These 10 studies seem to map to questions 
7 (two studies), 8 (one study), 10 (four studies), 14 (two studies) and 22 (one study, which may 
also map to Q8). Summary details of these ongoing studies are presented in Appendix 13.
TABLE 64  Comorbidities in children receiving other supplements 
Study Treatment arms p-value
Manary and Brewster 199780 High potassium (n = 37)a Standard potassium (n = 41)a
Clinical sepsis (days 2–7), n (%) 0 9 (22) 0.01
Clinical sepsis (days 8–24), n (%) 3 (9) 9 (22) 0.05
New skin ulcers (cases), n (%) 4 (11) 13 (33) 0.05
Mean days of cough ± SD 2.3 ± 2.6 3.9 ± 2.7 0.01
Dyspnoea (cases), n (%)  1 (3) 10 (24.4) 0.01
Mean days of irritability ± SD 3.4 ± 1.7 3.7 ± 2.1 0.47
Mean days of diarrhoea ± SD 0.9 ± 2.5 1.5 ± 1.7 0.14
Mean days with oedema (grade 2+ or grade 3+) ± SD 2.7 ± 2.2 2.7 ± 2.1 0.99
a  Excluding 21 early deaths.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Chapter 5  
Discussion
Statement of principal findings
The aim of this project was to evaluate the effectiveness of interventions to treat infants and 
children aged < 5 years who have SAM. The initial scope of the project was therefore extremely 
broad. It covered a series of possible research questions that related to the effectiveness of 
programmes and/or guidelines that have been developed (e.g. the WHO 10-step plan), as well 
as covering each discrete step or individual components that have been used to treat or manage 
severely malnourished children. In addition, factors that might affect the effectiveness of 
interventions (e.g. setting, presence of comorbidities such as HIV infection) and constraints to 
the implementation of interventions could also have been examined.
Delphi process
It would not have been possible to systematically review every aspect of the evidence relating to 
the treatment of children < 5 years of age with SAM during the course of this project. Therefore, a 
Delphi process was used to gain an understanding of the priority order of the research questions 
(findings reported in Chapter 3 and Appendix 5), so that the systematic review could focus on the 
areas identified as being of the highest priority by a panel of leading international experts in the 
field of malnutrition.
Through an iterative process, the panel of experts (containing academics, people working in the 
field, government departments, charities, NGOs and WHO) scored 18 questions developed from 
the WHO 10-step plan for the management of SAM, and added four new questions. After three 
rounds of the Delphi process, the expert panel had reached a consensus, identifying and ranking 
15 priority questions for consideration for the systematic review. All aspects were overseen by 
an independent chairperson appointed by the National Institute for Health Research (NIHR) 
HTA programme.
The priority areas identified tended to focus on the most effective approaches to managing 
specific subgroups (e.g. children infected with HIV, infants < 6 months old) or associated 
conditions/comorbidities (e.g. shock, diarrhoea, infection, TB and H. pylori). Factors affecting 
the delivery of the intervention or programme (e.g. factors affecting implementation and 
sustainability of interventions, effect of different settings) were also considered a priority. All of 
these priority areas potentially spanned the entire treatment pathway. Areas considered lower 
priorities and excluded from the final list, tended to focus on individual steps during the initial 
phase of treatment, particularly for hypothermia, hypoglycaemia and for correction of electrolyte 
imbalance. Also excluded were discharge criteria, methods for emotional and sensorial 
development, and strategies for different geographical locations.
Systematic review
The 69 studies that met the inclusion criteria of the review were mapped against the final list of 
research questions that had been prioritised by the panel of experts who took part in the Delphi 
process. No evidence was found to inform 5 of the 15 prioritised questions.90 Discussion
The questions for which no evidence was identified included (1) strategies for the management 
of specific subgroups of children, those infected with HIV or children with other comorbidities 
such as TB and H. pylori infection; (2) the overarching issues of programme sustainability, 
long-term survival and readmission rates, and factors limiting full implementation of treatment 
programmes; and (3) methods for increasing appetite and food intake to recover weight and aid 
catch-up growth during rehabilitation and follow-up.
Evidence was found that mapped against the remaining 10 prioritised questions; however, for one 
question only very limited evidence was available.
Project resources were available to review the evidence for the first six questions for which there 
was any evidence available. These six questions were among those ranked in the top 10 of the 15 
prioritised questions and each question is considered separately below.
What methods are effective for treating severe acute malnutrition 
among infants < 6 months old?
No research focused on treating SAM in infants < 6 months old. However, two cohort studies 
included this age group within their study populations (without reporting baseline data 
separately for this age group), and also provided a very limited quantity of separate outcome 
information. No formal quality assessment was undertaken.
In one cohort study,47 infants < 6 months old made up ≤ 10% of those admitted with SAM in 
three consecutive years. Outcomes before and after the introduction of the WHO guidelines for 
treatment of SAM were compared, but the only outcome commented on for the age group of 
interest was mortality. Mortality was reported as a proportion of overall admissions in a given 
year and compared with the proportional mortality of other age groups. In the < 12 months age 
group, proportional mortality was lower than in the other age groups. No statistical comparison 
was reported.
The second study,48 a prospective cohort study, compared a locally adapted protocol for treatment 
of SAM with the WHO protocol. The proportion of the study cohort aged < 6 months was 
not reported. Weight gain was the only outcome reported for the subgroup of children aged 
< 6 months and there was no statistically significant difference in weight gain between the groups.
The finding of a lack of evidence for this age group is in agreement with other reports. Most 
recently, the Management of Acute Malnutrition in Infants (MAMI) project,17 which focused 
on SAM in the context of emergency situations, overviewed 37 guidelines for the treatment 
of malnutrition. This project also included an analysis of data sets from 12 countries, which 
indicated that there is a higher rate of mortality in infants aged < 6 months. However, the only 
guideline86 reviewed that had a specific focus on infants < 6 months old acknowledges that there 
is little published evidence available on which to base recommendations for treatment in this 
age group.
In summary, no good-quality evidence or adequately reported studies assessed treatments for 
SAM in infants < 6 months old. As this was one of the highest ranked questions in the Delphi 
study, more research is needed to fill this gap in the evidence base.
Which form of intravenous fluid administration is most effective for 
treating shock?
The second of the four questions, which were prioritised equal first in the Delphi study was also 
informed by limited evidence as only one RCT of moderate methodological quality was identified 
that mapped to this question. This RCT49 compared the efficacy of three fluid resuscitation © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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solutions for treating hypovolaemic shock in children with SAM. The three solutions were 
RL, a standard WHO hypotonic fluid solution (HSD/5D) and HAS. The solutions were either 
provided according to the WHO recommendation (HSD/5D) or given at similar volumes and 
rates, but administered to a different schedule (RL and HAS). Participants had severe dehydrating 
diarrhoea/shock or presumptive septic shock (only the latter were eligible to receive HAS), and 
the principal comparison was between RL and HSD/5D because few participants received HAS. 
Other aspects of management in all groups followed the WHO guidelines.
Mortality was high (just over 50%) and there was no statistically significant difference in 
mortality rates between the treatment groups. Other outcomes related to shock (e.g. resolution 
of shock, oliguria and tachycardia) indicated inadequate correction of shock in both groups, 
although the isotonic RL fluid was associated with modest improvements and was found to be as 
safe as hypotonic HSD/5D solution.
This study found that neither the hypotonic HSD/5D nor the isotonic RL resuscitation fluids were 
effective in reducing mortality or adequately treating shock after 48 hours of treatment. The high 
priority given to this question in the Delphi study coupled, with the potential to improve survival 
if shock can be adequately treated, indicates that further research examining resuscitation 
regimens for shock is needed.
What are the best treatments for children with severe acute malnutrition who 
have diarrhoea?
This third question that had been prioritised equal first in the Delphi study was addressed by 
eight studies. Just over half of these studies focused on treating children with acute diarrhoea 
and SAM (five RCTs of strong or moderate methodological quality50,51,54,55,57), whereas the 
remainder focused on children with persistent diarrhoea and SAM (three RCTs of strong or weak 
methodological quality52,53,56).
Four50,51,54,57 of the five trials treating children with acute diarrhoea and SAM compared different 
ORSs. Of these, two trials compared H-ORS with the standard WHO-ORS.51,54 Although the 
trials differed in some respects, the findings were broadly similar and overall favour the use 
of H-ORS. One trial compared ReSoMal with standard WHO-ORS.50 There were no deaths 
in either group; however, one child in the ReSoMal group had a convulsion because of severe 
hyponatraemia. For the two outcomes of adequate rehydration at 12 hours and over-rehydration, 
there was no statistically significant difference between groups. The fourth trial to compare ORSs 
had three arms: glucose ORS, a glucose ORS plus ARS and a rice-based ORS.57 The rice-based 
ORS was more beneficial at 72 hours in promoting weight gain and reducing diarrhoeal output 
than the glucose-based ORS. In all groups, recovery to 80% W/H took about 7 days.
The fifth trial55 investigated standard WHO-ORS with zinc syrup added to therapy compared 
with WHO-ORS and placebo. This trial reported statistically significant differences in favour of 
the zinc-supplemented group for three outcomes, but this did not have an impact on weight gain, 
which was not significantly different between the groups. No safety issues related to the addition 
of zinc to therapy were reported.
In summary, children with acute diarrhoea benefited from the use of H-ORS compared with 
the standard WHO-ORS on measures of frequency, duration and recovery from diarrhoea, 
and consumption of ORS. In contrast, weight gain was significantly higher in those receiving 
WHO-ORS (one study).57 WHO-ORS was not significantly different from ReSoMal for adequacy 
of hydration or mortality, although ReSoMal may pose safety concerns. A rice-based ORS was 
more beneficial at 72 hours in promoting weight gain and reducing diarrhoeal output than the 
glucose-based ORSs, whereas the addition of zinc to a WHO-ORS had a favourable impact on 92 Discussion
some outcomes. It is not clear how generalisable the results of these studies are, given that all 
five trials50,51,54,55,57 excluded children with severe infections and all took place either in India or 
in Bangladesh.
Each of the three trials that focused on participants with persistent diarrhoea52,53,56 compared 
different dietary treatments. One diet in each trial was either entirely53,56 or predominantly52 
soy-based and was compared with an elemental diet in two of the trials (either Neocate52 or 
Vivonex56), or a local KY-based diet in one trial.53 One of the trials comparing an elemental diet 
with a soy-based diet had a third arm in which participants received a chicken-based diet.56
One trial52 reported that the elemental Neocate diet led to statistically significant greater increases 
in both weight gain and the anthropometric measures of W/A and W/H in comparison with 
a diet based on skimmed milk and soy. This trial did not report on measures of diarrhoea. In 
contrast, the three-arm trial56 reported that there were no differences between the elemental 
Vivonex diet, a soy-based and a chicken-based diet for outcomes of mortality, weight gain, 
frequency of diarrhoea and recovery, caloric intake and success.
The trial of a soy-based versus a KY-based diet53 reported that weight gain was greater, and 
statistically significantly so, by the end of the second week in the soy-based group when 
compared with the KY-based group, although overall recovery was similar.
Studies comparing different diets for children with persistent diarrhoea had conflicting findings, 
and only two of the three studies reported on diarrhoea outcomes. A comparison in one study of 
an elemental diet with a skimmed milk and soy-based diet showed significant improvements in 
anthropometric measures in the group receiving the elemental diet. However, two other studies 
found either no difference between an elemental diet, a soy-based and a chicken-based diet (for 
outcomes of mortality, weight gain, frequency of diarrhoea and recovery) or found a significant 
benefit (for anthropometric measures and ORS consumption) from a soy-based diet compared 
with a KY-based diet.
What methods are effective in treating infection?
One RCT59 and one retrospective cohort study with control60 investigated the use of antibiotic 
therapy in children with SAM, but neither focused on treating diagnosed infection. Nevertheless, 
these studies are included because they provide information about use of antibiotic therapy in the 
patient group of interest. Both studies were assessed to be of moderate methodological quality.
The RCT59 took place during inpatient therapy for SAM and compared two different systemic 
broad-spectrum antibiotic regimens. The majority of deaths occurred within 14 days of 
admission. There were very few infection-related deaths 14 days or more after admission in 
either group (a total of three deaths in 458 participants overall), and no statistically significant 
differences between the groups for outcomes relating to weight gain, success rate and length of 
hospital stay. A statistically significant greater proportion of adverse events occurred with orally 
administered amoxicillin than with i.m. injection of ceftriaxone.
The retrospective cohort study60 focused on children with uncomplicated SAM receiving 
home-based treatment with RUTF. One cohort attended malnutrition treatment clinics where 
antibiotics were not routinely provided, whereas the clinics that the other cohort attended 
provided amoxicillin routinely for 7 days. After analysing data from each cohort, the number of 
deaths was described as similar (although no p-value was reported). Overall recovery, however, 
was substantially greater at 4 weeks in the cohort that received RUTF alone (statistically 
significantly so in the subgroups with and without oedema, but p-value not reported for group 
as a whole). By 12 weeks, recovery rates in the two cohorts were described as similar. Trehan © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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and colleagues60 considered that antibiotic-associated diarrhoea and disruption of the intestinal 
biome could be biologically plausible reasons for the delayed recovery in the cohort receiving 
antibiotics. However, the study did not report on diarrhoea as an outcome and one of the expert 
advisory group for this project felt it was unlikely that antibiotic-associated diarrhoea alone could 
have accounted for such a large difference.
Retrospective observational evidence indicates that the systematic addition of a broad-spectrum 
antibiotic to the RUTF home-based treatment may have a statistically significant detrimental 
effect on the recovery of children with uncomplicated SAM during the first 4 weeks, although no 
effect was shown on mortality.60 A RCT comparing administration of i.m. ceftriaxone with orally 
administered amoxicillin, found no difference in effects on outcomes, apart from ceftriaxone 
being associated with fewer adverse events.59
What is the clinical effectiveness of interventions in different settings 
(e.g. hospital, community, emergency)?
Four included studies62–65 of moderate or weak methodological quality investigated the clinical 
effectiveness of treating malnutrition in different settings. All trials included the inpatient 
hospital setting, but the type of inpatient care provided varied. Three trials62–64 evaluated 
alternative settings for the rehabilitation phase of treatment after the same initial treatment for 
all participants as inpatients. The fourth trial, which had three arms,65 compared inpatient care 
during both the initial and rehabilitation phases of SAM treatment with either daily ambulatory 
care for initial and rehabilitation phases or daily ambulatory care for the initial phase followed by 
rehabilitation in the home setting.
Drawing comparisons between the included studies is difficult because of the numerous 
differences between them. These include differences in inpatient care (different diets, formulas, 
staffing), differences in home-based care (different follow-up arrangements, dietary provision) 
and differences in lengths of intervention and follow-up.
Two studies62,65 included a comparison between inpatient care and daily ambulatory care. 
Mortality appeared similar between the different settings, with no significant differences. 
Changes in weight were less clear. One study,65 reported statistically significant differences in 
favour of hospital inpatient treatment for greater daily weight gain and shorter treatment time 
to achieve 80% W/H. However, after 12 months, differences in weight gain were no longer 
statistically significant. The other trial62 that compared inpatient treatment with daily ambulatory 
care, found that there was no significant difference between the groups in W/H changes, although 
some patients did not receive the care they were assigned.
Three studies included a comparison between inpatient care and home-based care.63–65 In all three 
trials, mortality appears similar between the groups and the proportion of children who died 
in each study was comparable. Although one study65 found a statistically significant benefit in 
weight gain for the inpatient group,63,64 the other two studies reported no significant difference 
between inpatient care and home-based care. The anthropometry outcomes reported by two 
studies64,65 also statistically significantly favoured inpatient care initially, but at > 12 months’ 
follow-up this benefit had disappeared. In contrast, a third study63 found a statistically 
significantly greater improvement anthropometry outcomes in the group treated at home than in 
those treated as inpatients.
Different comparisons of inpatient, ambulatory and home-based care varied considerably in the 
nature of the intervention provided. It appears that children receiving inpatient care do as well 
as, if not better than, those receiving care in the ambulatory or home setting on anthropometric 94 Discussion
measures and response time to treatment. Longer-term follow-up shows limited differences 
between the different settings.
Which methods for correcting micronutrient deficiencies are effective?
Evidence was found for treating children with SAM and providing zinc supplements (10 trials68–
79), supplementary potassium (one study80), nicotinic acid (one study81) or NTs (one study82). 
Although the methodological quality of the studies was found to vary, the majority were assessed 
as either moderate (n = 3) or weak (n = 8). In general, micronutrient deficiencies were assumed 
to be present and most studies did not test for specified micronutrient deficiencies. None of the 
studies examined a mix of micronutrients such as those currently recommended in the WHO 
guidelines for the treatment of SAM, and no studies investigating vitamin A met the inclusion 
criteria for this systematic review.
In the trials of supplementary zinc, provision varied in a variety of aspects which made it 
difficult to compare zinc doses across the studies. The comparator was either a placebo (four 
trials 72,74,75,78,79), no zinc supplement (three trials70,73,77) or a different dose and/or duration of zinc 
(three trials68,69,71,76).
Mortality was explicitly reported in just two of the studies.68,69,74,75 One study74,75 reported 
significantly fewer deaths in the group receiving zinc. Although difficult to compare doses of 
zinc between studies, if the children in the study are assumed, as an example, to weigh between 
3 kg and 12 kg, the provided dose of 10 mg/day would be one of the lowest. In contrast, the other 
study68,69 to report mortality was halted early when a significant risk of death was identified 
for participants receiving 6 mg/kg/day zinc in comparison with those children receiving 
1.5 mg/kg/day. If the same example is used, with children assumed to weigh between 3 kg and 
12 kg, the 6 mg/kg/day dose would be one of the highest provided. Although zinc dose may be 
one explanation for the difference in findings on mortality reported by these two studies, other 
factors, such as characteristics of the participants or other aspects of care, may also be important.
All the studies assessing zinc supplements reported the effects of the intervention on weight gain 
or anthropometry outcomes (with two studies reporting on both types of outcome).68–79 The three 
studies that reported findings in favour of zinc were all studies in which a zinc supplement was 
compared with no supplement, and they provided zinc at doses which were probably higher than 
those in most other studies.70,73,77 Although the higher doses of zinc used in these studies may 
account for the positive effects of zinc reported, it is also worth bearing in mind that these three 
studies were all rated as methodologically weak with regard to blinding, and received a summary 
quality rating of weak.70,73,77 Of the remaining seven studies, five68,69,71,72,78,79 found no significant 
differences between the groups (four of which received an overall quality rating of strong) and 
two74–76 (both with an overall quality rating of medium) reported a mixture of results, some in 
favour of the zinc group and others indicating no significant difference between the groups.
The pattern of results reported for comorbidity outcomes and adverse events (if trials 
included these outcomes) followed the same pattern, as noted above, for weight gain and 
anthropometry. Of the five trials reporting on comorbidities,70,72,74–76,79 two found72,79 no 
significant differences between the groups (both also reported no significant differences for 
weight gain/anthropometry), two74–76 reported mixed results (alongside mixed results for weight 
gain/anthropometry) and one70 trial reported a statistically significantly benefit from zinc 
supplementation. In this last trial, the significant effects from zinc were on time taken to lose 
oedema and for skin lesions to heal, duration of diarrhoea and anorexia, and on weight gain. 
One study68,69 reported on the serious adverse event of increased mortality in the study group 
receiving 6 mg/kg/day zinc in comparison with those receiving 1.5 mg/kg/day. In the remaining 
nine studies,70–79 either adverse events were not reported, no adverse events were noted or the 
differences between groups were reported not to have had an adverse impact on rehabilitation.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Although studies assessing the effects of supplementary zinc were heterogeneous, those 
considered of a higher methodological quality showed no significant benefit from the addition of 
zinc supplementation. If there is a benefit to be obtained from zinc supplementation, the included 
evidence is insufficient to determine which dose of zinc might represent the optimal balance 
between maximising benefits and minimising any harms.
The final three trials80–82 each provided evidence on the use of a different dietary supplement and 
consequently they are considered separately.80–82
Providing a dose of potassium80 in the first 7 days of therapy that was 3 mmol/kg above the 
standard dose led to statistically significant fewer late deaths in an adjusted analysis, but the 
overall number of deaths in hospital did not differ between the groups. There were also no 
significant differences in length of hospital stay or weight loss, and the number of days with 
irritability, diarrhoea or oedema did not differ between the groups. The higher potassium 
treatment group did, however, have statistically significantly fewer episodes of sepsis, fewer new 
skin ulcers, fewer days of cough and fewer cases of dyspnoea.
The trial81 reporting on the addition of nicotinic acid to dietary therapy found a statistically 
significant benefit on mean weight gain in 1 month in favour of the group receiving the 
supplement, and for each gain of 1 g in weight fewer calories had to be consumed by the group 
receiving nicotinic acid (no p-value reported for the latter outcome). No other outcomes 
were reported.
Weight gain and increases in W/L and BMI were similar regardless of whether a milk-based 
formula supplemented with NTs82 was provided or a formula of the same energy density without 
added NTs. Reporting of statistical test outcomes was unclear for mean skinfold thickness 
measures, so it was not certain which statistically significant differences related to within-group 
differences and which to between-group differences.
Evidence on other micronutrients was limited, with significant benefits from the addition of 
potassium (i.e. reducing late deaths, sepsis, skin ulcers, coughs and dyspnoea) and nicotinic acid 
(i.e. weight gain), but no benefit from the addition of NTs.
Strengths and limitations of the assessment
The review has the following strengths:
  ■ This technology assessment report was conducted independent of vested interest. It was 
undertaken following the standard methodology and principles for conducting a systematic 
review. The methods were set out a priori in the research protocol, in which the inclusion 
criteria, the quality criteria, the data extraction process and the methods applied in the 
different stages of the review were defined. The research protocol was informed by an 
advisory group before the project started. The advisory group also reviewed and commented 
on the final report.
  ■ A Delphi study was carried out with an international panel of experts in order to identify and 
prioritise the research questions for the review.
  ■ The evidence on the effectiveness of interventions to treat severely malnourished children 
brought together in this report was critically appraised, and the results are presented in a 
consistent and transparent manner.96 Discussion
In contrast, the review also has certain limitations:
  ■ There was a lack of evidence for some questions. Also for those questions where there was 
some evidence, this did not always address the questions that the Delphi panel had identified 
as being of particular interest (see Appendix 5). For example, the little information available 
on treating infants < 6 months did not address the question of the most effective therapeutic 
milk for this age group. Similarly, although one study49 mapped to the question on i.v. fluid 
administration for treating shock, no studies addressed the question of the feasibility of 
blood transfusions for shock.
  ■ Some studies provided limited details of their methods, making quality assessment 
difficult. Consequently, 12 included studies52,53,58,64,65,70–73,77,78,81,82 were judged to be of weak 
methodological quality and this may have been partly related to their publication date. 
Of the 16 included studies that were published before the year 2000,57,62,64,65,68–73,76–81,95 10 
were judged to be of weak methodological quality.53,64,65,70–73,77,78,81 In contrast, among the 12 
included studies published in 2000 or later,49–52,54,55,57–60,63,74,75,82 only two52,58,82 were judged to be 
methodologically weak. Inevitably the nature of clinical trials, in terms of their methods and 
their reporting in publications, has changed significantly particularly in the last 10–15 years, 
for example in response to the Consolidated Standards of Reporting Trials (CONSORT) 
statement, which was first published in 1996.87
  ■ The length of follow-up in the majority of the studies was either for the duration of the 
intervention or to the point of discharge or recovery. A minority of studies followed up the 
children after discharge, with periods ranging from 14 days to 30 months. This means that 
there are very few data on readmission or relapse rates. In some studies, the length of the 
follow-up period was not clear or not reported.
  ■ A wide range of outcome measures were reported and the units of measurement for some 
outcome measures varied. This limited our ability to compare outcomes between studies. 
Not all studies reported on mortality, and the majority of trials offered no details on adverse 
events; however, it was unclear whether or not the absence of reporting was because there 
had been no deaths or adverse events. It is possible that deaths and adverse events may have 
been under-reported by some studies.
  ■ Variations between studies, for example in the participants recruited, interventions, 
settings and outcome measures, meant that meta-analysis was inappropriate and therefore 
not undertaken.
  ■ Project resources were available to review the evidence for the first six questions for which 
any evidence was available. This meant that four questions for which evidence was available 
were not reported on in detail. However, these were considered low priorities by the expert 
Delphi panel. These questions:
  – What is the overall effectiveness of current programmes/guidance, e.g. the WHO 
10-step plan?
  – What methods for treating dehydration are effective?
  – What are the most effective methods for feeding during the initial stages of treatment?
  – Which methods are effective in the rehabilitation phase?
  ■ Data were not extracted from studies that did not map to any of the research questions 
considered in the Delphi process or from studies which mapped to questions that were not 
systematically reviewed. Although all studies were briefly checked to identify whether or not 
they contained data of interest to the questions considered, it is possible that some relevant 
evidence may have been missed.
  ■ Full texts of non-English-language articles identified by the searches were not retrieved 
because of resource limitations. Again, this means that it is possible that some relevant 
evidence may have been missed.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Uncertainties
  ■ The generalisability of the findings in this review is unclear. The results of a multicentre study 
may be more likely to be generalisable,88 but the majority of the included studies (26 of 30) 
were conducted in single centres, so there is uncertainty about their generalisability to other 
centres (e.g. in other countries). Similarly, there is uncertainty regarding the transferability 
of results from a study conducted, for example, in children aged from 6 months to 2 years 
to a population of children aged from 4 to 5 years. This particularly holds true where there 
is variability in the definition of SAM between studies and the use of different classification 
systems. Also, some interventions may not be generalisable to other populations or settings 
because of cultural difficulties, available resources or funding limitations (e.g. for additional 
training of medical staff and/or caregivers). Finally, as far as is known, the included studies 
were conducted in hospitals, nutritional rehabilitation units or the community [under 
normal (non-emergency) operating conditions for the particular location]. Therefore, the 
generalisability to major emergency settings that may present additional logistical and 
operational challenges, for example during conflict or widespread famine situations, is 
not known.
  ■ No trial evidence was found that specifically evaluated the management of severely 
malnourished children who were also HIV+ve in terms of how their treatment may differ 
from children who were HIV–ve. Just 549,50,52,74,80 of the 30 studies that were data extracted 
reported that children who were HIV+ve formed part of the total study population. 
One study56 excluded children who were HIV+ve. Two of the studies49,52 that were data 
extracted, and whose study populations included children who were HIV+ve, provide some 
information regarding outcomes in HIV–ve versus HIV+ve children. One study52 reported 
that, although mortality was higher in HIV+ve children than in HIV–ve children, the 
benefits of the intervention (an elemental diet) were observed in both HIV–ve and HIV+ve 
children. The second study49 reported that mortality was similar in HIV+ve and HIV–ve 
children and HIV infection did not significantly increase the risk of death. Finally, one 
further study,89 which was not reported on in detail (and not data extracted), reported that, 
although home-based therapy with RUTF led to better outcomes than home-based therapy 
with traditional foods, the proportion of HIV+ve children reaching 100% W/H was smaller 
(56% vs 84% for HIV–ve children) and their recovery time was longer (86 days vs 35 days). 
These data suggest that it may be possible to extend the outcomes of the included studies 
to a HIV+ve population. However, the benefits may not be as great and, furthermore, the 
interaction with other factors such as antiretroviral therapy (ART) is not known.
  ■ There may have been an additional cost associated with some interventions (e.g. provision 
of elemental formula feed or dietary supplements). In some trials additional resources (e.g. 
community health workers and day-care facilities) may have been needed to implement the 
interventions being investigated. Additional costs and/or the need for additional resources 
could be a limiting factor in sustaining the implementation of an effective intervention 
beyond the trial period, or in trying to implement an intervention in additional locations. 
Little is known about how sustainable nutritional programmes would be in any particular 
country given such factors as the occurrence of severe droughts or other natural disasters, 
civil conflicts, government unrest, etc.
  ■ No studies were identified that focused on identifying the factors limiting full 
implementation of treatment programmes, but some factors mentioned in the studies 
reviewed for other questions included:
  – difficulty in obtaining (due to availability and/or cost) commercial supplies of formula, 
vitamin mix or other dietary supplement
  – insufficient staff to provide monitoring as frequently as indicated or to provide 
individualised doses of micronutrients to patients98 Discussion
  – caretakers’ resistance to aspects of treatment
  – caretakers did not have sufficient time and/or resources to implement intervention fully. 
This applied to studies in the inpatient, day-care and community settings.
  ■ As few studies continued to follow up children after recovery, there are uncertainties about 
the impact of the interventions on the longer-term survival and morbidity of children 
with SAM.
  ■ The treatment of children with SAM can be considered a complex intervention (an 
intervention with several interacting components). Management based on the WHO 
guideline for treatment of SAM is generally accepted to have improved survival, but it is 
not clear whether all the facets of management have been optimised. As already noted, 
the priority areas identified by the Delphi process tended to focus on particular aspects 
of management. However, in studies focusing on one facet of management, which varied 
between trial arms, children were also receiving other treatment during the trial period. 
Often this was as part of an overall management strategy, such as that set out in the WHO 
guideline, but just over half of the included studies were published in 1999 or earlier and 
so were undertaken before the 1999 WHO guidelines10 were published. It is uncertain 
how the other aspects of management may have impacted on the primary outcomes of the 
systematic review (mortality and weight gain), particularly in the earlier studies, in which 
overall management may have been inadequate. For example, it is not known whether an 
intervention effect may have been obscured or enhanced if one or more other aspects of 
treatment were not optimal. Similarly, when comparing different trials, it is not known what 
proportion of any difference in findings from two different trials could be due to differences 
between interventions or to more general differences in the overall management of SAM.
Other relevant factors
  ■ The included studies were published between 1982 and 2010 and, in general, employed the 
criteria for SAM in place at the time the research took place. However, as illustrated in the 
background section (see Chapter 1), ‘standard criteria’ have been revised more than once 
during the past decades. Our aim was to limit the variation in the children included in the 
different studies to allow comparison of the interventions assessed. However, it has to be 
acknowledged that, despite the care we have taken, there may be some differences, and some 
of the children enrolled in the included studies might not meet the current WHO criteria 
for SAM.
  ■ There is an absence of evidence, limited evidence or a lack of good-quality evidence for 
several of the questions that were prioritised by the Delphi process. Some questions relate 
to aspects of management that are included in the WHO guidelines for the treatment of 
SAM. In particular, treatment of children who are HIV+ve, emergency treatment of shock, 
treatment of diarrhoea, infections, comorbidities such as TB and correction of micronutrient 
deficiencies. More good quality research is needed to inform guidelines such as those 
produced by the WHO.
  ■ About half of the included studies calculated the sample size needed to achieve sufficient 
power for their study objective. However, not all of these trials achieved sufficient statistical 
power for the outcomes of interest to this review. In one trial sample size was calculated 
for a cost outcome, and in another study sample size was calculated for the whole trial 
population, of which children with SAM were a subgroup. Recruitment to three trials 
was suspended because of adverse outcomes, and in one study the outcomes were not as 
had been anticipated during the calculation of sample size, which led to the study being 
underpowered. Finally, in one study exclusion of participants after recruitment meant that 
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Chapter 6  
Conclusions
Implications for service provision
An international panel of experts reached a consensus when asked to identify priority areas for 
consideration in this systematic review of interventions to treat severely malnourished infants 
and children. However, this systematic review found that evidence was either lacking or was 
limited for many of the prioritised research questions that were systematically reviewed in 
depth. Therefore, although it has not been possible to draw firm conclusions from the evidence 
that can inform current service provision, a number of areas where research is needed have 
been identified.
Suggested research priorities
In many countries, current service provision for the treatment of SAM in infants and children is 
based on the WHO 10-step approach.10,37,38 This is a complex intervention and there is scope to 
improve outcomes, including survival, if all the necessary steps can be implemented optimally. 
It should be recognised, however, that there are many potential difficulties when undertaking 
research into the effectiveness of treatments for SAM in children. Some research questions 
may be relatively more straightforward to investigate by a RCT than others (e.g. provision of a 
micronutrient supplement during the rehabilitation phase of treatment in comparison with i.v. 
fluid administration for shock during the initial phase of treatment), and there may be fewer 
practical difficulties in certain settings than in others (e.g. a teaching hospital in comparison 
with a rural feeding centre or a community setting in comparison with a refugee camp). Thus, 
there may be a tension between the relative ease of conducting high-quality research and how 
generalisable the outcome will be to the majority of locations where children with SAM receive 
treatment. Further research will need to take account of these concerns in developing pragmatic 
studies that are appropriately designed, rigorously conducted and accurately reported. Although 
experimental studies are preferred, it is recognised that opportunities may be limited given the 
nature of the area under study and the availability of funding. As such, well-conducted quasi-
experimental and observational studies may provide important evidence.
One approach to research in this area may be to divide the WHO 10-step plan into packages of 
care (care bundles), so that different care bundles can be compared with one another. It will be 
necessary for such studies to report in detail on the package of care provided. This should help 
researchers and policy-makers in the future to make comparisons between studies, and to judge 
what contribution the differences in overall management may have made to the differences in 
outcomes between studies.
A difficulty encountered when reviewing and interpreting the evidence was the variation in the 
criteria used to define SAM. Future trials should include children identified using the current 
WHO criteria, and ideally should involve more than one centre to generate results with better 
generalisability to other locations and to aid comparison between different trials.100 Conclusions
One of the top-ranked questions focused on i.v. fluid administration for the treatment of shock, 
which is a cause of high mortality in children with SAM. The only evidence to inform this 
question was a RCT49 that found that neither of the interventions investigated was effective in 
reducing mortality or adequately correcting shock. Further prospective RCTs of i.v. resuscitation 
regimens for shock are therefore needed.49 Any RCT should be informed by an initial pilot 
study and should include measures of cardiac dysfunction and haemodynamic response to 
fluid expansion.
Furthermore, there is a need to optimise management in the specific subgroups identified among 
the top-ranked priorities for consideration, but for which evidence is lacking, i.e. infants aged 
< 6 months old, and infants and children with SAM who are HIV+ve. These priority areas are 
broader than a single research question and, therefore, there may be value in conducting further 
research to determine what the priority research question(s) are for each priority area. For 
instance, included on the scoring sheet during rounds 2 and 3 of the Delphi study alongside the 
overarching question ‘How should management of HIV-infected children with SAM differ from 
those who are severely malnourished but HIV–ve?’ were four example research questions: (1) 
how do fluid and electrolyte needs differ?; (2) how effective is zinc in the treatment of HIV+ve 
children?; (3) what is the most effective use of antibiotics for these patients?; and (4) what is the 
most effective stage of malnutrition treatment at which to start treatment with ARTs?
The use of antibiotics is another area where more research is needed because the topic was ranked 
highly, and yet little research was found that met the inclusion criteria of the review. This is 
another area where there is scope for further prioritisation of potential research questions.
Finally, additional research could be conducted on many other aspects of the management 
of SAM in children < 5 years, including the areas not mentioned above, which were also 
prioritised in the Delphi study, but for which little or no research was identified [e.g. the use of 
multivitamin supplements, optimum dose of vitamin A, or management strategies for children 
with TB or other comorbidities (other than HIV, covered above)]. It should also be remembered 
that although some research areas were considered a greater priority than others, there is 
also scope for research into questions of a lower priority that were not included among the 
questions systematically reviewed in depth for this study (e.g. overall effectiveness of the current 
WHO 10-step plan, clinical effectiveness of monitoring for and treating hypoglycaemia and 
hypothermia, or emotional stimulation through play).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 1  
Protocol methods
Systematic review
The systematic review will be undertaken in accordance with guidance from the Centre for 
Reviews and Dissemination (University of York).90
Delphi study to specify the research question
A Delphi method will be used to help identify and prioritise the key research questions that 
should be addressed by the systematic review. Through an iterative process a panel of experts 
will have the opportunity to identify questions and then reach a consensus about which they 
consider most important. There will be three-rounds in the Delphi process. In the first round 
a set of questions identified in the development of the research protocol will be sent to the 
panel members. They will be asked to score these on the basis of their importance, adding any 
additional questions. Responses from the panel members will be analysed and the questions 
prioritised on the basis of the median score [plus upper quartile (UQ) and lower quartile (LQ)]. 
A subset of the questions that receive the highest median scores will go forward to the subsequent 
rounds. Any additional questions suggested by the panel members will be assessed to see if they 
are already encompassed within the original list. Up to five new questions may be included 
in the second round, with selection based on the relevance to the scope of the review and the 
frequency with which they are identified by the panel members. For the second and third rounds, 
panel members will see the median score for each question from the previous round and decide 
whether or not they wish to revise their original score (i.e. whether they wish to move closer 
to the group consensus or maintain their original score for the question). In addition, they will 
be asked to score any new questions introduced as part of the first round. At the conclusion of 
the third round the panel members will be sent a list of the research questions in priority order 
for information. The prioritised list will form the basis from which the research questions to 
be addressed by the systematic review will be identified, with the final decision on how many 
questions will be addressed based on the extent of the evidence and the resources available for the 
research. Conduct of the Delphi process will be overseen by an independent Chair appointed by 
NIHR HTA programme.
Literature search
Literature will be identified from several sources including electronic databases, bibliographies 
of articles and consultation with experts in the area. A comprehensive database of relevant 
published and unpublished articles will be constructed using the Reference Manager 
software package.114 Appendix 1 
The searches carried out will include:
  ■ General health and biomedical databases: MEDLINE; EMBASE; PubMed (previous 
6 months); The Cochrane Library.
  ■ Specialist electronic databases: DARE; The Cochrane Library; Health Technology 
Assessment Database (HTA); NHS EED; EconLit; Specialist databases as appropriate.
  ■ Contact with individual experts and those with an interest in the field.
  ■ Checking of reference lists.
  ■ Research in Progress: UKCRN.
All databases will be searched from inception to the current date. In the first instance searches 
will be conducted in all languages with non-English-language articles set to one side in a separate 
foreign-language reference database. The primary focus will be English-language articles but the 
need to include non-English articles will be considered in the light of what is found and within 
the constraints of available time for translation.
Study inclusion
Studies will be selected for inclusion through a two-stage process using the predefined and 
explicit criteria. The full literature search results will be screened independently by two reviewers 
to identify all citations that may meet the inclusion criteria. Full manuscripts of all selected 
citations will be retrieved and assessed by two reviewers against the inclusion criteria. Studies 
published as abstracts or conference presentations will only be included if sufficient details 
are presented to allow an appraisal of the methodology and the assessment of results to be 
undertaken. Any disagreements over study inclusion will be resolved by consensus or if necessary 
by arbitration by a third reviewer.
The planned inclusion/exclusion criteria for the systematic review are shown in Table 65.
TABLE 65  Inclusion criteria for the systematic review
Participants Children < 5 years old with SM (marasmus or kwashiorkor)
[such as WHO definition is the presence of severe wasting (< 70% weight for height/length, or < –3 SD) and/or oedema affecting 
both feet or clinical signs of SM, or a MUAC < 110 mm]
Interventions Any intervention programme, in full or in part, to treat severely malnourished children (such as WHO guidelines and its 10 steps 
dealing with: hypoglycaemia; hypothermia; dehydration, electrolyte imbalance; infection; micronutrient deficiencies; cautious initial 
feeding; increased formula feeding; sensory stimulation; preparation of carers for discharge and follow-up). Interventions to be 
assessed will be prioritised by an expert panel through a Delphi process (see Chapters 2 and 3)
Outcome 
measures
Primary outcome measures are mortality and rate of weight gain
(Secondary outcomes specific to individual steps in any programme, such as WHO 10 steps; progression from initial phase to 
rehabilitation; catch-up growth; relapse rates)
Setting Inpatient; community; emergency
Design Pre and post intervention studies for treatment programmes (such as WHO protocol)
RCTs, CCTs, cohort with control, case–control, before and after intervention studies for individual steps of any protocol
Where evidence from different types of study design is identified, only those with the most rigorous designs will be included© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
115   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
Data extraction
The extraction of studies’ findings will be conducted by two reviewers using a pre-designed and 
piloted data extraction form to avoid any errors. Any disagreements between reviewers will be 
resolved by consensus or if necessary by arbitration by a third reviewer.
Quality assessment
The methodological quality of included studies will be assessed using formal tools specific to 
the design of the study and focusing on possible sources of bias. Quality assessment of RCTs 
will be conducted using criteria developed by the CRD (University of York)90 and observational 
studies will be assessed using criteria such as those developed by CRD (University of York),90 
Spitzer.91 Decisions about the quality assessment tool used will be made following selection of the 
evidence. Study quality will be assessed by two reviewers. Any disagreements between reviewers 
will be resolved by consensus or if necessary by arbitration involving a third reviewer.
Data synthesis
The methods of data synthesis will be determined by the nature of the studies identified through 
searches and included in the review. Studies will be synthesized through a narrative review with 
tabulation of results of included studies. Where possible the results from individual studies will 
be synthesized through meta-analysis, with sources of heterogeneity of results investigated by 
subgroup analyses if applicable. The specific methods for meta-analysis and for the detection and 
investigation of heterogeneity will depend upon the summary measure selected.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 2  
The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 
checklist
Section/topic Item Checklist item Reported on page number(s)
Title
Title 1 Identify the report as a systematic review, meta-analysis or both i, iii
Abstract
Structured 
summary
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number
Abstract iii–iv
Executive summary ix–xiii
Introduction
Rationale  3 Describe the rationale for the review in the context of what is already known 1–9
Objectives 4 Provide an explicit statement of questions being addressed with reference 
to PICOS
8
Methods
Protocol and 
registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g. 
web address), and, if available, provide registration information including 
registration number
11, Appendix 1
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length of follow-up) and report 
characteristics (e.g. years considered, language, publication status) used as 
criteria for eligibility, giving rationale
12–14
Information 
sources
7 Describe all information sources (e.g. databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched
11, Appendix 3
Search 8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated
Appendix 3
Study selection 9 State the process for selecting studies (i.e. screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis)
12–14
Data collection 
process
10 Describe method of data extraction from reports (e.g. piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators
14
Data items 11 List and define all variables for which data were sought (e.g. PICOS, funding 
sources) and any assumptions and simplifications made
12–14, Appendices 7–12
Risk of bias in 
individual studies
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level) and how this information is to be used in any data synthesis
14, Appendix 4
Summary 
measures
13 State the principal summary measures (e.g. RR, difference in means) N/A, narrative synthesis
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g. I2) for each meta-analysis
N/A, narrative synthesis
Risk of bias across 
studies
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g. publication bias, selective reporting within studies)
14, Appendix 4
Additional analyses 16 Describe methods of additional analyses (e.g. sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified
N/A, narrative synthesis118 Appendix 2 
Section/topic Item Checklist item Reported on page number(s)
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally with a flow 
diagram
17, 19
Study 
characteristics
18 For each study, present characteristics for which data were extracted (e.g. 
study size, PICOS, follow-up period) and provide the citations
19–20, 20–22, 26–29, 36–39, 
45–47, 50–51, 54–57, 63–67, 
81–82, Appendices 7–12
Risk of bias within 
studies
19 Present data on risk of bias of each study and, if available, any outcome 
level assessment (see Item 12)
23, 31, 40,48, 53, 58, 70, 83, 
Appendices 7–12
Results of 
individual studies
20 For all outcomes considered (benefits or harms), present, for each study: (1) 
simple summary data for each intervention group and (2) effect estimates 
and CIs, ideally with a forest plot
20, 22–25, 30–36, 39–45, 47–50, 
51–54, 59–63, 69–79, 84–87, 
Appendices 7–12
Synthesis of results 21 Present results of each meta-analysis done, including CIs and measures of 
consistency
N/A
Risk of bias across 
studies
22 Present results of any assessment of risk of bias across studies (see Item 
15)
23, 31, 40, 48, 53, 58, 70, 83
Additional analysis 23 Give results of additional analyses, if done [e.g. sensitivity or subgroup 
analyses, meta-regression (see Item 16)]
N/A
Discussion
Summary of 
evidence
24 Summarise the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g. health-care 
providers, users and policy-makers)
89–95, 99
Limitations 25 Discuss limitations at study and outcome level (e.g. risk of bias), and at 
review level (e.g. incomplete retrieval of identified research, reporting bias)
95–98
Conclusions 26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research
89–95, 99, 100
Funding
Funding 27 Describe sources of funding for the systematic review and other support 
(e.g. supply of data); role of funders for the systematic review
iv
N/A, not applicable; PICOS, participants, interventions, comparisons, outcomes and study design; RR, risk ratio.
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the 
PRISMA statement. PLoS Med 2009;6(7):e1000097. doi:10.1371/journal.pmed1000097.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
119   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
Appendix 3  
Search dates, example search strategy and 
grey literature sources
TABLE 66  Databases searched with search dates
Database searched Date of most recent search
MEDLINE (1950 onwards) 9 November 2010
MEIP 9 November 2010
EMBASE (1980 onwards) 9 November 2010
CAB Abstracts Ovid (this contains a specific database: Nutrition Abstracts, searched to December 2009, 
subscription subsequently withdrawn)
15 December 2009
Bioline 7 December 2010
CRD (DARE, HTA and NHS EED) 3 November 2010
The Cochrane Library (Cochrane Reviews, Cochrane Other Reviews, CENTRAL and Cochrane Technology 
Assessment)
9 November 2010
EconLit EBSCO 9 November 2010
Databases searched for ongoing research
UKCRN 7 December 2010
Current Controlled trials.com 7 December 2010
WHO ICTRP 8 December 2010
clinicaltrials.gov 8 December 2010
ANZCTR 8 December 2010
CTRI 8 December 2010
As an example, the MEDLINE Ovid (1950–2009) search strategy is shown in Box 1. In this initial 
search on 15 December 2009, 5067 records were identified and additional records were added 
following the most recent search on 9 November 2010. This search strategy was adapted for 
other databases.
In addition to the bibliographic databases searched, information was also sought from sources of 
grey literature (Box 2).120 Appendix 3 
Organisation and website(s)
CARE www.care.org
Save the Children www.savethechildren.org.uk
Médicins Sans Frontières www.msf.org.uk/ and http://fieldresearch.msf.org/msf/
Action against Hunger www.actionagainsthunger.org/
Aberdeen University www.abdn.ac.uk/medical/unicefprotect/
World for World Organization www.worldforworld.org/index.asp
UN Economic and Social Council www.un.org/en/ecosoc/
Friends of the World Food Programme www.friendsofwfp.org/
Project Concern www.projectconcern.org/
One International www.one.org/international/
World Vision www.worldvision.org.uk/
Department for International Development www.dfid.gov.uk/
UNICEF www.unicef.org/
UNICEF Innocenti Research Centre www.unicef-irc.org/
Valid International www.validinternational.org/
Concern Worldwide www.concern.net/
International Red Cross/Red Crescent www.ifrc.org/
BOX 2  Sources of grey literature searched
Search strategy
1.  (acute adj2 malnutrition).ti,ab. (267)
2.  (severe adj2 malnutrition).ti,ab. (1334)
3.  (chronic adj2 malnutrition).ti,ab. (588)
4.  “severe acute malnutrition”.ti,ab. (43)
5.  “severe malnutrition”.ti,ab. (1136)
6.  “acute malnutrition”.ti,ab. (190)
7.  “chronic malnutrition”.ti,ab. (344)
8.  “severe chronic malnutrition”.ti,ab. (12)
9.  “chronic severe malnutrition”.ti,ab. (8)
10.  “acute severe malnutrition”.ti,ab. (6)
11.  Protein-Energy Malnutrition/or Malnutrition/or Kwashiorkor/ (11,425)
12.  (kwashiorkor or marasmus).ti,ab. (1811)
13.  (undernutrition adj2 severe).ti,ab. (145)
14.  (undernutrition adj2 chronic).ti,ab. (187)
15.  (undernutrition adj2 acute).ti,ab. (39)
16.  undernutrition.ti. and lancet.so. (26)
17.  (severe* adj2 malnourish*).ti,ab. (851)
18.  (chronic* adj2 malnourish*).ti,ab. (112)
19.  (acute* adj2 malnourish*).ti,ab. (42)
20.  or/1–19 (13,940)
21.  limit 20 to (“all infant (birth to 23 months)” or “newborn infant (birth to 1 month)” or “infant (1 to 23 months)” 
or “preschool child (2 to 5 years)”) (5067)
Numbers in brackets denote number of references identified at each stage.
BOX 1  Example search strategy for MEDLINE Ovid (1950–2009)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 4  
Quality assessment
The quality assessment tool of Thomas et al.46 was chosen at the outset of this study because it 
can be used to assess the methodological quality of a range of study types. This tool is used by the 
Effective Public Health Practice Project (www.ephpp.ca) because it was developed for use in any 
public health topic area.
It should be noted that in section B, ‘Study design’, the tool asks the reviewer to note whether 
the method of randomisation is described, and if so whether the method of randomisation is 
appropriate (e.g. sequentially numbered, sealed, opaque envelopes). If the answer to either of 
these questions is no, then the study is scored as a CCT.
An amendment to the tool’s assessment of global study quality was made. The criterion for a 
global moderate rating in the original tool was ‘fewer than four strong ratings and one weak 
rating’. Some studies were found to have exactly four strong ratings and one weak rating and 
it was agreed that these should receive a global rating of ‘moderate’. Similarly, one study had 
five strong ratings and one weak rating, and reviewers agreed that it should be rated ‘moderate’ 
overall. Therefore, the global assessments of study quality were:
  ■ strong = four strong ratings with no weak ratings
  ■ moderate = one weak rating (altered from the original of fewer than four strong ratings and 
one weak rating)
  ■ weak = two or more weak ratings.
The quality assessment part of the data extraction sheet form is shown in Table 67, followed by 
the guidance that was provided to researchers on scoring each of the sections A–H (guidance 
based on the quality assessment tool dictionary).122 Appendix 4 
TABLE 67  Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat 
likely
Not likely Cannot tell
2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell
Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak
B. Study design
1.  What was the study design?
  (Please tick appropriate and specify design if 
categorise as ‘Other’)
RCT
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No
If answer to no. 2 is ‘No’, complete summary then go to section C, Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak
C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell
2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak
D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell
2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell
Summary of blinding
(Methodological strength of study)
Strong Moderate Weak© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell
2.  Were data collection tools shown to be reliable? Yes No  Cannot tell
Summary of data collection
(Methodological strength of study)
Strong Moderate Weak
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell
2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell
Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak
G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell
2.  Was the consistency of the intervention measured? Yes No Cannot tell
3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell
H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/office Provider Patient
2.  Indicate the unit of analysis Community Organisation/
institution
Practice/office Provider Patient
3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell
4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention 
received?
Yes No  Cannot tell
Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak
N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.
TABLE 67  Quality assessment for primary studies (modified for severe malnutrition) (continued)124 Appendix 4 
Guidance for use of the quality assessment tool – severe 
malnutrition project
A. Selection bias
Use the answers to question 1 (QI) and question 2 (Q2) to rate the selection bias section as strong, 
moderate or weak. Use the table below as a guide.
Q2. What percentage of selected 
individuals agreed to participate?
Q1. Are the individuals selected to participate in the study likely to be representative of the 
target population?
Very likely Somewhat likely Not likely Cannot tell
80–100% Strong Moderate Weak Weak
60–79% Moderate Moderate Weak Weak
< 60% Weak Weak Weak Weak
N/A
Cannot tell Weak Weak Weak Weak
N/A, not applicable.
B. Study design
Study design Methodological quality
RCT Strong
CCT Strong
Cohort analytic (two group pre + post) Moderate
Case–control Moderate
Cohort [one group pre + post (before and after)] Moderate
Interrupted time series Moderate
Other – specify Weak
Cannot tell Weak
If the study design is not described by the study, the reviewer should try to categorise it according 
to the descriptions listed in the quality assessment tool dictionary. In such a case, mark the study 
design as ‘Other’, and specify which study type you think it is (it may be a study type which is 
not listed in the dictionary), and note that this is the reviewer’s assessment not the author’s (e.g. 
Other – cohort analytic, reviewer’s opinion).
The tool states that ‘weak’ will be assigned to studies that did not state the method used, so use 
the ‘weak’ rating in these cases.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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C. Confounders
Potential confounders (Thomas et al. 200446) Examples
Race
Sex
Marital status/family Number of siblings, birth order
Age
SES (income or class)
Education Parental education
Health status Proportion with additional health issues, e.g. HIV infection, TB, diarrhoea, etc.
Pre-intervention score on outcome measure Severity/type of malnutrition, oedema (affects weight, can be corrected for)
Project specific confounders Staff involved (same staff feeding each group?)
Breast feeding
SES, socioeconomic status.
Note that this is not a complete list.
C. Confounders continued
Q2. If yes, indicate the percentage of relevant 
confounders that were controlled [either in 
the design (e.g. by stratification or matching) 
or in the analysis]
Q1. Were there important differences between groups prior to the intervention?
Yes No  Cannot tell
80–100% Strong Strong
60–79% Moderate
< 60% Weak
Cannot tell Weak Weak
D. Blinding
Unless explicitly stated otherwise, assume that outcome assessors and participants are aware of 
intervention/question.
2.  Were the study participants aware of the 
research question?
1.  Was the outcome assessor aware of the intervention or exposure status of 
participants?
Yes No Cannot tell
Yes Weak Moderate Weak
No  Moderate Strong Moderate
Cannot tell Weak Weak126 Appendix 4 
E. Data collection methods
Consult quality assessment tool dictionary which lists types of data sources which may have 
been used.
2.  Were data collection tools shown to be 
reliable?
1.  Were data collection tools shown to be valid?
Yes No  Cannot tell
Yes Strong Weak
No  Moderate Weak Weak
Cannot tell Moderate Weak Weak
F. Withdrawals and dropouts
2. Indicate the percentage of participants completing the study (if the percentage differs by groups, record the lowest)
80–100% Strong
60–79% Moderate
< 60% Weak
Cannot tell Weak
G. Intervention integrity
H. Analysis appropriate to question
Q1 and Q2 – the unit of analysis may be different to the unit of allocation.
Q3 – if there is no statistical analysis, answer ‘no’.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 5  
Delphi study
Round 1: question sheet
The question sheet for the first round of the Delphi study was based on the WHO 10-step plan,10 
with one question on its overall effectiveness and 10 further questions on the individual aspects. 
The remaining questions were suggested by experts who reviewed the draft protocol for the 
project. The round 1 question sheet and the accompanying instructions received by members of 
the Delphi panel are shown in Table 68.
Round 1: results
The top 15 questions were identified based on their median ranking (Table 69). It was not 
necessary to take the UQ and LQ limits into consideration for identifying the top 15 questions 
in this round, as there was a clear difference between the median values for question 13 (ranked 
15th, median = 5) and question 2 (ranked 16th, median = 4.5). The lowest ranking questions, 
questions 2, 3 and 4 (marked in italics) were removed for round 2.
Round 2: question sheet
The contributions and comments received by the seven panel members who took part in 
round 1, were tabulated and categorised into those that related broadly to existing questions 
and those that were new. These were used to refine the existing questions retained from round 
1, by either rewording or adding sub-questions, and four additional questions were added 
(the new questions, reworded questions and sub-questions can be seen in Table 70). The new 
questions (numbers 19–22), reflected the most frequently made observations and were essentially 
a refinement of the wider points alluded to in the first version of the questions. These are 
discussed below.
Question 19 is a new question about the treatment of infants < 6 months old. This is related 
to original question 16 [‘Should the different strategies/approaches to treatment differ among 
subgroups (e.g. age, settings, geographical locations)?’]. Several panel members commented that 
the most important subgroup would be children < 6 months old, so this was taken out of question 
16 and included as a separate question. Question 16 was then rewritten for round 2 and was 
restricted to asking about treatment in different geographical locations.
Question 20 is a newly defined question about the treatment of severely malnourished children 
who are also HIV+ve. Panel members commented that this was the most important aspect of 
original question 15 [‘What is the clinical effectiveness of management strategies for treating with 
comorbidities, (e.g. HIV)?’]. It has therefore been moved into a separate question and question 15 
has been reworded to include less severe comorbidities.
The treatment of shock was not explicitly stated in the questions scored in round 1 of the Delphi 
process. It forms part of the initial phase of treatment in the WHO’s 10-step plan, so would have 
come into consideration under question 2 ‘Which strategies are effective during the initial phase 
of treatment?’. However, three of the seven panel members who commented on the questions 128 Appendix 5 
TABLE 68  Delphi study round 1 question sheet and instructions  
Research questions to be considered in the systematic review. On a scale of 1–7, with 1 indicating low importance 
and 7 indicating high importance, please score your opinion of each question by marking an X below the appropriate 
number. Please score each question independently, i.e. you could score them all 7 if you think they are all of high 
importance. All questions relate to the treatment of children < 5 years old with SAM.
Research questions relating to the treatment of severe malnutrition  
in children < 5 years old
Importance
Low High
1 What is the effectiveness of current programmes/guidance (e.g. the WHO 10-step plan)?  1 2 3 4 5 6 7
2 Which strategies are effective during the initial phase of treatment? 1 2 3 4 5 6 7
3 What approaches are effective for treating hypoglycaemia? 1 2 3 4 5 6 7
4 Which of the different strategies for treating hypothermia are effective (e.g. the ‘kangaroo 
technique’)?
1 2 3 4 5 6 7
5 What methods for treating dehydration are effective (e.g. oral rehydration with ReSoMal)? 1 2 3 4 5 6 7
6 What is the effectiveness of different strategies for correcting the electrolyte imbalance (e.g. 
magnesium and potassium supplements)?
1 2 3 4 5 6 7
7 What strategies are effective in treating infection (e.g. broad-spectrum antibiotics?) 1 2 3 4 5 6 7
8 Which of the different approaches for correcting micronutrient deficiencies are effective (e.g. 
initial doses of vitamin A, daily doses of a multivitamin, folic acid, zinc and copper)?
1 2 3 4 5 6 7
9 What are the most effective strategies for beginning feeding (e.g. particular fortified milk 
formulas or special foods)?
1 2 3 4 5 6 7
10 Which approaches are effective in the rehabilitation phase? 1 2 3 4 5 6 7
11 What is the effectiveness of different strategies for increased feeding to recover lost weight 
and aid catch-up growth?
1 2 3 4 5 6 7
12 What approach should be taken to the emotional stimulation and sensorial development? 1 2 3 4 5 6 7
13 What is the most effective approach to preparing for discharge from inpatient care? 1 2 3 4 5 6 7
14 What is the clinical effectiveness of interventions in different settings (e.g. hospital, 
community, emergency)?
1 2 3 4 5 6 7
15 What is the clinical effectiveness of management strategies for treating children with 
comorbidities (e.g. HIV)? 
1 2 3 4 5 6 7
16 Should the different strategies/approaches to treatment differ among subgroups (e.g. age, 
settings, geographical locations)?
1 2 3 4 5 6 7
17 What confounding factors limit full implementation of treatment programmes (e.g. insufficient 
training, cultural difficulties, funding limitations)?
1 2 3 4 5 6 7
18 What factors affect sustainability of programmes (e.g. beyond initial disaster relief strategies 
or implementation of new protocols in hospitals)?
1 2 3 4 5 6 7© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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TABLE 69  Ranking of questions after round 1, n = 11 respondents
Rank
Question 
number Question LQ Median UQ
1 15 What is the clinical effectiveness of management strategies for treating children with 
comorbidities? 
6 7 7
2 18 What factors affect sustainability of programmes? 4 7 7
3 7 What strategies are effective in treating infection? 5.5 6 7
4 =  14 What is the clinical effectiveness of interventions in different settings? 5 6 7
4 =  17 What confounding factors limit full implementation of treatment programmes? 5 6 7
6 5 What methods for treating dehydration are effective? 4.5 6 6.5
7 1 What is the effectiveness of current programmes/guidance (e.g. the WHO 10-step 
plan)?
5.25 6 6
8 11 What is the effectiveness of different strategies for increased feeding? 4 6 6
9 9 What are the most effective strategies for beginning feeding? 4 5.5 7
10 10 Which approaches are effective in the rehabilitation phase? 4.25 5.5 6
11 16 Should the different strategies/approaches to treatment differ among subgroups? 5 5 6.5
12 6 What is the effectiveness of different strategies for correcting the electrolyte 
imbalance?
4.5 5 6
13 8 Which of the different approaches for correcting micronutrient deficiencies are 
effective? 
4 5 6
14 =  12 What approach should be taken to the emotional stimulation and sensorial 
development?
3.5 5 6
14 =  13 What is the most effective approach to preparing for discharge from inpatient care? 3.5 5 6
16 2 Which strategies are effective during the initial phase of treatment? 3.25 4.5 6
17 4 Which of the different strategies for treating hypothermia are effective? 1.5 3 4
18 3 What approaches are effective for treating hypoglycaemia? 2 3 3.5
mentioned that a question on the treatment of shock, particularly regarding specific i.v. fluids, 
would be appropriate. This has therefore been included as question 21.
The treatment of diarrhoea was specifically raised as a question by two panel members, and 
commented on by two others under two of the existing questions (5 and 15). Question 5 (‘What 
methods for treating dehydration are effective?’) would include an important part of treatment 
for children with diarrhoea, but also covers more general aspects of rehydration of children 
with SAM. Similarly, diarrhoea could be considered to be a comorbidity that could be included 
in question 15. However, given the importance of this comorbidity for children with SAM, 
it was decided to move it into a new question and reword the existing question 15 to exclude 
diarrhoea treatment.
The question sheet for round 2 was sent to all 14 of the original panel members who had 
expressed an interest in the project, plus two additional people. One of the extra people was 
suggested as a replacement by an expert unable to contribute to the project, and the second was 
someone contacted for round 1 who did not initially reply. It was decided to include these people 
in order to get as full a participation response as possible, with a view to carrying out separate 
analysis with and without those who contributed to round 1.
Panel members were sent an individually tailored question sheet that showed the panel’s median 
score and their own score for the top 15 questions from round 1, and the four new questions. 
They were asked to score each of the 19 questions for their overall importance, using the 
proposed sub-questions as a guide, but not scoring these sub-questions individually.130 Appendix 5 
Round 2: results
For round 2, 14 people replied, including one of the experts who joined at this round and did not 
contribute to round 1. The ranking of the questions after round 2 is shown in Table 70. The table 
also includes the questions’ ranks, medians, LQs and UQs from round 1.
The 19 questions scored for round 2 were sorted according to their median, UQ and LQ scores. 
The top 15 questions for round 3 were identified, and there was a clear cut-off between the 
median scores for questions 9 and 11, ranked 14th with a median score of 6, and question 6, 
ranked 16th with a median score of 5.5.
The new questions for round 2 were scored most highly by the panel, achieving the top four 
places in the ranking. This reflects the importance the panel places on these research questions, 
both their individual comments during round 1 and their overall scores as a panel. Changes 
to the ranked order of other questions are generally within 4 points between rounds, i.e. if 4 
points are added to the round 1 rank to simulate the addition of four popular questions, the 
ranked order remains broadly similar for many of the questions. However, larger than expected 
differences are apparent for some questions. For example, question 8 (‘Which of the different 
approaches for correcting micronutrient deficiencies are effective?’) actually increased in rank 
from 13th place in round 1 to 10th place in round 2. This may be because of the sub-questions 
used to clarify this question, which were expanded considerably from that in the previous round. 
Question 17, regarding limitations to the full implementation of programmes, dropped from 
being fourth equal to being 12th equal. It is not clear whether this was because of any particular 
factor or just because of changes in scores. The scoring is quite close, so small differences in 
median or lower/upper IQR limits can have quite a large difference in ranking order. Finally, 
question 16 dropped from 11th place to 19th place. This is probably because of a change to the 
wording of the question since the first round. In round 1 this included all subgroups including 
different age groups, whereas in round 2 the treatment of children aged < 6 months is considered 
in a separate question and question 16 refers only to different geographical locations.
The 14 respondents in round 2 included one panel member who joined the process after round 1 
had been completed, and two panel members who received score sheets for round 1 but did not 
complete them. For comparison purposes, further analysis was undertaken to assess whether or 
not the ‘new’ members’ scores affected the resulting ranking (Table 71, sub-questions not shown).
Comparison of rankings with and without panel members who did not contribute to round 1 (see 
Table 71) shows that most questions have similar rankings regardless of the panel’s composition. 
However, questions 8, 10 and 17 show considerable differences depending whether or not the 
additional contributors’ scores are used. Questions 8 and 17 are also those that showed the 
biggest change between round 1 and round 2. It therefore seems possible that the additional 
panel members’ scores for these questions have affected their position in the ranking in round 2 
compared with round 1.
Round 3: question sheet
For round 3, the same score sheet was used as for round 2, with the top 15 questions retained and 
an update of the median scores for each question provided.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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TABLE 70  Ranking of questions after round 2 compared with round 1, n = 14 respondents
Rank
Question 
number Question
Score in round 1 Score in round 2
Round 
2
Round 
1 LQ Median UQ LQ Median UQ
1 New 20 How should management of HIV-infected children 
with severe malnutrition differ from those who are 
severely malnourished but HIV–ve?
(a) How do fluid and electrolyte needs differ?
(b) How effective is zinc in the treatment of HIV+ve 
children?
(c) What is the most effective use of antibiotics for 
these patients?
(d) What is the most effective stage of malnutrition 
treatment at which to start treatment with ARTs?
New New New 6.25 7 7
2 =  New 19 What methods are effective for treating SAM among 
infants < 6 months old?
(a) Which is the most effective therapeutic milk for 
initial feeding of infants < 6 months with severe 
malnutrition?
New New New 6 7 7
2 =  New 21 Which form of i.v. fluid administration is the most 
effective for treating shock?
(a) Are blood transfusions feasible/practical during 
treatment of shock?
New New New 6 7 7
2 =  New 22 What are the best treatments for children with SAM 
who have diarrhoea?
(a) What is the most effective approach to the 
management of primary and secondary diarrhoea?
(b) What is the most appropriate therapeutic food for 
children with diarrhoea?
(c) What is the best approach to rehydration for 
children with diarrhoea?
New New New 6 7 7
5 =  3 7 What methods are effective in treating infection?
(a) What is the effectiveness of presumptive 
treatment of infections with broad-spectrum 
antibiotics for all children being treated for SAM?
(b) What are the best first- and second-line antibiotic 
choices?
(c) What is the effectiveness of selective antibiotic 
prescription compared with systematic antibiotic 
prescription?
5.5 6 7 6 6 7
5 =  4 =  14 What is the clinical effectiveness of interventions 
in different settings (e.g. hospital, community, 
emergency)?
(a) What is the effectiveness of RUTF used in the 
community setting compared with fortification of 
other family foods?
5 6 7 6 6 7
5 =  1 15 What is the clinical effectiveness of management 
strategies for treating children with comorbidities 
such as TB and H. pylori? (other than HIV and 
diarrhoea, which are considered in questions 20 
and 22)
6 7 7 6 6 7
8 2 18 What factors affect sustainability of programmes, 
long-term survival and readmission rates?
4 7 7 5 6 7
continued132 Appendix 5 
Rank
Question 
number Question
Score in round 1 Score in round 2
Round 
2
Round 
1 LQ Median UQ LQ Median UQ
9 6 5 What methods for treating dehydration are effective?
(a) What is the most effective oral rehydration 
fluid for the treatment of dehydration in severely 
malnourished children?
(b) Should priority be given to preventing dehydration 
or avoiding the risk of fluid overload?
(c) What is the effectiveness of i.v. rehydration?
4.5 6 6.5 5.25 6 6.75
10 13 8 Which methods for correcting micronutrient 
deficiencies are effective?
(a) What is the effectiveness of daily low dose of 
vitamin A (e.g. in therapeutic milk) compared with 
large vitamin A dose (e.g. in supplements)?
(b) Are there any subgroups that should be 
considered separately (e.g. children with measles)?
(c) What is the optimum timing of administration of 
vitamin A?
(d) What is the role of iron in the different stages of 
treatment of severe malnutrition?
4 5 6 5 6 6.75
11 7 1 What is the overall effectiveness of current 
programmes/guidance (e.g. the WHO 10-step plan)? 
5.25 6 6 6 6 6
12 =  10 10 Which methods are effective in the rehabilitation 
phase?
(a) What is the relative effectiveness of different 
formulations of RTUFs in the treatment of children 
with SAM?
(b) What are the most appropriate methods for 
transition of children once weight is gained?
4.25 5.5 6 5 6 6
12 =  4 =  17 What factors limit full implementation of treatment 
programmes (e.g. insufficient training, cultural 
difficulties and funding limitations)?
5 6 7 5 6 6
14 =  9 9 What are the most effective methods for feeding 
during the initial stages of treatment?
(a) Which methods of feeding are best?
(b) What is the contribution of milk-based 
ingredients in treatment products?
(c) What is the effectiveness of different formulas 
and food types?
4 5.5 7 4 6 6
14 =  8 11 What is the effectiveness of different methods for 
increasing appetite and food intake to recover lost 
weight and aid catch-up growth?
4 6 6 4 6 6
16 12 6 What is the effectiveness of different methods for 
correcting electrolyte imbalances?
(a) What are the optimum levels of potassium, 
phosphorous, protein, sulphur amino acids and other 
key components?
4.5 5 6 5 5.5 6
17 14 =  13 What level of weight gain and other indicators are 
effective and feasible for safe discharge of children 
being treated for SAM?
3.5 5 6 5 5 6
18 14 =  12 What methods are effective for emotional stimulation 
and sensorial development?
3.5 5 6 4 5 6
19 11 16 Should treatments differ depending on geographical 
locations?
5 5 6.5 5 5 5
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TABLE 71  Comparison of round 2 scores with and without additional panel members
Rank 
(n = 14)
Rank 
(n = 11)
Question 
number Questiona
Scores (n = 11) Scores (n = 14)
LQ Median UQ LQ Median UQ
1 1 20 How should management of HIV-infected children 
with SAM differ from those who are severely 
malnourished but HIV–ve?
7 7 7 6.25 7 7
2 =  2 =  19 What methods are effective for treating SAM 
among infants < 6 months old?
6 7 7 6 7 7
2 =  2 =  21 Which form of i.v. fluid administration is most 
effective for treating shock?
6 7 7 6 7 7
2 =  2 =  22 What are the best treatments for children with 
SAM who have diarrhoea?
6 7 7 6 7 7
5 =  6 7 What methods are effective in treating infection? 6 6 7 6 6 7
5 =  8 14 What is the clinical effectiveness of interventions 
in different settings (e.g. hospital, community, 
emergency)?
5.25 6 6.75 6 6 7
5 =  7 15 What is the clinical effectiveness of management 
strategies for treating children with comorbidities 
such as TB and H. pylori? (other than HIV and 
diarrhoea, which are considered in questions 20 
and 22)
5.5 6 7 6 6 7
8 5 18 What factors affect sustainability of programmes, 
long-term survival and readmission rates?
5.5 7 7 5 6 7
9 10 5 What methods for treating dehydration are 
effective?
5.5 6 6.5 5.25 6 6.75
10 14 8 Which methods for correcting micronutrient 
deficiencies are effective?
4.5 5 6.5 5 6 6.75
11 11 1 What is the overall effectiveness of current 
programmes/guidance (e.g. the WHO 10-step 
plan)? 
5.25 6 6 6 6 6
12 =  15 =  10 Which methods are effective in the rehabilitation 
phase?
5 5 6 5 6 6
12 =  9 17 What factors limit full implementation of treatment 
programmes (e.g. insufficient training, cultural 
difficulties and funding limitations)?
5 6 6.75 5 6 6
14 =  13 9 What are the most effective methods for feeding 
during the initial stages of treatment?
4 6 6 4 6 6
14 =  12 11 What is the effectiveness of different methods for 
increasing appetite and food intake to recover lost 
weight and aid catch-up growth?
4.25 6 6 4 6 6
16 15 =  6 What is the effectiveness of different methods for 
correcting electrolyte imbalances?
5 5 6 5 5.5 6
17 17 13 What level of weight gain and other indicators are 
effective and feasible for the safe discharge of 
children being treated for SAM?
4.5 5 6 5 5 6
18 18 12 What methods are effective for emotional 
stimulation and sensorial development?
4 5 5.75 4 5 6
19 19 16 Should treatments differ depending on 
geographical locations?
5 5 5 5 5 5
a  The sub-questions for each of the top-level questions are not shown in this table, but can be seen in Table 70.134 Appendix 5 
Round 3: results
Thirteen people completed score sheets for round 3, one of whom had not returned a score sheet 
for round 1 or round 2. The median and IQR limits were calculated for all 13 respondents’ scores, 
and these are shown in Table 72.
Although there were some changes to positions in the list, the median scores are so close that a 
small difference can have a big effect on ranked order. The ‘new’ questions added for the second 
round, based on panel members’ suggestions, remained the most highly scored, with median 
values of 7 points. All questions, with the exception of question 11, had a median score of 6.
The ranked order remained broadly similar for most questions. Question 18 increased from being 
ranked eighth to being ranked fifth equal, but this only reflected an increase in the LQ score 
from 5 to 6. Question 5 dropped from ninth place to 12th equal, owing to a decrease of 0.75 in 
the UQ value and of 0.25 in the LQ score. Question 17 increased from being 12th equal in the 
round 2 ranking to being seventh equal in round 3. This was because of a 1-point increase in the 
UQ limit, from 6 to 7. Question 14 decreased from being fifth equal to ninth place, because of a 
decrease of 0.25 in the LQ limit and of 0.75 in the UQ limit.
As there was one panel member who contributed to round 3 but not to round 1 or round 2, 
the analysis was repeated without their scores (Table 73). The ranked order of questions is very 
similar with and without this set of scores. However, question 5 increases from 12th equal when 
all 13 members are included to ninth place when this score sheet is removed from the analysis. 
This places it back in the same order that it was ranked in for round 2 (see Table 72), i.e. it is 
possible that the introduction of the 13th panel member’s scores may have moved it from the 
existing panel’s consensus. Similarly, the difference of 0.25 in the UQ and LQ limits for question 
14 could partially explain the decrease in rank of this question. Questions 18 and 17, which 
showed a change in ranked order between rounds 2 and 3, were not affected by the additional 
panel member’s score.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 72  Ranking of questions after round 3 compared with round 2, n = 13 respondents
Rank
Question 
number Questiona
Round 3
Round 3 Round 2 LQ Median UQ
1 =  1 20 How should management of HIV-infected children with SAM differ from those 
who are severely malnourished but HIV–ve?
6 7 7
1 =  2 =  19 What methods are effective for treating SAM among infants < 6 months old? 6 7 7
1 =  2 =  21 Which form of i.v. fluid administration is most effective for treating shock? 6 7 7
1 =  2 =  22 What are the best treatments for children with SAM who have diarrhoea? 6 7 7
5 =  5 =  7 What methods are effective in treating infection? 6 6 7
5 =  8 18 What factors affect sustainability of programmes, long-term survival and 
readmission rates?
6 6 7
7 =  5 =  15 What is the clinical effectiveness of management strategies for treating 
children with comorbidities such as TB and H. pylori? (other than HIV and 
diarrhoea, which are considered in questions 20 and 22)
5 6 7
7 =  12 =  17 What factors limit full implementation of treatment programmes? 5 6 7
9 5 =  14 What is the clinical effectiveness of interventions in different settings (e.g. 
hospital, community, emergency)?
5.75 6 6.25
10 10 8 Which methods for correcting micronutrient deficiencies are effective? 6 6 6
11 11 1 What is the overall effectiveness of current programmes/guidance (e.g. the 
WHO 10-step plan)? 
5.75 6 6
12 =  12 =  10 Which methods are effective in the rehabilitation phase? 5 6 6
12 =  9 5 What methods for treating dehydration are effective? 5 6 6
12 =  14 =  9 What are the most effective methods for feeding during the initial stages of 
treatment?
5 6 6
15 14 =  11 What is the effectiveness of different methods for increasing appetite and 
food intake to recover lost weight and aid catch-up growth?
4 5 6
a  The sub-questions for each of the top-level questions are not shown in this table, but can be seen in Table 70.136 Appendix 5 
TABLE 73  Ranking of questions after round 3, n = 12 compared with n = 13 respondents
Rank
Question 
number Questiona
Round 3 (n = 13) Round 3 (n = 12)
Round 3 
(n = 12)
Round 2 
(n = 13) LQ Median UQ LQ Median UQ
1 =  1 =  20 How should management of HIV-infected 
children with SAM differ from those who are 
severely malnourished but HIV–ve?
6 7 7 6 7 7
1 =  1 =  19 What methods are effective for treating SAM 
among infants < 6 months old?
6 7 7 6 7 7
1 =  1 =  21 Which form of i.v. fluid administration is most 
effective for treating shock?
6 7 7 6 7 7
1 =  1 =  22 What are the best treatments for children 
with SAM who have diarrhoea?
6 7 7 6 7 7
5 =  5 =  7 What methods are effective in treating 
infection?
6 6 7 6 6 7
11 =  9 14 What is the clinical effectiveness of 
interventions in different settings (e.g. 
hospital, community, emergency)?
5.75 6 6.25 5.5 6 6
7 =  7 =  15 What is the clinical effectiveness of 
management strategies for treating children 
with comorbidities such as TB and H. pylori? 
(other than HIV and diarrhoea, which are 
considered in questions 20 and 22)
5 6 7 5 6 7
5 =  5 =  18 What factors affect sustainability of 
programmes, long-term survival and 
readmission rates?
6 6 7 6 6 7
9 12 =  5 What methods for treating dehydration are 
effective?
5 6 6 5.75 6 6.25
10 10 8 Which methods for correcting micronutrient 
deficiencies are effective?
6 6 6 5.75 6 6
11 =  11 1 What is the overall effectiveness of current 
programmes/guidance (e.g. the WHO 10-
step plan)? 
5.75 6 6 5.5 6 6
13 12 =  10 Which methods are effective in the 
rehabilitation phase?
5 6 6 5 6 6
7 =  7 =  17 What factors limit full implementation of 
treatment programmes (e.g. insufficient 
training, cultural difficulties and funding 
limitations)?
5 6 7 5 6 7
14 12 =  9 What are the most effective methods for 
feeding during the initial stages of treatment?
5 6 6 4.75 6 6
15 15 11 What is the effectiveness of different 
methods for increasing appetite and food 
intake to recover lost weight and aid catch-
up growth?
4 5 6 4 5 6
a  The sub-questions for each of the top-level questions are not shown in this table, but can be seen in Table 70.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 7  
Question 19: data extraction tables
S
hortened data extractions were prepared to obtain information for question 19, ‘What 
methods are effective for treating SAM among infants < 6 months old?’. Only two studies 
presented information separately for this age group; however, neither study focused on this age 
group. No quality assessment was undertaken for either study.
Nu Shwe 200347
Data extraction table
Reference and 
design Intervention Participants  Outcome measures
Author: Nu Shwe47
Year: 2003
Country: Myanmar 
(Burma)
Study design: cohort 
with historic control
Setting: secondary 
care
Number of centres: 
one
Funding: NR
Intervention: the WHO guidelines 
for management of SAM (with two 
modifications – all assumed to have 
hypoglycaemia and given 10% sucrose 
on admission, monitoring of pulse and 
respiration every 30 minutes instead of 
every 10 minutes)
Control: standard management of 
SAM prior to introduction of the WHO 
guidelines. No details provided
Other interventions used: critical-care 
pathway introduced in late 2001
Definition of SAM: W/H or W/L < 70% 
of the NCHS/WHO reference and/or 
symmetrical oedema of the feet
Number of participants: control year 
1999 = 157, of which 18 (11.4%) 
were < 6 months of age; WHO year 
2000 = 196, of which 21 (10.7%) 
were < 6 months of age; WHO year 
2001 = 186, of which 12 (6.4%) were 
< 6 months of age; WHO year 2002 
January to August = 117, of which six 
(7.7%) were < 6 months of age
Sample attrition/dropout: NR
Sample crossovers: not applicable
Inclusion criteria: W/H or W/L < 70% 
of the NCHS/WHO reference and/or 
symmetrical oedema of the feet
Exclusion criteria: NR
General characteristics of participants: 
severely malnourished children 
admitted to Yangon Children’s Hospital
Primary outcomes: not stated
Outcomes: outcomes reported include 
mortality, duration of hospital stay, 
readmissions, time taken for recovery. 
The only outcome reported separately 
for the < 6 months age group was 
proportional mortality
Method of assessing outcomes: not 
stated
Adverse symptoms: not stated
Length of follow-up: not stated
Recruitment dates: January 2000 to 
August 2002
Characteristics of participants
Characteristic WHO year 2000 (n = 196) WHO year 2001 (n = 186) Control year 1999 (n = 157)
Age mean, months 
(range)
29 (39 days–12 years) 28 (2 months–12 years) 25 (39 days–11 years)
Children with 
oedema, n
12 12 15
Children with skin 
lesions, n (%)
34 (21.7)
Comments: characteristics are available only for the whole group, they are not available separately for the group of infants aged < 6 months. Only 
age, number of children with oedema and with skin lesions have been data extracted. Data on children with hypothermia, hypoglycaemia, mean 
weight and mean length have not been data extracted. Data extracted only for full years (not the partial year 2002)144 Appendix 7 
Results
Primary outcomes WHO year 2000 (n = 21) WHO year 2001 (n = 12) Control year 1999 (n = 18)
Proportional mortality 
for < 6 month age 
group (%)
Cases: 10.7 Cases: 6.5 Cases: 11.4
Deaths: 9.1 Deaths: 12.5 Deaths: 12
Comments: only results for the 0–6 month age group have been data extracted as these may inform question 19. The overall results have not been 
data extracted because they relate to question 1, which was not ranked in the top 10 questions by the Delphi process
The paper states that, comparatively, the proportional mortality in the age groups < 6 months and 6–12 months was lower than in the 
13–24 months and > 24 months age groups (9–24% vs 20–50%). The author also comments that overall SAM in children < 6 months of age 
had significantly reduced due to implementation of exclusive breastfeeding programmes in hospital, clinic and community. The lower proportional 
mortality observed in the < 12 months age groups may also be due to the impact of breastfeeding
Safety: NR
HIV: NR
Barriers to implementation
Some barriers reported relating to the overall study and implementation of the WHO guidelines, but no barriers specifically relating to children 
< 6 months of age were reported. Aspects that may have affected this age group include difficulty obtaining ready-made combined mineral–vitamin 
mix, impracticality of monitoring pulse and respiration every 10 minutes (staff did their best to monitor every 30 minutes) and blood glucose could 
not be tested in every child, so all children were assumed to have hypoglycaemia and given 10% sucrose solution on admission
Other barriers reported related to the critical-care pathway, but as the details of this are not clear these have not been extracted
Methodological comments
Allocation to treatment groups: not applicable as this was a cohort study with retrospective control
Blinding: not explicitly stated, but presume none
Comparability of treatment groups: comparability of the 0–6 month age group in each trial arm unknown as data not provided. Baseline 
characteristics of the participants for each year are broadly comparable although with some changes (e.g. number of children under 6 months 
admitted occurring over time)
Method of data analysis: NR
Sample size/power calculation: NR
Attrition/dropout: NR
General comments
Generalisability: difficult to assess. The numbers of children aged < 6 months were small and there was a lack of data presented separately for them
Outcome measures: only one outcome measure, proportional mortality, reported for the 0–6 month age group
Intercentre variability: not applicable, but there may have been variations between years
Conflict of interest: NR
NR, not reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Hossain et al. 200948
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Hossain et al.48
Year: 2009
Country: Bangladesh
Study design: prospective 
cohort with concurrent control
Setting: secondary care
Number of centres: two
Funding: ICMH
Intervention: ICMH protocol for 
management of SAM with no 
phasing
Control: WHO protocol with two 
phases of management of SAM; 
the ICMH and WHO protocols are 
outlined separately below
Other interventions used: none
Definition of SAM: W/H < 70% of the 
expected NCHS/WHO references with or 
without bilateral pitting oedema
Number of participants: 60 (number 
aged < 6 months NR), 30 in each group
Sample attrition/dropout: reported for 
whole group only
Sample crossovers: NR
Inclusion criteria: SAM children aged 
2–59 months with W/H < 70% of the 
expected (NCHS/WHO references) with 
or without bilateral pitting oedema
Exclusion criteria: children with major 
congenital abnormalities or disabilities 
and having feeding difficulty
General characteristics of participants: 
in addition to having SAM, all belonged 
to urban and periurban areas of Dhaka
Primary outcomes: not explicitly 
stated but presumed to be weight 
gain (in gram per kg per day) as 
the sample size calculation was 
based on this
Other outcomes: improved 
appetite, disappearance of 
oedema, improvement of other 
associated medical conditions, 
time taken for gaining target 
weight, mortality rate
Method of assessing outcomes: 
target weight-W/H reaching 
1 SD (90%) of NCHS/WHO 
median reference values
Adverse symptoms: NR
Length of follow-up: not 
explicitly stated, appears to be to 
discharge
Recruitment dates: June to 
December 2003
Characteristics of participants
Characteristic ICMH intervention (n = 30) WHO control (n = 30) p-value
Age (months), mean ± SD 17.90 ± 14.17 18.33 ± 13.76 0.90
Sex ratio, F : M 1 : 1 1 : 1
Nutritional status
 Marasmus,  n (%) 20 (66.8) 20 (66.8) NR
  Marasmic kwashiorkor, n (%) 5 (16.7) 4 (13.3) 0.9
 Kwashiorkor,  n (%) 5 (16.7) 6 (20) NR
Comments: characteristics are only available for the whole group, they are not available for the group of infants aged < 6 months. Only age, sex ratio 
and nutritional status have been data extracted. Data on parents’ education, profession and income has not been data extracted
Results
Primary outcomes ICMH intervention  WHO control p-value
Weight gain for 
0–6 month age group, 
mean ± SD g/kg/day
17.5 ± 7.5 (n unknown) 11.6 ± 6.8 (n unknown) 0.21
Comments: only results for the 0–6 month age group have been data extracted as these may inform question 19. The overall results have not been 
data extracted because they relate to question 1, which was not ranked in the top 10 questions by the Delphi process
Safety: NR for 0–6 month age group 
HIV: NR146 Appendix 7 
Barriers to implementation
Copper not available in the local market, so this could not be used in the provision of minerals and trace elements
Methodological comments
Allocation to treatment groups: children at one hospital were managed with the WHO protocol, children at the other hospital were managed with the 
ICMH protocol. No information regarding allocation of each hospital to which protocol
Blinding: not stated
Comparability of treatment groups: comparability of the 0–6 month age group in each trial arm unknown as data not provided. Baseline 
characteristics of the complete trial arms are comparable
Method of data analysis: data for appetite, weight, oedema and other clinical parameters were collected daily through a structured questionnaire and 
checked manually at collection period and prior to entry into Microsoft Access (Microsoft Corporation, Redmond, WA, USA) and subsequently SPSS/
PC+ for analysis. Student’s t-test was used for comparing continuous variables and the chi-squared test was used for comparing the mortality rate
Sample size/power calculation: a sample size for equivalence was calculated assuming that the mean time taken for targeted weight gain is 25 days 
in each group with a SD of 6 days. Minimum acceptable difference in the two groups was set at 4.5 days with alpha error of 0.05 and power 80%. 
Study unlikely to be powered for infants aged < 6 months and the number of such infants recruited is NR
Attrition/dropout: NR separately for the 0–6 month age group. Overall, this did not differ between the groups: two children in each group died, two 
children were discharged on request in the WHO group, three in the ICMH group and one child absconded in the WHO group
General comments
Generalisability: difficult to assess generalisability because the numbers of children aged 0–6 months are not known
Outcome measures: only one outcome measure, weight gain, reported for the 0–6 month age group
Intercentre variability: two centres, but each was applying a different protocol. Unclear how differences between the two centres, other than the 
different protocols, might have influenced the results
Conflict of interest: no competing interests are stated by the report authors
ICMH protocol WHO protocol
Management No phasing Divided into two phases: initial and rehabilitation 
phase as per WHO 1999 guidelines.10 Reference 
provided but no details; those below obtained from 
original WHO paper10
Identification of life-threatening problems, and management of unconsciousness, convulsion, hypothermia and 
hypoglycaemia done according to the WHO protocol for both groups
Correction of electrolyte 
imbalance and micronutrients 
deficiencies
Locally available minerals and trace elements as below Added to F75 and F100 formula at concentrations 
noted below
Potassium Potassium chloride 5 mmol/kg/day F75: 3.6 mmol per 100 ml
F100: 5.9 mmol per 100 ml
Magnesium Magnesium sulphate 10 mg/kg/day F75: 0.43 mmol per 100 ml
F100: 0.73 mmol per 100 ml
Sodium NR F75: 0.6 mmol per 100 ml
F100: 1.9 mmol per 100 ml
Zinc Zinc sulphate 2 mg/kg/day F75: 2.0 mg per 100 ml
F100: 2.3 mg per 100 ml
Folic acid 2.5 mg/day 5 mg of folic acid on day 1 and then 1 mg per day 
thereafter. Folic acid also present in vitamin mix 
0.35 mg per litre of liquid diet
Multivitamins 0.6 ml/day orally (composition per 0.6 ml of multivitamin: 
vitamin D1, 200 IU, thiamine 1 mg, riboflavin 1 mg, 
pyridoxine 1 mg, panthenol 2 mg, nicotinamide 5 mg and 
vitamin C 60 mg)
Added to liquid diet in all phases of treatment 
[per litre of liquid diet: thiamine 0.7 mg, riboflavin 
2.0 mg, nicotinic acid 10 mg, pyridoxine 0.7 mg, 
cyanocobalamin (vitamin B12) 1 μg, vitamin C 100 mg 
pantothenic acid 3 mg, biotin 0.1 mg, retinol (vitamin 
A) 1.5 mg, calciferol (vitamin D) 30 μg, vitamin E 
22 mg and vitamin K 40 μg]
Copper Not available in the local market for use F75: 0.25 mg per 100 ml
F100: 0.25 mg per 100 ml© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Iron Supplementation (6 mg/kg/day) was started on the 15th 
day
Iron should never be given during the initial phase of 
treatment. During the rehabilitation phase, children 
with moderate or severe anaemia were given 
elemental iron orally, 3 mg/kg per day in two divided 
doses, up to a maximum of 60 mg daily, for 3 months
Severe anaemia Blood transfusion given (with or without heart failure) Blood transfusion given
Vitamin A supplement Every child For all children, given orally
  < 6 months of age 50,000 IU
  6–12 months of age 100,000 IU
  > 12 months of age 200,000 IU
For those with clinical signs of vitamin A deficiency 
dose as above given on the first 2 days, followed by a 
third dose at least 2 weeks later
Antibiotics As recommended by WHO for both groups
Feeds Made using whole cow’s milk, sugar, soya oil and water 
to provide 100 kcal in 100 ml/kg/day administered every 
2 hours during day and night. If the child wanted more 
than the prescribed diet, extra family food was given ad 
libitum and breastfeeding was encouraged
Two formula diets, F75 and F100, are used made 
from dried skimmed milk, sugar, cereal flour, 
vegetable oil, mineral and vitamin mixes. F75 
(75 kcal th or 315 kJ/100 ml), is used during the 
initial phase of treatment, whereas F100 (100 kcal 
th or 420 kJ/100 ml) is used during the rehabilitation 
phase, after the appetite has returned
Play therapy, nutrition 
education and discharge 
criteria
Similar to those for children in the WHO group
IU, international units; NR, not reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Appendix 8  
Question 21: data extraction tables
Akech et al. 201049
Data extraction table
Reference and 
design Intervention Participants  Outcome measures
Author: Akech et al.49
Year: 2010
Country: Kenya
Study design: RCT 
(phase II)
Setting: inpatient 
(district hospital)
Number of centres: 
one
Funding: the 
Wellcome Trust 
(Sponsor: Oxford 
University)
Intervention: RL (see below for 
dosages)
Control: WHO fluid resuscitation 
regimen (HSD/5D) (see below 
for dosages)
Third treatment arm: 4.5% HAS 
for those with non-diarrhoeal 
shock
Children with severe 
dehydrating diarrhoea/
shock were randomised to 
RL or HSD/5D; children with 
presumptive septic shock 
(non-diarrhoeal shock) were 
randomised to RL, HSD/5D 
or HAS. Paper only reports 
mortality and safety outcomes 
for HAS group owing to small 
numbers (n = 6)
Other interventions used: all 
children treated according 
to WHO guidelines – 
hypoglycaemia treated ORS 
(ReSoMaL) given where 
appropriate, all received 
antibiotics, early nasogastric 
feeding withheld but 
maintenance i.v. dextrose fluids 
given until stabilised, intestinal 
ileus excluded and tolerance 
of oral feeds established (see 
below for further details)
Definition of SAM: any of:
  ■ W/H z-score < –3 or W/H percentile 
70%
  ■ MUAC < 11.0 cm
  ■ oedema involving at least both feet 
(kwashiorkor)
Number of participants: 86 assessed 
for eligibility, 61 enrolled and 
randomised (RL n = 29, HSD/5D n = 26, 
HAS n = 6)
Sample attrition/dropout: no 
withdrawals/dropouts; 31/61 (51%) 
deaths
Sample crossovers: none
Inclusion criteria: aged > 6 months 
with SAM, with evidence of shock. 
Shock criteria included children with 
more than one of the following: CRT 
> 2 seconds, lower limb temperature 
gradient, weak pulse volume, deep 
‘acidotic’ or ‘Kussmaul’ breathing, 
creatinine > 80 µmol/l, or depressed 
conscious state [prostration (inability to 
sit up if aged > 8 months)] if present 
after correction of hypoglycaemia
Exclusion criteria: severe anaemia 
(Hb ≤ 5 g/dl), pulmonary oedema 
(defined as clinical evidence of 
presence of fine crepitations in both 
lung fields plus oxygen saturations 
< 90% in air), raised intracranial 
pressure, known congenital heart 
disease
General characteristics of participants: 
SAM children aged > 6 months with 
hypovolaemic shock secondary to 
either dehydrating diarrhoea or sepsis, 
42% HIV+ve
Primary outcomes: resolution of features of 
shock [including tachycardia and oliguria 
(production of abnormally small volume of 
urine)] at 8 and 24 hours
Secondary outcomes:
  ■ adverse events
  ■ mortality
Method of assessing outcomes: resolution 
of shock defined as the absence of all 
of: severe tachycardia (heart rate > 160 
beats/minute), CRT > 2 seconds or oliguria 
(urine output < 1ml/kg/hour). Dehydrating 
diarrhoea defined as ≥ 6 watery stools per 
day
MUAC measured with a cloth (non-
stretchable) measuring tape; weight with 
an electronic scale (Soehnle model 7300; 
CMS Instruments, UK) and length using a 
measuring board of standard design
Temperature gradient defined as cooler 
extremities to warmer core, and was 
assessed by running the back of the palm 
of the hand up the lower limb. Radial pulse 
was used to assess pulse volume. Oxygen 
saturation continuously measured using 
a multichannel Siemens® monitor. Blood 
pressure and urine output monitored hourly 
and then every 4 hours after 8 hours
Adherence to protocol validated by an 
internal, but independent monitoring team
Adverse symptoms: respiratory distress, 
pulmonary oedema, allergic reaction (to 
HAS)
Length of follow-up: outcomes at 24 hours; 
reports that children were followed up 
intensively up to 48 hours and thereafter for 
in-hospital survival
Recruitment dates: November 2006 to May 
2008 (recruitment discontinued early)150 Appendix 8 
Characteristics of participants:
Characteristic RL (n = 29) WHO fluid HSD/5D (n = 26) p-value
Severe dehydration/
shock,a n (%)
21 (72) 19 (73) NR
Presumptive shock,b 
n (%)
8 (28) 7 (27) NR
Male, n (%) 17 (59) 15 (58) 0.94
Age, months (IQR)c 16 (6) 15 (14) 0.41
MUAC cm, mean ± SD 10.0 (1.9) 10.4 (1.4) 0.43
W/H z-score, 
mean ± SD
–3.9 (1.0) –3.4 (1.3) 0.18
Severe wasting, n (%) 21 (72) 14 (54) 0.15
Kwashiorkor, n (%) 4 (14) 8 (31) 0.19
HIV+ve,d n (%) 14 (48) 9 (35) 0.65
WHO shock criteria, 
n (%)
23 (79) 18 (69) 0.39
Tachypnoea 
(> 60 breaths/minute), 
mean ± SD
13 (45) 16 (62) 0.22
Severe tachycardia 
(> 160 beats/minute), 
mean ± SD
8 (28) 11 (42) 0.25
Hydration, n (%)
  Reduced skin turgor 16 (55) 8 (31) 0.07
  Sunken eyes 19 (66) 11 (42) 0.08
Comments: baseline characteristics data not presented in the paper for HAS group owing to small numbers, though described as similar to other 
participants with sepsis
  ■ Whole-group characteristics: median age was 15 months (IQR 12–23 months). Thirty-five children (64%) had severe marasmus, 13 (21%) had 
features of oedematous malnutrition (kwashiorkor) and 41 (75%) fulfilled the strict WHO definition of advanced shock
  ■ Children with severe shock/dehydration (owing to diarrhoea) had a significantly higher frequency of WHO SAM shock definition than children with 
presumptive sepsis shock [32/40 (80%) vs 10/21 (48%), respectively; p = 0.01]. The diarrhoeal group were also more severely acidaemic (pH 
7.22 ± 0.19 vs 7.34 ± 0.17, respectively; p = 0.03)
  ■ The mean (± SD) volume for the bolus infused was 39 ml/kg (± 22) and 30 ml/kg (± 10) for RL and HSD/5D groups, respectively
Other baseline characteristics such as severity of shock (e.g. deep breathing, hypoxia, tachycardia, etc.), consciousness, biochemistry and laboratory 
variables were presented, but have not been data extracted
Results
Primary outcomes RL (n = 29) WHO fluid HSD/5D (n = 26) p-value
Number with shock, n/N (%)
  8 hours 14/25 (56) 15/22 (68) 0.39
  24 hours 14/25 (56)e 14/18 (78) 0.14
Oliguria (< 1 ml/kg/hour), n/N (%)
  8 hours 3/25 (12)f 9/22 (41)g 0.02h
  24 hours 6/25 (24)i 8/18 (44)j 0.16
Tachycardia (> 160 beats/minute), n/N (%)
  8 hours 4/25 (16) 6/22 (27) 0.34
  24 hours 4/25 (16) 8/14 (44) 0.04© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Comments: there appear to be discrepancies in the paper between data presented in tables and data presented in figures, all estimated by reviewer 
(see table footnotes for details)
  ■ Authors report that a larger decline in the proportion with shock was observed in children who received RL vs HSD/5D, particularly in the 
diarrhoeal group. However, the differences were NS at any time point [table 2 and figure 2 (line graph) in publication]
  ■ Median AUC for the hourly urine output was significantly lower in HSD/5D participants compared with RL: 51 ml/kg/hour 
(IQR 36–116 ml/kg/hour) vs 101 ml/kg/hour (IQR 63–141 ml/kg/hour), respectively, Kruskal–Wallis chi-squared = 4.6; p = 0.03
  ■ Median AUC for heart rates were similar for both study interventions (Kruskal–Wallis chi-squared = 0.3; p = 0.59)
  ■ Paper also reports results for creatinine, but these have not been extracted here
Secondary 
outcomes RL (n = 29)
WHO fluid HSD/5D 
(n = 26)
4.5% albumin (HAS) 
(n = 6) p-value
In-hospital mortality, 
n/N (%)
13/29 (45) 15/26 (58) 3/6 (50) 0.62k
0.34l
Tachypnoea (> 60 breaths/minute), n/N (%):
  8 hours 2/25 (8) 7/22 (32) NR 0.04
  24 hours 3/25 (12) 7/18 (39) NR 0.04
Comments:
  ■ Of the children who died, 26/31 (84%) fulfilled the WHO malnutrition shock definition at admission. Case fatality rate in this high-risk subgroup 
was 59% (26/44), irrespective of allocated intervention and was associated with an increased risk of death (RR 2.0, 95% CI 0.92 to 4.36; 
p = 0.05) compared with those who did not have this criteria
  ■ In those with severe diarrhoea, mortality was higher in HSD/5D than RL group [13/19 (68%) vs 9/22 (43%) respectively; p = 0.11], but the 
difference was NS. [Reviewer note: possible error in text – RL should be 9/21 (43%)]
  ■ In those with presumptive shock (non-diarrhoeal shock), mortality was 2/7 (29%) in HSD/5D vs 4/8 (50%) in RL group, again the difference was 
NS (p = 0.61) (note: there is a possible error reported in the publication for presumptive shock for HSD/5D)
  ■ Nine out of 13 (69%) of children with kwashiorkor died irrespective of treatment arm. Deaths of children with kwashiorkor were 29% of the total 
deaths. Kwashiorkor was associated with a non-significant increased risk of death [OR 2.2 (95% CI 0.7 to 10.1); p = 0.14]
  ■ Twelve out of 31 (39%) of deaths occurred within 24 hours of recruitment, whereas 16 out of 31 (52%) occurred within 48 hours of enrolment. 
On Kaplan–Meier survival analysis, there was no significant difference in time to death when any of the intervention fluids were used for 
resuscitation (log-rank test combined p = 0.42)
  ■ Mean respiratory rate was significantly greater in the HSD/5D arm than RL arm at 8 hours and 24 hours (p = 0.002). (Reviewer: table 2 in paper 
reports p = 0.04 separately for 8 hours and 24 hours)
  ■ Overall, there was a trend towards higher median AUC of respiratory rates in those who died (2262; IQR 1938–2897) compared with survivors 
(2015; IQR 1547–2391), but did not reach statistical significance (Kruskal–Wallis chi-squared = 3.6; p = 0.06)
  ■ Paper also reports data for resolution of base deficit (acidosis), but these have not been extracted here
Safety:
  ■ No child developed clinical features of pulmonary oedema or allergic reaction (to HAS) during the course of study observation
  ■ Frusemide or other diuretics were not required or prescribed during the trial
  ■ There were no differences in the mean (± SD) sodium concentration at admission (133 ± 11 vs 134 ± 10; p = 0.81), 8 hours (134 ± 10 vs 
139 ± 10; p = 0.09) and 24 hours (138 ± 9 vs 140 ± 9; p = 0.47) between those who received HSD/5D and RL, respectively
HIV:
  ■ Thirteen (42%) of those who died were HIV+ve, 14 (45%) were HIV–ve and four (13%) declined HIV tests
  ■ Infection with HIV did not significantly increase the risk of death [OR 1.18 (95% CI 0.38 to 3.72); p = 0.76]
Barriers to implementation
Participant recruitment was discontinued early after an interim review of the safety data and thus the study was underpowered152 Appendix 8 
Methodological comments
Allocation to treatment groups: children were randomly assigned in two batches (1) those with severe dehydration/shock randomised to WHO 
HSD/5D or RL; and (2) those with presumptive (non-severe diarrhoea) shock randomised to WHO HSD/5D, RL or HAS. Random allocation was 
assigned by use of sealed cards. No further details were reported
Blinding: reports that study interventions were not masked (thus patients and care providers were not blinded). No details on blinding of outcome 
assessors
Comparability of treatment groups: no statistically significant differences between RL and HSD/5D treatment groups (p-values reported). Paper 
reports that baseline characteristics and disease severity indices were similar across the fluid intervention arms. Also, characteristics and 
haemodynamic responses in the six HAS individuals were similar to the other participants in the presumptive sepsis shock group who were 
randomised to HAS/5D and RL treatments (data were not presented because of small numbers)
Method of data analysis: the null hypothesis was that there is no difference in the safety profile or effect on physiological parameters of shock when 
using any of the three fluids for resuscitation. Dichotomous and categorical variables were created from continuous variables. Derived variables were 
created from clinical factors defined by guidelines as indicating a definitive need for urgent therapeutic intervention and for lab variables. Means 
and SDs were calculated for continuous variables using Student t-tests. Non-normally distributed data were compared using Sign-rank test and 
Kruskal–Wallis. Proportions were compared using chi-squared and Fisher’s exact tests as appropriate. Kaplan–Meier survival analysis was also 
used to compare time-to-event (death). AUCs were calculated for serial measurements and their medians compared using Wilcoxon rank-sum and 
Kruskal–Wallis tests. AUC was employed to compensate for confounding effect of early mortality, hence, missing observations, leading to biases in 
the highest risk group and resulting in imbalance within the survivors. Reports that all analyses were ITT; outcomes were reported for all those who 
survived
Sample size/power calculation: the study aimed to recruit 90 children: 45 RL, 45 HSD/5D and 20 HAS (reviewer note: numbers add to 110 not 90) 
to provide sufficient information on haemodynamic response and adverse events to the two fluid management regimes to understand the potential 
efficacy rather than for comparison. A specific sample size calculation was not presented. The numbers were not achieved as recruitment was 
discontinued after an interim review of safety data, and therefore the study was underpowered
Attrition/dropout: numbers and reasons reported. No dropouts/withdrawals and 31 deaths (15 HSD/5D, 13 RL, 3 HAS)
General comments
Generalisability: likely that most of the children would meet the current WHO criteria (W/H z-score < –3 SD). Population were largely infants (median 
age 15 months) with SAM and features of shock (75% had advanced shock as defined by WHO), severe or non-severe diarrhoea, and 42% were 
HIV+ve
Outcome measures: outcomes appropriate for study objectives; weight gain NR
Intercentre variability: N/A
Conflict of interest: no competing interests declared. All authors were associated with the Wellcome Trust Research Programme, but states that the 
funders had no role in the research or in the preparation of the manuscript
WHO fluid resuscitation regimen HSD/5D RL or albumin (HAS) resuscitation
  ■ Initial bolus of 15 ml/kg over 1 hour
  ■ Repeat bolus given once if some 
improvement in features of shock noted
  ■ If no improvement seen, 10 ml/kg whole 
blood transfusion given over 3 hours
  ■ Initial bolus of 10 ml/kg over 30 minutes
  ■ Repeated only twice over 1 hour if clinical reassessment demonstrated any of the following 
features of shock: CRT > 3 seconds, weak pulse volume, temperature gradient or hypotension 
(systolic blood pressure < 80 mmHg)
  ■ Additional boluses (10 ml/kg over 1 hour) only permitted if oliguria (< 0.5 ml/kg/hour) or 
hypotension (systolic blood pressure < 80 mmHg) developed (20 ml/kg over 1 hour). Maximum 
bolus volumes given were 40 ml/kg
  ■ At each clinical review, children were assessed for clinical resolution of shock and examined for signs of pulmonary oedema (if present, further 
boluses withheld and treated with diuretics)
  ■ No invasive monitoring, such as central venous pressure measurement, was used
  ■ Children did not receive inotropes, vasopressors or hydrocortisone
  ■ Other than initial fluid boluses, additional intravenous fluids boluses, intravenous rehydration for children with severe diarrhoea or maintenance 
fluids were not given (as per guideline recommendation), except if child was intolerant to feeding when low volume maintenance was provided© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Standard WHO management of SAM
In all other respects, children were treated according to WHO guidelines
  ■ Hypogylcaemia (blood glucose < 3 mmol/l) treated with 5 ml/kg of 10% dextrose
  ■ Malnutrition ORS (ReSoMaL) given to children with significant diarrhoea (greater than six loose stools/day) rather than i.v. rehydration, 
irrespective of the level of clinical dehydration
  ■ All children received i.v. ampicillin (50 mg/kg four times/day) and i.m. gentamicin (7.5 mg/kg once daily) for at least 5 days
  ■ Ceftriaxone used as second-line antimicrobial or when directed by microbiological results
  ■ Early nasogastric feeding recommended by the guideline immediately after resuscitation was withheld, and children were placed on 
maintenance i.v. dextrose fluids until children were stabilised, intestinal ileus excluded and tolerance of oral feeds established
Hb, haemoglobin; i.m., intramuscular; NA, not applicable; NR, not reported; NS, not statistically significant.
a  Severe diarrhoea.
b  Non-severe diarrhoea, per cent calculated by reviewer. The six participants in the HAS (albumin) group all had non-severe diarrhoea 
(presumptive shock).
c  Unclear if this is mean or median.
d  Seven children were missing HIV test results: three (10%) RL group and four (15%) HSD/5D group.
e  Shown to be approximately 60% at 24 hours in Figure 2 (line graph).
f  Shown to be approximately 21% at 24 hours in Figure 3 (line graph).
g  Shown to be approximately 46% at 24 hours in Figure 3 (line graph).
h  p = 0.05 in text.
i  Shown to be approximately 38% at 24 hours in Figure 3 (line graph).
j  Shown to be approximately 54% at 24 hours in Figure 3 (line graph).
k  Comparison of three groups.
l  HSD/5D vs RL.154 Appendix 8 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 9  
Question 22: data extraction tables
Alam et al. 200051
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Alam et al.51
Year: 2000
Country: India
Study design: double-blind RCT
Setting: inpatient (diarrhoea training 
and treatment unit)
Number of centres: one
Funding: Department of Pediatrics, 
Jawaharlal Nehru Medical College, 
Aligarh Muslim University, Aligarh 
(material and preparation of ORS)
Intervention: H-ORS (see end of 
table for details)
Control: standard WHO-ORS  
75 ml/kg of ORS to be taken in 
4 hours for both groups following 
study inclusion (five sachets 
formulated in 1 litre of water) (see 
end of table for details)
Other interventions used: if 
severely dehydrated, 50 ml/kg of 
i.v. RL in first hour prior to study 
inclusion
A single dose of doxycycline 
(8 mg/kg ) was administered 
to all with clinical suspicion of 
cholera or positive stool for motile 
organisms and dose was repeated 
if the child vomited within half an 
hour of taking the drug
Indications for i.v. fluids were 
severe dehydration, persistent 
vomiting (> 3 hours) and 
persistent dehydration at the end 
of 4 hours of oral rehydration 
therapy. 75 ml/kg of RL were 
given in the next 3 hours and then 
the child was put back on the 
study ORS
Khichri, Dalia, curds and banana 
feeds were offered once hydration 
improved breastfeeding was 
continued throughout
Definition of SAM: W/H 
< 70%, assessed as per the 
NCHS, but W/A (not height) is 
reported in the results
Total: n = 170 (88 H-ORS, 82 
WHO-ORS)
Number of SAM participants: 
H-ORS n = 41/88 (47%), 
cholera n = 19/35, non-
cholera n = 69/135; WHO-
ORS n = 40/82 (49%), cholera 
n = 16/35, non-cholera 
n = 66/135
Total sample attrition/dropout: 
n = 19/170 (11%) ; dropouts 
n = 11; removed n = 8, 
treatment failures put on 
WHO–ORS
Sample crossovers: none
Inclusion criteria: children 
with acute (< 4 days duration) 
diarrhoea with dehydration 
and > 3 months of age with 
clinical suspicion of cholera 
aged 3 months – 5 years with 
non-cholera diarrhoea
Exclusion criteria: children 
with clinical evidence 
of systemic infection, 
encephalopathy, electrolyte 
imbalance, convulsions or 
invasive diarrhoea
General characteristics of 
participants: children aged 
from 3 months to 5 years with 
cholera and acute non-cholera 
diarrhoea
Primary outcomes: not specifically 
reported
Outcomes:
  ■ per cent weight gain
  ■ caloric intake (kcal/kg/day)
  ■ rehydration phase – frequency 
(stools/4 hours), ORS 
consumed (litres) and duration 
(hours)
  ■ maintenance phase – 
frequency (stools/4 hours), 
ORS consumed (litres) and 
duration (hours)
  ■ overall – frequency 
(stools/4 hours) ORS 
consumed (litres) and duration 
(hours)
  ■ serum sodium (mEq/l)
  ■ urine output (boys; ml/kg/hour)
  ■ intravenous fluids (ml/kg)
Method of assessing outcomes: 
timescale for rehydration and 
maintenance phases not defined
Intake output records and 
assessment of dehydration 
measured four hourly
Nutritional status assessed as per 
NCHS
Recovery and discharge criteria: 
non-cholera diarrhoea – three 
consecutive semi-formed stools or 
no stools for 12 hours; cholera – 
no dehydration for 8 hours or no 
stools for 6 hours
Stool: frequency recorded by 
mother (tally marking). Motile 
organisms and stool culture was 
completed for all. Culture was 
collected on sterile rectal swab 
and stored in ‘Careyblair’s media’ 
and plated within 12 hours158 Appendix 9 
Urine: output collected for boys 
during initial 24 hours
Weight: taken at admission, end of 
rehydration and discharge
Serum sodium: estimation was 
done at 24 hours
Adverse symptoms: NR
Length of follow-up: none 
reported, but appears to be until 
recovery (see definition above)
Recruitment dates: only states that 
authors enrolled until August 1998
Comments: H-ORS treatment failures were transferred to WHO-ORS. Treatment failure definition: dehydration > 72 hours, diarrhoea > 7 days, 
consumption of ORS > 8 litres in < 5 years age group, or > 10 litters in > 5 years age group and needing i.v. fluids > 150 ml/kg. Children leaving 
study prior to recovery were considered treatment failures, if they had dehydration and or frequency of stools
Characteristics of participants 
Characteristic SAM only H-ORS (n = 41) WHO-ORS (n = 40) p-value
Mean age, month (SD) 25.29 (2.09) 24.17 (2.23) NR
Mean W/A, % (SD) 52.4 (1.64) 58.6 (1.12) NR
Comments: total sample only. There were no significant differences in the two groups at admission for mean duration (95% CI 11.9 to 20.5; 
p = 0.6) and frequency (95% CI 1.1 to 1.4; p = 0.79) of diarrhoea, whereas the per cent of children with vomiting (OR 1.06, 95% CI 0.43 to 2.31), 
with some (OR 0.89, 95% CI 0.71 to 1.12) or severe (OR-1.61, 95% CI 0.59 to 4.33) dehydration and those receiving ORS (OR 0.74, 95% CI 0.24 
to 2.22) at admission, were comparable. NR for SAM
CI for children with vomiting was reported as 96%. This is assumed to be an error, as all other CIs were reported as 95%
Results 
Outcomes, mean (SD) H-ORS (n = 41) WHO-ORS (n = 40) p-value (95% CI)
Weight gain (%) 4.54 (1.79) 4.45 (2.18) Not significantly different (p-value 
NR)
Caloric intake (kcal/kg/day) 42.72 (1.66) 39.73 (2.03) Not significantly different (p-value 
NR)
Rehydration frequency 
(stools/4 hours)
4.27 (2.029) 5.86 (1.73) p = 0.32a,b (0.55 to 0.97)
Rehydration ORS consumed (litres) 1.45 (0.002) 1.55 (0.002) Not significantly different (p-value 
NR)
Rehydration duration (hours) 10.95 (2.23) 11.72 (2.26) Not significantly different (p-value 
NR)
Maintenance frequency 
(stools/4 hours)c
1.72 (1.92) 2.45 (2.17) p = 0.035a (0.51 to 0.97)
Maintenance-ORS consumed (litres)c 0.69 (0.005) 0.74 (0.01) Not significantly different (p-value 
NR)
Maintenance duration (hours)c  10.45 (2.09) 16.36 (2.01) p = 0.007a (0.46 to 0.88)
Overall frequency (stool/4 hours) 3.39 (1.80) 4.70 (1.68) p = 0.011a (0.56 to 0.93)
Overall ORS consumed (litres) 2.74 (0.0017) 3.32 (0.0017) Not significantly different (p-value 
NR)
Overall duration (hours) 24.35 (1.57) 30.12 (1.69) Not significantly different (p-value 
NR)
Serum sodium (mEq/l) 134.89 (1.03) 137.03 (1.03) Not significantly different (p-value 
NR)
Urine output (boys) (ml/kg/hour)d 55.79 (1.65) 55.73 (1.89) Not significantly different (p-value 
NR)
i.v. fluids (ml/kg)e 121.23 (1.81) 70.73 (1.51) Not significantly different (p-value 
NR)
Other (total sample): treatment failure n = 12/170 (7%); H-ORS n = 3/88, WHO-ORS 9/82 (OR 0.28, 95% CI 0.07 to 1.1)
Discharged n = 151 (two children recovered after rehydration phase)
The paper also reported results for H-ORS vs WHO-ORS in total cases and for H-ORS vs WHO-ORS in non-cholera diarrhoea. These were not data 
extracted. However, the significant results for the SAM subgroup were in the same direction as the results for H-ORS vs WHO-ORS in total cases© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Safety: NR 
HIV: not applicable
Barriers to implementation
None reported
Methodological comments
Allocation to treatment groups: cases were serially allotted the study ORS packet
Blinding: states double-blind trial; packets of sachets were reported to be identical. No details reported on blinding of outcome assessors
Comparability of treatment groups: characteristics in whole group were reported to be compatible at admission (p-value or OR plus 95% CI given). 
Only age and W/A reported for SAM group and not significantly different (p-value not given)
Method of data analysis: analyses of different parameters were conducted in the re-hydration phase, in the maintenance phase, for overall 
combined data, for children split into cholera/non-cholera and repeated for children with W/H < 70% (but W/A reported in tables) and breast fed/
non-breastfed children < 2 years old using SPSS (Version 7.5; SPSS Inc., Chicago, IL, USA). Variables with skewed distribution were log transformed 
and two-tailed Student’s t-test used to compare the groups. Chi-squared tests were used to correlate the qualitative variables. For treatment 
failures/dropouts, the data that were collected during their stay in the study was included in the analysis. Only data for SAM (W/A < 70%) was 
extracted, with reference made to direction of whole group results
Sample size/power calculation: the study was planned to detect a 30% difference in the frequency and duration of diarrhoea of the two ORS. It 
was calculated that 82 children were needed per group to detect this difference with a power of 90% and a significance level of 5%. Previous data 
(frequency of 4.11 ± 2.67 stools/4 hours and duration of diarrhoea 36 ± 20.0 8 hours) from the Diarrhoea Treatment and Training Unit of 70 non-
cholera children treated on WHO-ORS was used to determine the sample size. SAM is a subgroup (less than half of the total sample) and analysis is 
unlikely to be powered
Attrition/dropout for total sample: numbers reported, but details omitted. Four cases had a frequency of 310 (meaning unclear) in last 24 hours and 
were considered treatment failure, six cases required more than the pre-determined volume of ORS, one case had dehydration phase of > 72 hours, 
one case needed > 150 ml/kg i.v. fluids and 12 cases (7%) of treatment failures on H-ORS were moved to WHO-ORS
General comments
Generalisability: SAM defined using a NCHS criteria of < 70% W/H; however, only W/A is reported in all tables. It is unclear whether or not the 
participants are severely malnourished as per WHO criteria (< 70% W/H), although in SAM group mean W/A is well below the 70% benchmark 
(~ 55%). SAM subgroup represents less than half of the total sample (47% H-ORS; 49% WHO-ORS) and children around 2 years of age with 
dehydration and with/without cholera diarrhoea
Outcome measures: appear to be suitable and appropriate
Intercentre variability: not applicable, one centre only
Conflict of interest: none
Details of intervention and control
WHO-ORS and H-ORS packets prepared in the departmental research lab
H-ORS WHO-ORS
Component, g
 NaCl 2.6  3.5 
 KCl 1.5  1.5 
  Trisodium citrate  2.9  2.9 
 Glucose 13.5  20 
Concentration of, mmol/l
 Sodium 75 90
 Potassium 20 20
 Chloride 65 80
 Citrate 10 10
 Glucose 75 111
Osmolarity, mosmol/l: 245 311
NR, not reported.
a  Significantly less in those receiving H-ORS.
b  Reported as p = 0.32, but as this is not significant it would appear to be an error and should probably read p = 0.032.
c H-ORS,  n = 22; WHO-ORS, n = 19.
d H-ORS,  n = 4; WHO-ORS, n = 7.
e  No key provided by authors.160 Appendix 9 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the 
study likely to be representative of the target 
population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals 
participated?
80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if 
categorise as ‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of 
randomisation described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups 
prior to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant 
confounders that were controlled [either in the 
design (e.g. by stratification or matching) or in the 
analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the 
intervention or exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms 
of numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing 
the study (If the percentage differs by groups, 
record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the 
allocated intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that 
may influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the 
study design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention 
received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.
The data extraction is based on the SAM subgroup only, but the quality assessment is based on the total population of the RCT.162 Appendix 9 
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Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Alam et al.50
Year: 2003
Country: Bangladesh
Study design: double-blind RCT
Setting: inpatient [Clinical Research 
and Service Centre of International 
Centre for Diarrhoea, Disease 
Research (ICDDR), Bangladesh: 
Centre for Health and Population 
Research]
Number of centres: one
Funding: grant from WHO (no. 
C6/181/377)
Intervention: oral ReSoMaL 
(see end of table for details)
Control: standard WHO-ORS 
(see end of table for details)
Fluid deficit was corrected 
with 10 ml/kg/hour of the 
assigned ORS given over 
the first 2 hours, followed by 
5 ml/kg/hour over a period of 
10–12 hours until the deficit 
was corrected (dehydration 
was categorised according to 
the modified WHO guidelines). 
Ongoing stool losses were 
corrected with 5–10 ml/kg after 
each watery or loose stool. 
In patients with high purging 
rates, fluid intake was adjusted 
according to the ongoing 
stool output. ORS therapy 
was continued until diarrhoea 
ceased
Other interventions used: 
pneumonia cases received i.m. 
or i.v. ceftriaxone 75 mg/kg/day 
once daily for 5 days and 
gentamicin 5 mg/kg/day in two 
divided doses. Other infections, 
complications, nutritional 
therapy or aspects of case 
management were provided 
consistent with the WHO 
guidelines
All children were treated 
following the protocol of 
the WHO manual for the 
standardised treatment of 
SAM children and received 
acute and rehabilitation phase 
treatment until discharged. 
Children remained in the 
study until diarrhoea resolved, 
with subsequent transfer to a 
nutritional rehabilitation unit or 
home-based nutritional follow-
up programme of the Clinical 
Research and Service Centre
Definition of SAM: W/L < 70% of the 
NCHS median or with bilateral pedal 
oedema
Number of participants: n = 130 
(ReSoMaL n = 65; WHO-ORS n = 65)
Sample attrition/dropout: n = 12. 
ReSoMaL: n = 7 (three severe 
dehydration requiring i.v.’s, one 
symptomatic hypokalaemia, one 
severe hyperkalaemia; one severe 
pneumonia and one symptomatic 
hyponatraemia with seizure). 
WHO-ORS: n = 5 (one symptomatic 
hypokalaemia, one severe 
dehydration, one severe pneumonia 
and two parental withdrawal)
Sample crossovers: none reported
Children requiring i.v. fluid therapy for 
severe dehydration, septic shock or 
convulsion, children with concomitant 
illness requiring more intensive care, 
cases with severe hyperkalaemia 
(serum potassium ≥ 6.0 mmol/l), 
cases with severe hypokalaemia 
(serum potassium ≤ 1.5 mmol/l with 
or without symptoms or < 2.5 mmol/l 
with symptoms) and cases with 
severe hyponatraemia (serum 
sodium < 120 mmol/l with symptoms 
or < 115 mmol/l with or without 
symptoms) were withdrawn from the 
study
Inclusion criteria:
  ■ children aged 6–36 months 
(either sex) with history of watery 
diarrhoea for ≤ 10 days and SAM 
(< 70% of the NCHS median or 
with bilateral pedal oedema)
Exclusion criteria:
  ■ bloody diarrhoea, severe 
dehydration requiring i.v. fluids
  ■ signs of severe infection (i.e. 
severe pneumonia, sepsis, 
meningitis)
General characteristics of participants: 
children aged 6–26 months with 
history of watery diarrhoea, and with 
or without cholera
Primary outcomes: number 
of children developing over-
hydration and number of 
children with correction of basal 
hypokalaemia after 24 and 
48 hours of treatment
Secondary outcome: number 
of children remaining 
hyponatraemic at 24 and 
48 hours of treatment
Method of assessing outcomes:
  ■ laboratory tests on 
admission included blood 
tests (haematocrit, total 
and differential white blood 
cell count, serum protein 
and albumin); serum 
electrolytes (also at 24 and 
48 hours); stool microscopy 
for leucocytes, red blood 
cells and parasites 
(including Giardia lamblia, 
Entamoeba histolytica and 
Cryptosporidium); stool 
culture for Salmonella, 
Shigella and Vibrio; stool 
culture for rotavirus 
by enzyme-linked 
immunosorbent assay
  ■ tests for diarrheagenic 
Escherichia coli were not 
performed
If clinically indicated, urine for 
microscopy and culture and 
chest radiograph
  ■ Children were placed on a 
cholera cot and a paediatric 
urine collector was applied 
to collect urine separately
  ■ Stool weight, supplemented 
food and body weight 
were measured with an 
electronic scale (Sartorius, 
Göttingen, Germany) with a 
precision of 1.0 g
  ■ All intakes (ORS solutions, 
plain water and food) and 
outputs (stool, urine and 
vomitus) were quantified 
every 6 hours© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  ■ Body weight, vital signs 
(pulse, temperature and 
respiration) and other 
evidence of overhydration 
(i.e. puffy face, pedal 
oedema, respiratory hurry/
distress) were recorded 
every 6 hours
  ■ Overhydration was defined 
as > 5% weight gain after 
correction of dehydration 
at any time during the 
study period with any 
of the following signs: 
periorbital oedema/puffy 
face, increased heart rate 
(> 160/minute), or increased 
respiration (> 60/minute)
  ■ Hypokalaemia was 
defined as serum 
potassium < 3.5 mmol/l, 
hyperkalaemia as serum 
potassium > 5.5 mmol/l, 
hyponatraemia as serum 
sodium < 130 mmol/l, and 
hypernatraemia as serum 
sodium > 150 mmol/l
  ■ Duration of diarrhoea was 
calculated as the time 
in hours from the time 
of randomisation to the 
last watery stool followed 
by two consecutive soft/
formed stools or no stool 
for 12 hours
Adverse symptoms: 
hyponatraemia
Length of follow-up: none 
reported, but states all children 
remained in the study until 
diarrhoea resolved
Recruitment dates: February 
1998 to January 2000
Characteristics of participants
Characteristic ReSoMaL (n = 65) WHO-ORS (n = 65) p-value
Mean age, months (SD) 15 (7) 15 (6) NR
Sex, n (M : F) 39 : 26 42 : 23 NR
Mean body weight, kg (SD) 5.22 (0.92) 5.26 (0.95) NR
Mean W/A % of NCHS median (SD) 50 (7) 51 (7) NR
Mean WAZ (SD) −4.7 (1) −4.6 (0.7) NR
Mean W/L % of NCHS median (SD) 66 (4) 66 (3) NR
Mean WLZ (SD) −3.6 (0.6) −3.5 (0.5) NR
Breastfed, n (yes : no) 45 : 21 47 : 17 NR
Mean duration of diarrhoea before admission, hours (SD) 77 (62) 74 (59) NR
Mean number of stools in 24 hours before admission (SD) 12.5 (5) 14 (9) NR
Dehydration status, n (none : some) 21 : 45 23 : 42 NR
Oedema present, n (%) 15/65 (23) 14/65 (22) NR164 Appendix 9 
Stool pathogen, n (%) NR
Vibrio cholerae 18/65 (28) 19/65 (29)
Shigella  5/65 (8) 2/65 (3)
Salmonella  2/65 (3) 0/65
Other Vibrio 3/65 (5) 5/65 (8)
Rotavirus 10/65 (15) 12/65 (18)
Results
Primary outcomes ReSoMaL (n = 65)
WHO-ORS 
(n = 65) p-value; OR (95% CI)
Children adequately rehydrated at 12 hours,  
n/N (%)
45/59 (76) 51/63 (81) p = 0.68; OR 0.16 (95% CI 0.29 to 1.96)
Overhydration, n/N (%) 3/65 (5) 8/65 (12) p = 0.20; OR 0.3 (95% CI 0.1 to 1.5)
Basal hypokalaemia (potassium < 3.5 mmol/l), 
n/N (%)
39/65 (60) 44/65 (68) p = 0.47; OR 0.7 (95% CI 0.3 to 1.6)
Hypokalaemia corrected at 24 hours, n/N (%) 14/38 (36) 2/44 (5) p = 0.0006; OR 12.3 (95% CI 2.4 to 117)
Hypokalaemia corrected at 48 hours, n/N (%) 18/38 (47) 7/44 (16) p = 0.004; OR 1.5 (95% CI 1.5 to 15.6)
Secondary outcomes ReSoMaL (n = 65) WHO-ORS (n = 65) p-value; OR (95% CI)
Mean serum potassium, mmol/l (SD)
  0 hours 3.03 (1) 3.3 (1) p = 0.7; OR < 0.08 (–0.3 to 0.4)a
  24 hours 4.0 (1) 3.2 (0.7) p = 0.01; OR (0.49 to 1.1)a,b
  48 hours 4.6 (0.8) 3.4 (0.8) p = 0.01; OR 1.2 (0.3 to 1.0)a
Hyponatraemia (serum sodium < 130 
mmol/l), n/N (%)
  0 hours 25/65 (38) 19/65 (29) p = 0.35; OR 1.5 (0.7 to 3.4)
  24 hours 24/62 (39) 15/64 (23) p = 0.9; OR 2.1 (0.9 to 4.8)
  48 hours  17/59 (29) 6/60 (10) p = 0.017; OR 3.6 (1.2 to 12.2) 
Severe hyponatraemia (serum sodium 
≤ 120 mmol/l), n/N (%)
  0 hours 0/65 1/65 (2) p = 1.0; OR 0 (0 to 39)
  24 hours 3/62 (5) 1/64 (2) p = 0.36; OR 3.2 (0.3 to 171)
  48 hours 0 0
Mean serum sodium, mmol/l (SD)
  0 hours 132.1 (6) 132.9 (8) p = 0.51; OR –0.8 (–3.3 to 1.7)a
  24 hours 130.5 (6) 133.3 (6) p = 0.01; OR–2.8 (–4.9 to 0.7)a
  48 hours 132.1 (4) 134.5 (4) p = 0.001; OR–2.4 (–3.9 to–1.0)a
Comments: three new cases of severe hyponatraemia developed in the ReSoMaL group. Although not explicitly stated, presumably no new case 
developed in the WHO-ORS group. Stool output, urine output, ORS intake, water intake, calorie intake from supplemented food and duration of 
diarrhoea and weight gain before discharge reported similar between groups, but no data shown
Other: 
hyponatraemia 
(serum < 130 mmol)
Non-cholera diarrhoea  Cholera diarrhoea
ReSoMaL 
(n = 47) Standard (n = 46)
p-value; OR  
(95% CI) ReSoMaL (n = 18)
Standard 
n = 19
p-value: OR  
(95% CI)
0 hours, n/N (%) 13/47 (28) 11/46 (24) NS; OR 1.2 
(0.4 to 3.5)
12/18 (67) 9/19 (47) NS; OR 2.2 (0.5 
to 10)
24 hours, n/N (%) 11/47 (23) 7/46 (15) NS; OR 1.7 
(0.5 to 5.8)
13/18 (72) 8/19 (42) NS; OR 3.6 (0.8 
to 18)
48 hours, n/N (%) 7/47 (15) 4/46 (9) NS; OR 1.84 
(0.4 to 8.2)
10/11 (56) 2/19 (11) NS; OR 10.63 
(1.6 to 92.1)
Safety: the child in the ReSoMal group who was withdrawn owing to hyponatraemia with associated seizure was reported as having had a high 
purging rate (18 g/kg/hour) during the first 24-hour period
Convulsions: n = 1 ReSoMaL (case did not have cholera). The study authors believed that the occurrence of the convulsion in the ReSoMal group 
should limit the use of ReSoMal in its current formulation in severely malnourished children with diarrhoea
Death: n = 0 
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Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: cases were allocated using serially numbered, sealed envelopes supplied to the pharmacist of ICDDR
Blinding: states double-blind controlled study, with children assigned on enrolment thorough randomisation list (prepared by the WHO) following a 
permuted table of variable length. Pharmacist prepared the ORS in a clean bottle marked only with the child’s name and study number according to 
list inside the serially numbered envelopes. The ORS solutions were reported to look identical and a code in the form of A and B was provided to the 
investigators for analysis. The group identity was disclosed for preparation of the final report, after preparation of data analysis tables
Comparability of treatment groups: states that baseline clinical characteristics such as age, body weight, W/A, W/L, breastfeeding status, 
oedematous state and dehydration status were comparable between the groups (p-values NR)
Method of data analysis: Student’s t-test for comparison between groups of continuous variables for non-continuous variables; the chi-squared test/
Fisher’s exact test, using SPSS/PC+. For withdrawals, data collected until the time of withdrawal were included in the analysis
Sample size/power calculation: based on an expected reduction of persistence of hypokalaemia from 33% with standard WHO-ORS to 12% with 
ReSoMaL. Sample size was calculated to be 65 in each group (5% level of significance, 80% power and 10% dropout). Authors state that no reliable 
data exist on the development of overhydration quantified objectively. A sample size of 52 in each group was estimated, assuming a 20% difference 
in the development of overhydration between the groups (25% of WHO-ORS group and 5% of ReSoMaL group considered to develop overhydration, 
with a 5% level of significance, 80% power and 10% dropout). A subgroup analysis for hyponatraemia excluded children with cholera and is unlikely 
to be powered
Attrition/dropout: numbers and reasons reported. Children withdrawn from the study were followed and final outcome recorded
General comments
Generalisability: SAM defined using criteria of < 70% of the NCHS median W/L, which is in agreement with the WHO criteria for SAM
Outcome measures: appear to be suitable and appropriate. Outcomes are defined where necessary
Intercentre variability: not applicable, one centre only
Conflict of interest: NR, but staff from WHO reviewed protocol and supplied the ReSoMaL
Details of intervention and control
Composition of ReSoMaL and standard ORS
ReSoMaL Standard ORS
Concentration of, mmol/l
 Sodium 45 90
 Potassium 40 20
 Chloride 76 80
 Citrate 7 10
 Glucose 125 111
 Magnesium  6
Concentration of, μmol/l
 Zinc  300
 Copper 45
Osmolarity, mosmol/l 300 311
NR, not reported; NS, not statistically significant; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.
a  Difference between means (95% CI).
b  OR at 24 hours not presented in the paper.
Note: although standard WHO-ORS does not contain magnesium, zinc or calcium, the WHO-ORS group did receive supplements as part of the 
centres’ routine treatment of SAM.166 Appendix 9 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely to 
be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No
 
If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study 
(If the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.168 Appendix 9 
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Data extraction table
Reference and 
design Intervention Participants  Outcome measures
Author: Alam et al.57
Year: 2009
Country: Bangladesh
Study design: RCT
Setting: inpatient 
(Dhaka hospital 
of the ICDDR 
followed by nutrition 
rehabilitation unit)
Number of centres: 
one
Funding: Nestlé 
Foundation and 
ICDDR, Bangladesh
Intervention 1: glucose-ORS
Intervention 2: glucose-
ORS + ARS
Intervention 3: rice-ORS
ORS had the same salt 
composition, but different 
substrates (see table at end for 
further details)
Children with some dehydration 
were randomised to receive the 
assigned ORS within 1 hour, and 
those with severe dehydration 
within 6 hours of admission 
after i.v. rehydration. ORS given 
on hospital ward and continued 
until cessation of diarrhoea 
(acute phase)
Other interventions used: 
i.v rehydration of severe 
dehydration, antibiotics where 
appropriate, erythromycin 
for cholera, vitamin A, folic 
acid and other multivitamin 
supplements, glucose solution 
for hypoglycaemic children, 
breastfeeding continued ad 
libitum, supplementary feeding 
with F100 diet, semi-solid food 
for older children. Further details 
at end of paper
Definition of SAM: W/L < 70% of NCHS 
median or with bipedal oedema
Number of participants: 316 screened, 
175 randomised (glucose-ORS n = 58, 
glucose-ORS + ARS n = 59, rice-ORS 
n = 58)
Sample attrition/dropout: 170 (97%) 
completed acute phase (five withdrew 
consent: one glucose-ORS, three 
glucose-ORS + ARS, one rice-ORS). 137 
(78%) completed convalescent phase (42 
glucose-ORS, 50 glucose-ORS + ARS, 
45 rice-ORS) – reasons not given for 
convalescent dropouts
Sample crossovers: none reported
Inclusion criteria: SAM children of 
either sex, aged 6–60 months, acute 
watery diarrhoea < 48 hours duration 
and stool dark-field microscopy 
demonstrating presence of cholera. 
Those with hypoglycaemia, hypothermia, 
hyponatraemia, dehydration and other 
associated-infections were also eligible
Exclusion criteria: dysentery (blood 
in stool), severe infections (severe 
pneumonia, clinical sepsis, meningitis)
General characteristics of participants: 
SAM children aged 6–60 months with 
acute watery diarrhoea and cholera
Primary outcomes:
  ■ stool output
Secondary outcomes:
  ■ days to attain oedema-free W/L of 
80% (of NCHS median)
  ■ diarrhoea duration
  ■ weight gain
  ■ fluid losses (urine and vomit output)
  ■ fluid intake (ORS, water and milk)
  ■ recovery
Method of assessing outcomes: 
study eligibility confirmed by physical 
examination, blood, stool and urine 
samples
‘Some dehydration’ defined as presence 
of ≥ 2 signs or symptoms (irritable/less 
active,* sunken eyes, dry mucosa, thirst, 
reduced skin turgor*) with at least one sign 
marked by*
‘Severe dehydration’ defined as the 
presence of signs of ‘some dehydration’ 
plus at least one key sign (lethargy/coma,* 
inability to drink, but not refusal to drink,* 
uncountable/absent radial pulse*)
Therapeutic failure defined as continuation 
of diarrhoea beyond seventh day of 
randomisation
Unscheduled i.v. therapy defined as 
requirement of i.v. fluid any time after 
randomisation owing to appearance of 
signs of severe dehydration, excessive 
vomiting preventing adequate ORS intake 
or dehydration signs lasting > 6 hours
Hypokalaemia = serum potassium < 3.5 
mmol/l; severe hypokalaemia = serum 
potassium < 1.5 mmol/l; 
hyperkalaemia = serum potassium 
> 6.0 mmol/l; hyponatraemia = serum 
sodium < 130 mmol/l; severe 
hyponatraemia = serum sodium 115 
mmol/l; hypernatraemia = serum sodium 
> 150 mmol/l
Acute illness = diarrhoea phase; 
convalescent phase = after resolution of 
diarrhoea and until oedema-free W/L of 
80% attained© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Children weighed on admission and placed 
on a cholera cot. Paediatric urine collector 
used to collect stools and urine separately. 
Body weight and weight of stools and 
supplemented foods weighed on an 
electronic scale (Sartorius) with gram 
precision. All intakes (ORS, water, i.v. fluids 
and foods) and outputs (stool, urine and 
vomit) measured for each 6-hour period in 
acute phase. Vital signs and dehydration 
and signs of overhydration monitored 
every 6 hours
Duration of diarrhoea calculated from time 
of randomisation to last watery stool
Adverse symptoms: none reported
Length of follow-up: ORS continued until 
cessation of diarrhoea (the last watery 
stool is followed by ≥ 2 soft/formed stools 
or no stool for 12 hours). After discharge, 
children followed-up at home weekly 
for at least 6 weeks (these data are not 
presented in this paper)
Standard treatment lasted through a 
convalescent phase until 80% W/L 
reached
Recruitment dates: July 2001 to 
December 2004
Characteristics of participants
Characteristic Glucose-ORS (n = 58)
Glucose-ORS + ARS 
(n = 59)
Rice-ORS 
(n = 58) p-value
Age, months 27.17 ± 12.36 28.36 ± 13.42 27.33 ± 11.97 0.858
Sex M : F 26 : 32 34 : 25 32 : 26 0.357
Weight, kg 6.90 ± 1.32 7.09 ± 1.52 6.78 ± 1.43 0.513
Length, cm 76.84 ± 7.11 77.34 ± 8.31 76.54 ± 8.15 NR
W/A (% of NCHS 
median)
54.51 ± 9.50 53.42 ± 6.86 53.16 ± 7.94 0.645
W/L (% of NCHS 
median)
68.99 ± 4.92 69.01 ± 5.27 67.54 ± 6.19 0.257
WAZ –4.38 ± 68a –4.31 ± 0.63 –4.39 ± 0.71 0.793
WLZ –3.14 ± 1.88 –2.76 ± 46a –3.38 ± 0.60 0.185
MUAC, mm 112.7 ± 9.9 113.6 ± 9.7 111.9 ± 10.8 0.678
MUAC with 
< 110 mm, n (%) 
19 (33) 18 (31) 23 (39) 0.70
Diarrhoea duration 
before admission, 
hours
12.59 ± 8.27 13.07 ± 9.11 10.98 ± 5.73 0.326
Stools in last 
24 hours before 
admission, n
14.36 ± 6.00 14.02 ± 6.09 14.55 ± 7.16 0.901
Vomiting duration 
before admission, 
hours
11.29 ± 8.01 11.31 ± 8.28 10.16 ± 4.7 0.613
Vomiting in last 
24 hours, n
10.12 ± 6.93 11.83 ± 8.03b 12.28 ± 7.67c 0.271170 Appendix 9 
Breastfed at illness 
onset, n (%)
32 (55) 18 (31) 29 (50) 0.018
Severe dehydration 
at admission, n (%)
48 (84) 49 (83) 49 (84) 0.971
Pedal oedema, n (%) 47 (81) 48 (81) 40 (69) 0.193
Hypothermia, n (%)d 12 (20) 7 (12) 11 (19) 0.405
Have received i.v. 
fluids, n (%)
50 (86) 50 (86) 49 (84) 0.961
Hyponatraemia, 
n (%)
10 (17) 14 (24) 14 (24) 0.599
Hypokalaemia, n (%) 23 (40) 14 (24) 20 (34) 0.170
Hypoglycaemia, 
n (%)
2 (4) 4 (7) 8 (14) 0.161
Comments: data are mean ±SD unless stated otherwise
Baseline characteristics were comparable between the three groups, except for breastfeeding; paper reports this was less frequent in glucose-ORS 
group, but data indicate lower frequency in the glucose-ORS + ARS group. 147/175 (84%) were clinically assessed to have severe dehydration 
in agreement with their mean weight gain of 11.4% (95% CI 10.4 to 12.5) at resolution of diarrhoea. Approximately one-third were acutely 
malnourished as indicated by MUAC < 110 mm; other risks of death included pedal oedema (77%) and hypothermia (17%). Hypernatraemia or 
severe hyponatraemia was not observed in any child. The paper reports other baseline characteristics including sociodemographic characteristics, 
serum concentrations of electrolytes and Hb, but these have not been extracted
Results
Primary outcomes Glucose-ORS (n = 58)
Glucose-ORS + ARS 
(n = 59)
Rice-ORS 
(n = 58) p-value (95% CI)
Stool output, ml/kg
  At 24 hours 355 309 236 0.004, difference 109 (44 to 174), 32% 
reductione
  At 48 hours 600 518 382 0.007, difference 213 (79 to 346), 37% 
reductione
  At 72 hours  735 645 475 0.018, difference 242 (73 to 412), 36% 
reductione
Comments: Data are mean per cent of initial body weight. The 72-hour results (and 24- and 48-hours results for stool output) reported here for 
individual study groups are estimated by reviewer from bar charts. SE presented, but not data extracted. The paper presents results for every 
6-hourly period up to 72 hours, but these have not been data extracted. Statistical difference was entirely contributed by the rice-ORS group. The 
trend towards reduction of stool output in glucose-ORS + ARS group vs glucose-ORS group was NS
Secondary 
outcomes Glucose ORS (n = 58)
Glucose-ORS + ARS 
(n = 59)
Rice-ORS 
(n = 58) p-value
Weight gain at 
72 hours, % initial 
weight
11 9.7 13 0.05
Median diarrhoea 
duration, hours 
(95% CI)
72 (62 to 82) 60 (50 to 70) 54 (44 to 54) 0.530
Days to attain 80% 
of median W/L, 
mean ± SD
7.14 ± 2.26 7.12 ± 2.2 7.2 ± 3.78 0.99
Vomit output at 
72 hours, ml/kg
30 37 33 NR/NS
Urine output at 
72 hours, ml/kg
184 186 177 NR/NS
ORS intake at 
72 hours, ml/kg
710 620 450 0.012, 38% reductionf
Water intake at 
72 hours, ml/kg
215 230 260 0.03g
Milk formula intake 
at 72 hours, ml/kg
329 333 346 NR/NS© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Required 
unscheduled i.v. 
therapy, n (%)
10/56 (18) 11/59 (19) 6/57 (11) 0.858
Therapeutic failure, 
n (%)
2 (3.6) 1 (1.8) 2 (3.6) 0.785
Deaths, n 0 0 0 NR
Comments: outcomes reporting results at 72 hours are estimated by reviewer from bar charts. The paper presents results for every 6-hourly period 
up to 72 hours, but these have not been data extracted. Significant differences in weight gain, ORS intake and water intake were entirely accounted 
for by the rice-ORS group, according to the least significant difference post hoc analysis. Overall mean weight gain at 72 hours was 114 g/kg (95% 
CI 103 to 124 g/kg). Overall mean duration of diarrhoea was 66 hours (95% CI 62 to 71 hours) with an overall median duration of 60 hours (95% 
CI 54 to 66 hours). Diarrhoea duration compared by log-rank test, df = 2, log-rank = 1.27. A survival plot for recovery from diarrhoea after inclusion 
was also presented for 167 children, but has not been data extracted. No statistical difference was observed between groups (log-rank = 1.27, 
df = 2, statistical value = 0.53)
Safety: during the acute phase of treatment, no children developed features of overhydration, cardiac failure, hypoglycaemia, severe hypo- or 
hyperkalaemia or severe hypo- or hypernatraemia
HIV: none reported
Barriers to implementation
None reported
Methodological comments
Allocation to treatment groups: randomisation using consecutive sealed envelopes. A statistician not involved in the study prepared the 
randomisation list and sequentially numbered sealed envelopes containing a slip of paper identifying the allocated ORS. The list was retained by the 
hospital pharmacist who prepared the ORS in bottles marked with the patient’s name and study number
Blinding: states that treatment could not be blinded to the people involved in the study (assume this refers to patients and care providers alike) 
because of visible differences in the ORS solutions. No details regarding blinding of outcome assessors
Comparability of treatment groups: baseline characteristics were comparable between the three groups (p-values reported), except for breastfeeding 
– paper reports this was less frequent in glucose-ORS group, but data indicate lower frequency in the glucose-ORS + ARS group
Method of data analysis: not ITT analysis. The five children withdrawn from the study by their parents were not included in the analysis. States 
that the baseline characteristics of these children did not differ from the remainder of the included children. Fewer children were analysed at the 
end of the convalescent phase than the acute phase. Baseline characteristics and outcomes were compared using one-way ANOVA followed by a 
post hoc least significant difference test, and a non-parametric Kruskal–Wallis test was used for the continuous variables. Chi-squared test used 
for comparison of categorical variables and Fisher’s exact test was applied when appropriate. Kaplan–Meier survival analysis was performed for 
comparing diarrhoea duration
Sample size/power calculation: Authors state that sample size was not calculated to detect a significant difference in death rates owing to ethical 
and statistical reasons (requirement of huge sample size). Instead, sample size was calculated to detect a 30% reduction in stool output in first 
24 hours of treatment with either glucose-ORS + ARS or rice-ORS. This level of stool output reduction was based on results of an unpublished pilot 
study in similar children having mean stool weight (± SD) of 158 g (± 95) and of published data in adults. This required a sample size of 63 per 
group for a two-sided alpha-level of < 0.05 and a beta-level of 0.2
Attrition/dropout: numbers and reasons reported for acute phase, but only numbers given for convalescent phase. 170 (97%) completed acute 
phase (five withdrew: one glucose-ORS, three glucose-ORS + ARS and one rice-ORS). 137 (78%) completed convalescent phase (42 glucose-ORS, 
50 glucose-ORS + ARS, and 45 rice-ORS)
General comments
Generalisability: likely that most of the children would meet the current WHO criteria (W/L < 70%, W/L z-score < –3 SD) given a mean of 68% and 
–3.09, respectively. Age ranged from 6 to 60 months but mean age 27 months, therefore, it is likely to be representative of infants and toddlers. All 
had cholera and some had comorbidities (e.g. electrolyte disturbances)
Outcome measures: outcomes were appropriate
Intercentre variability: N/A
Conflict of interest: funded by Nestlé Foundation and ICDDR. No conflicts of interest reported172 Appendix 9 
Standard management
After randomisation, all children were treated as per the standard ICDDRB protocol for management of severely malnourished children
  ■ Children without an apparent extraintestinal infection received 100 mg/kg parenteral ampicillin and 5 mg/kg gentamicin in four and two divided 
doses, respectively, for 5 days
  ■ All received 12.5 mg/kg erythromycin every 6 hours for 3 days for cholera
  ■ Those with oral candidiasis received 100,000 units nystatin oral suspension every 6 hours until resolution of condition
  ■ All received oral vitamin A: 200,000 IU for those without xerophthalmia and > 1 year, 100,000 IU for those aged 6–12 months, for those with 
xerophthalmia > 1 year 200,000 IU on admission and on following day and again at discharge and children < 1 year received same schedule, 
but half the dose
  ■ All children received 1.25 mg folic acid and 2 mg/kg elemental zinc daily for 15 days
  ■ All received multivitamin supplements (composition reported but not data extracted) twice daily for 15 days if > 1 year, or half dose if < 1year
  ■ Children with hypoglycaemia or blood glucose < 3 mmol/l were fed 50 ml of 10% glucose solution orally or by nasogastric tube; those with 
symptomatic hypoglycaemia received 2 ml/kg of 25% glucose solution i.v.
  ■ Breastfeeding continued ad libitum
  ■ Supplementary feeding with a F100 diet (100 kcal/100 ml) given in an amount of 10 ml/kg (10 kcal/kg) for each feed every 2 hours on the first 
day. This was gradually increased to deliver 150 kcal/kg/day for the next 7 days according to needs. If the child was reluctant to feed or weak or 
with painful mouth sores, food was administered via a nasogastric tube until the child could take it orally
  ■ Semi-solid food (cooked rice, lentils and vegetables) were given to older children during the convalescence and rehabilitation phase in addition 
to F100
Rehydration
  ■ Children with severe dehydration were initially rehydrated using i.v. ‘cholera saline’ containing sodium 133, potassium 13, chlorine 98 and 
acetate 48 (all mmol/l) until their recovery from shock or severe dehydration
  ■ Children with some dehydration on admission or following i.v. rehydration, the estimated fluid deficit was corrected with one of the assigned 
ORSs, 100 ml/kg for 6 hours. Additionally, after each watery stool, 5–10 ml/kg of the same ORS was used for matching ongoing stool losses
  ■ Children with some dehydration were randomised to receive the assigned ORS within 1 hour, and those with severe dehydration within 6 hours 
of admission after i.v. rehydration
Composition of ORS (differed only in glucose, ARS and rice composition)
  ■ ORS given on hospital ward and continued until cessation of diarrhoea (acute phase)
  ■ After resolution of diarrhoea, children were transferred to the hospital nutritional rehabilitation unit until oedema-free W/L 80% attained
  ■ Following this, children were discharged from hospital and followed up in their home weekly for at least 6 weeks
Ingredient Glucose-ORS
Glucose 
ORS + ARS Rice-ORS
Glucose, mmol/l 90 90 0
Rice powder, g/l 0 0 50
Amylase-resistant starch, g/l 0 50 0
Sodium, mmol/l 75 75 75
Potassium, mmol/l 40 40 40
Chloride, mmol/l 87 87 87
Citrate, mmol/l 10 10 10
Magnesium, mmol/l 3 3 3
Zinc, µmol/l 300 300 300
Copper, µmol/l 45 45 45
Calculated osmolarity, mosmol/l 305 305 215
ANOVA, analysis of variance; Hb, haemoglobin; ICDDRB, International Centre for Diarrhoeal Disease Research, Bangladesh; IU, international units; 
N/A, not applicable; NR, not reported; NS, not statistically significant; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score..
a  Possible errors.
b  Paper reports a second figure of 11.83 ± 8.03, but appears to be a typeset error.
c  Paper reports a second figure 12.28 ± 7.67, but appears to be a typeset error.
d  Rectal temperature ≤ 36 °C. p-values based on one-way analysis of variance or chi-squared or Fisher’s exact test as appropriate.
e  Compared with glucose-ORS group; difference between rice-ORS and glucose-ORS groups reported in paper (i.e. not estimated by reviewer).
f  Significantly lower in rice-ORS group compared with glucose-ORS group.
g  Significantly greater in rice-ORS group.
The glucose-ORS is a modification of the WHO ReSoMaL ORS containing higher sodium (75 vs 45 mmol/l) to address the greater stool sodium 
loss in cholera diarrhoea. The rice-ORS is routinely used in hospitals and is prepared by mixing the salt mixture and rice powder in 1050 ml of 
water and boiling for 7–8 minutes.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell
 of those 
randomised
Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
174 Appendix 9 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Dutta et al. 200055
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Dutta et al.55
Year: 2000
Country: India
Study design: double-blind, RCT
Setting: inpatient 
(hospital) + community after 
discharge and until follow-up
Number of centres: one
Funding: not stated
Intervention: zinc-
supplemented syrup 
(177 mg/day in three 
divided doses, 40 mg 
elemental zinc/day)
Control: placebo syrup
Other interventions used: 
all children received 
standard ORS initially plus 
standard feeding regimen 
(see end of table for 
details)
Definition of SAM: not specifically stated. 
Uses the IAP W/A classification system, 
though results are reported for all 
children (not separately by grade). Mean 
baseline MUAC is < 11 cm
Number of participants: n = 80 (zinc: 
n = 44, control n = 36)
Sample attrition/dropout: unclear (see 
Methodological comments on page 177)
Sample crossovers: none
Inclusion criteria: male children, aged 
3–24 months, < 80% Harvard standard 
W/A, history of watery diarrhoea (more 
than four times within previous 24 hours) 
for ≤ 72 hours and clinical signs and 
symptoms of ‘some’ dehydration (e.g. 
sunken eyes, reduced skin elasticity, 
rapid pulse, dry mouth and thirst)
Exclusion criteria: history of treatment 
with antibiotics, other systemic infections 
(e.g. septicaemia, meningitis, pneumonia, 
urinary tract infection, otitis media), 
chronic underlying diseases (TB, liver 
diseases), need for intensive care (i.e. 
life-support system, blood transfusion 
or total parenteral nutrition), exclusively 
breastfed
General characteristics of participants: 
malnourished male children, aged 
3–24 months, with acute dehydrating 
diarrhoea; majority have SAM (grade III 
or IV)
Primary outcomes: not specifically 
stated as primary, but appear 
to be:
  ■ recovery
  ■ diarrhoeal duration
  ■ diarrhoeal volume
  ■ ORS consumption
Recovery defined as passage of 
normal stool or no stool for last 
18 hours
Secondary outcomes:
  ■ weight gain
  ■ gain in MUAC
  ■ height gain
Method of assessing outcomes: 
weighed unclothed at same 
time every day using scales 
with a sensitivity of 20 g; 
nutritional status assessed using 
IAP classification; degree of 
dehydration assessed by the WHO 
criteria; stool samples collected 
in sterile MacCartney’s bottles 
for detection of enteropathogens 
using ‘standard methods’92
Stool losses measured on pre-
weighed disposable diapers; urine 
separated from stools using urine 
collection bags; vomitus weighed 
on pre-weighed gauze pads. 
All intake and output measured 
and recorded every 8 hours until 
diarrhoea stopped, withdrawal 
from study, or up to day 5 if child 
did not fulfil criteria of recovery
Adverse symptoms: NR
Length of follow-up: treatment 
until diarrhoea ceased or up to 
day 5. Additional follow-up up to 
30 days (including up to 5 days 
hospitalisation)
Recruitment dates: June 1997 to 
May 1998176 Appendix 9 
Characteristics of participants
Characteristic Zinc syrup (n = 44) Placebo syrup (n = 36) p-value
Mean age ± SD, months 10.4 ± 5.4 11.0 ± 4.9
Mean body weight ± SD, kg 5.5 ± 1.6 5.8 ± 1.5
Mean height ± SD, cm 65.5 ± 8.4 67.5 ± 6.9
Mean MUAC ± SD, cm 10.3 ± 1.3 10.5 ± 1.0
Nutritional status, n W/A (%)
  Grade I ≥ 80% of median – –
  Grade II 70% < 80% of median 6 (13) 6 (17)
  Grade III 60% < 70% of median 10 (23) 11 (30)
  Grade IV < 60% of median 28 (64) 19 (53)
Diarrhoea before admission ± SD
  Mean duration, hours 33.4 ± 11.5 38.3 ± 10.3
  Frequency/24 hours 13.8 ± 3.8 13.3 ± 3.9
Degree of dehydration Some Some
Enteropathogens, n (%)
  Single pathogen 34 (77) 23 (64)
  Mixed pathogens 7 (16) 9 (25)
  No pathogen 3 (7) 4 (11)
Comments: the study reports n (%) for specific single and mixed pathogens, but these have been summed by reviewer. Pathogens identified were: 
single pathogens – enteropathogenic E. coli, enteroaggregative E. coli, Salmonella typhimurium, Shigella flexneri, Shigella sonnei, V. cholera O1, 
Clostridium difficile, rotavirus, V. cholera non-O1 non-O139; mixed pathogens – EPEC + S. typhimurium, EPEC + rotavirus, EPEC + S. flexneri, 
rotavirus + S. flexneri, rotavirus + S. typhyimurium. No p-values were reported
Results
Primary outcomes Zinc syrup (n = 44) Placebo syrup (n = 36) p-value
Patients recovered, n (%)a 44 (100) 32 (89) 0.04
Mean recovery ± SD, hourb 70.4 ± 10.0 103.4 ± 17.1 0.0001
Total liquid stool output, kg 1.5 ± 0.7 2.4 ± 0.7 0.0001
Total liquid, ml (liquid food + water) 867.0 ± 466.1 1354.7 ± 675.6 0.0001
Consumption of total ORS, litres 2.5 ± 1.0 3.6 ± 0.8 0.0001
Comments: assumed that total stool output, total liquid and consumption of ORS were calculated to recovery or up to day 5
Secondary outcomes Zinc syrup (n = 44) Placebo syrup (n = 36) p-value
Per cent weight gain on recovery 
(% admission weight) ± SD
3.9 ± 4.1 3.2 ± 2.9 0.41
Per cent weight gain on 30th day 
(% recovery weight) ± SD
2.6 ± 3.3c 2.9 ± 3.7d 0.88
Per cent gain in mid-arm 
circumference on 30th day (% 
recovery MAC) ± SD
5.2 ± 3.4c 3.4 ± 2.3d 0.08
Per cent gain in height on 30th day 
(% recovery height) ± SD
1.1 ± 0.9c 0.6 ± 0.5d 0.06
Comments: in subgroup analysis of different nutritional status, the duration of diarrhoea, stool output, consumption of ORS and other fluids were 
significantly less in the zinc-supplemented group than in the placebo group (numerical data not presented in the paper)
Safety: NR
HIV: NR
Barriers to implementation
NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Methodological comments
Allocation to treatment groups: randomised using a random numbers table and patients were allocated a specific-numbered bottle of either zinc or 
placebo syrup
Blinding: double blind. The taste, colour and consistency of the zinc and placebo syrups were identical, as were the bottles that were numbered. 
The person who made the randomisation was not associated with the study. The serial code numbers were kept in a sealed envelope with a senior 
officer who identified the groups after the study completion
Comparability of treatment groups: paper states that groups were comparable for baseline characteristics, although no p-values were reported. 
Note that the zinc status of the participants was not assessed, so it is not known whether children were zinc deficient or whether or not this was 
comparable between the groups
Method of data analysis: appears to be ITT analysis for primary outcomes and also weight gain at recovery. The other secondary outcomes were 
analysed on a proportion of patients. Comparability of the study and control groups according to patient characteristics, and differences in proportion 
of cured patients in the two groups, were determined using chi-squared tests. Means of outcome variables of the two groups were compared by 
applying Student’s t-test
Sample size/power calculation: NR
Attrition/dropout: does not specifically report any dropouts, but outcomes at 30-days follow-up are only presented for 18 and 16 patients in the zinc 
and placebo groups, respectively. Thus, can possibly assume 26 and 20 patients, respectively, dropped out/withdrew by this time point
General comments
Generalisability: young infants (aged 3–24 months) and males only. Definition of SAM is not provided and it is unclear whether or not the children 
would meet the current WHO criteria as only 59% (47/80) of population are < 60% Harvard standard W/A, but the majority have a MUAC < 11 cm
Outcome measures: outcomes were appropriate, although mortality was not a specified outcome (no deaths reported)
Intercentre variability: N/A
Conflict of interest: funding not stated. Greenco Biologicals (Pvt) Ltd prepared the zinc syrup and placebo syrup
All children received standard ORS solution (mmol/l: sodium, 90; potassium, 20; citrate, 10; chloride, 80; glucose, 111) at the rate of 75–100 ml/kg 
body weight for first 4–6 hours of admission for correction of initial dehydration. If not achieved, the same solution was repeated for another 
4–6 hours. When all the signs and symptoms of dehydration disappeared, ORS solution was given as maintenance therapy in amounts matching 
stool volume and loss in vomitus. However, more fluid was given if the child wanted it and if there were clinical indications. If any patient developed 
severe dehydration during the follow-up period, he received i.v. infusion of RL according to WHO guidelines
Zinc-supplemented syrup
177 mg/day in three divided doses, 40 mg elemental zinc/day. Each 5 ml of zinc syrup 
contained 59 mg of zinc sulphate
Placebo syrup
Identical in taste, consistency and colour to the zinc 
syrup
Immediately after rehydration, feeding was resumed in both groups. Breastfeeding was allowed as wanted. Non-breastfed children received half-
strength milk for the first 24 hours, and the strength gradually increased until discharge. Older children were offered the standard hospital diet of 
rice, lentils and fish (cereal/vegetable diet) appropriate for their age
At the time of discharge, all the children were advised to continue the assigned bottle of syrup until it was finished. Mothers were advised to give at 
least one extra meal or liquid feed per day during the recovery period
N/A, not applicable; NR, not reported.
a  Within 5 days of hospitalisation.
b  Mean recovery time denotes duration of diarrhoea.
c  Follow-up of 18 patients.
d  Follow-up of 16 patients.178 Appendix 9 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the 
study likely to be representative of the target 
population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals 
participated?
80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if 
categorise as ‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of 
randomisation described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.   Were there important differences between groups 
prior to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant 
confounders that were controlled [either in the 
design (e.g. by stratification or matching) or in the 
analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the 
intervention or exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms 
of numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing 
the study (If the percentage differs by groups, 
record the lowest)
80–100% 60–79% < 60% Cannot tell
a (primary outcomes) a (secondary 
outcomes)
Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak
b a
G. Intervention integrity
1.  What percentage of participants received the 
allocated intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention 
measured?
Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) 
that may influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/office Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/office Provider Patient

3.  Are the statistical methods appropriate for the 
study design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention 
allocation status (i.e. ITT) rather than actual 
intervention received?
Yes No  Cannot tell

Global rating for studyb
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  The percentage of participants completing the study varied according to outcomes – for the primary outcomes of recovery, diarrhoeal volume 
and duration and ORS consumption as well as weight gain on recovery – data appeared to be available for all participants. For secondary 
outcomes of gain in weight, mid-arm circumference and height on 30th day, data were available for ~ 42% of participants only. Therefore, 
have indicated both strong and weak ratings for this section.
b  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.180 Appendix 9 
Dutta et al. 200154
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Dutta et al.54
Year: 2001
Country: India
Study design: double-blind, 
RCT
Setting: inpatient (hospital)
Number of centres: one
Funding: not stated
Intervention: H-ORS (224 mmol/l)
Control: standard WHO/UNICEF 
ORS (311 mmol/l)
All children were rehydrated 
orally within 4–6 hours using the 
assigned ORS solution. It was 
then given to replace continuing 
losses (liquid stool and vomitus) 
until diarrhoea stopped (two 
formed stools passed, or no stool 
for 12 hours) or for up to 5 days 
if diarrhoea persisted. Children, 
other than those who were very 
ill, were discharged on recovery
Other interventions used: all 
children were allowed to drink 
water ad libitum, breastfeeding 
and formula/animal milk were 
permitted, older children received 
the normal diet, which they were 
used to before the illness. No 
drug therapy was given
Composition of ORS at end of 
table
Definition of SAM: < 60% Harvard 
standard W/A (without oedema)
Number of participants: n = 64 (H-ORS 
n = 32, standard ORS n = 32)
Sample attrition/dropout: appears none 
(though NR)
Sample crossovers: none
Inclusion criteria: male children, 
aged 6–48 months, < 60% Harvard 
standard W/A without oedema, 
marasmic, history of watery diarrhoea 
(three or more loose, watery stools/day) 
for ≤ 72 hours and clinical signs and 
symptoms of ‘some’ dehydration (e.g. 
thirst or eagerness to drink, sunken 
eyes, dry mouth and tongue and loss 
of skin elasticity)
Exclusion criteria: history of another 
episode of diarrhoea 1 month prior 
to onset of present illness, receipt of 
antibiotics or ORT during this episode 
of diarrhoea, obvious parenteral 
infection (septicaemia, meningitis, 
pneumonia, urinary tract infection), 
need for special medical care (i.e. 
life-support system, blood transfusion 
or total parenteral nutrition), exclusively 
breastfed, obvious signs of kwashiorkor
General characteristics of participants: 
severely malnourished, marasmic, 
male children, aged 6–48 months, with 
dehydrating acute watery diarrhoea
Primary outcomes: not specifically 
stated
Outcomes:
  ■ recovery
  ■ duration of diarrhoea
  ■ volume of diarrhoea (stool 
output)
  ■ ORS intake
  ■ fluid intake
  ■ weight gain
  ■ sodium and potassium 
concentrations
Recovery not specifically defined, 
but assume is until diarrhoea 
stopped (two formed stools passed 
or no stool for 12 hours)
Method of assessing outcomes: 
weighed unclothed at same 
time each day on a balance 
of 10 g precision; nutritional 
status assessed using IAP 
classification; stool samples 
examined using ‘standard 
techniques’92 for characterisation 
of bacterial isolates; detection of 
enteropathogens using microscopic 
examination (trophozoites and 
cysts of Entamoeba histolytica and 
Giardia lamblia), enzyme linked 
immunosorbent assay (ELISA) and 
polyacrylamide gel elecrophoresis 
(rotavirus)
Serum Sodium and potassium 
estimated from blood samples
Stool losses measured on pre-
weighed disposable diapers; 
urine separated from stools using 
urine collection bags; vomitus 
weighed on pre-weighed gauze 
pads; measurement units sensitive 
to 1 g or 1 ml. Intake and output 
measured and recorded 8 hourly 
until diarrhoea stopped or for up to 
5 days if it persisted
Adverse symptoms: NR
Length of follow-up: not specifically 
stated but treated until diarrhoea 
stopped or for up to 5 days
Recruitment dates: July 1997 to 
August 1999© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Characteristics of participants:
Characteristic H-ORS (n-32) Standard ORS (n = 32) p-value
Age, months  17.3 (9.7) 22.5 (15.6)
Weight on admission, kg 5.7 (1.7) 5.8 (1.6)
W/A, n (%)
 60–69% 2 (6) 1 (3)
  < 60% 30 (94) 31 (97)
Duration of diarrhoea before 
admission, daysa
21.3 (8.2) 22 (8.0)
Stool frequency/day 15 (3) 13 (4)
Vomiting, n (%) 8 (25) 9 (28)
Degree of dehydration:
  ‘Some’ dehydration, n (%) 32 (100) 32 (100)
  Serum sodium, mmol/l 130.0 (3.3) 129.7 (3.1)
  Serum potassium, mmol/l 3.1 (0.3) 3.1 (0.3)
  Per cent weight loss 6.1 (2.2) 6.3 (2.1)
Enteropathogens, n (%)
  Single pathogen 24 (75) 26 (81)
  Mixed pathogens 5 (16) 4 (13)
  No pathogens 3 (9) 2 (6)
Comments: results are expressed as mean (SD) unless otherwise stated. The study reports n (%) for specific single and mixed pathogens, but 
these have been summed by reviewer. Pathogens identified were: enteropathogenic E. coli, rotavirus, Vibrio cholerae, Shigella flexneri, Salmonella 
typhimurium, Giardia lamblia, Aeromonus sp., Klebsiella. No p-values were reported
Results
Outcomes H-ORS (n = 32) Standard ORS (n = 32) p-value
Patients recovered within 
5 days, n (%)
32 (100) 29 (91) > 0.05
Median survival time to 
recovery, hours
36 53 0.001
Duration of diarrhoea after 
initiation of therapy, hours
41.5 (25.1) 66.4 (32.3) 0.001
Stool output
  0–24 hours, g/kg 73.4 (23.1) 105.9 (44.6) 0.001
  24–48 hours, g/kg 34.9 (13.5) 87.5 (66.5) 0.001
  48–72 hours, g/kg 28.4 (18.0) 90.4 (67.7) 0.01
  At recovery, g/kg/day 52.3 (21.3) 96.6 (42.8) 0.0001
ORS intake
  0–24 hours, ml/kg 109.7 (32.2) 184.5 (53.7) 0.0001
  24–48 hours, ml/kg 73.4 (22.7) 151.2 (81.3) 0.0001
  48–72 hours, ml/kg 54.9 (28.3) 151.5 (65.0) 0.001
  At recovery, ml/kg/day 111.5 (39.4) 168.9 (52.4) 0.0001
Fluid intake 
(ORS + water + liquid food), 
ml/kg/day
214.6 (61.2) 278.3 (99.3) 0.003
Per cent of weight gainb (% 
of admission weight)
4.3 (1.2) 5.4 (1.3) 0.001
Comments: results are expressed as mean (SD) unless otherwise stated
  ■ Increases in sodium and potassium in the two groups were the same; mean serum sodium and potassium concentrations at time of recovery or 
on day 5 for those who did not recover, were similar in both treatment groups (table presented in paper, but not extracted here)182 Appendix 9 
Safety: none of the children in either group became overhydrated in the course of treatment
  ■ Blood samples were drawn to measure hypernatraemia (serum sodium > 150 mmol/l) and hyponatraemia (serum sodium < 130 mmol/l) and 
hyperkalaemia (serum potassium > 5 mmol/l) and hypokalaemia (serum potassium < 3.5 mmol/l), but incidence was NR in the results, thus, 
assume this reflects some safety element
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: a computer-generated randomisation table was used to allocate the different ORS packets. An individual not 
associated with the study provided the ORS packets
Blinding: double blind. The packets of ORS were similar in appearance and packaged in identical sachets. The randomisation table was held by an 
individual not associated with the study. Decoding was performed at the end of the study
Comparability of treatment groups: groups appear similar for baseline characteristics, although the mean age of children in the H-ORS group was 
slightly lower. The study reports characteristics are comparable although no p-values were reported
Method of data analysis: appears to be ITT analysis. Groups were compared using the chi-squared test. Means of the outcome variables of the two 
groups (time-specific stool output, intake of ORS, total fluid intake, weight gain or loss and electrolyte concentrations on recovery) were compared 
using the Student’s t-test. The difference in proportions of cured patients between the two groups was examined using the chi-squared test. 
Recovery time of patients in the two groups was calculated using a survival analysis technique in accordance with the Kaplan–Meyer method
Sample size/power calculation: NR
Attrition/dropout: none reported, but may have occurred as study reports intake and output measuring took place but stopped if child was withdrawn 
from study
General comments
Generalisability: vast majority of children were SAM (61/64, 95%) based on W/A criteria (defined here as < 60% Harvard standard W/A); young 
children (aged 6–48 months), males only. As W/H and W/L is NR it is uncertain whether or not the study group meet the current WHO criteria. 
However, as they are described as marasmic, it is likely that they would
Outcome measures: outcomes appear appropriate, although mortality was not a specified outcome (no deaths are reported)
Intercentre variability: N/A
Conflict of interest: NR
Composition of ORS H-ORS Standard ORS recommended by WHO/UNICEF 
Sodium, mmol/l 60 90
Potassium, mmol/l 20 20
Chloride, mmol/l 50 80
Glucose, mmol/l 84 111
Citrate, mmol/l 10 10
Made by dissolving the following in one litre of 
water
  NaCl, g 1.75 3.5
  KCl, g 1.5 1.5
  Trisodium citrate dehydrate, g 2.9 2.9
  Glucose, g 15 20
  Resulting osmolarity 224 311
Ten 1-litre packets were provided for each child
N/A, not applicable; NR, not reported; ORT, oral rehydration therapy.
a  Duration of diarrhoea does not fit with the inclusion criterion of acute diarrhoea for ≤ 72 hours.
b  At discharge or on day 5 if they did not recover during this period.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely to 
be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as ‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot 
tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot 
tell

2.  Were the study participants aware of the research question? Yes No  Cannot 
tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
184 Appendix 9 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot 
tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot 
tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot 
tell

2.  Indicate the percentage of participants completing the study (If 
the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot 
tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot 
tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot 
tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot 
tell

Global rating for studya
(Overall methodological strength of study – based on sections A–F)
Strong Moderate Weak

N/A, not available.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Amadi et al. 200552
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Amadi et al.52 and Amadi 
200258
Year: 2005
Country: Zambia
Study design: single-blind RCT
Setting: inpatient [malnutrition 
ward in university teaching 
hospital (UTH)]
Number of centres: one
Funding: grant received from 
SHS International Ltd (Scientific 
Hospital Supplies); one author is 
supported by the Wellcome Trust 
Intervention: Neocate amino 
acid-based elemental infant 
formula feed that excluded cow 
milk, soy and cereal antigens, 
4 weeks (see end of table for 
details)
Control: standard nutritional 
rehabilitation therapy for 
persistent diarrhoea and 
malnutrition using a skimmed 
milk/soy-based diet, 4 weeks 
(see end of table for details)
Other interventions used: 
The UTH followed the WHO 
guidelines for management 
of persistent diarrhoea and 
malnutrition. All children 
received ORT with i.v. fluids 
given only when strictly 
indicated. All received oral 
micronutrient supplements and 
broad-spectrum antibiotics 
according to clinical condition
Some children treated for TB on 
clinical grounds, usually after 
failure to respond to antibiotic 
therapy for pneumonia
Children were tested for HIV 
infection and given full pre- and 
post-test counselling where 
indicated
Definition of SAM: used Wellcome 
classification to define malnutrition. 
States children had SAM and 
baseline WAZs were –4
Number of participants: n = 200 
(Neocate n = 100, control: n = 100)
Sample attrition/dropout: 45/200 
(22.5%): n = 24 (12%) Neocate 
(22 died, two withdrawn); n = 21 
(10.5%) control (17 died, four 
withdrawn)
Overall, 39 died and of the six 
withdrawn, three were discharged 
prematurely owing to a cholera 
outbreak (NR by group) and three 
withdrew (mothers needed at home)
Sample crossovers: none
Inclusion criteria: children aged 
6–24 months with malnutrition and 
persistent diarrhoea (≥ 14 days 
duration)
Exclusion criteria: children with 
features of measles, chickenpox, 
neurological disorder (e.g. cerebral 
palsy), serious systemic disorder or 
being exclusively breastfed
General characteristics of 
participants: children with persistent 
diarrhoea and malnutrition, aged 
6–24 months, 54% HIV+ve
Primary outcomes:
  ■ weight gain
  ■ diarrhoea
  ■ mortality
Secondary outcomes:
  ■ developmental milestones 
achieved
  ■ activity and play
  ■ laboratory indicators 
of severity of illness 
(haemoglobin and albumin)
Method of assessing outcomes: 
all feeds, fluid balance and stools 
passed were documented daily
Weight recorded three times per 
week
Lactose intolerance tested using 
Clinitest (Bayer Corporation, 
Pittsburgh, PA, USA).
Blood sugar monitored during 
feeds and treated appropriately. 
All initial investigations repeated 
at the end of 4 weeks (except 
chest radiography and HIV 
testing)
Adverse symptoms: none 
reported
Length of follow-up: 4 weeks
Recruitment dates: April 1998 to 
June 2000
Characteristics of participants
Characteristic Neocate (n = 100) Control (n = 100) p-value
Sex, M : F 49 : 51 45 : 55 0.64
Age, months 17 (14–20) 18 (13–22) 0.31
Diagnosis:
 Underweight 10 9
 Marasmus 21 24
 Kwashiorkor 44 49
  Marasmic kwash 25 18 0.65
HIV infecteda 51 54 0.86
Fever 24 34 0.15
TB
 Definite 13 14 0.98
 Probable 15 21 0.35
Chest radiograph
 Normal 16 12
 Abnormal 69 83 0.35186 Appendix 9 
Intestinal infection
  C. parvum 28 23 0.54
  Salmonella sps. 23b 13 0.10
  Giardia intestinalis 6 5 0.99
  Shigella spp. 2 2 0.69
  Ascaris 3 7 NR
 Hookworm 1 2 NR
WAZ –4.0 (–4.6 to –3.4) –4.1 (–4.8 to –3.6) 0.38
HAZ –2.9 (–3.6 to –2.1) –3.0 (–3.6 to –2.1) 0.40
MUAC, cm 11 (10–12.2) 11 (10–12) 0.55
Haemoglobin concentration, g/dl 9.3 (8.3–10.1) 9.0 (8.3–10.0) 0.28
Serum albumin concentration, g/dl 28 (23–31) 29 (24–34) 0.41
Comments: results with brackets are median (IQR)
Text states 106 participants were HIV+ve, although tables suggests 105 participants
Results
Primary outcomes Neocate Control p-value
Weight gain, kg n = 79 n = 78
  From admission 1.10 (0.55–1.55) 0.75 (0.2–1.3) 0.006
  From nadir 1.7 (1.2–2.0) 1.2 (0.6–1.7) 0.002
Increase in WAZ n = 79 n = 78
  From admission 0.83 (0.35–1.22) 0.43 (0–0.9) 0.018
  From nadir 1.23 (0.89–1.57) 0.87 (0.47–1.25) 0.002
Increase in WHZ n = 79 n = 78
  From admission 1.28 (0.52–1.88) 0.56 (0–1.15) < 0.001
  From nadir 1.77 (1.30–2.26)c 1.23 (0.59–1.70) < 0.001
Increase in z-score from nadir in 
HIV+ve children
n = 38 n = 40
 W/A 1.2 (0.8–1.5) 0.70 (0.4–1.2) 0.007
 W/H 1.8 (1.1–2.3) 0.8 (0.4–1.6) < 0.001
Increase in z-score from nadir in 
HIV–ve children
n = 41 n = 38
 W/A 1.29 (0.98–1.57) 0.95 (0.5–1.45) 0.01
 W/H 1.82 (1.47–2.38) 1.43 (0.81–1.86) 0.009
Mortality (over 4 weeks) 22% (22/100) 17% (17/100) 0.48
Mortality by nutritional status, 
n (%)
 Underweight 2 (10.5)
 Marasmus 12 (26.7)
 Kwashiorkor 10 (10.8)
  Marasmic kwashiorkor 15 (34.9) 0.004
Comments: data are presented as median (IQR)
Neocate was associated with a 41% better gain in weight
Diarrhoea, assessed as total number of stools passed over each time period, was not different in the two groups over the 28-days follow-up, nor 
was there any difference in stool frequency between the groups in the fourth week of follow-up (numerical data not presented in paper)
Similar numbers in each group were tested for malabsorption of reducing sugars and there was no significant difference in positive tests between 
the groups (numerical data presented, but not extracted)
Overall deaths = 19.5% (39/200), of which 31% was in week 1, 43% in week 2, 26% in week 3 and 10% in week 4. Amadi et al.52 reports that 
death was more likely in children with marasmus, and children with cryptosporidiosis (data NR). However, Amadi58 reports data and shows death 
was more likely in marasmic kwashiorkor
Mortality was lower in HIV–ve children than in HIV+ve children (11% vs 24%, respectively), irrespective of nutritional regimen
There was significant correlation between mortality and severity of initial diagnosis of nutritional status, and being HIV+ve, but these results were 
only reported for the overall study group, not by trial arm© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Secondary outcomes – achievements of developmental milestones, activity and play and laboratory indicators of severity of illness (haemoglobin 
and albumin concentrations) – were reported, but have not been extracted here
Other outcomes Neocate (n = 100) Control (n = 100) p-value
Week 1 Intake, kcal/kg/day 116 (86–143), n = 95 167 (130–214), n = 97 < 0.0001
Week 2 Intake, kcal/kg/day 168 (135–203), n = 85 258 (210–301), n = 93 < 0.0001
Week 3 Intake, kcal/kg/day 184 (166–206), n = 75 283 (229–337), n = 85 < 0.0001
Week 4 Intake, kcal/kg/day 187 (163–210), n = 70 269 (214–305), n = 79 < 0.0001
Comments: presentation of data believed to be median (IQR), but this is not explicitly state
Intake of calories (per kg per day), as liquid feeds for each of the 4 weeks of the study in the control group, were statistically significantly higher 
(p < 0.0001). Note, in addition to the liquid feed (based on skimmed milk) intake in the control group, soy-based porridge was also given, beginning 
in week 2
Safety: NR
HIV: the Neocate diet benefit was seen in both HIV+ve and HIV–ve patients
The statistically significant improvement in weight gain was not only true for the Neocate group as a whole, but also for HIV+ve (p = 0.007) and 
HIV–ve (p = 0.01) children
Death was statistically significantly more likely (p = 0.04) in HIV+ve children (23.6%, n = 25) vs HIV–ve children (11.1%, n = 10)
Barriers to implementation
Study authors did not believe an elemental feed such as Neocate should be adopted because of the expense. Fifty-one per cent (284/548) of 
eligible children were not randomised because no bed was available on the day when judged to be eligible. Rate of recruitment had to be limited as 
the number of eligible patients exceeded the capacity of the nursing staff and laboratory technicians to carry out the full range of study procedures 
and investigations. A cholera outbreak also temporarily interrupted the study leading to premature discharge of three patients
Methodological comments
Allocation to treatment groups: randomisation using consecutive sealed envelopes. The randomisation code was blocked so as to equalise active 
and placebo for every 20 patients
Blinding: single-blind (patients) study because of preparation and administration of feeds; apart from feeds, care was identical in all other respects. 
Study was double blind up until randomisation and single blind thereafter (care providers and outcome assessors not blinded). However, control 
group children were given porridge from week 2, thus, participants may have been aware, although knowledge of group assignment was not likely 
to affect outcomes as these were objective measures
Comparability of treatment groups: paper states that groups were well-matched; groups were not significantly different (p-values reported)
Method of data analysis: not ITT analysis. Comparison of categorical variables used chi-squared or Fisher’s exact tests, and of continuous variables 
used the Kruskal–Wallis test
Sample size/power calculation: NR
Attrition/dropout: numbers and reasons reported. 45/200 (22.5%): n = 24 (12%) Neocate; n = 21 (10.5%) control. Of the 45 participants, 39 died 
(n = 22, Neocate; n = 17, control), three withdrew and three discharged prematurely because of cholera outbreak (n = 2, Neocate; n = 4, control)
General comments
Generalisability: likely that most of the children would meet the current WHO criteria of MUAC < 115 mm. Population was a subsection of children 
with SAM admitted to the unit (not all eligible children owing to limitation on resources), young infants ( aged 6–24 months), approximately half 
were HIV+ve. Participants had a high prevalence of intestinal infection, respiratory and systemic infectious disease. The study was designed to 
investigate a feed for treatment of SAM in children with persistent diarrhoea, it is not clear whether or not this feed would be a suitable treatment 
for children with SAM, but who do not have persistent diarrhoea. None of those enrolled in the study were > 2 years of age so it is not clear whether 
or not the results of the study would hold in children aged ≥ 2 years
Outcome measures: outcomes appropriate although no numerical data for diarrhoea reported
Intercentre variability: N/A
Conflict of interest: a grant was received from SHS International Ltd (Scientific Hospital Supplies); the corresponding author is supported by the 
Wellcome Trust
Neocate infant formula feed Standard nutritional rehabilitation therapy
Amino acid-based elemental feed (Neocate) + routine care
Complete infant formula feed based on amino acids, 
maltodextrin and a combination of safflower oil, refined 
coconut oil and soya oil, with a calorific value of 
70 kcal/100 ml. The vitamin and mineral composition reflects 
that of breastmilk
Standard therapy as per hospital protocol + routine care
Complete feed: mixture of skimmed milk, sugar and vegetable oil given 
as a liquid feed (100 kcal/100 ml). At beginning of week 2, children given 
a soya-based, high-energy protein supplement in porridge form providing 
400 kcal/100 ml, beginning at 100 ml/day and increasing to 200–300 ml/day
Liquid feeds given at 3-hour intervals (2 hours for weaker children) using cup and spoon or via nasogastric tube if necessary. Feeds were 
introduced gradually, beginning at 80 kcal/kg/day to avoid the refeeding syndrome. If diarrhoea worsened or reappeared, stools were tested for 
presence of reducing substances to detect lactose intolerance188 Appendix 9 
If lactose intolerance test was positive (≥ 1%), feeds were 
diluted to half strength and gradually reintroduced to full 
strength
If lactose intolerance test was positive (≥ 1%), skimmed milk was withdrawn and 
replaced by a commercial fermented milk
Components of the WHO guidelines for management of persistent diarrhoea employed at UTH:
  Emphasis on oral/NG rehydration If i.v. fluids are necessary (for severe dehydration and shock), they are given for 
shorter periods of 4–6 hours, with close monitoring and a change to the oral 
route as soon as improvement is noted
  Vitamin, zinc, copper Vitamins and mineral supplements given when available
 Multivitamin
  Folic acid
 Potassium
 Antibiotics Often necessary because these children have severe infections (e.g. septicaemia, 
pneumonia)
 Antimalarials Given because malaria is endemic in Zambia
HAZ, weight-for-age z-score; N/A, not applicable; NG, nasogastric; NR, not reported; ORT, oral rehydration therapy; WAZ, weight-for-age z-score; 
WHZ, weight-for-height z-score.
a  HIV test results available for 196 children.
b Amadi58 reports n = 22.
c  Interquartile range given in paper (130–2.26), but we assume the 130 is an error and the value should be 1.30.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled (either in the design (e.g. by 
stratification or matching) or in the analysis)?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
190 Appendix 9 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider 
3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not available.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Bhutta et al. 199453
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Bhutta et al.53
Year: 1994
Country: Pakistan
Study design: RCT
Setting: inpatient (Gastroenterology-
Nutrition Research Ward at the Aga 
Khan University Hospital, Karachi, 
Pakistan)
Number of centres: one
Funding: provided by the Applied 
Diarrhoeal Disease Research 
Project at Harvard University via 
a co-operative agreement with 
the US Agency for International 
Development
Intervention (soy group): soy 
formulation (full strength)
Control (KY milk group): half-
strength buffalo milk with KY
Details of diet composition 
provided at end of table
Both diets were provided for 
14 days and given in gradually 
increasing amounts. Day 1 at 
least 50 kcal/kg/day, increasing 
by 25 kcal/kg/day to provide a 
minimum of 100 kcal/kg/day 
by day 3. Diets were given by 
nasogastric tube if children were 
unable to take the stipulated 
amount orally
Other interventions used: NR
Definition of SAM: W/A ≤ 80th 
centile of the median NCHS 
standard, i.e. Gómez grades II 
and III malnutrition
Number of participants: 51 (soy 
group, n = 25; KY milk group, 
n = 26)
Sample attrition/dropout: after 
randomisation, 11 participants 
were subsequently excluded 
(four from the soy group and 
seven from the KY milk group); 
one for pneumonia, four for 
development of septicaemia, 
four for hyperpyrexia ≥ 39 °C, or 
withdrawal by the parents prior 
to completion of study protocol 
(two, one in each group)
Sample crossovers: NR
Inclusion criteria: male children, 
aged 6–36 months, with 
persistent diarrhoea (diarrhoea 
lasting ≥ 2 weeks), and with 
severe PEM
Exclusion criteria: breastfed 
infants, presence of intercurrent 
infections, ileus and bloody 
diarrhoea. Children with 
kwashiorkor (clinical oedema 
and/or serum albumin ≤ 20 g/l) 
excluded because weight gain 
difficult to interpret in these 
children
In addition, children admitted 
for the duration of the study 
were examined twice daily 
and excluded from the study 
if they developed a significant 
intercurrent illness (pneumonia, 
pyrexia ≥ 39 °C, persistent 
vomiting, or clinical signs of 
septicaemia)
General characteristics of 
participants: economically 
disadvantaged children in 
Karachi (mean z-score W/A 
–4.2, SD 0.8)
Primary outcomes: stool output 
and weight gain
(not explicitly stated, but assumed 
primary outcomes as used for 
sample size calculation)
Secondary outcomes: not explicitly 
stated
Method of assessing outcomes: 
vital signs, food and fluid intake, 
and stool, urine and emesis 
output were accurately recorded. 
Adhesive urine bags were 
used to collect urine separately 
from stools. Stool volume was 
measured by weighing pre-
weighed diapers on electronic 
scales accurate to ± 2g (Tanita 
Inc., Amsterdam, the Netherlands). 
Daily nude weight obtained 
prior to morning feed on a 
double-beam balance accurate 
to ± 20 g (Detecto, Webb City, 
MO, USA). Length measured on 
an infant stadiometer, mid-arm 
circumference measured using 
fibreglass tape
Growth quotient comparing actual 
daily weight gain with expected 
weight gain for age calculated 
using the method of Ellerstein and 
Ostrov93
Clinical failure defined as weight 
loss for ≥ 3 days after meeting 
the minimum caloric target of 
100 kcal/kg/day or persistence of 
diarrhoea with inability to maintain 
hydration orally
Cessation of diarrhoea defined 
as passage of semisolid stool, 
a reduction of stool frequency 
to ≤ 3/day or a stool volume 
< 30 g/kg/day
A range of laboratory 
investigations were carried out 
on stools daily, and metabolic 
balance studies on days 4–6 and 
12–14 of dietary therapy on every 
third patient admitted (details not 
data extracted)
Adverse symptoms: NR
Length of follow-up: not explicitly 
stated, presumed to be 14 days
Recruitment dates: NR192 Appendix 9 
Characteristics of participants
Characteristic, all (mean ± SD) Soy group (n = 25) KY milk group (n = 26) p-value
Age, months 16.0 ± 8.6 13.8 ± 5.8 NS
Weight, kg 5.8 ± 1.1 6.1 ± 1.1 NS
W/L (%) 88.4 ± 4.3 89.5 ± 4.3 NS
L/A (%) 71.1 ± 7.6 74.5 ± 9.1 NS
z-score W/A –4.41 ± 0.6 –3.91 ± 0.9 NS
Mid-arm circumference, cm 9.9 ± 1.3 10.6 ± 1.7 NS
Total protein, g/dl 5.6 ± 0.9 6.1 ± 0.9 NS
Albumin, g/dl 3.4 ± 0.7 3.8 ± 0.7 NS
Haemoglobin, g/dl 9.5 ± 1.3 8.7 ± 1.4 NS
History
  Duration of diarrhoea, days 75.0 ± 77.0 150.0 ± 117.0 NS
  Stool frequency, n/day 8.2 ± 2.7 8.1 ± 2.7 NS
Observations in first 24 hours
  Stool volume, g/kg/day 69.8 ± 51.9 62.3 ± 42.1 NS
  Stool frequency, n/day 7.4 ± 4.7 7.1 ± 4.5 NS
  ORS intake, ml/kg/day 47.0 ± 84.5 52.8 ± 77.3 NS
  Urine volume, ml/kg/day 38.4 ± 21.3 30.0 ± 20.8 NS
Comments: median (range) duration of diarrhoea in the soy group was 180 (15–300) days and in the KY milk group 150 (15–270) days. Two 
patients in the soy group had pathogens in their stools (one entropathogenic E. coli, one S. paratyphi a), and one patient in the KY milk group had a 
parasitic infection (G. lamblia). Further information from laboratory investigation of stool samples not data extracted
Results
Primary outcomes Soy group (n = 21) KY milk group (n = 19) p-value
Stool volume, g/kg/day
  Week one 68.8 ± 43.1 60.9 ± 40.6 NS
  Week two 36.2 ± 23.2 63.9 ± 61.8 NS
 Overall 58 ± 33 62 ± 49 NS
Weight change, g/kg/day
  Week one 7.1 ± 11.3 3.1 ± 12.1 NS
  Week two 11.6 ± 10.0 4.3 ± 7.2 < 0.02
Mean daily weight change, 
g/kg/day
3.7 ± 5.9 7.9 ± 9.7 NS
Comments: not explicitly stated but presume data are mean ± SD
In the soy group, 10% (2/21) lost weight, in the KY milk group 37% (7/19) lost weight (p = NS)
Secondary outcomes Soy group (n = 21) KY milk group (n = 19) p-value
Caloric intake, kcal/kg/day
  Week one 140.1 ± 33.4 115.1 ± 25.1 < 0.02
  Week two 157.1 ± 72.3 151.6 ± 32.3 NS
 Overall 154.2 ± 36.8 132.8 ± 27.6 NS
Stool frequency, n/day:
  Week one 7.0 ± 3.1 6.6 ± 4.4 NS
  Week two 4.0 ± 2.4 5.5 ± 3.8 NS
 Overall 6 ± 3 6 ± 4 NS
ORS intake, ml/kg/day:
  Week one 33.9 ± 41.0 37.9 ± 46.2 NS
  Week two 1.7 ± 3.6 29.2 ± 58.1 < 0.05
Time to recovery 6 ± 4 5 ± 3 NS
Growth quotient over 14 days 13.6 ± 13.2 7.5 ± 6.9 NS
Improvement in MUAC, cm 1.0 ± 0.1 0.1 ± 0.05 < 0.001
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Comments: not explicitly stated, but presume data are mean ± SD
Overall the soy group consumed nearly 15% more calories than the KY milk group, but the difference was NS. Only two children in each group 
required nasogastric feeding. The improvement in WAZ was significantly greater in the soy group (z-score from –4.4 ± 0.6 to –3.6 ± 0.6; p < 0.001) 
than in the KY milk group (z-score from –3.9 ± 0.9 to –3.6 ± 1.0; p = NS). Daily urine output and serum sodium levels after 48 hours of therapy were 
described as similar between the groups, but no numerical data presented
Data on normalisation of serum bicarbonate for a subgroup of children not data extracted
Data from two nutritional balance studies performed on a subgroup of children not data extracted. Details on the clinical failures not data extracted
Safety: NR
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: block randomisation process using sealed envelopes
Blinding: not described, presume that study was not blinded
Comparability of treatment groups: described as similar with regard to age, degree of malnutrition and severity of diarrhoea prior to presentation. 
Stool volume, frequency, ORS intake and serum electrolytes in both groups were also described as comparable in the first 24 hours after the 
initiation of dietary therapy
Method of data analysis: data were analysed for differences between means using a two-tailed Student’s t-test. Differences in proportions were 
assessed by chi-squared analysis
Sample size/power calculation: estimated that using an alpha-level of 0.05 and a power of 80%, 40 children in each group would be needed to 
demonstrate a 25% difference in stool output or weight gain between the study groups. However, the mid-term evaluation of the study identified 
more failures and significantly poorer weight gain the children receiving the KY and buffalo milk diet, and the study was therefore concluded with a 
total of 51 children randomised (and 11 of these were subsequently excluded)
Attrition/dropout: overall number excluded from the study after randomisation given, and deducible for each group from results tables. Reasons 
given for the population overall, but not by study group (except in stating that one from each group was withdrawn from the study by the parents 
prior to completion of the study protocol)
General comments
Generalisability: children initially identified as potentially eligible from the outpatient and emergency services of a large Government hospital in 
Karachi. Only male children enrolled (to allow for collection of urine and faeces separately), but it is likely that the results would be generalisable to 
girls. To be eligible children had to be ≤ 3 years, therefore, the results may not be generalisable to children aged 4–5 years old. The study ward had 
a research nurse and medical officer in constant attendance, this level of supervision may not be possible in all settings
Outcome measures: primary outcomes were not explicitly identified. Methods for assessing outcomes were reported, and definitions for outcome 
measures such as treatment failure were provided
Intercentre variability: not applicable
Conflict of interest: NR
Composition of buffalo milk + KY diet compared with the soy formula diet (based on feeding a 10 kg child at 120 kcal/kg/day)
KY milk
Soy formula Khitchri  Yoghurt
Buffalo 
milk (half 
strength) Total
Volume, ml 376 260 1025 1661 1790
Calories, kcal 444 156 600 1200 1200
Carbohydrate, g 71.4 10.4 25.6 107.4 118.2
Protein, g 12.4 8.1 22.6 43.1 35.8
Fat, g 11.7 10.4 45.1 67.2 64.5
Other details Mixed amounts of khitchri and yoghurt were provided at a 3 : 1 ratio and 
approximately 50–60% of the daily caloric intake was provided by buffalo milk
Khitchri (60 g rice, 30 g lentils, 10 g dry weight cottonseed oil and 1 g salt) 
prepared in bulk by cooking lentils in water with rice and oil added subsequently 
until a homogeneous consistency achieved. Aliquots frozen and distributed 
under supervision of a clinical nutritionist
Yoghurt and buffalo milk obtained regularly from a single commercial source. 
Lactose content of yoghurt 3.0 g/dl, and of half-strength buffalo milk 2.5 g/dl
One hundred grams of powder 
consisted of soy protein (15.5 g), 
glucose polymers (50 g), a fat 
blend (28 g) of equal amounts of 
corn oil and coconut oil, and the 
recommended dietary allowance 
of vitamins and minerals. Also 
fortified with l-methionine, taurine, 
and l-carnitine, and had an 
osmolality of 200 mOsm/kg
L/A, length-for-age; NR, not reported; NS, not statistically significant.194 Appendix 9 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely to be 
representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as ‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation described? Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot 
tell

2.  If yes, indicate the percentage of relevant confounders that were 
controlled [either in the design (e.g. by stratification or matching) 
or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or exposure 
status of participants?
Yes No  Cannot 
tell

2.  Were the study participants aware of the research question? Yes No  Cannot 
tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot 
tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot 
tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot 
tell

2.  Indicate the percentage of participants completing the study (If 
the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot 
tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the results?
Yes No  Cannot 
tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot 
tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot 
tell

Global rating for studya
(Overall methodological strength of study – based on sections A–F)
Strong Moderate Weak

N/A, not applicable; WAZ, weight-for-age z-score.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.196 Appendix 9 
Nurko et al. 199756
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Nurko et al.56
Year: 1997
Country: Mexico
Study design: double-
blind RCT
Setting: inpatient 
(Hospital Infantil de 
Mexico Federico Gómez, 
Mexico City)
Number of centres: one
Funding: part-funded 
by Applied Diarrhoeal 
Disease Research Project 
at Harvard University, by 
means of a co-operative 
agreement with the US 
Agency for International 
Development and in part 
by a National Institutes 
of Health grant (T32-DK 
07703)
Intervention 1: local chicken-based 
diet
Intervention 2: soy diet – Nursoy 
(Wyeth Laboratories)
Control: elemental diet – Vivonex 
Standard (Norwich Eaton)
See end of table for details
Diets differed in macronutrient 
composition and started at the 
lowest concentration (150 ml/kg/
day) via a nasogastric tube and 
concentrations were advanced every 
48 hours after initial overnight fast 
and hydration. Full concentration 
was achieved by the ninth day if 
no intolerance occurred, otherwise 
the concentration was either: 
maintained if there were 2% or 
3% positive reducing substances 
(before or after hydrolysis) or if there 
was an increase in stool output of 
> 50% (> 20 ml/kg); or decreased 
if Clinitest results showed 4% or 
there was an increase of ≥ 75% 
in stool output (> 20 ml/kg). Cases 
received 7 days of the maximum 
diet concentration, followed by 
whole cows milk administered half-
strength (10 ml/kg) and advanced 
to full strength if tolerated. Milk-
tolerant cases continued with 
lactose-containing formula or whole 
milk, depending on age (no further 
details reported). If lactose-intolerant 
(i.e. return of liquid stools with pH 
< 5 and > 2% reducing substances 
in the stool, a milk-free diet was 
instituted
Other interventions used: cases 
were hydrated on admission 
following WHO/UNICEF guidelines 
(standard glucose-electrolyte i.v. 
solution). When the maximum 
concentration of the diet was 
achieved, daily supplementation with 
1 mg folic acid, 1 ml multivitamin 
(Poly-Vi-Sol), and 6 mg/kg elemental 
iron was added. Suspected systemic 
infections were treated with 
broad-spectrum i.v.-administered 
antibiotics. Otitis media, urinary 
tract infections and pneumonia 
were treated with appropriate 
antibiotics, and dysentery with 
trimethoprim–sulfamethoxazole and 
children infected with G. lamblia 
with metronidazole
Definition of SAM: third-degree 
malnutrition of the marasmatic 
type as defined by the Gómez 
criteria. W/A < 60% of the 
NCHS 50th percentile
Number of participants: n = 56 
(enrolled, n = 60; chicken, 
n = 19; Nursoy, n = 19; Vivonex, 
n = 18)
Sample attrition/dropout: 
n = 15 (27%) treatment failures 
(Chicken, n = 4; Nursoy, n = 6; 
Vivonex, n = 5). Of these five 
died (Chicken, n = 2; Nursoy, 
n = 1; Vivonex, n = 2) and 10 
successfully managed and 
discharged home
Sample crossovers: none, 
although 15 treatment failures 
(see Sample attrition/dropout) 
changed diets (chicken and 
Nursoy for Vivonex; parental 
nutrition then enteral Vivonex 
for those originally on Vivonex 
diet). However, these children 
discharged home and were not 
counted as crossovers per se
Inclusion criteria: children aged 
3–36 months with third-degree 
malnutrition of the marasmatic 
type and persistent diarrhoea 
(defined as three or more loose 
stools for ≥ 14 days)
Exclusion criteria:
  ■ Exclusively breastfed
  ■ Chronic illness (i.e. AIDS, 
TB)
  ■ Congenital malformation
  ■ An abdominal condition 
that would preclude enteral 
feedings a severe condition 
requiring intensive care
  ■ Lack of parental consent
General characteristics of 
participants: children aged 
3–36 months with SAM and PD
Associated conditions on 
admission: 64% (non-
gastrointestinal infection 50%, 
gastrointestinal infection 
14.3%)
Primary outcomes: not specifically reported
Outcomes: diarrhoea status, weight, 
nitrogen balance, nutritional recovery, 
treatment success and failure
Method of assessing outcomes: all 
measurements were obtained by trained 
nutritionists and their accuracy was 
validated before start of study. All intake/
output was recorded, nasogastric tube was 
inserted by trained nursing staff
  ■ Nude weight – electronic scale (Tronix, 
Wheaton Ill, Wheaton, IL, USA) accurate 
to at least 10 g on admission, the 
morning of the start of the diet (i.e. 
post-hydration weight was baseline 
weight) and same time every morning 
thereafter
  ■ Recumbent length (measured using 
specially designed board, no further 
details) on admission, at the end of 
2 weeks and before discharge
  ■ Baseline laboratory values at admission, 
including complete blood cell count, 
electrolyte concentrations, d-xylose 
concentration, stool and urine cultures, 
and stool tests for ova and parasites
  ■ Blood culture specimens were obtained 
only if indicated
  ■ Nitrogen: 72-hour, balance test at 
end of second week (starting 4 days 
after the maximum diet concentration 
achieved). Nitrogen balance measured 
by the micro-Kjeldahl method. Tests 
for pH and reducing/non-reducing 
substances in stool were performed 
daily (no further details)
  ■ Stool collection: beginning and end of 
the time were marked by the faecal 
excretion of orally administered 
activated charcoal. All children were 
placed on metabolic beds/cots for 
separation of stool from urine. To 
confirm successful separation of stool 
and urine for girls, a separate analysis 
for all the variables associated with 
stool collection was performed at end 
of study
Definitions:
  ■ Cessation of diarrhoea: passage of 
formed stool not followed by liquid 
stools for ≥ 24 hours
  ■ Successful treatment: able to advance 
formula to highest concentration and 
cessation of diarrhoea at end of the 
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  ■ Onset of nutritional recovery: diarrhoea 
ceased and consistent weight gain for 
≥ 48 hours
  ■ Treatment failure: ≥ 5% dehydration 
during administration of diet clinical 
deterioration precluding further enteral 
therapy diarrhoea persisting until end of 
study, or if unable to advance formula 
to full concentrationa
Adverse symptoms: diet intolerance and 
intestinal pneumatosis
Length of follow-up: NR, approximately 
9 days if no intolerance to diet + addition 
7 days
Recruitment dates: NR
Characteristics of participants
Characteristic Chicken (n = 19) Nursoy (n = 19) Vivonex (n = 18) Total (n = 56)
Age, months (SD) 6.7 (3.7) 5.6 (4.0) 6.9 (5.3) 6.4 (4.4)
Sex, n (M : F) 10 : 9 11 : 8 9 : 9 30 : 26
Initial weight, g (SD) 3647.3 (884.4) 3575.3 (1397.1) 3589.8 (1393.5) 3604.1 (1232)
Per cent W/A (% NCHS) (SD)  50.8 (7.4) 51.0 (7.5) 52.9 (7.5) 51.4 (7.2)
Weight z-score (SD) –4.2 (1.0) –3.9 (0.7) –4.0 (1.2) –4.0 (1.0)
Diarrhoea duration, days (SD) 36.6 (3.9) 48.7 (5.1) 41.8 (4.0) 42.4 (4.4)
Severe dehydration, n (%) 4 (21.1) 5 (26.3) 6 (33.3) 15 (26.8)
Faecal output, ml/kg/day (SD) – first 
24 hours
41.6 (12.1) 45.8 (13.6) 52.3 (19.6) 46.4 (15.1)
Laboratory tests, (SD)
  Sodium, mmol/l 135.3 (7.8) 138.3 (6.9) 137.6 (6.1) 137.1 (6.9)
  Potassium, mmol/l 3.9 (0.8) 4.2 (1.0) 4.3 (0.9) 4.1 (0.9)
  Bicarbonate, mEq/l 15.5 (3.4) 15.1 (3.8) 16.5 (5.3) 15.7 (4.2)
  Blood urea nitrogen, mg/dl 22.0 (8.6) 24.8 (14.9) 29.2 (14.6) 24.9 (13.1)
  Albumin, g/dl 3.0 (0.6) 3.3 (0.6) 3.2 (0.6) 3.2 (0.6)
  D-xylose, mg/dl 22.1 (7.8) 19.0 (10.5) 25.6 (13.9) 22.2 (11.0)
Associated conditions on admission, n (%)
 None 6 (31.6) 9 (47.4) 5 (27.8) 20 (35.7)
 Sepsis 5 (26.3) 7 (36.8) 5 (27.8) 17 (30.4)
  Urinary tract infection 2 (10.5) 3 (15.8) 2 (11.1) 7 (12.5)
 Pneumonia 2 (10.5) 0 2 (11.1) 4 (7.1)
  + stool culture 2 Shigella (10.5) 0 2 Shigella, 1 
Salmonella 
(16.6)
5 (8.9)
+ stool ova and parasites 1 G. lamblia (5.2) 0 1 
Cryptosporidium 
(5.5)
2 (3.6)
+ stool culture + ova and parasites 1 Salmonella and 
Cryptosporidium (5.2)
0 0 1 (1.7)
Comments: results are mean (± SD) unless otherwise stated
No significant differences between groups (p-values NR)198 Appendix 9 
Results
Outcomes Chicken (n = 15) Nursoy (n = 13) Vivonex (n = 13) p-value
Diarrhoea status, (SD)
  Mean total stool output/kg/day 19.1 (7.5) 18.5 (6.6) 18.8 (9.2) NS
  Mean stools/day (SD) 3.2 (1.2) 2.5 (0.7) 3.4 (1.3)
  Day of cessation (SD) 6.9 (4.7) 3.9 (3) 8 (5.1) NS
Weight, g (SD)
  At admission 3572 (823) 3270 (1167) 3764 (1575)
  At end of protocol 3736 (870)b 3495 (1172)b 3940 (1599)b
  At time of discharge 4133 (1160)c 3797 (1128)c 4225 (1706)c
Mean number of total calories/kg/day after full 
diet tolerated (SD)
116.0 (9.6) 111.3 (9.1) 115.2 (8.3) NS
Protein/kg/day ingested after full diet tolerated, 
g (SD) 
3.5 (0.4)  3.4 (0.3)  2.4 (0.2)  < 0.05
Nitrogen balance, mg/kg /day (SD) 358.2 (13)d 291.4 (111.6) 226.6 (61.2)
  Per cent absorption 86.0 (10.8) 85.9 (8.5) 89.5 (5.4)
  Per cent retention 60.7 (19.3) 50.9 (16.8) 59.3 (14.0)
  Biological value 69.7 (17.3) 58.7 (16.8) 66.1 (14.4)
Nutritional recovery, n (%) 13 (86.6) 12 (85) 10 (77)
Successful outcome, n (%) 15 (78.9) 13 (68.4) 13 (72.2) NS
Safety, n (%)e
  Some formula intolerance 9 (47.4) 11 (57.9) 14 (77.8) NS
Treatment failure, n 4 6 5
Mean time from diet start to failure, hours (SD) 97.5 (99.9) 98.5 (99.9) 60.6 (45.7) NS
Intestinal pneumatosis, n 1 1 2
Death, n  2 1 2 NS
Comments: Chicken group had a significantly higher nitrogen balance (p < 0.02) and states tendency towards a higher number of nutritional 
recoveries (NS), but no p-value reported
Results per serum albumin and d-xylose concentration, electrolyte abnormalities and results for milk tolerance tests were also reported, but not data 
extracted
Treatment success all: n = 41 (73.2%)
Formula intolerance all: n = 34/56 (61%), of which transient formula intolerance n = 19/34 (56%)
Treatment failure all: 15 (44%)
Mean time from diet start to failure all: 85.6 (72 hours); one treatment failure (Nursoy) was because of allergy to the formula, 10 treatment failures 
were successfully managed: Mean stay (SD): 50 (30) days
Death all: n = 5 (8.9%) because of intestinal pneumatosis (n = 2), central line-associated sepsis (n = 2), bacterial sepsis (K. pneumoniae) (n = 1)
Sodium concentration < 130 mmol/l (RR 3.07, 95% CI 1.41 to 6.64) and presence of associated infections (RR 3.61, 95% CI 1.1 to 14.42), 
particularly Crytosporidium (RR 4.15, 95% CI 1.53 to 6.9), were associated with treatment failure
Significant differences (p < 0.05) between treatment success and failure associated with albumin (3.2 vs 2.9 g/dl), sodium concentration (138.4 vs 
133.5 mmol/l) and the incidence of associated infections (56.1 vs 86.7%). There were additional differences in stool output on the second day (20.9 
vs 47.4 ml/kg) and third day (16.7 vs 54.0). Differences in serum albumin and d-xylose concentration, electrolyte abnormalities and results for milk 
tolerance tests were also reported, but not data extracted
Intestinal pneumatosis all: 7.14%
HIV: N/A© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Barriers to implementation
None reported
Methodological comments
Allocation to treatment groups: cases randomly assigned to treatment using a table of random numbers
Blinding: only the nutritionist who prepared the formula was aware of assignment group. Investigators, nurses and residents remained masked to 
the type of diet. Aluminium foil was used to cover the formula bag and tubing. Code was broken for treatment failures and diet changed
Comparability of treatment groups: states no significant differences between groups (no p-values reported), but Nursoy group was slightly younger 
and had higher percentage of children without associated conditions or infections with parasites on admission
Method of data analysis: descriptive analyses were used to define the presenting characteristics. To test differences between the groups, 
multivariate and repeated-measures analyses of variance were used. The data were transformed if they were not normally distributed (no further 
details reported). Duration of the diarrhoea was compared using survival analysis and chi-squared tests used for categorical variables. For small 
cells, the Fisher’s exact test was used (no definition of small cells was given). Statistical analysis were performed using SPSS/PC and Epi-Info 
software (version 5.01; Centers for Disease Control and Prevention,  Atlanta, GA, USA), with significance assumed when p < 0.05
Sample size/power calculation: it was calculated that a sample size of 20 children per group would be needed assuming a power of 0.80, an alpha 
of 0.05 and a difference of 30% in the duration of diarrhoea (no further details reported). A separate analysis was performed to confirm successful 
separation of stool and urine in girls for all the variables associated with the stool collection at the end of the study. As no differences between sexes 
were found (data not shown), all data were pooled, however, the analysis is unlikely to be powered
Attrition/dropout: numbers and reasons per treatment group reported
General comments
Generalisability: SAM defined using the Gómez criteria of W/A < 60% of the NCHS’s 50th percentile would appear to meet the WHO criteria for SAM. 
To be eligible children had to hospitalised in a children’s hospital in Mexico, be aged 3–36 months with third-degree malnutrition of the marasmatic 
type and persistent diarrhoea. The results may not be generalisable to younger or older children
Outcome measures: appear to be suitable and appropriate. Primary outcomes were not explicitly identified, but methods for assessing outcomes 
were reported and definitions for outcome measures such as treatment failure were provided
Intercentre variability: N/A, one centre only
Conflict of interest: none reported
Composition of diets at maximum 
concentration Chicken Nursoy Vivonex
Total calories, kcal/dl 85.6 82.0 84.87
Protein, g/dl 1.7 2.5 2.6
Carbohydrate, g/dl 19.5 8.3 10.7
Fat, g/dl 0.1 4.3 3.5
Sodium, mEq/dlf 1.7 1.3 1.6
Potassium, mEq/dlg 2.5 2.3 2.2
Calcium, mg/dl 47 72 47
Phosphorus, mg/dl 47 50 47
Magnesium, mg/dl 19 8 18
Zinc, mg/dl 0.78 0.65 0.11
Osmolarity, mOsm/l 420 292 292
Percentage of total calories
 Protein  7.94 12.1 12.2
 Carbohydrate 90.9 40.4 50.5
 Fat  1.12 47.1 37.2200 Appendix 9 
Total calories/total protein per dayh 128.4/2.6 123.0/3.8 127.4/3.9
Diet was designed 
with the use of food 
composition tables: 
8 g boiled comminuted 
chicken breast; 3 ml 
vegetable cooking 
oil; 10.5 g table 
sugar. Components 
were blended and 
minerals added: 5 ml 
calcium gluconate 
(10% solution, PISA); 
2.7 ml of dibasic 
sodium phosphate 
(PISA); 1.7 ml of 
magnesium sulphate 
(10% solution, PISA). 
Boiled water was 
added to achieve the 
total volume required 
(150 ml/kg per day)
Soy formula contained soy 
protein, coconut, safflower 
and soy oils, sucrose, 
minerals and vitamins
Vivonex contains crystalline 
amino acids, glucose and glucose 
oligosaccharides, a small amount 
of highly purified safflower oil, 
electrolytes, minerals, micronutrients 
and vitamins
Starting at 150 ml/kal per day 
in a concentration that provides 
47.8 kcal/dl (12.5% weight/volume) 
and advancing slowly by 2.5% per 
day to a maximum concentration of 
85.6 kcal/dl (22.5% weight/volume)
After the milk challenge, all cases restarted a complete age-appropriate, complex-balanced diet, continued until discharge. All diets were prepared 
in the paediatric nutrition kitchen of the hospital under the supervision of a trained nutritionist
AIDS, acquired immunodeficiency syndrome; N/A, not applicable; NR, not reported; NS, not statistically significant; PD, persistent diarrhoea.
a  When cases were declared treatment failure, those on a Nursoy or chicken diet were started on Vivonex. For those on Vivonex or unable to 
continue with enteral feedings, total parenteral nutrition alone was initiated and continued until stabilisation and weight was achieved, followed 
by the addition of continuous enteral feedings with Vivonex (advanced every 24 hours as tolerated). Once full enteral feedings is achieved, 
Vivonex diet continued for another 2 weeks (nutritional rehabilitation continued as outlined above).
b  p < 0.05 at admission vs at end.
c  p < 0.05 at admission vs at discharge.
d  p < 0.05 comparison between the three groups.
e  The percentage relates to the study populations before dropouts (Vivonex, n = 18; Nursoy, n = 19; chicken, n = 19).
f  Sodium chloride was added to achieve a sodium intake of 4 mEq/kg/day per person.
g  Potassium was added to achieve a potassium intake of 3 mEq/kg/day per person.
h  Given at 150 ml/kg/day (calories measured in cal/kg body weight/day; protein measured in grams of protein/kg body weight/day).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely to 
be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
202 Appendix 9 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study 
(If the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 10  
Question 7: data extraction tables
Dubray et al. 200859
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Dubray et al.59
Year: 2008
Country: Sudan
Study design: 
randomised, unblinded, 
superiority-controlled trial
Setting: inpatient TFC
Number of centres: one
Funding: Médecins Sans 
Frontières
Intervention: once daily i.m. 
injection of 75 mg/kg body 
weight/day of ceftriaxone for 
2 days
Control: twice daily oral 
amoxicillin (80 mg/kg/day) over 
5 days (tablets or syrup)
Other interventions used: 
when necessary, a second 
antimicrobial treatment was 
administered (as per the 
TFC protocols): ceftriaxone, 
chloramphenicol, cotrimoxazole, 
amoxicillin or metronidazole
All participants received the 
same nutritional rehabilitation 
in three phases of increasing 
caloric intake:
  ■ Phase I (stabilisation): 
therapeutic milk F100; 
100 kcal/kg/day
  ■ Transitional phase: F100; 
130 kcal/kg/day
  ■ Phase II (rehabilitation): 
F100, Plumpy nut or 
therapeutic food biscuit 
BP100 to provide 
200–300 kcal/kg/day
Standard treatment at the TFC 
could also include: vitamin A, 
mebendazole, folic acid and iron 
supplementation (the latter given 
2 weeks after admission)
Dehydration treated according 
to guidelines for SAM using 
rehydration solution salts 
(ReSoMal, Nutriset)
Vaccinations were completed 
according to the Sudanese 
national immunisation schedule
Definition of SAM:
  ■ W/H < 70% of the reference median 
(NHCS/CDC 1977 growth reference 
curves) and/or
  ■ Bilateral oedema (bilateral pitting 
persisting after three seconds of 
thumb pressure on the dorsum of 
both feet) and/or
  ■ MUAC < 110 mm
Number of participants: n = 460 
randomised (458 in ITT analysis) 
[intervention ceftriaxone n = 230 (but two 
secondarily excluded so only 228 in ITT 
analysis), per protocol analysis n = 140, 
control amoxicillin n = 230 (ITT), n = 141 
(PP)]
Sample attrition/dropout: ceftriaxone 
intervention had 21 defaulters, one 
rescue treatment and 66 owing to 
concomitant treatment; amoxicillin 
control had 12 defaulters, 8 rescue 
treatment, 62 concomitant treatment 
and 7 both rescue and concomitant 
treatment
Sample crossovers: NR
Inclusion criteria: severely malnourished, 
weight ≥ 5 kg, 65 cm < height 
≤ 109.9 cm (usually corresponding to 
age 6–59 months)
Exclusion criteria: parents who refused 
permission to participate; treatment 
with any of the study drugs in the 
7 days before admission; admission 
in the last 7 days to any health facility 
for SAM; known hypersensitivity to 
amoxicillin or ceftriaxone; decision by the 
physician to use a different antimicrobial 
drug on admission; AOM or severe 
complications [ongoing vomiting; severe 
infections; respiratory distress and shock 
(hypovolaemic or septic); history of a 
convulsion or impaired consciousness 
in the 24 hours preceding admission] 
diagnosed on admission
General characteristics of participants: 
comprised internally displaced population 
mainly from southern Sudan
Primary outcomes:
  ■ proportion of children with a 
weight gain increase ≥ 10 g/kg/
day calculated over a 14-day 
period starting on the first day of 
weight gain after admission
Secondary outcomes:
  ■ recovery rate (TFC exit criteria) for 
children discharged;
  ■ overall CFRs
  ■ defaulter rate
  ■ referral rate
  ■ adverse events
Definitions:
  ■ recovery: maintained a W/H 
≥ 85% for 7 consecutive days
  ■ CFR: the proportion of children 
who died during their stay in the 
TFC
  ■ defaulter rate: proportion of 
children absent from the TFC after 
3 consecutive days
  ■ referral rate: proportion of children 
referred to another medical facility 
who did not return to the TFC after 
3 days
  ■ treatment success: weight gain 
≥ 10 g/kg/day by the 14th day of 
weight gain or discharged before 
14 days of weight gain because 
had met the TFC exit criteria
Method of assessing outcomes:
  ■ weight: measured daily by trained 
staff using a 25 kg Salter scale® 
(100 g precision)
  ■ height: measured fortnightly with 
standard UNICEF measuring 
boards (0.1 cm precision)
  ■ MUAC measured weekly with 
MUAC armbands reading at 2 mm
  ■ length of stay in the TFC from 
admission to exit was calculated 
for recovered/discharged children204 Appendix 10 
Length of follow-up: not clearly stated, but 
appears to be to exit from TFC
Recruitment dates: January 2002 to 
September 2003
Characteristics of participants
Characteristic
Intervention, ceftriaxone  
(n = 228)
Control, amoxicillin 
(n = 230) p-value
ITT analysisa n (%) n (%)
Age (months)
  Mean (SD) 17 (7) 18 (8) NR
  Median (IQR) 16 (12–20) 18 (12–23) NR
Male 119 (52.2%) 127 (55.2%) NR
W/H % < 70%b 169 (74.1%) 166 (72.1%) NR
Bilateral oedema 23 (10.1%) 28 (12.2%) NR
MUAC < 110 mmc 36 (15.8%) 36 (15.7%) NR
Feverd 70 (30.7%) 67 (29.1%) NR
Abnormal respiratory ratee 41 (18.0%) 40 (17.4%) NR
Moderate dehydration 33 (14.5%) 23 (10.1%) NR
Paracheck positive 4 (1.9%) 2 (0.9%) NR
Hb < 8 g/dl 37 (16.4%) 41 (18.1%) NR
Comments: baseline characteristics for the per protocol groups were also reported, but have not been data extracted
Results
Primary outcomes
Intervention, ceftriaxone 
(n = 228)
Control, amoxicillin 
(n = 230) p-value
ITT analysis n (%) n (%)
Success ratef 127 (55.7) 123 (53.5) 0.63
Difference 2.2% (95% CI –6.9 to 11.3)
Mean overall weight gain (g/kg/day) 11.4 (95% CI 10.5 to 12.2) 11.2 (95% CI 10.2 
to 11.9)
0.69
Comments: subgroup analyses of success rate and weight gain according to admission criteria (W/H per cent < 70%, bilateral oedema or MUAC 
< 110 mm) and age (6–23 months and 24–59 months) are presented, but have not been data extracted. It is not stated whether or not these 
subgroups were pre-specified and the study may not have been powered for these subgroup analyses
A per protocol analysis (and subgroup analyses by baseline characteristics and age) of the primary outcome was also reported, but has not been 
data extracted
The median time from admission to first weight gain was 1 day in both groups (p = 0.33). Median time spent in phase one of treatment was 5 days 
in the amoxicillin group and 4 days in the ceftriaxone group (p = 0.4)
Secondary outcomes
Intervention: ceftriaxone 
(n = 228)
Control: amoxicillin 
(n = 230) p-value
ITT analysis n (%) n (%)
Deaths within 14 days after admissiong 5 (2.2) 8 (3.5) NR
Total deaths during follow-uph  7 (3.1) 9 (3.9) 0.62
Overall CFR 3.5% (16 deaths in 458 participants)
Infection-related deaths after 14 days from admissioni
Meningoencephalitis syndrome 1 (26th day after admission) 0 NR
Severe respiratory infection 0 1 (30th day after 
admission)
NR
Pulmonary TB 1 (50th day after admission) 0 NR
Recovered 170 (74.6) 161 (70) 0.27
Defaulted 43 (18.9) 39 (17.0) 0.59
Referred 2 (0.9) 4 (1.7) 0.68
Weight gain at exit (g/kg/day) 10.2 (9.7–10.7) 10.2 (9.4–11.0) 0.50
Length of stayj (days) 31.4 (29.4–33.3) 33.5 (31.5–35.5) 0.07© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Adverse eventsg 2 (0.88) 8 (3.5) 0.05
 Vomiting 1 1 NR
 Diarrhoea 1 6 NR
  Facial oedema (allergic reaction) 0 1 NR
Safety: neither infection at injection site nor post-injection local pain was reported by the guardians or medical staff in the ceftriaxone group
HIV: NR
Barriers to implementation
None reported
Methodological comments
Antibiotic policy: the administration of systemic broad-spectrum antibiotic therapy on admission aimed at improving the outcomes of SAM (reduce 
mortality and improve nutritional response to feeding)
Intervention administered to all participants (with or without infection)
Reported limitations
(i) The primary outcome (mean daily weight gain) was measured from the first day of weight gain. When weight began to increase, children might 
have already recovered from infections and therefore the primary outcome might no longer have depended on antibiotic treatment. However, the 
delay between admission and first weight gain (median time = 1 day) did not differ between the two treatment groups either (p = 0.33)
(ii) More than 25% of children in each group received a second antimicrobial treatment (ceftriaxone, chloramphenicol, cotrimoxazole, amoxicillin or 
metronidazole). Prescriptions were in accordance with the TFC treatment protocols. Where bacteriological analyses are not available (culture and 
drug susceptibility), the presence or nature of infection cannot be verified
(iii) Centre-acquired infections are a frequent source of complications
(iv) Staff members might therefore be overcautious and overprescribe antibiotics when they suspect severe bacterial infections, which could 
attenuate any difference in the ITT analysis. In such a context, results of the per protocol analyses do not reflect the actual situation in the TFC where 
treatment for complications associated with SAM requires frequent adjustment
(v) In 14 patients, amoxicillin was interrupted and replaced by ceftriaxone, in the majority because of respiratory infection, septic shock and allergy. 
In the absence of blinding, it is not unlikely that this stemmed from a lack of trust in amoxicillin and this switch might have contributed to the 
reduced difference in the ITT analysis
Allocation to treatment groups: a computer-generated randomisation list of a 20-patient block (10 in each treatment group) was drawn by a 
statistician. A research assistant allocated the next available number to each child on entry to the trial and each number corresponded to a sealed 
envelope containing the allocated treatment. A nurse administered the treatment under the supervision by the research assistant
Blinding: medical staff and patients’ guardians were not blinded to the allocated treatment
Comparability of treatment groups
The distribution of baseline sociodemographic, anthropometric and clinical characteristics did not differ significantly between the groups. In both 
groups, the median time from admission to first weight gain was 1 day (p = 0.33). The median time spent in phase I was 5 days in the amoxicillin 
group and 4 days in the ceftriaxone group (p = 0.7)
Method of data analysis
ITT analysis: included children who had received at least one dose of the study drug, therefore, not a true ITT (because of post-randomisation 
exclusion of two children)
Differences in distributions between groups in the distribution of the baseline characteristics on admission and for secondary outcomes were tested 
using the chi-squared or Fisher’s exact test for categorical variables. For means and 95% CIs, the Student’s t-test (continuous variables, normal 
distribution) or Mann–Whitney non-parametric test (continuous variables, distribution not normal) was used
Per protocol analysis: excluded from the denominator were children who defaulted before the primary outcome was measurable, children in whom 
the trial drug failed and had to be replaced by another antimicrobial drug (rescue treatment) and/or children who received one or more additional 
antimicrobial drug(s) (concomitant treatment) before they reached 14 days of weight gain (ceftriaxone, chloramphenicol, cotrimoxazole, amoxicillin or 
metronidazole). Results from the per protocol analysis have not been extracted
Sample size/power calculation
The objective of the study was to discover whether or not the intervention improved success in weight gain by at least 10%. Given a success rate 
of 80% in children receiving amoxicillin and 90% in those receiving ceftriaxone, and with a power of 80% and a one-sided significance level of 5%, 
the required sample size was calculated to be 177 children per group (a total of 354). The sample size was increased by 10% to adjust for losses to 
follow-up and for children who died or left the TFC before 14 days of weight gain because of default or referral to other sites (no primary outcome 
calculable). The final sample included 230 children in each group
Attrition/dropout: of the 430 children who met the eligibility criteria, 230 were randomised to each treatment group. However, in the ITT analysis, 
only 228 participants were assigned to the ceftriaxone group, as one of the allocated children was withdrawn by the mother before the first injection 
and because another allocated child was secondarily diagnosed with AOM
Twenty-four children in the amoxicillin group and 30 in the ceftriaxone group left the TFC before 14 days of weight gain because they had recovered, 
died, defaulted or were referred to other sites
Treatment interruption was significantly more common in the amoxicillin group (17/230, 7.4%) than in the ceftriaxone group (1/228, 0.4%; 
p < 0.001). There were no significant differences in the administration of an additional treatment before 14 days of weight gain206 Appendix 10 
General comments
Generalisability: the study site was chosen because the working conditions were satisfactory, the centre adhered to international standards of 
nutritional rehabilitation programmes, and the political situation was stable. Therefore, its results might not be applicable to centres with poorer 
operational conditions
All children admitted to the centre meeting the SAM criteria were enrolled. The criteria used to define SAM were broadly in line with current WHO 
criteria
Outcome measures: methods used for measuring anthropometric variables were given and definitions for outcomes such as ‘success’ were 
provided
The primary outcome measures, needed to indicate how interventions impact mortality and nutritional response to feeding, were reported (mortality 
and weight gain). Additional outcomes of interest, such as time to recover (length of stay) and adverse effects associated to antibiotics, were 
reported as well
However, no data on resolution of existing infections, development of new infections, relapse or development of antibiotic resistance outcomes seem 
to have been collected or reported. Only fatal infections were enumerated but without clearly identifying the treatment group in which they occurred
Intercentre variability: not applicable
Conflict of interest: no potential conflict of interest were reported or identified
NR, not reported.
a  Quantitative data are mean (SD) or median (IQR), categoricals are numbers (%).
b  No bilateral oedema.
c  No bilateral oedema and W/H ≥ 70%.
d  ≥ 37.5 ºC (axillary).
e  Respiratory rate > 50 for children aged 6–11 months, > 40 for children aged 12–59 months.
f  Successful treatment: weight gain ≥ 10 g/kg/day by the 14th day or discharge before 14 days of weight gain because the TFC exit criteria 
were met (maintained a W/H ≥ 85% for 7 consecutive days).
g  Percentage calculated by the reviewer. The 13 deaths during the first 14 days were because of septic shock (five), lower respiratory tract 
infections (three), fluid overload (four) and severe dehydration (one).
h  Total deaths during follow-up includes the deaths within 14 days of admission.
i  These three deaths, which occurred after 14 days from admission, are included in the reporting of total deaths during follow-up.
j  Quantitative data are mean (95% CI).© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
208 Appendix 10 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.   Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study 
(If the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Trehan et al. 201060
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Trehan et al.60
Year: 2010
Country: Malawi
Study design: retrospective 
cohort with control
Setting: home based
Number of centres: NR. Two 
different feeding projects, one 
operating in one district of 
Malawi, the other operating in 
two districts of Malawi
Funding: USA National 
Institutes of Health National 
Research Service Award (T32 
HD049338)
Intervention: amoxicillin (60 mg/kg/day, 
7 day supply) + RUTF (175 kcal/kg/day)
Control: RUTF (175 kcal/kg/day)
Treatments with RUTF were given 
until child had a WHZ ≥ –2 and no 
peripheral oedema and for a minimum 
of 4 weeks and maximum of 12 weeks
Other interventions used: none 
specified, although caretakers were 
referred to local health providers with 
any concerns about other acute illness. 
Caregivers educated about child’s 
illness and instructed on optimal 
feeding practices
Definition of SAM: WHZ ≤ –3 and or 
presence of bilateral pitting oedema
Number of participants: N = 2453 
(amoxicillin + RUTF n = 498, RUTF 
n = 1955)
Sample attrition/dropout: defaulters 
at 4 weeks amoxicillin n = 26 (5.2%), 
RUTF n = 121 (6.2%). Defaulters at 
12 weeks amoxicillin n = 39 (7.8%), 
RUTF n = 182 (9.3%)
Sample crossovers: none
Inclusion criteria: children aged 
6–59 months, uncomplicated SAM, 
with good appetite, qualified for 
outpatient treatment, attending two 
clinics between 2003–5
Exclusion criteria: children with 
poor appetite, altered mental status, 
compromised perfusion, respiratory 
distress or who were being transferred 
from inpatient to outpatient therapy 
were excluded
General characteristics of participants: 
children aged 6–59 months with a 
SAM from rural subsistence farming 
villages in Malawi
Primary outcomes: 
nutritional recovery rate 
(WHZ > –2 without oedema)
Secondary outcomes: 
survival, WHZ, WAZ, HAZ 
and presence of oedema
Method of assessing 
outcomes: data collected 
on presentation at the 
clinic by nurses and trained 
health professionals. 
Length, weight and MUAC 
measured and pedal 
oedema assessed by 
pressing thumb on dorsa 
of both feet for 5 seconds 
and noting visible pitting. 
Children assessed every 
1–2 weeks. If children 
missed two follow-up visits 
they were categorised as 
defaulters
Adverse symptoms: not 
stated
Length of follow-up: 
between 4 and 12 weeks
Recruitment dates: 2003–5
Characteristics of participants
Characteristic Amoxicillin + RUTF (n = 498) RUTF (n = 1955) p-value
Oedema 388 (77.9%) 1574 (80.5%) NS
Age (months)
 Overall 25.5 ± 11.7 22.3 ± 10.6 < 0.0001
  With oedema 27.3 ± 12.0 23.3 ± 10.8 < 0.0001
  Without oedema 19.1 ± 7.9 18.0 ±9 0 NS
Sex [female n (%)]
 Overall 246 (49.4) 986 (50.4) NS
  With oedema 195 (50.3) 849 (53.9) NS
  Without oedema 51 (46.4) 138 (36.2) NS
WHZ
 Overall –1.99 ± 1.26 –1.91 ± 1.45 NS
  With oedema –1.62 ± 1.15 –1.49 ± 1.25 NS
  Without oedema –3.28 ± 0.67 –3.64 ± 0.77 NS
HAZ
 Overall –3.41 ± 1.45 –3.18 ± 1.68 0.0059
  With oedema –3.33 ± 1.44 –3.06 ± 1.64 0.0026
  Without oedema –3.67 ± 1.47 –3.69 ± 1.74 NS210 Appendix 10 
WAZ
 Overall –3.51 ± 1.20 –3.05 ± 1.36 < 0.0001
  With oedema –3.19 ± 1.10 –2.72 ± 1.23 < 0.0001
  Without oedema –4.63 ± 0.82 –4.41 ± 1.00 0.0380
Comments: p > 0.05, values for WHZ, HAZ and WAZ are mean ± SD
Results
Primary outcomes 4 weeks p-value 12 weeks p-value
Amoxicillin + RUTF RUTF Amoxicillin + RUTF RUTF
Recovered, n (%)
 Overall 198 (39.8) 1385 
(70.8)
NR 417 (83.7) 1673 
(85.6)
NR
  With oedema 170 (43.8) 1206 
(76.6)
< 0.001 336 (86.6) 1385 
(88.0)
NR
  Without oedema 28 (25.5) 179 
(47.0)
< 0.001 81 (73.6) 288 
(75.6)
NR
Remained malnourished, n (%)
 Overall 264 (53.0) 423 
(21.6)
NR 29 (5.8) 66 
(3.4)
NR
  With oedema 191 (49.2) 254 
(16.1)
NR 13 (3.4) 36 
(2.3)
NR
  Without oedema 73 (66.4) 169 
(44.4)
NR 16 (14.5) 30 
(7.9)
NR
Died, n (%)
 Overall 10 (2.0) 26 
(1.3)
NR 13 (2.6) 34 
(1.7)
NR
  With oedema 8 (2.1) 16 
(1.0)
NR 10 (2.6) 19 
(1.2)
NR
  Without oedema 2 (1.8) 10 
(2.6)
NR 3 (2.7) 15 
(3.9)
NR
Defaulted, n (%)
 Overall 26 (5.2) 121 
(6.2)
NR 39 (7.8) 182 
(9.3)
NR
  With oedema 19 (4.9) 98 
(6.2)
NR 29 (7.5) 134 
(8.5)
NR
  Without oedema 7 (6.4) 23 
(6.0)
NR 10 (9.1) 48 
(12.6)
NR
Comments: at 12 weeks, the overall proportion who recovered in each group was described as similar. Rates of death and defaulting were described 
as similar between the two groups at 4 and 12 weeks
Secondary outcomes
Regression analysis 4 weeksa p-value Up to 12 weeksb p-value
Exploratory variable Exp(β)§ (95% CI) Exp(β) (95% CI)
Age (months) 1.02 (1.01 to 1.03) < 0.001 1.01 (1.00 to 1.02) NS
WHZ 1.72 (1.30 to 2.28) < 0.001 1.30 (0.93 to 1.82) NS
WAZ 0.83 (0.55 to 1.25) NS 1.15 (0.70 to 1.90) NS
HAZ 1.22 (0.97 to 1.53) NS 1.05 (0.79 to 1.38) NS
Presence of oedema 1.29 (0.99 to 1.69) NS 1.08 (0.79 to 1.48) NS
Received amoxicillin 0.22 (0.17 to 0.28) < 0.001 0.90 (0.65 to 1.25) NS© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Comments: in the subgroup of children who recovered after 4 weeks the WHZ was significantly higher in the RUTF group than those in the 
Amoxicillin + RUTF group (–0.37 vs –0.75; p < 0.0001)
§ the exponentiated β coefficient corresponds to change in odds resulting from a unit change in the predictor variable with all other variables are 
held constant. Values > 1 indicate that as the predictor variable increases, the odds of recovery increases. Values < 1 indicate that as the predictor 
variable increases, the odds of recovery decreases
p > 0.05
Seven cases had incomplete information and were omitted from the model. It is not clear if defaulters were also omitted from the model
Safety: NR
HIV: NR for the study cohorts, although authors note that HIV infection rates differed in the district using amoxicillin (7% inferred from mortality rate) 
to that in districts using RUTF (rates expected to be) 15% and 16.5%
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: non-random allocation
Blinding: not applicable
Comparability of treatment groups: children receiving amoxicillin + RUTF were older, more stunted (lower HAZ) and more underweight (lower WAZ)
Method of data analysis: continuous variables – mean and SD; dichotomous variables – number and per cent. WAZ, HAZ and WHZ were calculated 
using the US NCHS/WHO International Growth Reference standards (NCHS 1977). Enrolment and recovery characteristics were compared using 
Student’s t-test for continuous parameters and Fisher’s exact test for dichotomous parameters. Length measurements were converted to height 
measurements for children > 2 years by subtracting 0.5 cm from length measurements over 85 cm. Recovery rates were compared using logistic 
regression modelling while controlling for baseline variables
Sample size/power calculation: a sample of 400 children per group was calculated to detect a difference of at least 5% on the recovery rate
Attrition/dropout: results show that 39 children (7.8%) receiving amoxicillin + RUTF and 182 children (9.3%) receiving RUTF only defaulted from the 
study by 12 weeks
General comments
Generalisability: it was felt that as most patients had kwashiorkor and mild oedema, that the results were not generalisable to those with marasmus
Outcome measures: yes
Intercentre variability: differences in study populations were examined. Centre differences within each feeding programme are not specifically 
mentioned, but assumed to be minimal. Differences between feeding programmes in addition to use of antibiotics are discussed
Conflict of interest: study funded by USA National Institutes of Health National Research Service Award (T32 HD049338). No other competing 
interests
HA2, height-for-age z-score; NR, not reported; NS, not statistically significant; WAZ; weight-for-age z-score; WHZ, height-for-height z-score.
a  Chi-squared = 439 with 6 df for the model; p < 0.001.
b  Chi-squared = 112 with 6 df for the model; p < 0.001.212 Appendix 10 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise 
as ‘Other’)
RCT
CCT
Cohort analytic (two group pre + post) 
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups 
prior to the intervention?
Yes No  Cannot 
tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell

Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention 
or exposure status of participants?
Yes No  Cannot 
tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot 
tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot 
tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot 
tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot 
tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the 
allocated intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot 
tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that 
may influence the results?
Yes No  Cannot 
tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot 
tell

4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention 
received?
Yes No  Cannot 
tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not available.
Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 11  
Question 14: data extraction tables
Chapko et al. 199462
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Chapko et al.62
Year: 1994
Country: Niger
Study design: CCT
Setting: inpatient and 
outpatient
Number of centres: 
12 (1 inpatient and 11 
outpatient)
Funding: partly 
supported by a Fulbright 
Fellowship to Dr Chapko
Intervention: home based, with daily 
ambulatory rehabilitation at 1 of 11 
centres distributed around Niamey 
(capital of Niger) see end of table for 
details)
Control: hospital-based rehabilitation 
(special 20-bed section reserved for 
malnourished children in the National 
Hospital, Niamey) see end of table for 
details)
Other interventions used: none reported 
Definition of SAM: defined according 
to WHO (1986),94 i.e. children 
with W/H between –2 and –3 
SD = moderate acute malnutrition, 
< –3 SD = severe wasting; H/A 
between –2 and –3 SD = moderate 
chronic malnutrition or stunting, < –3 
SD = severe stunting
Number of participants: N = 100 
(home based n = 47, hospital based: 
n = 53)
Sample attrition/dropout: n = 14 
(14%; four during first 15 days of 
follow-up, two between days 15 and 
30, four between days 30 and 60, 
two between days 60 and 90 and two 
between days 90 and 180
Sample crossovers: none
Inclusion criteria: discharge from 
paediatric service of the hospital 
(occurred when conditions such as 
diarrhoea, dehydration, bronchitis or 
other acute conditions were resolved)
W/H < –2 SD or diagnosis of 
kwashiorkor residence within 
Niamey, mother agreed to child’s 
randomisation to either hospital or 
ambulatory rehabilitation
Exclusion criteria: none reported
General characteristics of 
participants: children with SAM 
discharged from hospital after 
treatment for conditions such as 
diarrhoea, dehydration, bronchitis or 
other acute conditions, but still W/H 
–2 SD or diagnosis of kwashiorkor 
and resident within the capital city 
of Niger
Primary outcomes: not specifically 
reported
Outcomes:
  ■ utilisation
  ■ cost of care
  ■ mortality
  ■ W/H
  ■ W/A
Method of assessing outcomes: 
details of general condition, 
symptoms and diagnosis at 
entry to paediatric service (i.e. 
initial inpatient treatment prior 
to discharge and entry to trial), 
length of stay and anthropometric 
measures at entry and discharge 
were abstracted from medical 
records
Anthropometric assessment of child 
and mother was through interview 
by research personnel at discharge 
from paediatric service. Information 
obtained from mother: child’s 
age and sex, mother’s age and 
education, and feeding practices
Follow-up anthropometric 
assessment of child [weight (kg), 
height (cm), age (months) and 
sex] and brief interviews with 
mother were obtained by research 
personnel in child’s home or in 
hospital at 15, 30, 60, 90 and 
180 days post-discharge from 
paediatric service
A computer program available from 
the Centers of Disease Control, 
Atlanta, GA, USA was used to 
calculate WHZ and HAZ expressed 
as SD were used to report W/H 
and H/A
Details of cost of care calculations 
were reported, but not extracted
Adverse symptoms: none reported
Length of follow-up: 6 months (15, 
30, 60, 90 and 180 days)
Recruitment dates: March 1990 to 
April 1991 216 Appendix 11 
Characteristics of participants
Characteristic All (NR separately for each group)
Age range, months 5 –28
Age, months %
 5–6 6
 7–12 45
 13–18 29
 19–24 17
  > 24 3
Sex, M : F % 54 : 46
Median W/H SD –3.16
W/H between –2 and –3 SD % 33
W/H < –3 SD % 59
Marasmus % 89
Kwashiorkor % 9
Mixed % 2
Median age of mothers, years (range) 26 (18–52)
Still nursing % 58
Comments: at entry to the hospital’s paediatrics service (initial inpatient treatment prior to discharge and randomisation into the trial), median W/H 
was –3.38 SD, median H/A –2.22 SD, 76% with marasmus, 14% with kwashiorkor and 10% mixed. Length of hospitalisation prior to nutritional 
rehabilitation was a median of 7 (range 1–43) days. Details of condition and presenting symptoms prior to randomisation were reported, but not 
data extracted. W/H between –2 and –3 SD was reported as 33% and W/H < –3 SD as 59%, leaving 8% unaccounted for. It is unclear if this was 
because details for the 8% were missing or if the 8% did not fit into the two categories
Results
Outcomes Home based (n = 47) Hospital based (n = 53) p-value
Deatha 33% 41% 0.172
Hospital, mean daysb 2.2 12.9 < 0.001
Ambulatory, mean daysb 11.9 5.6 < 0.01
Comments: data on location of care indicated that some patients did not receive the assigned care, for example 11% of those assigned to 
ambulatory treatment received hospital rehabilitation at the insistence of their mothers
No significant differences of H/A at follow-up between treatment arms (no data or p-value reported)
A figure in the paper presented the comparison of W/H between the home-based and hospital-based groups. Data for those who died was 
presented separately to the data for those who survived. The paper reports that within both the group that survived and the group that died, there 
was no significant difference between the home-based and hospital-based groups in W/H (no p-value reported)
Comparison of W/H were also made between children who survived, those lost to follow-up and those who died, and an analysis of W/A > 6 months 
of follow-up in children who survived, but these were not compared between study groups, data not extracted
Results of utilisation and cost were also reported. None of these results were data extracted
Safety: NR
HIV: NR
Barriers to implementation
States that there are indications that some children assigned to hospital or ambulatory rehabilitation did not receive the assigned care. Of those 
assigned to ambulatory rehabilitation, 11% received hospital rehabilitation at the insistence of their mothers
Also states that no extra resources were allocated to either setting or that the findings might have been different if more resources were available for 
the programmes© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Methodological comments
Allocation to treatment groups: states children randomised to either hospital or ambulatory setting after discharge from paediatric service (no details 
of procedure)
Blinding: none reported
Comparability of treatment groups: states that groups were compared on variables of age, sex, currently nursing, W/H, H/A, diagnosis, length of 
hospitalisation, mother’s age and education prior to randomisation. No significant differences were found between the groups with or without 
dropouts (no data per treatment group or p-value reported)
Method of data analysis: comparisons on variables at or prior to randomisation of the two groups was performed using chi-squared for nominal or 
ordinal variables and Student’s t-tests for continuous variables including utilisation and cost. For anthropometric outcomes, analysis of covariance 
was used, with the anthropometric assessment at entry into study as covariate. Survival analysis was used to compare mortality in the two groups. 
Main analyses do not appear to be ITT. In addition, three sensitivity analyses were performed, but details have not been extracted because results 
were NR in detail for survival as they were not substantially different to the main results. These included an ITT analysis of mortality
Sample size/power calculation: none reported. A number of subgroup analysis in W/H at the different assessment points were conduced (survivors, 
deceased and dropouts), but it is unclear if the study was powered for these kind of analysis
Attrition/dropout: total number and timing of loss reported. Reasons for dropout or numbers per treatment group not given, but states that equal 
numbers were lost between groups and that there were no significant differences between the two groups in timing of loss to follow-up (no data or 
p-value reported)
General comments
Generalisability: the study was designed to compare nutritional rehabilitation in two different settings (ambulatory vs hospital based), as they occur in 
a developing country. However, nutritional rehabilitation differed between ambulatory centres and between the hospital and the ambulatory centres. 
It is unclear if one meal in an ambulatory centre is sufficient for the treatment of SAM and how generalisable the results are to other settings. The 
majority of children in the study sample were aged 7–12 months (45%), followed by those aged 13–18 months (29%). It is unclear whether or not 
the results of the study would hold in children of other age groups
Outcome measures: no primary outcome was defined, but outcomes appear to be suitable and appropriate
Intercentre variability: unclear how many children were assigned to individual ambulatory centres. Differences in centres appear to have not been 
accounted for in the analysis
Conflict of interest: none reported, but study partly supported by funding from a Fulbright Fellowship to Dr Chapko
Rehabilitation details
Hospital-based rehabilitation Home-based rehabilitation
Three daily meals prepared by staff and mothers in a common 
kitchen. Provision of formal and informal educational sessions 
each day. Full-time staff of the hospital rehabilitation programme 
included a nurse, social worker and janitor, with 20% of a 
physician’s time, who made morning rounds. After discharge, 
children returned home and may have attended an ambulatory 
rehabilitation centre
One or two daily meals. Mother and child attended the centre early in the 
morning, preparing a meal with food partially provided by the centre and 
partially by the mother. Depending on the centre, children left at the end of 
the morning or stayed for a midday meal and then left. A typical morning 
included some form of education for the mother. Centres had variable 
staffing levels, typically one to three full-time nurses and/or social workers, 
plus one centre had a full or part-time physician as part of the staff
HAZ, weight-for-age z-score; NR, not reported; WHZ, weight-for-height z-score.
a  Excluding dropouts. Authors report trend for hospital-based children to die earlier.
b  Means based on all children, including those that did not actually receive care.218 Appendix 11 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the 
study likely to be representative of the target 
population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals 
participated?
80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if 
categorise as ‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of 
randomisation described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between 
groups prior to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant 
confounders that were controlled [either in the 
design (e.g. by stratification or matching) or in 
the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the 
intervention or exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the 
research question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in 
terms of numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants 
completing the study (If the percentage differs by 
groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the 
allocated intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention 
measured?
Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) 
that may influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/office Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/office Provider Patient

3.  Are the statistical methods appropriate for the 
study design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention 
allocation status (i.e. ITT) rather than actual 
intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.220 Appendix 11 
Ciliberto et al. 200563
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Ciliberto et al.63
Year: 2005
Country: Malawi
Study design: CCT
Setting: home or inpatient
Number of centres: seven
Funding: Doris Duke Clinical 
Scholars Program; St Louis 
Children’s Hospital Foundation; 
the World Food Programme; 
and Valid International (unclear 
if this is funding for authors, 
study, or both). Publication 
enabled by support to the 
Food and Nutrition Technical 
Assistance (FANTA) Project by 
the Office of Foreign Disaster 
Assistance of the Bureau 
for Democracy, Conflict and 
Humanitarian Assistance, and 
the Office of Health, Infectious 
Diseases and Nutrition of the 
Bureau for Global Health at the 
US Agency for International 
Development, under terms 
of a co-operative agreement 
awarded to the Acadmy for 
Educational Development
Intervention: home-based 
therapy for the second 
phase of treatment for 
childhood malnutrition. A 
2-week supply of RUTF 
was provided at clinic visits 
based on the weight of the 
child at that visit
Control: standard therapy 
for the second phase of 
treatment for childhood 
malnutrition based on 
WHO guidelines provided 
at nutritional rehabilitation 
units (NRUs) providing 
inpatient care. Children 
either received feeds 
in hospital or received 
additional cereal–legume 
supplement for use at home
Study participation lasted 
8 weeks in both groups 
after which all children were 
discharged
If children reached a WHZ 
> 0 (based on admission 
height); clinically relapsed 
(recurrence of oedema or 
systemic infection requiring 
admission to NRU); or died, 
they were discharged from 
the study before week 8
Details of interventions in 
separate table which follows
Other interventions used: 
None reported
Definition of SAM: a WAZ < – 2, mild 
oedema (< 0.5 cm of pitting oedema 
on the dorsum of the foot), or both 
(subgroup identified using WHO criteria 
of either WHZ < –3 or oedema)
Number of participants: N = 1178 
[home-based therapy, n = 992 
(separate results for n = 532 meeting 
WHO criteria for SAM); standard 
therapy, n = 186 (separate results 
for n = 113 meeting WHO criteria for 
SAM)]
Sample attrition/dropout: home-based 
therapy: 35/992 did not attend follow-
up ever, 63 did not complete 8 weeks 
of follow-up. Standard therapy: 6/186 
did not attend follow-up ever, 9 did 
not complete 8 weeks of follow-up. 
Attrition from subgroup with SAM NR
Sample crossovers: stepped wedge 
design meant that NRUs switched 
over from standard to home therapy 
during the course of the trial. It 
does not appear that any individuals 
switched over, although it is possible 
that if children who had received 
standard therapy did not recover 
and were referred back to the health 
centre for further evaluation they 
may subsequently have been offered 
home-based therapy if the centre had 
crossed over by then
Inclusion criteria: age 10–60 months; 
attending one of seven NRUs 
(inpatients and children brought from 
surrounding community); WHZ < − 2, 
mild oedema (< 0.5 cm of pitting 
oedema on the dorsum of the foot), or 
both; a good appetite (determined by 
observing child eat test dose of 30 g 
RUTF and by questioning carer)
Exclusion criteria: children 
< 10 months of age. Children with 
severe oedema (> 0.5 cm of pitting 
oedema on the dorsum of the foot); 
evidence of systemic infection 
or anorexia (but after phase one 
treatment at the NRU most such 
children became eligible for enrolment 
and did join the study of phase two 
treatment)
General characteristics of participants: 
children aged 10–60 months with 
moderate or SAM
Primary outcomes: successful 
recovery, relapse or death
Secondary outcomes:
Rates of growth in:
  ■ body weight
  ■ MUAC
Length and number of days of:
  ■ fever
  ■ cough
  ■ diarrhoea during the first 2 weeks 
of treatment
Method of assessing outcomes: all 
follow-up data were collected in the 
same manner for children receiving 
standard therapy and home-based 
therapy with RUTF
Carers and children returned to the 
clinic for reassessment every 2 weeks 
when weight, length and MUAC were 
measured. Weight gain and growth in 
MUAC were determined by calculating 
the change per day during the first 
4 weeks of the study. The growth in 
stature rate was calculated as change 
in height per day over 8 weeks
Carers for both groups were asked 
about the number of days of fever, 
cough and diarrhoea experienced by 
the child in the previous fortnight. 
Follow-up for assessing morbidity 
was limited to 2 weeks because many 
children receiving RUTF recovered 
before 8 weeks
Active case finding began 3-weeks 
after a child’s last follow-up visit 
for children failing to attend for 
follow-up. The aim was to determine 
whether or not the child had died or 
relapsed. Reported child deaths were 
considered to be a consequence of 
malnutrition
Recovery defined as reaching WHZ 
> −2 while remaining free of oedema, 
relapse or death
Rate of relapse was assessed by 
asking all children reaching WHZ > –2 
to return for follow-up anthropometric 
measurements after 6 months
Adverse symptoms: NR
Length of follow-up: 6 months
Recruitment dates: December 2002 to 
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Characteristics of participants: note that demographics were provided for the whole group, except for WHZ and oedema which were provided 
separately for the severely malnourished group
Characteristic Home-based therapy with 
RUTF (n = 992)
Standard therapy (n = 186) p-value
Male % (n) 53 (526) 53 (98) NR
Age, mean months ± SD 23 ± 10 24 ± 12 NR
Oedema, % (n) 44 (434) 46 (86) NR
Weight, mean kg ± SD 7.7 ± 1.7 7.6 ± 1.9 NR
Length, mean cm ± SD 74.8 ± 6.6 75.0 ± 7.6 NR
W/A, mean z-score ± SD –3.5 ± 1.0 –3.7 ± 1.0 NR
H/A, mean z-score ± SD –3.0 ± 1.5 –3.2 ± 1.6 NR
W/H, mean z-score ± SD –2.2 ± 0.8 –2.5 ± 0.9 < 0.05
MUAC, mean cm ± SD 11.6 ± 1.4 11.6 ± 1.5 NR
Children still breastfeeding, 
% (n)
52 (505) 58 (72) NR
Age when breastfeeding 
stopped, mean months ± SD
21 ± 7 21 ± 8 NR
Mother alive, % (n) 98 (905) 94 (164) NR
Father alive, % (n) 93 (842) 92 (158) NR
Clean water source, % (n/N) 83 (812)a 82 (133/162) NR
Grass used as roofing material, 
% (n/N)
88 (863)a 90 (137/153) NR
Subgroup: children with 
oedema or WHZ < –3
Home-based therapy with 
RUTF (n = 532)
Standard therapy (n = 113) p-value
W/H, mean z-score ± SD –2.5 ± 1.0 –2.5 ± 1.1 NR
Oedema, % (n) 81 (437) 78 (87) NR
Results
Primary outcome for 
subgroup with SAM
Home-based therapy with 
RUTF (n = 532)
Standard therapy (n = 113) Difference (95% CI)
Successful recovery (reaching 
WHZ > –2) after 8 weeks of 
therapy, % (n)
72 (382) 49 (55) 21 (10 to 32)
Children relapsed or died, % (n) 10 (53) 16.8 (19) 6.8 (0.3 to 24.7)
Children who died, % (n) 3.7 (20) 6.2 (7) 2.5 (–0.8 to 6.8)
Comments: the subgroup of children with SAM who received home-based therapy with RUTF were 2.0 (95% CI 1.7 to 2.3) times as likely to recover 
as those receiving standard care (covariates of age, sex, oedema, recent inpatient admission in a NRU, month of admission and WHZ on admission 
controlled for in the multivariate regression analysis)
Results also provided for the whole population, but these have not been data extracted
Secondary outcomes for 
subgroup with SAM
Home-based therapy with 
RUTF (n = 532)
Standard therapy (n = 113) Difference (95% CI)
Rate of weight gain during first 
4 weeks, mean g/kg/day ± SD
3.7 ± 4.3 3.0 ± 8.8 0.7 (–0.4 to 1.8)
Rate of height gain during first 
8 weeks, mean mm/day ± SD
0.2 ± 0.33 0.04 ± 0.35 0.16 (0.09 to 0.23)
Rate of MUAC gain during first 
4 weeks, mean mm/day ± SD
0.42 ± 0.71 0.28 ± 0.44 0.14 (0.04 to 0.24)
Comments: the subgroup of children with SAM who received home-based therapy with RUTF were 0.5 times (95% CI 0.3 to 0.7) as likely to die 
or relapse as those receiving standard care (covariates of age, sex, oedema, recent inpatient admission in a NRU, month of admission and WHZ 
on admission controlled for in the multivariate regression analysis). The rate of weight gain was 1.4 (95% CI 1.1 to 1.7) times as great among the 
severely malnourished children in the home-based therapy group than the standard therapy group
Results also provided for the whole population, but these have not been data extracted222 Appendix 11 
Secondary outcomes for 
subgroup with SAM
Home-based therapy with 
RUTF (n = 532) Standard therapy (n = 113) p-value
Prevalence of fever during first 
14 days, mean days ± SD
1.0 ± 2 1.8 ± 3.3 < 0.001
Prevalence of cough during first 
14 days, mean days ± SD
0.8 ± 2.4 1.8 ± 3.6 < 0.001
Prevalence of diarrhoea during 
first 14 days, mean days ± SD
0.7 ± 1.7 1.3 ± 2.7 < 0.001
Comments: results also provided for the whole population, but these have not been data extracted
Safety: states that no adverse reactions to RUTF were observed
HIV: children who participated for 8 weeks but who did not recover were referred to the health centre for further medical evaluation where 
presumably some of the children received a HIV diagnosis. No indication of HIV prevalence provided
Barriers to implementation
Poor outcomes with standard therapy may in part be because of the time and resources required from the caretaker to comply with standard 
therapy. The caretaker must leave the home and stay with the child in the NRU, and then on returning home prepare cereal porridges seven times 
a day over an open fire in a rural setting. Findings suggest that in this operational setting, practical constraints and challenges were important 
limitations in the standard treatment
Methodological comments
Allocation to treatment groups: stepped wedge design (intervention rolled-out sequentially to NRUs over a number of time periods – only one 
NRU offered home therapy at the start, other NRUs switch over to offer home therapy at the rate of two NRUs after the first 3 weeks, and one 
NRU every 3 weeks therafter). Randomisation was not possible owing to resource constraints and cultural beliefs. The stepped wedge design 
meant that although children receiving standard therapy were enrolled throughout the study, they were present in fewer numbers. The stepped 
wedge design was used to control bias that might be introduced by seasonal variations in the severity or type of childhood malnutrition in the pre-
harvest (December to April) season when most cases of childhood malnutrition occur. As a RCT could not be conducted, the authors followed the 
Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) statement for reporting of non-randomised clinical trials
Blinding: not explicitly stated, but because of the nature of the study design it is unlikely that this was a blinded study
Comparability of treatment groups: most children in the home-based therapy group (645/992, 65%) did not receive treatment in a NRU before 
enrollment, whereas all those in the standard-therapy group began their treatment in a NRU. For those in the home-based therapy group who did 
begin treatment in a NRU (n = 347), their average stay was 11 ± 9 days, whereas those in the standard group were hospitalised for 22 ± 14 days 
(difference between groups: 11 days 95% CI 8 to 14 days; no p-value reported). For the groups as a whole, WHZ was significantly different between 
the two groups (less severe in the home-based group), the paper authors speculate this may have been because when mothers knew the NRU 
was offering home-based therapy they were more willing to present with a moderately malnourished child than when standard inpatient care was 
offered. For the subgroup of severely malnourished children WHZ appears comparable between the groups although this is not commented on
Method of data analysis: ITT analysis was used. Outcomes were determined for the entire group of participants (those meeting criteria for treatment 
in Malawi) and also for those children that met the WHO criteria for SAM (oedema or a WHZ < –3). Comparisons for outcomes were made by 
calculating the differences and 95% CI of the differences between standard therapy and home therapy with RUTF. Linear and logistic regression 
modelling were used to account for the effect of covariates on the comparisons (using SPSS). Time-event analysis was used to compare rates of 
reaching a WHZ > –2 over the 8-week study duration. A p < 0.05 was considered to be statistically significant. To compare the case fatality rate of 
home-based therapy with RUTF to international standards, an estimate of the predicted case fatality rate was made by using a published method 
(referenced) and this was compared with the actual case fatality rate
Sample size/power calculation: because the period of time in which children could be enrolled to standard therapy was much shorter than that for 
home-based therapy it was anticipated that about 80% of participants would receive home-based therapy and only about 20% standard therapy. A 
sample size of 1030 children would have provided 95% confidence and 80% power to detect a minimum of a 10% absolute increase in recovery 
rate, and a 7% absolute decrease in mortality rate, assuming a 1 : 4 allocation of children to standard and home-based groups, and a 70% recovery 
rate and a 15% mortality rate in the standard group
Attrition/dropout: numbers reported for whole group, but no reasons given. NR separately for the subgroup with SAM. The proportion of dropouts 
in each group was described as similar by the study authors (9.8% home-based group, 8.1% standard group). The authors also state that loss to 
follow-up was unlikely to be a significant cause of bias in the primary outcome because the differences between the two groups were so great
Other: the authors noted that implementation of the interventions was not checked. No observations were made to confirm that mothers fed their 
children the RUTF, nor that standard therapy was being rigorously administered© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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General comments
Generalisability: children had to have a good appetite to be included so might not be generalisable to those with poor/no appetite. Children met the 
anthropometric criteria for admission which were those used in Malawi, not those given in WHO guidelines. As children < 10 months were excluded, 
the study may not be generalisable to this age group. However, the intervention may not be appropriate for this age group anyway because the 
reasons for this exclusion were (1) few children of this age range were treated at NRUs, and (2) concern that RUTF consumption might interfere with 
breastfeeding
Outcome measures: outcomes appear appropriate
Intercentre variability: participating NRUs were in both mission and public facilities in small towns and rural areas of southern Malawi. No indication 
is given regarding the similarity or differences between the NRUs
Conflict of interest: states that none of the authors had a conflict of interest related to the study. Additionally the development and implementation of 
the study and the data analyses were conducted entirely independently of the study sponsors. Study sponsors had no role in interpretation of data or 
in preparation of the published paper
Home therapy: RUTF was produced as a co-operative effort by the study team and Tambala Foods (Blantyre, Malawi). It was packed in plastic jars 
containing 260 g without an airtight seal. The amount in each jar was approximately the amount consumed by the malnourished child in 1 day. 
Typically, children ate the RUTF directly from the jar, without diluting it or mixing it with other foods
Peanut butter 25%
Sugar 28%
Full-cream milk 30%
Vegetable oil 15%
Imported vitamin and mineral supplement (CMV; 
Nutriset)
1.4%
Energy content 733 kJ/kg/day (175 kcal/kg/day)
Protein content 5.3 g protein/kg/day
Micronutrient content Identical to that of F100 before dilution and in accordance with WHO recommendations for 
catch-up growth
Inpatient therapy: children fed F100 while inpatients. On discharge from the hospital, the malnourished children received a generous supply of 
a supplemental blended flour (50 kg, composition below) to be consumed seven times a day. Because this maize–soy flour blend was familiar to 
mothers as an everyday food, they were expected to prepare it for their children as they would their staple food (i.e. usually consumed as a soft–
solid dough)
Maize flour 80%
Soy flour 20%
Vitamins and minerals According to standard specifications of the World Food Programme
HAZ, weight-for-age z-score; NR, not reported; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.
a  No denominator reported and n/N assumed as not stated.224 Appendix 11 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely to 
be representative of the target population?
Very likely Somewhat likely Not likely Cannot 
tell

2. What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as ‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to the 
intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell

Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of numbers 
and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study (If 
the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status (i.e. 
ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.226 Appendix 11 
Heikens et al. 199464
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Heikens et al.64
Year: 1994
Country: Jamaica
Study design: CCT
Setting: inpatient (university 
hospital) and community
Number of centres: one
Funding: fully funded by 
Ministry of Development 
Cooperation, the 
Netherlands, with 
co-operation of Ministry of 
Health, Kingston, Jamaica
Intervention: long stay. Hospital 
care with high-energy diet (until 
wasting corrected) + standard 
health service care at home for 
6 months
Control: short stay. Home care 
with high-energy supplement 
and standard health service care 
for 3 months + standard health 
service care for 3 months
(Further details of interventions 
given at end of table)
Other interventions used: all 
children received initial treatment 
of malnutrition and concurrent 
illnesses before being randomised. 
Specific therapy for infections and 
parasites was instituted if deemed 
necessary
Definition of SAM: reports nutritional 
status according to Gómez, Wellcome 
and Waterlow classifications, but this 
showed inconsistencies with only one-
third to a half of the study population 
classified as SAM. However, states 
children did have SAM and mean 
baseline W/A expressed as per cent of 
NCHS reference value was ≤ 60%
Number of participants: N = 81 (long 
stay, n = 40; short stay, n = 39)
Sample attrition/dropout: not clear, 
but appears to be 14% (11/79); n = 5 
long stay (one died, four lost for other 
reasons) and n = 6 short stay (two 
died and four lost for other reasons) 
(see Attrition section in Methodological 
comments on page 228)
Sample crossovers: none reported
Inclusion criteria: all children referred 
from public health clinic and judged to 
require hospital admission based on W/A 
< 80%, oedema, anorexia, dermatosis 
or hair condition symptomatic of 
kwashiorkor, the need for treatment with 
parenteral antibiotics
Exclusion criteria: known congenital 
abnormality, sibling in present study or in 
authors’ community study
General characteristics of participants: 
severely malnourished children, aged 
3–36 months referred from 40 public 
health clinics in low income areas of 
the city
Primary outcomes: longer-term 
anthropometric status was focus 
of paper, though not specifically 
stated as primary outcomes per 
se. z-scores (W/A, L/A, W/L) at 
12, 18, 24, 30 and 36 months
Secondary outcomes: 
anthropometric status at 
discharge and after 6 months 
home care:
  ■ days post-admission
  ■ z-scores (W/A, L/A, W/L)
Method of assessing outcomes: 
clinical assessments were 
made at admission, during 
hospital treatment and monthly 
throughout the home-care period 
of 6 months. Anthropometric 
measurements were made at 
baseline and 6-monthly intervals. 
No methods reported
Adverse symptoms: NR
Length of follow-up: 36 months 
post-admission
Recruitment dates: March 1985 
to May 1987, with follow-up 
measurement until November 
1990
Characteristics of participants
Characteristic Long stay (n = 40) Short stay (n = 39) p-value
Age, months 11.7 (0.9) 10.8 (1.1) NR
Birthweight, kg 3.0 (0.2) 2.8 (0.2) NR
Weight, kg 5.6 (0.2) 5.3 (0.3) NR
Length, cm 65.0 (6.1) 63.5 (8.9) NR
W/Aa 60.3 (1.7) 57.9 (1.7) NR
L/Aa 88.1 (0.8) 87.1 (0.8) NR
W/La 80.6 (1.7) 81.6 (1.5) NR
BMI (weight/height2) 13.2 (1.5) 12.8 (1.3) NR
Number of siblings 3.2 (0.3) 3.1 (0.3) NR
Birth rank 2.9 (0.3) 2.8 (0.3) NR
Mother’s age, years 27.6 (1.7) 23.7 (1.0)b NR
Mother’s height, m 1.6 (0.06) 1.6 (0.05) NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Diarrhoeac 21.4 (4.6) 20.7 (3.8) NR
Feverc 13.2 (3.7) 11.4 (3.2) NR
Coughc 22.9 (4.7) 20.7 (4.6) NR
Coldc 18.6 (4.8) 14.9 (4.2) NR
Comments: all data are mean (SE). The groups did not differ significantly on any measure (p-values NR)
Results
Primary outcomes: NCHS 
z-scoresd Long stay (n = 40) Short stay (n = 39) p-value
W/A
 Admission –3.55 (0.30) –3.70 (0.35)
 Discharge –2.50 (0.25) –3.35 (0.30) < 0.001
  12 months –1.55 (0.30) –2.30 (0.45) < 0.001
  18 months –1.40 (0.30) –2.05 (0.40) < 0.001
  24 months –1.20 (0.30) –1.90 (0.35) < 0.01
  30 months –1.20 (0.30) –1.45 (0.30)
  36 months –1.25 (0.45) –1.30 (0.25)
L/A
 Admission –3.20 (0.40) –3.35 (0.45)
 Discharge –2.95 (0.40) –3.30 (0.50) < 0.1
  12 months –1.80 (0.35) –2.60 (0.60) < 0.05
  18 months –1.10 (0.40) –2.20 (0.45) < 0.001
  24 months –0.95 (0.40) –1.85 (0.50) < 0.01
  30 months –0.80 (0.40) –1.40 (0.40) < 0.05
  36 months –0.95 (0.40) –1.20 (0.40)
W/L
 Admission –1.95 (0.35) –1.85 (0.30)
 Discharge –0.45 (0.20) –1.20 (0.35) < 0.001
  12 months –0.60 (0.30) –1.00 (0.40) < 0.1
  18 months –0.75 (0.30) –0.95 (0.30)
  24 months –0.75 (0.30) –0.95 (0.35)
  30 months –0.80 (0.30) –0.70 (0.30)
  36 months –0.55 (0.30) –0.65 (0.35)
Comments: the paper reports the data in the form of bar charts showing group means and SE. The data here are all estimated to nearest 0.05 by 
the reviewer from bar charts using Engauge Digitiser version 4.1 (http://digitizer.sourceforge.net; Copyright Mark Mitchell 2002). Cross-sectional 
data (n at 12, 18, 24, 30 and 36 months: long stay = 37, 35, 35, 31 or 28 months; short stay = 28, 35, 30 or 26 months). Owing to reduced sample 
size and a change in group constitution as the long-term study progressed, the stability of the findings was tested in longitudinal analyses, adjusting 
for baseline differences but are not extracted here
Two-tailed post-analysis of covariance tests established that the group differences in length were significant at p < 0.02, p < 0.0001, p < 0.005 and 
p < 0.06 at 12, 18, 24 and 30 months post-admission, respectively
Similar comparisons for weight were p < 0.003, p < 0.01, p < 0.033 and p < 0.19 at 12, 18, 24 and 30 months post-admission, respectively. The 
effect was greater earlier, but was lost sooner than for length
The groups did not differ significantly at 36 months on either measure
During the first 14 days in hospital, weight velocities were similar between groups (range –8 to 24 g/kg/day). During the following 2 weeks, children 
remaining in hospital gained rapidly (10.4 vs 12.1 g/kg/day for long- and short-stay, respectively), settling to 6/7 g/kg/day average thereafter for 
children still in hospital, with no difference between groups at any treatment stage except the final velocity of 6/7 g/kg/day average was maintained 
over a longer period for the long-stay group. By 3 months post-discharge, velocities were similar at 1.13 vs 1.05 g/kg/day, respectively (range –4 to 
7 g/kg/day). After a further 3 months, average velocity was ~ 0.85 g/kg/day for both groups228 Appendix 11 
Secondary outcomes Long stay (n = 40) Short stay (n = 39) p-valuee
Discharge
Days post-admission 39.45 (2.35) 17.99 (1.43) 0.001
z-scores
 W/A –2.49 (0.12) –3.38 (0.16) 0.001
 L/A –3.02 (0.18) –3.52 (0.22) 0.086
 W/L –0.49 (0.11) –1.17 (0.16) 0.001
After 6 months home care
Days post-admission 218.09 (2.56) 195.29 (1.91) 0.001
z-scores
 W/A –1.81 (0.16) –2.45 (0.15) 0.006
 L/A –2.38 (0.17) –2.82 (0.18) 0.059
 W/L –0.46 (0.14) –0.80 (0.16) 0.105
Comments: data are mean (SE)
Safety: none reported other than one child in each group died from severe electrolyte disturbance during the first week after admission
HIV: NR
Barriers to implementation
A hurricane during the follow-up period accounted for some missing data owing to being unable to trace the children in the immediate aftermath 
and industrial action closed the hospital wards causing early discharge for some
Methodological comments
Allocation to treatment groups: just states random allocation made, no further details
Blinding: not possible because of nature of interventions
Comparability of treatment groups: reports that there were no significant differences between groups for any baseline characteristics or clinical 
findings presented in table nor for any morbidity indicator recorded, but not presented in table (p-values not presented). Mother’s age (27.6 years 
long stay vs 23.7 years short stay) approached significance at p < 0.05
Method of data analysis: not much detail reported. Not ITT analysis. Groups were compared by analysis of variance and covariance. Repeated 
measures analyses of covariance using a maximum likelihood method were made on NCHS z-scores at 12, 18, 24, 30 and 36 months. Reports all 
test assumptions were met.95 Initial data screening used SPSS and final analysis BMDP Statistical Software programs. Eight children had missing 
data for between one and three test points as a result of hurricane Gilbert (the values were equally distributed across the groups). Missing data (for 
primary outcomes) were mostly because of subjects lost at a particular test point, rather than lost altogether. Although 79 cases contributed data to 
the analyses, only 44 had data for all five test sessions (12, 18, 24, 30 and 36 months)
Sample size/power calculation: NR
Attrition/dropout: total = 11 (long stay, n = 5; short stay, n = 6). Reasons given: failed to respond to treatment and died from severe electrolyte 
disturbance in first week after admission (one long stay and one short stay); died during follow-up for reasons unconnected with nutrition or infection 
(accidental aspiration) (one short stay); dropped from study after admission because of cardiac defect (one short stay); remained in hospital longer 
than intended because of home difficulties (one short stay); migrated at 24 months post-admission (one long stay); discharged early because 
industrial action closed hospital wards (one long stay); and lost because of lack/withdrawal of parental consent (two long stay and two short stay)
General comments
Generalisability: all children with SAM referred from public health clinics in low income urban areas, aged 3–36 months. Unclear whether or 
not most would meet the WHO criteria [no, if based on NCHS reference value of < 70% W/L (baseline mean is 81–82%), yes if based on NCHS 
reference value of < 60% W/A (baseline mean is 58–60%)]
Outcome measures: outcomes were appropriate although presentation of graphs required estimation of data points
Intercentre variability: N/A
Conflict of interest: fully funded by Ministry of Development Cooperation, the Netherlands, with co-operation of Ministry of Health, Kingston, Jamaica. 
No conflicts of interest reported
After hospital admission, initial treatment of malnutrition and other concurrent illnesses was undertaken following established Tropical Metabolism 
Research Unit (university hospital) procedures.96–98 When the children had lost oedema, could tolerate 5-hourly feeds, gained weight on 3 successive 
days by at least 5 g/kg/day and no longer needed hospital treatment of concurrent illness or infection, they were randomised to long- or short-stay 
treatment© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
229   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
Long stay, hospital care Short stay, home care
  ■ Remain in hospital. Continue to receive the regular high-energy diet given to both 
groups while in hospital.96–98 This diet was similar to the short-stay diet and was given 
for, on average, 3 weeks
  ■ Discharged only when wasting was corrected (95–100% NCHS W/L) according to usual 
Tropical Metabolism Research Unit procedures
  ■ Standard Health Service care including multivitamins and folic acid for 6 months
  ■ Within a day of randomisation, children were 
taken home and further treatment was provided 
by CHAs
  ■ High-energy supplement (3.31 MJ with 20.6 g 
protein daily given as a gruel containing full-
cream milk powder 52%, sugar 32%, soya oil 
16%) + standard health service care including 
multivitamins and folic acid for 3 months
  ■ Standard health service care without the 
supplement for further 3 months
Follow-up continued for the remainder of the 3-year period after treatment ceased where there was no intervention other than 6-monthly 
anthropometric measurements
Standard health service community care comprised training of CHAs, monitoring of CHAs and home-feeding, weighing and bacteriological testing of 
returned supplement containers, provision of multivitamins and folic acid, outpatient treatment of minor illnesses and infections, nutritional advice on 
breastfeeding and weaning following Ministry of Health guidelines (refs cited)
L/A, length-for-age; N/A, not applicable; NR, not reported.
a  Expressed as a percentage of the NCHS reference value.
b  Approaches significance at p < 0.05.
c  Per cent of previous 28 days (mother’s recall).
d  Deviations from the expected value for age in SD units.
e  Two-tailed test.230 Appendix 11 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot 
tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot 
tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot 
tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.   Were data collection tools shown to be valid? Yes No  Cannot 
tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot 
tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot 
tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot 
tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot 
tell

H. Analysis
1. Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2. Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3. Are the statistical methods appropriate for the study design? Yes No  Cannot 
tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot 
tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.232 Appendix 11 
Khanum et al. 199465
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Khanum et al.65
Year: 1994
Linked papers: Ashworth and 
Khanum 199799 and Khanum et 
al. 1998100
Country: Bangladesh
Study design: controlled trial
Setting: inpatient, day care, or 
at home depending on group 
allocation (additional details at 
end of table)
Number of centres: one
Funding: Save the Children 
Fund, UK and Overseas 
Development Agency UK
Intervention 1: inpatient. Children 
admitted with their mothers and 
resident until reaching 80% W/H
Intervention 2: day care. Children 
attended with their mothers 0800 to 
1700 hours every day except Friday 
until 80% W/H reached. Mothers 
permitted to bring another young 
sibling
Intervention 3: care at home. 7 days 
treatment in day-care facility (or up 
to 9 days if poor appetite or poor 
clinical condition persisting). Then 
home where visited weekly for 
1 month, then twice monthly until 
reaching 80% W/H. Weekly visits 
continued if children not oedema-
free at 1 month
Details of diet and nutrition/education 
interventions provided at end of table
Other interventions used: all 
children received an initial clinical 
examination including chest 
radiograph, blood tests, urine and 
stool tests, laryngeal and wound 
swabs (full details not extracted), 
all received a broad-spectrum 
antibiotic (details at end of table). 
Xerophthalmia treated following 
WHO guidelines. Immunisations 
(diphtheria–pertussis–tetanus, BCG, 
measles)
All breastfed patients continued to 
receive breast milk
Definition of SAM: W/H 
< 60% of NCHS median, 
and/or oedema. Wellcome 
classification also used
Number of participants: 
N = 573 [inpatient n = 200, 
completed n = 173 (86.5%); 
day care n = 200, completed 
n = 134 (67%); at home 
n = 173, completed n = 130 
(75.1%)]
All 437 children completing 
the trial entered the 12-month 
follow-up. At entry to follow-
up all had reached 80% W/H
Sample attrition/dropout: 
late exclusion (owing to TB 
or given blood): inpatients, 
n = 18 (9%); day care, n = 22 
(11%); at home, n = 30 
(17.4%). Deaths: inpatients, 
n = 7 (3.5%); day care, n = 10 
(5%); at home, n = 6 (3.5%)
Discontinued allotted group: 
inpatients, n = 2 (1%); day 
care, n = 34 (17%); at home, 
n = 7 (4%)
Eligible children whose 
parents later requested 
treatment in a different 
group to that assigned were 
dropped from the trial
Attrition from 12-month 
follow-up:
  ■ Lost (no trace) n = 33 
(inpatient 11.5%, day 
care 3.7%, at home 
6.1%)
  ■ Excluded (TB) n = 4 
(inpatient 1.8%, day care 
0.7%, at home 0.0%)
  ■ Excluded (incomplete 
data) n = 47 (inpatient 
13.3%, day care 9.7%, at 
home 8.5%)
  ■ Readmitted to unit n = 8 
(inpatient 1.7%, day care 
1.5%, at home 2.3%)
  ■ Died n = 10 (inpatient 
3.4%, day care 1.5%, at 
home1.5%)
  ■ 135 children (77%) 
completed ≥ 18 morbidity 
visits and were included 
in analyses
Primary outcomes: not stated in initial 
paper.65 Focus of one linked study92 
was on costs, and on morbidity, 
growth relapse and mortality in the 
paper reporting 12-month follow-up94
Secondary outcomes:
  ■ completion of treatment
  ■ mortality
  ■ rate of oedema loss
  ■ weight gain
  ■ days taken to achieve 80% 
oedema-free W/H
Method of assessing outcomes: 
completion of treatment – attaining 
80% oedema-free W/H (NCHS median 
as reference). If this was achieved 
in the home group when visits were 
fortnightly, interpolation was used to 
calculate to the nearest week when 
this occurred
Weight measured daily for inpatients 
and day care. Home group measured 
weekly for the first month then 
fortnightly
Height measured weekly for inpatients 
and day care. Home group measured 
as for weight
Structured questionnaire used 
at every visit to the home group 
to assess compliance with 
recommendations for meal frequency, 
quantities and types of food offered, 
and amounts consumed
Cost data were noted (details not 
extracted)
During 12-month follow-up: children 
visited at home every 2 weeks by one 
of eight specially trained field workers. 
Mothers asked to recall whether child 
was well or had specific morbidity 
signs (diarrhoea, vomiting, cough, 
fever, eye infection, ear infection, 
passing worms). Mothers recorded 
presence of morbidity for each day 
using a pictorial calendar. Study staff 
recorded morbidity on a pre-coded 
form during fortnightly interviews with 
mothers. Children were also examined 
for infection by the fieldworker and 
presence of illness recorded © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Sample crossovers: none
Inclusion criteria: W/H < 60% 
of the NCHS median, and/or 
oedema
Exclusion criteria: conditions 
requiring > 7 days medical 
supervision: packed-cell 
volume < 20% necessitating 
blood transfusion, critical 
illness (e.g. meningitis, 
encephalitis or other cerebral 
lesion, haemolytic anaemia), 
children < 12 months in age, 
TB or congenital or metabolic 
disorders, home more 
than 10 km from unit, age 
> 60 months
General characteristics of 
participants: W/H < 60% of 
NCHS median. Ninety per cent 
of children come from urban 
slums [brought by family 
(60%) or referred from other 
hospitals]
Children referred to outpatient 
department if major illness suspected. 
Outpatient records of children referred 
or attending independently were 
linked to derive total attendances per 
child during the year
Weight: recorded monthly using 
electronic scales calibrated daily
Length/height: measured monthly 
to nearest 0.1 cm (using standard 
technique with a locally made board), 
mean of two values taken (difference 
of < 0.5 cm between measurements 
considered acceptable)
Relapse definition: child has become 
oedematous or < 60% W/H
Deaths: fieldworkers interviewed 
mother about cause and place of 
death
Adverse symptoms: NR
Length of follow-up: to attainment 
of 80% W/H, and for those reaching 
80% W/H a further 12 months
Recruitment dates: December 1990 
to November 1991
Characteristics of participants
Characteristic Inpatients (n = 200) Day care (n = 200) At home (n = 173)
Mean age, months (SD) 25 (13) 26 (13) 28 (13)
Mean W/H (% of NCHS median) 
including oedema (SD)
67 (7) 70 (8) 70 (7)
Mean W/A (% of NCHS median) 
including oedema (SD)
48 (9) 50 (10) 51 (9)
Mean packed cell volume, % 
(SD)
28 (3) 29 (3) 29 (3)
Mean total protein, g (SD) 4 (1) 4 (1) 4 (1)
Xerophthalmia (%) 45 46 40
Angular stomatitis (%) 32 27 26
Infections %
  Diarrhoea with dehydration 58 60 60
History of measles in last 
3 months
57 58 52
  Upper respiratory infection 35 31 31
Lower respiratory tract 
infection
19 16 18
Upper and lower respiratory 
infection
18 22 20
  Skin infection 33 30 28
  Urinary tract infection 10 17 17
Middle ear infection (otitis 
media)
14 11 14
Septicaemia (diagnosed 
clinically)
7 9 7
Intestinal parasites (%)
  Entamoeba histolytica 24 29 26
  Ascaris lumbricoides 24 25 25
  Trichuris trichiura 19 23 25234 Appendix 11 
Characteristic at start of 
12-month follow-up Inpatients (n = 118) Day care (n = 111) At home (n = 106)
Age, mean in months 26 27 31a
Weight kg, mean ± SD 7.73 ± 1.81 7.46 ± 1.89 7.83 ± 2.00
Height cm, mean ± SD 73.3 ± 8.1 72.4 ± 8.4 74.4 ± 9.7
Comments: 60% of children had three or more infections in addition to SAM. According to Wellcome classification, of the 437 children who 
completed the study, 83% were marasmic kwashiorkor and 15% kwashiorkor (98% oedematous overall)
Results
Outcomes of initial study, 
until children attained 80% 
W/H Inpatients (n = 200) Day care (n = 200) At home (n = 173)
Mortality n/N (%) 7/200 (3.5) 10/200 (5.0) 6/173 (3.5)
Rate of oedema loss, median 11 days 13 days 19 days (significantly longer than 
the other two groups, median test 
p < 0.001)
Mean weight gainb from 
admission to 80% W/H, g/kg 
body weight/day
11 6 4
Days to achieve 80% oedema-
free W/H, median
18 23 35 (significantly longer than the other 
two groups, median test p < 0.001)
Comments: 70% of deaths occurred within 48 hours of admission. Causes of death were respiratory infection n = 15, diarrhoea with dehydration 
n = 7 and traffic accident n = 1. Those who died had poorer nutritional status on admission than survivors (mean W/H 64%, mean W/A 47%)
Costs data not extracted
Outcomes at 12-month follow-up of those who had attained 80% 
weight initially Inpatients (n = 118)
Day care 
(n = 111) At home (n = 106)
Readmitted to unit, % (n)c 1.7 (3) 1.5 (2) 2.3 (3)
Died, % (n)c 3.4 (6) 1.5 (2) 1.5 (2)
Weight gain (kg), mean ± SD 2.15±1.12 2.39 ± 0.98 2.47 ± 1.13
Height gain (cm) mean ± SD 6.4 ± 2.6 7.2 ± 2.3 7.3 ± 2.3
Diarrhoea – percentage of time reported, mean ± SD 9.5 ± 10.6 9.3 ± 10.0 7.4 ± 9.1
Diarrhoea episodes, n, mean ± SD 7.3 ± 6.8 7.1 ± 6.1 5.7 ± 5.5
Diarrhoea episode duration, days mean ± SD 4.9 ± 2.0 4.8 ± 2.2 4.6 ± 1.5
Fever (no diarrhoea, no cough) – percentage of time reported, mean ± SD 10.7 ± 7.1 10.1 ± 10.4 7.3 ± 7.3d
Cough (no diarrhoea, no fever) – percentage of time reported, mean ± SD 25.0 ± 16.6 25.0 ± 15.2 15.0 ± 10.2d
Fever and cough – percentage of time reported mean ± SD 12.6 ± 15.2 12.6 ± 15.0 7.5 ± 10.0d
Comments: during the 12-month follow-up, emergency readmission (1.2%), relapses (0.6%) and mortality (2.3%) were low and did not differ among 
the three treatment groups
There were no significant differences in weight gain or height gain between the groups (p-values NR). Gains in weight improved children’s mean 
W/H from 80% at the start of follow-up to 91% of the NCHS median at the end of the year (from z-score –1.60 to –0.92). Weight gains greater in 
the first semester of follow-up (presumed to be 6 months) than the second (results presented in figure for the whole group and not data extracted). 
Stated improvement not restricted to the youngest children but no data presented
H/A did not change during the year (small positive gain for children ≥ 48 months at start of follow-up, slight negative change for those aged 
< 48 months)
Diarrhoea was experienced by 92% of children during the year, and cough with fever by 96%. Cough and fever were less frequently reported for 
children in the at home group (p < 0.03)
No difference in morbidity found by field worker examination was found among the groups. Outpatient attendance was high (data presented for 
whole group only and not extracted) and paper states there was no difference between the groups
Effect of morbidity on growth reported, but not data extracted (NR by treatment group)
Safety: deaths were comparable between groups indicating that for the population selected, at home treatment could be an alternative strategy to 
inpatient care. Paper indicates that although difference in time to recovery were marked, once children reached 80% W/H no group was significantly 
disadvantaged during the following 12 months
HIV: NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Barriers to implementation
Day care was an unpopular option, only 4% of parents indicated they would have chosen this option if they had been offered a free choice, and of 
those children who discontinued in their assigned group, 79% were in the day-care group. Full-time commitment was needed by a family member 
for 1 month on average and the sick child had to be transported to and from the facility in busy traffic each day
In the at-home group, there was difficulty in preparing salt-free meals (foods for child largely derived from family foods), addition of oil to milk (to 
increase energy content) was deemed unacceptable by some families, 16% could not achieve recommended meal frequency and 12% could not 
achieve recommended meal quantity
Inpatient care had high institutional costs. Although mothers were expected to be resident day and night, in practice other members were allowed to 
substitute and this option was more acceptable to families than day care
Methodological comments
Allocation to treatment groups: sequential allocation by daily rotation such that recruitment to each group occurred every third day. The initial 
sequence was randomly determined. From the description provided in the paper approximately equal numbers in each group might be expected, 
however, this is not the case (n = 200, n = 200, n = 173). The reasons for this are not clear. After registration in the outpatients’ section, mothers 
proceeded to the unit where a doctor explained the planned treatment and asked consent
Blinding: neither mothers, nor the admission officers, were aware of which treatment was available on a particular day
Comparability of treatment groups: states groups were similar in age, nutritional status, complications, socioeconomic background, and late 
exclusions and deaths (although see comment below about discontinuation in day-care group)
Method of data analysis: NR for initial-follow-up. For long-term follow-up, data were subjected to range and consistency checks. Data analysed 
using SPSS/PC+ (version 4) and the Anthro software package (Centers for Disease Control and Prevention, Atlanta, GA, USA) used to obtain 
anthropometric indexes. ANOVA and chi-squared tests used to test for statistical significance. p < 0.05 accepted as significant. Children expected 
to receive 24 morbidity visits during 12 months of follow-up. Children with < 18 visits (75%) were excluded from the analysis. An appropriate 
adjustment was made for those with 18–23 visits to yield morbidity measures for 1 year. Children with ≥ 18 morbidity visits had also completed all 
12 of the expected anthropometric measurements
Sample size/power calculation: the aim of the study was to identify the most cost-effective method of treatment. Consequently sample size was 
estimated on the basis of mean (SD) costs of treatment for inpatients and day care. A minimum of 100 children per group was considered sufficient 
to detect a 15–20% reduction in cost for treatment in the at-home group (90% power, 5% significance level)
Attrition/dropout: reported with reasons for each group, however, there is a small discrepancy between one paper65 and the second paper.92 The 
discontinuation rate was significantly higher in the day-care group than in the other two groups (p < 0.01). Also reported with reasons for each 
group for the 12-month follow-up.94 Losses and intermittent follow-up were more common for children who had been inpatients leading to a lower 
completion rate compared with the other groups (p = 0.003). Data not shown in paper, but states when groups were combined there were no 
significant differences for a wide range of anthropometric variables between those who completed follow-up (n = 335), those excluded from analysis 
for incomplete data (n = 47), and those lost without trace (n = 33)
General comments
Generalisability: not generalisable to critically ill children who were excluded (because > 7 days inpatient care needed), and also not generalisable 
to children < 1 year in age who were also excluded because the mortality risk for domiciliary care was unknown. Likely that the children would 
meet the current WHO criteria for SAM. Contact during months 6–12 of follow-up was twice as frequent as the usual post-discharge service and all 
follow-up in the year after discharge took place at home (usual service contact at outpatients), this was likely to have resulted in greater contact with 
unit staff than would normally occur. The long-term results may therefore not be achievable when long-term follow-up is less frequent, and/or occurs 
only in outpatient clinics
Outcome measures: a primary clinical outcome was not defined because the focus was on costs. Clinical outcome measures that were reported 
seem appropriate
Intercentre variability: not applicable
Conflict of interest: no statement made. An author on one paper65 was supported by the UK Overseas Development Administration. Study received 
funding from Save the Children
Inpatients Day care Care at home
Setting and staffing   ■ 60-bed inpatient ward
  ■ Seven doctors
  ■ 12 nurses
  ■ Forty-children 
facility.
  ■ Seven doctors
  ■ One nurse and 
three auxiliaries
  ■ Mothers prepare 
meals with typical 
household foods 
and utensils
Team of eight specially 
trained home visitors
Broad-spectrum antibiotic on admission: i.m. injection for first 3 days  Oral delivery (10-day 
course)
Oral delivery (10-day 
course)
  ■ ampicillin 50 mg/kg/day for 10 days
  ■ penicillin for acute respiratory infection or 
ampicillin 200 mg/kg/day with gentamicin 5 mg/
pk/day if septicaemia suspected)
Oral delivery thereafter
Comments: provision of broad-spectrum antibiotics adjusted appropriately once results of laboratory investigations became known236 Appendix 11 
Per day week 1
Modified milk (75 kcal and 1.5 g protein/100 ml)
Anorexic patients fed milk by nasogastric tube 
(removed for patients going home at night)
80–100 ml/kg 2-hourly 80–100 ml/kg 2-hourly between 0800 and 
1700 hours
Parents advised to give two further milk feeds at home 
(note, care at home group children were in day care 
for week 1)
On Friday (no day care), parents advised to give at 
least four cups of milk
Rice-based salt-free meals Four Three between 0800 and 1700 hours
Parents advised to give one further meal at home
On Friday (no day care), parents advised to give at 
least four rice-based meals
Per day week 2 onwards
High-energy milk (100 kcal and 3 g protein/100 ml)
(omitted for children aged > 24 months)
Four feeds (120–150 ml/kg/day) Three feeds between 
0800 and 1700 hours
Mothers advised to give 
one feed at home
Mothers provided with a 
180 ml cup and asked to 
give three to four milk feeds
Rice-based salt-free meals (recommended for day- 
and home-care groups: rice pudding, rice with dhal, 
rice with pumpkin, dhal or potato, oil, and if affordable 
meat or fish)
Three feeds (four if 
> 24 months)
Three feeds (four if 
> 24 months) between 
0800 and 1700 hours
Mothers advised to give 
two meals at home
Mothers provided with a 
bowl (capacity 340 g food 
when full) and asked to feed 
three rice-based meals (four 
if > 24 months)
Snacks Two feeds Two feeds between 
0800 and 1700 hours
Asked to provide two feeds
Comments: all mothers/caretakers received 20 minutes of structured instruction each day of their stay on topics relevant to infant feeding, disease 
prevention and family planning. They also received 20 minutes of practical guidance everyday except Friday. The day-care group had a longer 
recovery time and therefore received slightly more days of instruction. The at-home group attended the sessions, but only during the initial week 
of inpatient care. Mothers/caregivers of the day-care and at-home group received additional instruction on what to feed their children at home, 
how much (quantities to be served in the bowl and cup provided), and how often (meal frequency). This included a practical exercise in which the 
caregiver prepared a family meal, keeping in mind the special needs of the malnourished child. Additional instruction was required because after the 
first week children in the at-home group were entirely dependent on home-prepared meals for their rehabilitation, and the day-care group were also 
expected to receive extra meals at home and all meals on Fridays. Home visitors continued to provide guidance to the at-home group during visits 
that lasted about 1 hour. Visitors were trained to examine the child for oedema, dehydration, fever, rapid breathing, and throat and ear infection, and 
to refer child to the unit for consultation if necessary
The diets provided described above provided the energy and protein indicated below, with additional dietary supplements also being provided as 
listed. A cautious approach to feeding was followed in the first week, the emphasis on small but frequent feeds so that the reduced capacity of the 
malnourished children to absorb and utilise nutrients was not exceeded. Thereafter, the dietary regimen changed to provide high intakes of energy 
and nutrients to enable rapid ‘catch-up’ growth 
Week 1 – all groups
Week 2 onwards – 
inpatients and day-
care group
Week 2 onwards – at-
home group
Energy, kcal/kg/day 100–200 150–200 150–200
Protein, kcal/kg/day 2–3 3–4 3–4
Potassium chloride, mmol/kg/day 5–6 5–6e
Magnesium sulphate, mmol/kg/day 0.5–1.0 0.5–1.0e
Riboflavin, mg/day 5 5
Folic acid, mg/day 5 5
Ferrous sulphate, mg/kg/day 4 4
Multivitamin drops Yes Yes Yes
Vitamin A IU (day 1 onlyf) 200,000
ANOVA, analysis of variance; BCG, Bacillus Calmette–Guerin; IU, international units; NR, not reported.
a  At-home group were older at the start of 12-month follow-up because they were older at admission and because their recovery time 
was longer.
b  Mean weight gain differed between the groups (ANOVA p < 0.001).
c  n calculated by reviewer based on the number of participants who entered the 12-month follow-up (inpatients, n = 173; day care, n = 134; 
home, n = 130).
d  Significantly different from other groups p < 0.03.
e  Week 2 only.
f  Unless child had xerophthalmia, in which case WHO guidelines followed.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the 
study likely to be representative of the target 
population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals 
participated?
80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if 
categorise as ‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No note: mentioned random determination of 
sequence, but title of paper is controlled trial 
If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of 
randomisation described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between 
groups prior to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant 
confounders that were controlled [either in the 
design (e.g. by stratification or matching) or in 
the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the 
intervention or exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the 
research question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
238 Appendix 11 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell
 12-month follow-up  initial study
2.   Were data collection tools shown to be reliable? Yes No  Cannot tell
 12-month follow-up  initial study
Summary of data collection
(Methodological strength of study)
Strong Moderate Weak
 12-month follow-up  initial study
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in 
terms of numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants 
completing the study (If the percentage differs 
by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell
 initial study  12-month 
follow-up
Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak
 initial study  12-month 
follow-up
G. Intervention integrity
1.  What percentage of participants received the 
allocated intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention 
measured?
Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) 
that may influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/office Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/office Provider Patient

3.  Are the statistical methods appropriate for the 
study design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention 
allocation status (i.e. ITT) rather than actual 
intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based 
on sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Appendix 12  
Question 8: data extraction tables
Doherty et al. 199868
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Doherty et al.68
Year: 1998
Linked paper: Doherty et 
al69 2002
Country: Bangladesh
Study design: double-
blind RCT
Setting: secondary care
Number of centres: one
Funding: Nestlé UK and 
the Department of Child 
Life and Health, University 
of Edinburgh. Ciba-Geigy, 
Bangladesh, provided zinc 
suspensions
Intervention one: 1.5 mg zinc/kg 
body weight for 15 days followed 
by placebo for 15 days
Intervention two: 6.0 mg zinc/kg 
body weight for 15 days followed 
by placebo for 15 days
Intervention three: 6.0 mg zinc/kg 
body weight for 30 days
Elemental zinc was provided as 
zinc sulphate in all groups. Mothers 
were instructed how to administer 
the supplements using labelled 
syringes, which they continued to 
use at home up to day 30
Other interventions used: on 
recruitment, all were treated 
identically with broad-spectrum 
antibiotics, diarrhoea and skin 
sepsis was treated if present. All 
received a liquid diet with gradually 
increasing energy and protein 
according to malnutrition type, 
vitamin A and a daily multivitamin 
supplement. Full details in separate 
table. Days 1–15 involved intensive 
inpatient nutritional rehabilitation 
and health education (no details 
of the latter provided). Subjects 
discharged on day 15 if clinically fit 
and followed as outpatients
Definition of SAM: not explicitly stated, 
but presumed the same as the inclusion 
criteria, i.e. W/A < 60% of NCHS 
median for age, had nutritional oedema, 
or both
Number of participants: N = 141 
[intervention one (1.5 mg zinc/placebo) 
n = 49; intervention two (6 mg zinc/
placebo) n = 49; intervention three 
(6 mg zinc/6 mg zinc) n = 43]
Sample attrition/dropout: 106 (75%) 
completed; n = 16 (11%) dropouts (six 
because caregiver discharged them, 10 
lost to follow-up); 19 (13.5%) deaths.
Dropouts by group: 1.5 mg zinc/placebo 
n = 4; 6.0 mg zinc/placebo: n = 3; 
6.0 mg zinc/6.0 mg zinc n = 9
Sample crossovers: none
Inclusion criteria: aged 6–36 months 
and were W/A < 60% of NCHS median 
for age, had nutritional oedema, or 
both. Clinically stabilised within 1 week 
of admission and able to tolerate oral 
nutritional rehabilitation. Caregivers 
agreed that their child would remain in 
hospital for a further 15 days, and be 
followed up for a total of 90 days
Exclusion criteria: strong suspicion 
of underlying TB (contact history and 
history of prolonged temperature 
elevation or cough)
General characteristics of participants: 
severely malnourished children living 
within 2-hour travelling distance of 
hospital. 57% were aged < 1 year and 
average WHZ was –2.66
Primary outcomes: not explicitly 
stated
Outcomes included: mortality (during 
inpatient and outpatient phases) and 
changes in anthropometric variables 
(z-scores, knemometry, skinfold 
thickness, MUAC)
The linked paper69 reports on 
insulin-like growth factor-1, its 
binding proteins, bone formation 
and collagen turnover. No further 
information relating to these 
outcomes has been data extracted
Method of assessing outcomes: 
weight and length were measured 
by a team of four nurses and four 
nutritionists who had received an 
8-week training course
Two observers undertook all of the 
knemometry (distance between 
knee and heel), skinfold and MUAC 
measurements after an 8-week 
training period. Five knemometric 
readings were taken at each 
assessment and the mean was 
accepted unless the SD was > 1 mm
All staff involved in anthropometric 
data gathering were subject to 
regular, unscheduled, formal 
assessments of measurement 
technique
Weight – electronic scale, 
graduations to 20 g
Length – rollameter with 
graduations to 1 mm. All 
measurements taken with child 
supine
Skin-fold thickness – calipers 
graduated to 0.2 mm
MUAC – standard non-stretch tape 
measure with graduations to 1 mm
All anthropometric variables were 
based on NCHS medians240 Appendix 12 
During in patient phase: body 
weight recorded daily, knemometry 
on alternate days, all other 
anthropometric variables on days 1, 
8 and 15
During follow-up: all nutritional 
measurements recorded together in 
the morning
Adverse symptoms: none reported
Length of follow-up: during inpatient 
phase (15 days), and subsequently 
as outpatients on days 21, 30, 45, 
60, 75 and 90
Recruitment dates: November 1995 
to November 1996
Characteristics of participants:
Characteristic
Intervention one (1.5 mg zinc/
placebo) (n = 49)
Intervention two (6 mg zinc/placebo) 
(n = 49)
Intervention three  
(6 mg zinc/6 mg zinc) (n = 43)
Age, months 15.5 ± 8.7 15.0 ± 9.0 16.3 ± 8.6
WAZ –4.47 ± 0.91 –4.56 ± 0.98 –4.66 ± 0.86
WHZ –2.56 ± 0.97 –2.73 ± 0.90 –2.71 ± 0.93
HAZ –3.89 ± 1.3 –3.79 ± 1.4 –3.98 ± 1.45
Malnutrition, n
 Marasmus 29 27 26
  Marasmic kwashiorkor 15 14 11
 Kwashiorkor 5 7 6
Time from admission to 
recruitment, days
2.5 ± 1.5 3.5 ± 2.2 2.7 ± 1.8
Lower leg length, cm 17.08 ± 2.30 16.91 ± 2.23 17.31 ± 2.24
Comments: data presented are mean ± SD unless otherwise stated
57% of participants were < 1 year of age. Participants were both severely wasted and severely stunted
Results
Outcomes Intervention one (1.5 mg zinc/
placebo) (n = 49)
Intervention two (6 mg zinc/placebo) 
(n = 49)
Intervention three (6 mg 
zinc/6 mg zinc) (n = 43)
Inpatient death, n 2 5 6
Outpatient death, n 0 3 3
Self-discharge or loss to 
follow-up, n
4 3 9
Comments: there were more deaths in the groups receiving 6.0 mg zinc/kg as inpatients. This trend was identified at the interim analysis of the 
first 100 subjects and enrolment was suspended after 141 recruits. When supplementation regimens two and three were combined, the risk of 
death was significant (p = 0.03) with exposure to 6.0 mg zinc/kg as compared with 1.5 mg zinc/kg initially (Yates-corrected chi-squared value of 
risk of death at RR 4.52, 95% CI 1.09 to 18.8). Clinician’s impression was that cause of death was sepsis in most cases, and 13 of the 18 deaths 
occurred when children were inpatients. The paper presents an analysis looking for possible predictors/prognostic factors for death, but none of the 
factors considered (age, degree of wasting and stunting, severity of initial illness, type of malnutrition) were found to predict death in association with 
exposure to the higher initial dose of zinc (data not extracted here)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Change in 
anthropometric 
outcomes over 90 days
Intervention one  
(1.5 mg zinc/placebo)  
(n = 43)
Intervention two   
(6 mg zinc/
placebo) (n = 38)
Intervention three  
(6 mg zinc/6 mg zinc) 
(n = 25) 95% CI for mean difference
WAZ 1.35 ± 0.69 1.51 ± 0.65 1.45 ± 0.66 Intervention two–intervention one: 
(–0.27 to 0.52)
Intervention three–intervention two: 
(–0.47 to 0.38)
WHZ 1.54 ± 0.93 1.67 ± 0.78 1.62 ± 0.86 Intervention two–intervention one: 
(–0.14 to 0.46)
Intervention three–intervention two: 
(–0.39 to 0.27)
HAZ 0.44 ± 0.32 0.48 ± 0.38 0.49 ± 0.27 Intervention two–intervention one: 
(–0.11 to 0.2)
Intervention three–intervention two: 
(–0.17 to 0.18)
Lower leg length change 
(knemometry), cm
1.04 ± 0.48 1.03 ± 0.49 1.03 ± 0.33 Intervention two–intervention one: 
(–0.23 to 0.2)
Intervention three–intervention two: 
(–0.22 to 0.22)
Skinfold thickness, mm 3.06 ± 1.94 3.63 ± 1.87 3.61 ± 1.86 Intervention two–intervention one: 
(–0.29 to 1.43)
Intervention three–intervention two: 
(–0.97 to 0.94)
MUAC, cm 1.66 ± 1.40 1.98 ± 1.17 1.9 ± 1.38 Intervention two–intervention one: 
(–0.26 to 0.89)
Intervention three–intervention two: 
(–0.72 to 0.57)
Comments: all values mean ± SD. No significant differences in change of any anthropometric variable between regimens
Good catch-up growth was achieved over 90 days with the average intragroup WHZ improved from 1.54 to 1.67 units, and the HAZ improved from 
0.44 to 0.49 units. Lower leg length grew on average 1.03–1.04 cm in 90 days (data presented in figures, but not extracted)
Safety: in discussion the authors speculate that the detrimental effect of zinc seen in their study may have been because most children had 
intercurrent infections when micronutrient supplementation was started early in the treatment regimen. Other trials of zinc supplementation have 
administered zinc at a later stage of rehabilitation, a point when ongoing sepsis is much less likely, although this is unlikely to be representative of 
practice in most nutritional rehabilitation units
HIV: NR
Barriers to implementation
A general difficulty in this setting is the pressure on caregivers to leave hospital as quickly as possible. This is presumably why in this study, 
caregivers were required to consent to their child remaining in hospital for 15 days. Nevertheless, some caregivers still discharged their child early 
before completion of treatment242 Appendix 12 
Methodological comments
Allocation to treatment groups: an independent observer performed stratified randomisation into three zinc supplementation regimens. Variable 
length blocks within six strata generated by age (< 13 months and 13–36 months) and type of malnutrition (as defined by Wellcome classification: 
marasmus; marasmic kwashiorkor and kwashiorkor) were used
Blinding: double-blind study. The zinc sulphate and placebo suspensions were indistinguishable and both were formulated and provided by Ciba-
Geigy, Bangladesh. Bottles were identical and labelled sequentially from one to 300. On recruitment to the study, two bottle numbers were provided 
by the independent observer and the corresponding bottles were then selected for that patient [labelled as Bottle A for days 1–15 (either 1.5 or 
6.0 mg zinc/kg), and Bottle B for days 16–30 (either 6.0 mg zinc/kg or placebo)]
Comparability of treatment groups: states that baseline characteristics were similar between the groups (no p-values reported). Also, numbers of 
children with kwashiorkor (10–15%), marasmic kwashiorkor (25–30%) and marasmus (55–60%) were equally distributed between the groups
Method of data analysis: not ITT analysis. Epi-Info (version 6) was used for data recording and generation of z-scores. All anthropometric data were 
entered twice with a validation performed between the two entry records and against the hard copy of the data at the end of the data-gathering 
period. Differences between groups were compared by using Student’s t-tests or one-way analysis of variance for quantitative variables with 
approximately normal distributions. Mann–Whitney or Kruskal–Wallis tests were used for ordinal variables, long-rank test for length of breastfeeding, 
and chi-squared tests for categorised variables, with Yates’ correction used for 2 × 2 tables. For outcomes after discharge, the three treatment 
groups were treated as ordinal, and trends were tested by using Pearson or Spearman correlations as appropriate. Analysis of covariance was used 
to test differences in quantitative outcomes between groups after adjustment for other factors. An interim analysis of growth and mortality was 
planned after the first 100 subjects had been studied. When this took place, a trend for more inpatient deaths was observed in the groups receiving 
6 mg zinc/kg and recruitment was suspended
Sample size/power calculation: sample size was calculated with a requirement for 90% power at the 5% level for 11 anthropometric and 
biochemical outcome variables, and a sample size of 60 was chosen, which was at the upper end of the calculated sample sizes. Although not 
explicitly stated, it appears that 60 should have been the sample size for each group; however, recruitment was suspended when 141 children had 
been enrolled, therefore the overall sample size of 180 was not reached. The authors of the paper do not comment on this
Attrition/dropout: reported for each group with reasons provided for the whole sample (not by group). A follow-up worker visited each dwelling at 
least twice after a subject defaulted from follow-up. All defaulters could not be found
General comments
Generalisability: no children < 6 months or > 36 months were included. It is not clear what proportion of the children would have met the current 
WHO criteria for SAM based on W/H (average initial z-score –2.66), and baseline data on MUAC were not presented. However, the majority of the 
sample were classified as having marasmus, which may suggest most participants would meet current criteria for SAM
Outcome measures: appropriate outcome measures were reported, together with information about data collection and methods for ensuring data 
quality
Intercentre variability: not applicable
Conflict of interest: NR
Standardised clinical management protocol: for all participants 
For all if not already receiving them Broad-spectrum antibiotics, usually ampicillin and gentamicin
For those with a history of invasive diarrhoea Nalidixic acid or mecillinam
For those with skin sepsis Cloxacillin
Liquid dietary regimen according to type of malnutrition and whether diarrhoea present or not, and number of days since recruitment
Per 100ml No diarrhoea Diarrhoea present
 Type Dried skim-milk based Rice based
 Energy 264 kJ 259 kJ
 Protein 2.2 g 1.1 g
 Zinc 0.3 mg 0.3 mg
Volume delivered every 2 hours (by 
nasogastric tube initially until appetite 
improved and child able to take full volume 
offered by mouth)
Oedematous malnutrition: 80 ml/kg/day
Non-oedematous malnutrition 120 ml/kg/day
With incremental steps up to 200 ml/kg/day during the inpatient stay of each child
Breastfeeding was encouraged and solid food was offered ad libitum (no details of solid food provided)
For those aged > 1year Vitamin A at admission 200,000 IU retinyl palmitate (60,000 µg retinol equivalent)
For those aged < 1 year Vitamin A at admission 100,000 IU retinyl palmitate (30,000 µg retinol equivalent)
For all those recruited Daily multivitamin supplement: 3000 IU vitamin A; 30 mg vitamin C; 600 IU vitamin D; 0.96 mg 
thiamine; 0.6 mg riboflavin; 0.6 mg pyridoxine; 0.6 mg nicotinamide
If blood film taken on day 30 of the trial 
indicated iron deficiency anaemia
Iron supplementation (no details of dose provided)
HAZ, weight-for-age z-score; IU, international units; NR, not reported; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
244 Appendix 12 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

HAZ, weight-for-age z-score; N/A, not applicable; ; WAZ, weight-for-age z-score; WHZ, weight-for-height z-score.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Gatheru et al. 198870
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Gatheru et al.70
Year: 1988
Country: Kenya
Study design: CCT
Setting: inpatient
Number of centres: one
Funding: partly 
supported by the Kenya 
Medical Research 
Institute and the Ministry 
of Health
Intervention: zinc supplement 
of 5 mg elemental zinc/kg 
body weight/day given in three 
divided doses
Control: no zinc
The study also included a 
third group of children without 
kwashiorkor who are NR on 
here
Other interventions used: both 
groups managed with high 
protein diet, motherly care 
and warmth. Breastfeeding 
continued if it was occurring. 
Antibiotics given if infection 
suspected or confirmed
Definition of SAM: kwashiorkor 
as defined by Wellcome 
classification
Number of participants: N = 82 
(zinc group, n = 42; control 
group, n = 40)
Sample attrition/dropout: 24 
participants did not complete the 
study, 11 in the zinc group and 
13 in the control group
Sample crossovers: none
Inclusion criteria: diagnosis 
of kwashiorkor (Wellcome 
classification), aged 1–3 years
Exclusion criteria: transfusions 
required, serious disease-like 
TB or measles present, sickle 
cell disease, absconded before 
clinical cure, and if death 
occurred before completion of 
study
General characteristics of 
participants: patients aged 
1–3 years with kwashiorkor
Primary outcomes: not specifically stated
Outcomes included:
  ■ weight
  ■ serum zinc
  ■ diarrhoea
  ■ anorexia
  ■ oedema
  ■ skin ulcerations
Method of assessing outcomes: weights 
recorded using the Toledo machine model 1361 
Sentinel (Toledo, OH, USA) on admission and 
daily thereafter until discharge
Serum zinc determined for admission (or latest 
on second day) and again on 10th day of 
treatment from a clotted blood sample by the 
atomic absorption spectroscopy method. One 
senior technician made all measurements
Signs and symptoms were obtained at 
admission and daily by the author. Diarrhoea 
was noted if a patient passed more than 
three loose stools in 24 hours. Anorexia was 
noted if the child showed no interest or will to 
eat or drink the feeds given. Improvement in 
anorexia was marked by willingness to feed. 
Skin ulcerations included raw, wet, oozy lesions 
regardless of the presence of scalding and/or 
skin dyspigmentation. Healing of lesions was 
noted as drying up and return of normal colour
Discharge criteria: oedema had subsided, 
diarrhoea had stopped, weight gain on three 
consecutive readings
Adverse symptoms: NR
Length of follow-up: 10 days
Recruitment dates: presumably the same as the 
period of study which was March to September 
1985
Characteristics of participants
Characteristic Zinc (n = 42) Control (n = 40) p-value
Weight, mean kg 8.2 7.8 NR
Weight 6–10 kg, n 37 38 NR
Weight > 10 kg, n 5 2 NR
Serum zinc, mean (SD) 
μmol/l
6.4 (1.36) 6.4 (1.36) NR
Sex, M : F, n 20 : 22 23 : 17 NR
Age 12–14 months, n 35 35 NR
Age 25–36 months, n 7 5 NR
Comments: the majority (70/82, 85.4%) of the participants were < 2 years of age
The mean (range) serum zinc of the whole group of kwashiorkor patients was 6.4 μmol/l (4.0–12.9 μmol/l), this was statistically significantly lower 
(p < 0.05) to serum zinc values obtained from a group of children without kwashiorkor246 Appendix 12 
Results
Outcomes Zinc  Control  p-value
Total weight gain,a mean 
(SD) g
531 (277) 338b (235) < 0.05
Daily weight gain, 
mean g
67 47.3 NR
Serum zincc after 
10 days of treatment, 
mean change from 
baseline μmol/l
0.62 –0.06 < 0.05
Diarrhoead duration, 
mean days (SD)
3.62 (2.78) 10.8 (3.4) < 0.001
Anorexiad duration, 
mean days (SD)
6 (3.16) 10.3 (5.01) < 0.01
Oedemae duration, 
range in days
2–18 2–18 NR
Oedemae lost by end of 
day 7, %
77 55 NR
Days taken to lose 
oedemae, mean (SD)
6.3 (4.6) 8.1 (4.4) < 0.05
Days taken for skin 
lesionsd to heal, mean 
(SD)
7.9 (3.1) 11.1 (2.1) < 0.03
Duration of hospital stay, 
mean days
15.9 16.9 > 0.05, NS
Safety: NR
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: children assigned to two groups in alternating order at the time of admission
Blinding: not blinded, although not explicitly stated. Paper refers to a need for a study using a double-blind design
Comparability of treatment groups: a limited amount of information was provided about the treatment groups at baseline and this was not 
commented on by the study authors except to note that both groups contained about equal numbers of males and females
Method of data analysis: to test the significance of differences observed in the results the conditional test for the mean using chi-squared 
approximation was used. A value of p < 0.05 was accepted as significant. The analysis was not by ITT
Sample size/power calculation: none reported
Attrition/dropout: numbers reported for each group, but no reasons given
General comments
Generalisability: results likely to be applicable to other patients of this age (1–3 years) with kwashiorkor. The authors do not comment on whether 
the results could be extrapolated to different ages or patients with different forms of malnutrition (e.g. marasmus)
Outcome measures: appear appropriate. Mortality was not noted as an outcome, but as the paper states that those dying before completion of the 
study were excluded, it is presumed that some participants may have died
Intercentre variability: not applicable
Conflict of interest: not statement made
NR, not reported; NS, not statistically significant.
a  Weight outcomes reported for n = 31 of the zinc group and n = 27 of the control group.
b  Mean weight gain was reported differently in text (338 g) and table (383 g), it is not clear which value is the correct one.
c  Numbers of participants contributing data to these outcomes is NR.
d  Numbers of participants contributing data to these outcomes varied, and it is not known how many participants had diarrhoea, anorexia or 
skin lesions at baseline (zinc group: n = 17 for diarrhoea, n = 26 for anorexia and n = 10 for skin lesion outcomes; Control group: n = 22 for 
diarrhoea, n = 22 for anorexia and n = 9 for skin lesion outcomes).
e  Oedema outcomes reported for n = 31 of the zinc group and n = 26 of the control group.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.   What was the study design?
(Please tick appropriate and specify design if categorise 
as ‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.   Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.   If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention 
or exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
248 Appendix 12 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that 
may influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention 
received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Golden and Golden 199271
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Golden and 
Golden71
Year: 1992
Country: not clearly 
stated but appears to be 
Jamaica, West Indies
Study design: CCT
Setting: inpatient
Number of centres: one
Funding: not explicitly 
stated but appears to be 
Medical Research Council 
and the Wellcome Trust
Moderate Zinc: basic diet 
supplemented with 76 μmol zinc/kg 
feed (equivalent to 5 mg zinc)
High Zinc: basic diet supplemented 
with 153 μmol zinc/kg feed (equivalent 
to 10 mg zinc)
Low Zinc: received basic diet 
throughout recovery (equivalent to 
3.5 mg zinc)
Zinc supplement a solution of zinc 
acetate containing 15.3 μmol (1 mg) 
zinc/ml
Other interventions used: prior to 
selection children had been treated 
with antibiotics and antihelminthics 
as appropriate. They had been fed 
according to a standard protocol 
(details at end of table)
After selection all received a high-
energy soy-based formula (details at 
end of table)
Definition of SAM: Wellcome 
criteria
Number of participants: N = 11 
(moderate zinc, n = 4; high zinc, 
n = 3; low zinc, n = 4)
Sample attrition/dropout: NR
Sample crossovers: NR
Inclusion criteria: within 2 weeks 
of admission, free of oedema and 
signs of systemic infection, ready 
to commence high-energy feeds
Exclusion criteria: NR
General characteristics of 
participants: all boys
Primary outcomes: no primary 
outcome explicitly stated
Outcomes included:
  ■ dietary intake
  ■ weight gain
  ■ outcomes from balance studies 
reported, but not data extracted
Method of assessing outcomes: daily 
dietary intakes calculated from the 
sum of the weight of formula taken at 
the eight daily feeds
Body weights measured to nearest 
gram at 0800 hours each day. 
Minimum weight was taken as 0% 
recovery, 100% recovery was defined 
as the weight of a reference child 
(NCHS) of same length as the patient 
at the time of minimum weight 
measurement
Metabolic balance studies were 
performed, but details of these not 
data extracted
Adverse symptoms: not explicitly 
reported (although diarrhoea occurred 
during 9 of 32 balance experiments)
Length of follow-up: not stated, 
but outcomes reported here are for 
6-week follow-up
Recruitment dates: NR
Characteristics of participants
Characteristic Low zinc (n = 4) Moderate zinc (n = 4) High zinc (n = 3) p-value
Age, months 18 ± 4 15 ± 2 13 ± 4 NR
Plasma zinc, μmol 9.6 ± 1.9 11.1 ± 1.4 9.9 ± 1.3 NR
Weight, kg 4.9 ± 0.3 5.1 ± 0.4 4.9 ± 0.8 NR
Length, cm 67 ± 1 70 ± 2 68 ± 4 NR
L/A % 82 ± 3 88 ± 3 90 ± 1 NR
W/L % 63 ± 2 60 ± 4 61 ± 2 NR
Comments: baseline data reported as mean ± SEM
Overall age range 6–31 months (median 15 months). Before selection to the trial, nine children had marasmic kwashiorkor and two had marasmus
L/A % and W/L % are per cent of NCHS reference values250 Appendix 12 
Results
Outcomes during first 6 weeks of 
recovery
Low zinc (n = 4) Moderate zinc 
(n = 4)
High zinc (n = 3) p-value
Energy intake, kJ/kg/day 705 ± 18 730 ± 26 701 ± 35 NR but states not significantly 
different for either measure Nitrogen intake mmol/kg/day 41 ± 3 42 ± 4 42 ± 3
Rate of weight gain, g/kg/day 10.10 ± 0.22 11.60 ± 0.95 11.67 ± 1.41 No significant difference, 
p-value NR
Energy cost of tissue deposition, kJ/g 29.3 ± 2.6 24.8 ± 1.7 25.0 ± 0.6 NR
Comments: values are mean ± SEM
Although zinc-supplemented children gained weight faster, difference with low-zinc group was NS. Energy cost of tissue deposition (ECTD) values 
higher in the low-zinc group, no p-value reported and states will be published separately
Outcomes from metabolic balance studies not data extracted
Safety: NR 
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: selected within 2 weeks of admission. Consecutive children assigned first to moderate-zinc group, then to low-zinc 
group, then to high-zinc group
Blinding: NR
Comparability of treatment groups: states that at selection there were no significant anthropometric differences among the groups, and plasma zinc 
was also not different among the zinc groups
Method of data analysis: data were analysed using the statistical routines in Systat (Systat Software Inc., Evanston, IL, USA). ANOVA with post-
analysis contrasts and repeated measures analysis of variance were used to assess differences in results. Statistical significance was assumed at 
the 5% level. The results were presented as means ± SEM, and in some cases as individual values
Sample size/power calculation: none reported
Attrition/dropout: NR, appears to be none
General comments
Generalisability: participants were all boys (presumably to facilitate separate collection of urine and faeces during metabolic balance experiments); 
however, there does not seem to be any reason why the results would not hold for girls also
Outcome measures: appear appropriate, but the method of obtaining weights and lengths was NR
Intercentre variability: not applicable
Conflict of interest: no statement made. Funding appears to come from the Medical Research Council and the Wellcome Trust
Initial feeding protocol (before selection into trial) Cow’s milk diet:
  ■ 0.4 MJ/child/day
  ■ 0.6 g protein/kg/child/day
Supplemented with:
  ■ potassium 4 mmol/kg/child/day
  ■ magnesium 1 mmol/kg/child/day
  ■ vitamins Tropivite 1 ml/day (contains A, B1, B2, C and nicotinamide)
  ■ folic acid 5 mg/day
None received oral or topical zinc prior to selection
High-energy feeding protocol (after entry into trial) Sobee, Mead Johnson diet (Mead Johnson and Company, Evansville, IN, USA):
  ■ 133 g/kg, supplemented with arachis oil 59 g/kg, and sucrose 50 g/kg
Contents per kg feed:
  ■ 5.6 MJ
  ■ 29 g protein
  ■ 1.33 mmol phytic acid
  ■ 54 μmol zinc
Fed by cup 3-hourly, to appetite (notes that this usually increased rapidly)
Potassium, magnesium and vitamin supplements continued as previous dosage
Ferrous sulphate commenced 0.4 mmol/child/day
ANOVA, analysis of variance; ECTD, energy cost of tissue deposition; L/A, length-for-age; NR, not reported; NS, not statistically significant; SEM, 
standard error of the mean.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.   If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
252 Appendix 12 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.   Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Hemalatha et al. 199372
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Hemalatha et 
al.72
Year: 1993
Country: India
Study design: CCT (after 
quality assessment)
Setting: inpatient
Number of centres: one
Funding: NR
Intervention: zinc as zinc sulphate 
(zincSO4) in a capsule (40 mg 
elemental zinc per capsule). Single 
dose each day. Estimated to be 
about 6 mg/kg body weight/day
Control: placebo capsule, one each 
day
zinc and placebo administered from 
admission for 21 days
Other interventions used: all 
children received a cereal-based 
diet and dairy milk provided ad 
libitum. Details in separate table 
at end
IM injection of vitamin A 100,000 IU
Definition of SAM: [v]Gómez 
classification with W/A < 60% of that 
expected (NCHS standard). Those 
with loss of subcutaneous fat and 
with muscle wasting (marasus), those 
with oedema with wasting (marasmic 
kwashiorkor)
Number of participants: N = 33 (zinc 
n = 16, placebo n = 17)
Sample attrition/dropout: NR (but 
there is missing data)
Sample crossovers: none
Inclusion criteria: children hospitalised 
for rehabilitation from severe PEM
Exclusion criteria: clinical evidence of 
any infection
General characteristics of 
participants: children aged 1–5 years 
in hospital with SAM
Primary outcomes: none specifically 
reported
Outcomes included:
  ■ time taken for oedema to resolve
  ■ weight change
  ■ duration of morbidity because of 
infections
  ■ biochemical measures 
(haemoglobin, serum albumin, 
plasma copper, plasma and 
leucocyte zinc)
Method of assessing outcomes:
  ■ food intake assessed by 24-hour 
dietary records
  ■ biochemical measures obtained 
from blood sample collected 
after overnight fast. Full details of 
methods used not extracted. Repeat 
measures at 4 weeks only possible 
in 25 children (remainder unwilling 
to provide sample)
  ■ zinc content of three random 1-day 
diet samples were analysed
Adverse symptoms: NR
Length of follow-up: 1 month
Recruitment dates: August 1990 to 
August 1991
Characteristics of participants
Characteristic Zinc (n = 16) Placebo (n = 17) p-value
Age (years)
 1–2 6 NR
 2–5 27
Marasmic kwashiorkor, 
n and mean weight (SD)
n = 7, 7.5 kg (0.56) n = 7, 7.3 kg (0.49) NR
Marasmic. n and mean 
weight (SD)
n = 9, 6.7 kg (0.56) n = 10, 7.2 kg (0.38) NR
Leucocyte zinc μg/1010 
cells, n and mean 
weight (SD)
n = 12, 46.9 (5.490) n = 10, 45.7 (4.409) NR
Plasma zinc μg/dl, n 
and mean weight (SD)
n = 13, 80.4 (9.972) n = 12, 83.6 (10.363) NR, but stated they were comparable 
at baseline
Plasma copper μg/dl, n 
and mean weight (SD)
n = 13, 112.1 (9.487) n = 12, 99.1 (15.346) NR, but stated they were comparable 
at baseline
Comments: initial zinc and copper status of the zinc group and placebo group described as comparable, and statistically significantly lower 
(p < 0.001) than levels in healthy children (not data extracted). Few details about baseline characteristics presented254 Appendix 12 
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Primary outcomes Zinc (n = 16) Placebo (n = 17) p-value
Leucocyte zinc μg/1010 
cells, n and mean (SE)
n = 12,a 107.2 (13.224) n = 10, 70.9 (8.414) NR
Leucocyte zinc, change 
from baselineb μg/1010 
cells
n = 12a
60.3
p < 0.001
n = 10
25.2
p < 0.025
Plasma zinc, μg/dl, 
mean (SE)
n = 13, 107.5 (11.822) n = 12, 68.2 (7.031) NR
Plasma zinc, change 
from baseline,b μg/dl
n = 13
27.1
p < 0.01
n = 12
–15.4
p = NS
Plasma copper μg/dl, n 
and mean (SE)
n = 13
145.3 (8.621)
n = 12
144.8 (13.258)
NR
Plasma copper, change 
from baseline,b μg/dl
n = 13
33.2
p < 0.01
n = 12
45.7
p = 0.025
Days for oedema to 
disappear, mean (SE)
9.0 (2.035) 15.7 (2.7) NS
Duration of morbidity, 
days, mean (SE)
6.3 (0.959) 7.7 (1.040) c
Weight gain g/kg body 
weight/day, n and mean 
weight (SE) in:
  Week one n = 16, 22.2 (8.365) n = 16, 31.1 (9.629) NR
  Week two n = 15, 25.1 (5.892) n = 17, 23.7 (7.494) NR
  Week three n = 14, 23.1 (4.945) n = 16, 22.3 (6.155) NR
  Week four n = 12, 22.6 (5.100) n = 15, 24.5 (5.035) NS
Comments: data on haemoglobin and albumin levels are presented (again no between-group comparison), but have not been data extracted. Data 
on average energy intake in the two groups is provided separately for each of weeks 1 to 4 but these have not been data extracted
Overall reports that zinc supplementation did not have any additional benefit on the clinical or biochemical responses measured
Safety: NR other than a statement that the zinc supplements as given in the study were not found to adversely affect plasma copper levels
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: no details provided. Only states that zinc capsule or placebo was randomly administered
Blinding: capsules coded in a laboratory by a person not connected with the study. After analysing clinical findings and completing the biochemical 
estimations, data were decoded and results analysed
Comparability of treatment groups: initial zinc and copper status described as comparable in the two groups, but statistically significantly lower 
(p < 0.001) than healthy children (based on data from 34 health children with normal nutritional status tested as part of the study). Few baseline 
characteristics presented
Method of data analysis: states that as the results were similar in marasmic and marasmic kwashiorkor children, the findings were pooled for each 
group. Similarly, results for boys and girls were combined because no significant sex-related differences were observed. t-tests used to compare 
between groups for outcomes of body weight gain and energy intake, paired t-tests used to compare before and after outcomes within groups for 
some outcomes. No other information provided
Sample size/power calculation: NR
Attrition/dropout: NR. However, it is clear from the information provided about numbers of participants contributing data to the different outcomes 
that there is missing data. For data derived from blood samples (leucocyte zinc, plasma zinc, plasma copper), data is missing because only 25 
(of the 33) participants allowed a second blood sample to be taken at 4 weeks. For other outcomes, e.g. duration of morbidity, weight gain, no 
explanation for missing data is provided© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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General comments
Generalisability: results likely to be generalisable to children > 1 year in age with PEM, providing they do not have infection
Outcome measures: appear appropriate but, in general, between group comparisons have not been reported
Intercentre variability: not applicable
Conflict of interest: none reported
Rehabilitation diet
Energy/day 700 kJ (8–10% derived from protein)
Protein/kg body weight/day 3–4 g
Multivitamin One tablet
Ferrous sulphate 20 mg elemental iron in one capsule
Dietary analysis showed mean dietary zinc values of 7.3 ± 0.49 mg/1 day’s diet. Although not explicitly stated it is assumed that this was the dietary 
content received by all participants, with those in the zinc group receiving additional zinc via the supplement
IU, international units; NR, not reported; NS, not statistically significant.
a  It is not explicitly stated, but has been assumed by the reviewer that numbers of participants contributing outcome data to the outcomes of 
leucocyte zinc, plasma zinc and plasma copper are the same as those reported for the baseline values – baseline and post-treatment values 
only available for the 25 children who allowed a second blood sample to be taken after treatment at 4 weeks.
b  Change from baseline values calculated by reviewer. The p-values reported are for the within-group comparison between baseline and follow-
up. No comparisons between the groups are reported for leucocyte zinc, plasma zinc and plasma copper.
c  States groups were comparable, but no p-value reported.256 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
257   Health Technology Assessment 2012; Vol. 16: No. 19 DOI: 10.3310/hta16190
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell
 – zinc  – weight
2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak
 – zinc  – weight
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study 
(If the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.258 Appendix 12 
Khanum et al. 198873
Data extraction table
Reviewer: DM Date: 6 September 2010 Version: 2 Checked by: DH
Reference and design Intervention Participants  Outcome measures
Author: Khanum et al.73
Year: 1988
Country: Bangladesh
Study design: CCT
Setting: inpatient 
(Children’s Nutrition Unit)
Number of centres: one
Funding: NR
Intervention: zinc supplement 
[10 mg zinc/kg/day as zinc sulphate 
(zincSO4) for those weighing < 6 kg; 
50 mg daily for those > 6 kg] 
given on the 15th hospital day for 
3 weeks
Control: standard care (no zinc 
supplement)
Other interventions used: all 
children received milk feeds, rice-
based solid foods ad libitum up to 
four times/day, and vitamins and 
iron supplementation (see end of 
table for further details)
Infections had been treated 
before the administration of the 
intervention (15th hospital day)
Definition of SAM: Waterlow 
1976.101 All children with oedema 
and all those, with or without 
oedema, who were ≤ 60% W/H
Number of participants: N = 60 
(zinc supplemented, n = 30; control, 
n = 30)
Sample attrition/dropout: NR
Sample crossovers: NR
Inclusion criteria: SAM children who 
had been admitted to the Children’s 
Nutrition Unit
Exclusion criteria: NR
General characteristics of 
participants:
  ■ all children were classified 
clinically as either kwashiorkor 
or marasmic kwashiorkor
  ■ age range: 5–60 months
  ■ mean age: 29 months
  ■ both sexes were equally 
represented
The prevalence of infections such 
as diarrhoea (80%), pneumonia 
(56%), and of other nutrient 
deficiencies such as xerophthalmia 
(76%) and anaemia (50%) was 
similar in both groups
Primary outcomes: not specifically 
stated
Outcomes:
  ■ mean plasma zinc concentration
  ■ weight gain
  ■ W/H
  ■ W/A
Method of assessing outcomes: 
nutritional status was assessed by W/A 
(Harvard standard) for < 1 year, and by 
W/H (Stuart and Stevenson 195925) and 
presence or absence of oedema for 
> 1 year
One ml of venous blood was drawn 
for measurement of plasma zinc and 
albumin on admission, on the 15th 
hospital day, and on discharge (36th 
hospital day)
Plasma zinc concentration was 
estimated by atomic absortion 
spectrophotometry
Weight, height and mid-arm 
circumference were measured on 
admission. Body weight was recorded 
at the same time each day, initially each 
morning, then weekly, by the same 
person. Height was measured weekly
Dietary intakes were measured by 
weighting each plate of food and 
leftovers; any vomitus was recorded 
for each feed and the total daily intake 
calculated. The energy value of samples 
of the diet was estimated by bomb 
calorimetry, and energy intake was 
calculated for each week as the average 
intake/day divided by the average 
weight of the child during that week
Adverse symptoms: NR
Length of follow-up: 5 weeks total 
study time (2 weeks lead in, 3 weeks of 
treatment; no additional follow-up after 
treatment ceased)
Recruitment dates: NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Characteristics of participants
Characteristic Zinc supplemented (n = 30)
Control (non-supplemented) 
(n = 30) p-value
Age (months)
  5 –12 4 2 NR
 12–24 6 8 NR
 24–36 8 8 NR
 36–48 6 8 NR
  > 48 6 4 NR
Kwashiorkor, n (%)a 13 (43) 9 (30) NR, NS
Results
Outcomes Zinc supplemented (n = 30) 
Control (non-supplemented) 
(n = 30) p-value
Plasma zinc concentration (mmol/l)b
  On admission day 8.23 ± 0.7 7.90 ± 0.7 NR
  15th day (zinc started) 7.88 ± 0.7 8.07 ± 0.5 NR
  36th day (discharged) 18.53 ± 1.5 10.56 ± 0.9 < 0.001
Weekly weight gain (g/week)
  First week 600 ± 99.9 468 ± 81.7 NR
  Second week 521 ± 75.4 330 ± 65.9 NR
  Third week (zinc started) 580 ± 67.6 342 ± 86.5 < 0.05
  Fourth week  403 ± 41.6 269 ± 47.1 < 0.05
  Fifth week 462 ± 42.4 374 ± 48.9 NR
Mean weight gain rate 
> 10 g/kg/day
66% 33% 0.02
W/Hc
  On admission day 70 ± 1.3 67 ± 1.3 NR
  Eighth day 76 ± 1.4 72 ± 1.0 < 0.05
  15th day (zinc started) 80 ± 1.4 75 ± 1.1 < 0.05
  22nd day 87 ± 1.2 79 ± 1.3 < 0.001
  29th day 91 ± 1.4 82 ± 1.4 < 0.001
  36th day (discharged) 95 ± 1.2 86 ± 1.2 < 0.001
W/Ac (n = 29) (n = 28)
  On admission day 50.3 ± 1.61 47.6 ± 1.60 NR
  Eighth day 52.5 ± 1.44 49.9 ± 1.44 NR
  15th day (zinc started) 58.1 ± 1.53 52.3 ± 1.60 < 0.05
  22nd day 62.0 ± 1.57 55.2 ± 1.75 < 0.01
  29th day 64.8 ± 1.58 57.1 ± 1.85 < 0.01
  36th day (discharged) 68.1 ± 1.58 59.7 ± 1.77 < 0.001
Per cent of patients with 
W/H according to the 
Harvard standard on 
discharge (36th day), 
n (%)
(n = 30) (n = 30)
  < 80 0 (0) 5 (16.7) NR
 80–90 7 (23.3) 18 (60.0) NR
  ≥ 90 23 (76.6) 7 (23.3) < 0.001260 Appendix 12 
Comments: results were reported as mean ± sem
Reports no significant difference in energy intake between groups during the total treatment period. The authors also report that weight gain was the 
same in both sexes; an increase in appetite following zinc supplementation was not observed, and supplemental zinc did not increase energy intake 
(both groups had a mean energy intake of 200 kcal/kg/day)
Safety: NR
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: children were randomly selected during recovery at the Children’s Nutrition Unit and were alternately allocated to the 
treatment or the control group
Blinding: NR. Assumed patients, care providers nor outcome assessors were blinded
Comparability of treatment groups: the supplemented group contained more cases of kwashiorkor (13 out of 30) compared with the unsupplemented 
controls (9 out of 30), but the difference was not significant. The age distributions, the prevalence of infections and the H/A on admission was similar 
in both groups (p-values NR)
Method of data analysis: Student’s t-test and chi-squared test were used for statistical interpretation of data. A p-value of < 0.05 was accepted as 
significant. ITT analysis for all outcomes except W/A
Sample size/power calculation: NR
Attrition/dropout: NR, but appear to be none
General comments
Generalisability: the authors refer to the paper by Waterlow (1976) to define SAM.101 However, it is not clear which were the criteria considered. 
According to the reported W/H on admission data, on average, participants just meet the WHO criteria (W/H < 70%). All children were diagnosed 
either kwashiorkor or marasmic kwashiorkor. Participants also met the Gómez severe third-degree malnutrition on admission (W/A < 60%)
The age range was 5–60 months, although the majority of participants were 12–48 months
A subsection of the population admitted to the Children’s Nutrition Unit was randomly selected during recovery from SAM
Outcome measures: the outcome measures were appropriate. However, the impact of the intervention on mortality nor its adverse effects were 
reported
Intercentre variability: not applicable
Conflict of interest: NR
Recovery diets
Aimed to achieve a calorie intake of 100–120 kcal/kg/day in the first week, and thereafter 150–200 kcal/kg/day with approximately 
2.5 g protein/kg/day; consisted of dried skimmed milk reconstituted with oil and sugar (100 kcal/100 ml), initially given 2-hourly day and night. Given 
90–100 ml/kg/day during the first week and increased gradually to 120–250 ml/kg/day in four to six feeds a day
Solid cooked meals were offered from the first week; some children refused it initially, but within a few days solid diets were taken
Solid diets
Rice pudding or Suji (68 kcal/100 g) at 0800 hours; rice + vegetable + meat (beef) mixture (100 kcal/100 g) at 1200 hours; rolls or chapatti 
(60 kcal/100 g) at 1500 hours and rice + dal (100 kcal/100 g) at 1800 hours
All children received supplements of vitamins (Pharmavit), oral iron [4 mg Fe/kg/day as iron sulphate (FeSO4)] and vitamin A capsules 
(100,000–200,000 IU)
The zinc content of individual food items ranged from 1.5–7 p.p.m.
IU, international units; NR, not reported; NS, not statistically significant; p.p.m., parts per million; sem, standard error of the mean.
a  Percentage calculated by the reviewer.
b  Plasma zinc concentration of healthy controls are reported, but have not been data extracted.
c  As a percentage of the Harvard reference.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
262 Appendix 12 
E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell a

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell
 
Summary of data collection
(Methodological strength of study)
Strong Moderate Weak b
 
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studyc
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak d
 
N/A, not applicable.
a  ‘Yes’ for zinc status, ‘cannot tell’ for weight.
b  ‘Moderate’ for zinc status, ‘weak’ for weight.
c  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.
d  ‘Moderate’ if scoring using zinc (which is related to weight gain), ‘weak’ if scoring using weight gain. As our primary outcome of interest is 
weight gain, overall score is ‘weak’.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Makonnen et al. 200374,75
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Makonnen et al.74
Linked paper: Makonnen 
et al.75 (paper excluded on 
outcomes)
Year: 2003
Country: South Africa
Study design: described 
as prospective, double-
blinded RCT, but judged 
as CCT in quality 
assessment
Setting: inpatient and 
community
Number of centres: one
Funding: Central Research 
Fund of the University of 
Free State and Nestlé, 
South Africa
Intervention: standard 
management with zinc 
supplementation [10 mg/d of 
zinc as zinc sulphate (zincSO4) 
suspension given in drop form 
from first day of admission]
Control: standard management 
with placebo
Other interventions used: 
all children received initial 
management to treat 
hypoglycaemia and hypothermia, 
dehydration, electrolyte imbalance, 
septic shock, infections and any 
other problems, including vitamin 
deficiencies and anaemia
Both groups received the standard 
treatment regimen: formula diet or 
continued breastfeeding
Health education was given to 
mothers and carers when child 
was ready for discharge
(Further details are at the end of 
the table)
Definition of SAM: PEM as 
defined by the Wellcome 
Trust Working Party102 (see 
Generalisability for further 
details)
Number of participants: N = 300 
(zinc supplemented, n = 150; 
control, n = 150)
Sample attrition/dropout: total 
46/300 (15%) did not complete 
follow-up three (90 days)
Zinc group: 12/150 (8%), of 
which eight died
Control group: 34/150 (23%), of 
which 28 died
Sample crossovers: NR
Inclusion criteria: PEM as defined 
by the Wellcome classification; 
aged 6–60 months, > 80% of 
expected W/A with signs and 
symptoms of kwashiorkor
Exclusion criteria: severe 
congenital abnormalities, other 
medical conditions such as 
congenital heart disease, Down’s 
syndrome, cerebral palsy, or 
refusal to participate in the study
General characteristics of 
participants: aged 6–60 months. 
Approximately half the 
population had HIV, > 25% 
suspected to have TB, ≈ 40–
50% had diarrhoea, vomiting 
and fever
Primary outcomes: mortality, morbidity 
(including infections), length of hospital 
stay, anthropometry and biochemical 
assays (such as serum zinc levels reported 
in linked paper75)
Secondary outcomes: weight gain and other 
clinical assessments (including oedema, 
diarrhoea, fever and other infections)
Definitions: criteria for discharge from 
hospital:
  ■ W/A > 80% or progressive weight gain 
> 5 g/kg/day for 3 successive days
  ■ Fever: temperature > 38 ºC
  ■ Hypothermia: temperature < 35.5 ºC
Method of assessing outcomes: all data 
collection and physical examinations were 
done by the same trained medical officer 
and anthropometric data were collected by 
the same nurses
Weight was recorded on admission daily 
using a UNICEF scale to the nearest 100 g, 
with the child naked or minimum clothing 
and preferably taken at the same time of 
the day with the same scale
Length was recorded for 6–18 months 
of age using a firm horizontal board with 
a fixed vertical headpiece and a sliding 
vertical foot apiece. In older children, height 
was taken in a standing position
The mid-arm circumference for all age 
groups was measured (in cm) with a non-
stretchable tape measure, with the arms 
hanging loosely to the side. The measure 
was passed around the circumference of 
the arm at the same horizontal level as 
for the measurement of triceps skin-fold 
thickness
A clinical examination and blood tests 
were done on admission. Venous blood 
was obtained under fasting conditions for 
measurement of serum zinc by atomic 
absorption spectrometry using Fernandez 
and Kahn’s method.103 HIV test using 
enzyme-linked immunosorbent assay 
(ELISA), TB test using Mantoux read at 
48 hours
Follow-up assessments done at 30, 60 and 
90 days post-discharge
Adverse symptoms: NR
Length of follow-up: mean hospital 
stay was 11–12 days and follow-up for 
3 months post-discharge
Recruitment dates: from 1 January 1999264 Appendix 12 
Characteristics of participants
Characteristic Zinc supplemented (n = 150)
Control (non-zinc 
supplemented) (n = 150) p-value
Male, % 48.7  50.7  NR
Aged 12–23 months, % 41  52  NR
Morbidity, n (%)
  Poor appetite 89 (59.3) 70 (46.7) NR
  Swelling of body 95 (63.3) 78 (52.0) NR
 Diarrhoea 72 (48.0) 67 (44.7) NR
 Vomiting 77 (51.3) 83 (55.3) NR
 Cough 55 (36.7) 57 (38.0) NR
 Fever 82 (54.7) 59 (39.3) NR
  Loss of weight 118 (78.7) 114 (76.0) NR
  Oral lesions 125 (83.3) 121 (80.7) NR
Per cent of expected W/A on admission, n (%)
  < 60% 56 (37.3) 54 (36.0) NR
 60–80% 81 (54.0) 77 (51.3) NR
  > 80% with oedemaa 12 (8) 18 (12) NR
  > 80% without oedema 1 (0.7) 1 (0.7) NR
Mid-arm circumference 
lower than fifth percentile, 
n (%)
96 (90.6) 105 (87.5) NR
Weight on admission, 
mean ± SD
7.2 ± 2.0 7.5 ± 2.4 NR
Height on admission, 
mean ± SD
72.2 ± 8.2 72.7 ± 8.6 NR
Mid-arm circumference, 
mean ± SD
11.8 ± 1.6 11.9 ± 1.8 NR
HIV+ve, % 44.7 52 NR
Serum zinc (μmol/l), 
mean ± SDb
6.23 ± 1.83 6.25 ± 1.74 NR; 95% CI for difference –0.43 to – 0.39
Comments: the percentage of children with weight > 80% of expected weight on admission was 8.7% in the zinc group and 12.7% in the control 
group. These differences were not statistically significant. More than 98% of participants in both groups with PEM were admitted for the first time. 
The majority were < 2 years of age
The number and percentage of participants from rural areas, orphans and breastfed for ≥ 12 months, as well as the past medical history of subjects 
and controls on admission were reported, but have not been data extracted© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Results
Primary outcomes Zinc supplemented (n = 150)
Control (non-zinc 
supplemented) (n = 150) Difference (95% CI)
Discharged after 
hospitalisation, %
92.7 80c NR
Death after hospitalisation, 
n (%)
7 (4.7) 26 (17.3) NRd
Death after readmission, n 1 2 NR
Total deaths, n (%)e 8 (5.3) 28 (18.7) NR
Morbidity on follow-up 
(90 days), n (%)
n = 138, 85–95 daysf n = 116, 83–95 daysf 95% CI for difference
 Diarrhoea  4 (2.9) 31 (36.7) –32 to –15.0
 Vomiting 1 (0.7) 8 (6.9) –11.2 to –1.2
 Fever 4 (2.9) 12 (10.3) –13.8 to –1.1
 Oedema 0 (0) 0 (0) –2.0 to 1.2
Acute respiratory 
infections
4 (2.9) 45 (38.8) –44.7 to –26.2
  Skin infection 1 (0.7) 8 (6.9) –11.2 to –1.2
 Pallor  32 (23.2) 62 (53.4) –41.3 to –18.4
Anthropometry on 
discharge
n = 139 n = 120
W/A, n (%)
  < 60% 44 (31.7) 30 (25) –4.4 to 17.4
 60–80% 78 (56.1) 74 (61.7) NR
  > 80% without oedemab 17 (12.2) 16 (13.3) NR
Mid-arm circumference 
percentiles lower than fifth 
percentile, n (%)
92 (92.9) 82 (85.4) –1.3 to 16.1
Anthropometry on follow-
up (90 days)
n = 138 n = 116
W/A, n (%)
  < 60% 5 (3.6%) 16 (13.8) –17.2 to –3.1
 60–80% 52 (37.7%) 67 (57.8) NR
  > 80% without oedema 81 (58.7%) 33 (28.4) NRs
Mid-arm circumference 
percentiles lower than fifth 
percentile, n (%) 
66 (54.1) 81 (77.9) –35.2 to –11.5
Length of hospital stay, 
mean ± SD
10.9 ± 3.9 11.7 ± 5.9 NR; not statistically significant
Serum zinc at 
90 days follow-up 
(μmol/l), mean ± SDh
10.13 ± 2.93 7.84 ± 1.72 95% CI for difference 1.68 to 2.90
Comments: p-values were NR
Data were presented for morbidities during the first 3 weeks of hospitalisation (no morbidity, poor appetite, oedema, diarrhoea, vomiting, cough, 
fever, weight loss, and oral lesions). The paper reports a general trend for the zinc-supplemented group to recover more rapidly, though it is not true 
for all symptoms, nor were there any statistically significant differences over the first 3 weeks
Data also presented for morbidities at 30-day and 60-day follow-up, but these have not been data extracted
Although length was measured at discharge and every follow-up visit, these results were clearly inaccurate and therefore omitted
Results for biochemical assays (additional primary outcomes) were reported on linked paper,75 from which only serum zinc at 90 days has been 
extracted
Gastroenteritis was an important diagnosis in both groups, but showed regression during hospitalisation (78% in both groups in first week, 30.4% 
and 37.4% in zinc and control groups in second week, respectively)
The authors mention further monitoring and evaluation being carried out for secondary outcomes, but results for these were NR266 Appendix 12 
Safety: NR
HIV: six out of seven (85.7%) children in the zinc group and 15 out of 26 (57.7%) children in the control group, who died in the hospital before 
discharge, were diagnosed to be HIV+ve. All of them had clinical evidence of HIV-related disease. According to the authors, these data suggest that 
even if the contribution to the death rate caused by possible HIV disease is eliminated, significantly more children in the control group died during 
hospitalisation than in the supplemented group
TB: TB distribution and related findings for both groups were very similar and would not have been a confounding variable for differences in outcome
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: children were randomly assigned to one of two treatment regimens. Randomisation was stratified by sex, age 
and percentage of expected W/A. If children were > 80% of expected weight, but had all the clinical features of PEM (kwashiorkor), they were 
randomised according to the list for 60–80%. No details of the randomisation method used were provided
Blinding: double-blinded study. For the non-zinc group, placebo was presented in a similar bottle and colour with similar taste and smell, so that 
medical personnel and parents could not differentiate between the zinc sulphate and placebo. No details on whether or not outcome assessors were 
aware of groups
Comparability of treatment groups: the demography of the subjects and controls was similar. Reports that the zinc group might have had a more 
severe disease profile on admission as more children in this group presented with a history of oedema and fever (table 2), but opposite is shown in 
table 3. The distribution of symptoms, anthropometry and past medical history was quite similar and comparable in both groups. No p-values were 
reported
Method of data analysis: an ITT analysis was not performed. The two groups were compared with respect to the outcome measures using 95% CIs 
for the differences in percentages or means. Characteristics were summarised per group by frequencies and percentages (for categorical variables) 
and means, SDs, medians, minima and maxima (for numerical variables). Anthropometric analyses were done using Epi-Info. Arm circumferences 
were categorised into percentiles according to tables provided by Frisancho.104 All other analyses were done using Statistical Analysis System 
software (SAS Institute Inc, Cary, NC). Duration of breastfeeding was analysed using survival analysis. To compare children within a treatment group 
who survived with those who died, 95% CI for differences in medians were calculated, because of small group size and skewed distribution
Sample size/power calculation: the decision to include 150 children in each group was derived after analysis of the data of a pilot study, which 
included 60 children with PEM and 60 similar children in the control group
Attrition/dropout: in the zinc group, 150 children were entered, of which four (2.7%) absconded and seven (4.7%) died before discharge. One child 
was readmitted after 5 days discharge from hospital and therefore not assessed at follow-up one (30 days), but the four children who absconded 
did attend the first follow-up visit. Therefore, 142 supplemented children were assessed at follow-up one. One of these was readmitted at follow-up 
one and subsequently died, leaving 141 at follow-up two (60 days). At follow-up three (90 days), three children could not be traced and 138 were 
assessed. In the control group, of the 150 children that entered, four (2.7%) absconded and 26 (17.3%) died before discharge. Three children were 
readmitted, of which one died and two were discharged. At follow-up one, 121 children were assessed. The four children who absconded did attend 
the first follow-up visit. One child was readmitted and died. One did not turn up for assessment. One hundred and nineteen children were assessed 
at follow-up two. At follow-up three, three children could not be traced and 116 were assessed
In the two groups, the percentage of children who absconded was similar (2.7%). These eight children were all traced, attended the first follow-up, 
and it was decided to keep them in the study and their data analysed with the rest
General comments:
Generalisability: malnutrition is defined according to the Wellcome classification as a reduction in the expected body weight < 80% (of the Boston 
50th percentile). Between 60% and 80% of expected weight is underweight in the absence of oedema, and kwashiorkor if oedema is present; 
< 60% of expected weight is marasmus in the absence of oedema, and marasmic kwashiorkor if oedema is present. It is not clear whether or not 
participants meet the WHO criteria for SAM. The majority of participants had 60–80% W/A on admission using the Wellcome classification, and the 
majority had MUAC lower than fifth percentile
Outcome measures: outcome measures such as W/A, mortality and morbidity were appropriate. However, outcomes as weight gain and adverse 
effects of the intervention were NR
Intercentre variability: not applicable
Conflict of interest: NR © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Initial treatment began with admission to the hospital and lasted for about 7 days. Its principal aims were to treat or prevent hypoglycaemia, 
hypothermia, dehydration and electrolyte imbalance; treat septic shock; start feeding the child; treat infections; identify and treat any other problems, 
including vitamin deficiencies and manage severe anaemia and heart failure
RL (20 ml/kg/hour) was given intravenously for severe dehydration or septic shock
Most dehydrated children of both groups received ORS through a nasogastric tube. Children were reassessed every hour and rehydration stopped 
when the child was clinically rehydrated. ORS was continued until diarrhoea stopped or decreased significantly
Standard treatment regimen: the treatment of the intervention and control groups was identical, with the exception of the addition of zinc in the 
management of the supplemented group. To avoid overloading of the intestine, liver and kidneys, small frequent amounts of food were given (50–
100 ml every 4 hours). Children who were unable or unwilling to eat were fed by nasogastric tube as a temporary measure. Patients who did not 
require other emergency treatment (especially for dehydration or septic shock) were given formula diet (Disco-dried skimmed milk-sugar-oil mixture 
(DSM): 80 g DSM + 60 g oil + 50 g sugar + water up to 1000 ml) or continued breastfeeding in both the study and control group
The rehabilitation phase began at about the second week of admission and lasted around 6 weeks. A child entered the rehabilitation phase when 
his/her appetite returned. The principal aims during this phase were to encourage the child to eat healthily, stimulate physical and emotional 
development and prepare the mother or caregivers to continue caring for the child after discharge
Health education was given to mothers and carers on nutrition, care (e.g. feeding and nutrition), how to recognise the symptoms and signs of illness, 
when to seek medical assistance, home treatment for diarrhoea, fever and acute respiratory infections
Children were followed up at the hospital at 30, 60 and 90 days after discharge. The aims of this stage were to increase feeding appropriately, 
monitor weight gain and mid-arm circumference, monitor the physical well-being and mental and emotional development of the child and determine 
their serum zinc levels
NR, not reported.
a  The clinical impression of kwashiorkor was confirmed in that all these children had an admission serum albumin < 30 g/l.
b  Reported in linked paper;74 median, minimum and maximum values were reported as well, but have not been data extracted.
c  Reported as 80.7% in text but 120/150 = 80% according to study’s Table 1.
d  Significantly more children died by the end of hospitalisation in the control group than the zinc-supplemented group (reported as 95% CI 5.5 
vs 19.5 in text, but not clear what this CI refers to).
e  Calculated by the reviewer.
f  Time elapsed from discharge to third follow-up.
g  Reports in text that this difference is statistically significant but no p-value or CI is provided.
h  Most children likely to have been discharged based on progressive weight gain of > 5 g/kg/day (rather than having W/A > 80%) as proportion 
with W/A > 80% on discharge is relatively small.268 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification 
or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.270 Appendix 12 
Schlesinger et al. 199276
Data extraction table
Reference and 
design Intervention Participants  Outcome measures
Author: Schlesinger 
et al.76
Year: 1992
Country: Chile
Study design: 
double-blind CCT
Setting: inpatient, 
tertiary care (closed 
nutritional recovery 
centre)
Number of centres: 
one
Funding: Nestlé 
Nutrition Research 
Grant Programme
Intervention: zinc-supplemented 
formula (zinc 15 mg/l), ad libitum, for 
105 days
Control: standard infant formula (zinc 
3.2 mg/l), ad libitum, for 105 days
Both formulas based on full-fat 
powered cow’s milk fortified with 
vitamins and minerals as per standard 
infant formula (Nestlé, Switzerland) 
except for iron and zinc (see end 
of table for further details). The 
formulas differed only in zinc content, 
which was 3.2 mg/l in the standard 
formula. No other energy-containing 
supplements were given to either 
group
Other interventions used: none 
reported
Definition of SAM: not 
specifically stated, but 
mean NCHS WAZ were 
< 3 SD on admission
Number of participants: 
N = 39 (zinc 
supplemented, n = 19; 
control, n = 20)
Sample attrition/dropout: 
none reported
Sample crossovers: none
Inclusion criteria: only 
reports marasmic infants 
with SAM
Exclusion criteria: NR
General characteristics of 
participants: SAM infants 
(< 1 year)
Primary outcomes: not specifically stated
Outcomes were:
  ■ zinc status
  ■ trace element status
  ■ nutritional status (HAZ, WAZ and WHZ z-scores)
  ■ immune function
Method of assessing outcomes: anthropometric 
measurements performed by a registered nurse 
on admission and at 15-day intervals. Intake was 
determined by weighing each bottle before and after 
feeding. Nude weights obtained before first morning 
feed with an infant scale (Condor, Santiago, Chile) 
with a 5-g precision, calibrated at regular intervals. 
Lengths to nearest 0.1 cm determined by standard 
procedures with a portable infantometer. Weight 
and length measurements assessed using NCHS 
growth percentile curves. z-scores calculated with 
the PCTL9Z Anthropometry Subroutine (US Centre for 
Health Promotion and Education, National Centre for 
Disease Control, Atlanta, GA, USA)
Plasma and polymorphonuclear leucocyte zinc 
concentrations determined using atomic absorption 
spectrophotometry. Polymorphonuclear leucocytes 
were isolated by dextran sedimentation and Ficoll 
Hypaque-gradient centrifugation. Iron nutrition 
assessed on admission and after 60 and 105 days 
by haemoglobin with the cyanomethemoglobin 
method (Coulter Counter ZBI, Fl, USA) and by 
serum ferritin with a radioimmunoassay (Travenol, 
Massachusetts). Serum copper concentrations 
determined by atomic absorption spectrophotometry 
on admission and after 30, 60 and 105 days
Detailed methodology is reported for assessment of 
the immunological profile but is not extracted here
Signs and symptoms of morbidity were recorded 
daily on a chart by the attending physician. Every 
infectious episode was analysed using: mean 
episodes/infant, mean duration days of each 
episode/infant, and mean per cent of infected days 
in the 105 days: [(number days with infection/
number observed days) × 100]
Adverse symptoms:
  ■ upper and lower respiratory infection
  ■ otitis media
  ■ acute diarrhoeal episode (presence of liquid 
stools for > 12 hours)
  ■ skin and mucous candidiasis
  ■ purulent conjuctivitis
Length of follow-up: nothing further than the 
105 days of nutritional rehabilitation treatment
Recruitment dates: NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Characteristics of participants
Characteristic Zinc-supplemented formula (n = 19) Control formula (n = 20) p-value
Sex, M : F 10 : 9 10 : 10 NS
Age, months 7.05 (2.0) 8.1 (3.0) NS
WAZ on admission –3.13 (0.71) –3.21 (0.87) NS
Birth weight, g 2886 (307) 3040 (268) NS
Plasma zinc μmol/l, 
mean ± SD
19.4 ± 5.5 (n = 18) 23.4 ± 8.4 (n = 17) NS
Serum copper 
μmol/l, mean ± SD
19.5± 7.0 (n = 18) 20.1 ± 7.4 (n = 17) NS
Intakes/kg/day
  Energy, kJ 674 (105) 682 (80) NS
  Protein, g 4.4 (0.7) 4.5 (0.5) NS
  Zinc, mg 1.9 (0.3) 0.35 (0.04) < 0.01a
  Iron, mg 1.9 (0.3) 1.9 (0.2) NS
  Copper, mg 0.04 (0.007) 0.04 (0.005) NS
Comments: values are mean (± SD) unless otherwise stated
Outcomes Zinc-supplemented formula (n = 19) Control formula (n = 20) p-value
z-scores, mean (± SD)
H/A
  On admission –3.27 (0.93) –3.19 (1.34) NS
  30 days –3.02 (0.89) –3.06 (1.04) NS
  60 days –2.73 (0.95) –2.78 (1.12) NS
  105 days –2.64 (0.86) –2.56 (0.84) NS
W/A
  On admission –3.13 (0.71) –3.21 (0.87) NS
  30 days –2.32 (0.62) –2.36 (0.74) NS
  60 days –2.04 (0.1) –1.95 (0.91) NS
  105 days –1.66 (0.64) –1.59 (0.88) NS
W/H
  On admission –0.83 (0.6) –1.18 (0.81) NS
  30 days –0.07 (0.75) –0.02 (1.15) NS
  60 days 0.12 (0.84) 0.17 (1.27) NS
  105 days 0.42 (0.81) 0.32 (1.22) NS
Increase in L/A percentile score in relation to admission,% (n/N)
  30 days 58 (11/19) 20 (4/20)b < 0.002
  45 days 79 (15/19) 45 (9/20)b < 0.03
Plasma zinc μmol/l, 
mean ± SD 105 days
18.6 ± 4.3 (n = 18) 18.0 ± 5.8 (n = 17) NS
Serum copper 
μmol/l, mean ± SD 
105 days
24.4 ± 4.4 (n = 18) 22.8 ± 4.6 (n = 17) NS272 Appendix 12 
Comments: plasma zinc and serum copper concentrations at 30 and 60 days have not been data extracted. There were no significant differences 
between the groups
Nutritional status:
  ■ Data were further analysed by using the mean increment of L/A z-score at 0, 15, 30, 45, 60, 75, 90 and 105 days and presented in line graphs 
for the whole group and separately for males and females (but data not extracted here as graphs are not clear). The zinc group began to grow 
earlier than the control group, becoming significant after 30 days (p-value unreadable), whereas the increment for the control group started to be 
significant at day 45 (p < 0.01)
  ■ Male infants in the zinc group grew significantly before control group males (p-value unreadable), but there was no difference in increment of HAZ 
in females
Other outcomes (micronutrients, immune function):
  ■ Results are reported for trace element status (Hb, serum ferritin, anaemia, etc.) and immunocompetence, but these data are NR in relation to 
weight gain, z-score or mortality and therefore have not been data extracted
  ■ A statistically significant difference was found in the proportion of participants defined as having a low plasma zinc and this favoured the zinc-
supplemented group
  ■ No statistically significant differences in leucocyte zinc were found between the groups
Safety:
  ■ The number of otitis media episodes (mean ± SD) during the 105 days rehabilitation was 0.73 ± 0.9 vs 1.85 ± 2.3 for the zinc and control groups, 
respectively (0.05 > p < 0.1, Student’s t-test)
  ■ The number of acute diarrhoeal episodes was average two versus zero for the zinc and control groups, respectively. A statistically significant 
difference appeared when analysing the data using all three indices mentioned in Method of assessing outcomes (p-value NR). The diarrhoeal 
episodes lasted 1 or 2 days, exerting no impact on nutritional rehabilitation
  ■ No differences were observed between groups in number or duration of upper and lower respiratory infection, purulent conjunctivitis, and skin 
and mucous candidiasis
HIV: NR
Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: not a randomised study. No details regarding allocation of treatments
Blinding: states double blind, but no further details are given as to how blinding was ensured in the patients and care providers (formula was provided 
in bottles). No details whether or not outcome assessors were blinded
Comparability of treatment groups: few baseline characteristics were presented; reports there were no significant differences between groups nor 
between males and females (though no p-values reported)
Method of data analysis: appears to be ITT analysis for z-scores (full number of patients allocated to each treatment group were analysed). The 
Statistical Analysis System software (SAS Institute Inc., Cary, NC, USA) was used. The paired and non-paired t-test, Cochrane Mantel–Hanzel test, 
Fisher’s exact probability test and stepwise logistic regression were used in the analysis of data. Significance was determined at p < 0.05
Sample size/power calculation: NR
Attrition/dropout: none reported
General comments
Generalisability: likely that most of the children would meet the current WHO criteria (mean WAZ < –3 SD). Unclear whether the children admitted to 
the tertiary centre were all those with SAM or a subsection. In addition, the mean age was 7–8 months on admission and, therefore, would not be 
generalisable to all children < 5 years
Outcome measures: outcomes were appropriate although mortality data not specifically reported (even though it appears to be zero)
Intercentre variability: N/A
Conflict of interest: funded by The Nestlé Nutrition Research Grant Program; no conflicts of interest are apparent
Composition of formula (per gram of powder)
Fat 0.26 g, protein 0.26 g, vitamin A 15.2 IU, cholecalciferol 3 IU, vitamin E 0.06 IU, vitamin C 1.5 mg, folic acid 0.45 µg, thiamine 3 µg, niacin 
0.038 mg, vitamin B6 3 µg, biotin 0.11 mg, pantothenate 0.023 mg, riboflavin 4.5 µg, vitamin B12 0.011 µg, vitamin K 0.42 µg, choline 0.38 µg, 
inositol 0.23 mg, iodine 0.38 µg, copper 3.5 µg, iron 0.15 mg (as ferrous sulphate) and zinc 0.15 mg (as zinc chloride). Formula was prepared at 10% 
dilution
HAZ, weight-for-age z-score; IU, international units; L/A, length-for-age; NR, not reported; NS, not statistically significant; WAZ, weight-for-age 
z-score; WHZ, weight-for-height z-score.
a Student’s  t-test, reports p < 0.01 in table but p < 0.001 in text.
b  Differences between groups tested using Cochrane Mantel–Hanzel test. © Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification 
or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
274 Appendix 12 
E. Data collection methods
1. Were data collection tools shown to be valid? Yes No  Cannot tell

2. Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Simmer et al. 198877
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Simmer et al.77
Year: 1988
Country: Bangladesh
Study design: CCT
Setting: inpatient 
(Children’s Nutrition Unit)
Number of centres: one
Funding: Save the 
Children Fund (UK); 
Heinz Fellowship of 
the British Paediatric 
Association
Intervention: zinc supplement [50 mg 
of zinc as zinc sulphate (zincSO4) daily 
or 10 mg/kg daily if weight < 5 kg] for 
2 weeks
Control: standard care (no zinc 
supplement)
Third group: well-nourished children 
(no details extracted here)
Children were allocated to the two 
groups after ≥ 3 days and usually 
after 7 days
Other interventions used: participants 
were fed milk every 2 hours 
(80–120 ml/kg/day increasing to 
250 ml/kg/day). Weaning food was 
also given, consisting of rice, dal 
(pulses) and vegetables. Meat and 
bananas were often included, oil 
was added when more calories were 
required and an egg was added 
when serum proteins were low. A 
full diet (three cooked meals and 
four milk feeds a day) was usually 
tolerated by the third day. Additional 
vitamin A (100,000–200,000 IU/day) 
and ferrous sulphate (4–6 mg/kg/day) 
were routinely given
A play area with volunteer therapists 
provided some psychological 
stimulation for the children
Associated diseases and 
complications of nutritional 
rehabilitation, such as hypothermia, 
hypoglycaemia, and fluid overload, 
were treated promptly
TB: diagnosed and treated if at least 
two of the following criteria were met: 
history of contact, gradual wasting, 
fever and cough for 1 month, failure 
to gain weight despite adequate 
caloric intake, painless enlargement 
of cervical nodes or pneumonia that 
failed to respond to antibiotics
Definition of SAM: not specifically 
defined; the nutritional diagnosis 
was based on McLaren’s criteria.105 
The Children’s Nutrition Unit is 
specifically for children with third-
degree malnutrition, defined as 
nutritional oedema or W/A < 60% 
and W/H < 70% of local standards 
(or < 42% and 63%, respectively, of 
Western standards)
Number of participants: N = 25 (zinc 
group, n = 13; control group, n = 12)
Sample attrition/dropout: one patient 
was excluded from each group
Sample crossovers: none reported
Inclusion criteria:
  ■ 1–7 year-old children
  ■ absence of dehydration
  ■ loss of oedema
  ■ packed cell volume > 0.25
  ■ children who had been at 
Children’s Nutrition Unit for 
≥ 3 days and were expected to 
stay for ≥ 3 weeks
Exclusion criteria: not stated
General characteristics of 
participants:
  ■ SAM children, average age 
≈ 39 months
  ■ tuberculosis: 52%
  ■ pneumonia: 48%
  ■ clinical signs of vitamin A 
deficiency: 83%
Primary outcomes: not specifically 
stated, but appears to be levels of 
zinc (plasma + polymorphonuclear) 
and plasma protein
Secondary outcomes: not stated, 
but appears to be vitamins A and E, 
ferritin, weight gain, calorie intake 
and protein intake
Method of assessing outcomes: 
weight and height measured on 
admission
Blood was collected at the beginning 
and, when possible, at the end of 
the study period for measurement of 
polymorphonuclear zinc and plasma 
levels of zinc, vitamins A and E, and 
ferritin
Zinc concentration was measured 
by flame atomic absorption 
spectrophotometry. Vitamin A and 
vitamin E were measured by high-
performance liquid chromatography 
and ferritin levels by an 125I 
immunoradiometric assay
(Details on blood collection and 
preparation for analysis are given 
by the authors, but have not been 
extracted)
Protein and calorie intake were 
calculated daily by the dietitians at 
Children’s Nutrition Unit; the quantity 
and type of food was recorded 
and duplicate food samples were 
collected from seven children aged 
24–48 months and ashed for zinc 
concentration measurement by 
atomic absorption spectrophotometry
Discharge: usually within 3 weeks if 
75–80% W/H (Western standards), 
haemoglobin > 100 g/l and total 
serum proteins > 65 g/l. Children 
with TB were admitted for 6 weeks to 
ensure adequate drug therapy
Adverse symptoms: medical and 
nursing staff were aware of the 
possibility of side effects in the 
children receiving zinc supplements. 
Protein and calorie intake of both 
groups were monitored to study 
anorexia as a potential adverse effect 
of zinc supplementation
Length of follow-up: 2 weeks for 
outcomes although hospital stay was 
usually 3 weeks (6 weeks for children 
with TB)
Recruitment dates: NR276 Appendix 12 
Characteristics of participants
Characteristic Zinc supplemented (n = 12)
Control (non-supplemented) 
(n = 11) p-value
Age, months (range) 35.3 ± 5 (12–96) 42.8 ± 7.8 (12–96) NR
Weight, kg 6.7 ± 0.6 7.9 ± 1.1 NR
W/A, % 46 ± 3 48 ± 3 NR
W/H, % 70 ± 2 66 ± 2 NR
Height, cm 76 ± 3 80 ± 5 NR
H/A, % 80 ± 2 78 ± 4 NR
Nutritional diagnosis (McLaren’s criteria), n
 Marasmus 1 1 NR
 Kwashiorkor 5 3 NR
  Marasmic kwashiorkor 6 7 NR
Comments: results are reported as mean ± SE unless otherwise stated
No statistically significant differences between groups were reported
Whole group mean age = 38.9 ± 4.6 months, mean weight = 7.3 ± 0.6 kg, mean W/A = 47.1 ± 2.3%, mean W/H = 68.1 ± 1.8%
Birth order, number of living siblings and family income per month and per capita per day are reported, but have not been extracted
Results
Primary outcomes Zinc supplemented (n = 12)
Control (non-supplemented) 
(n = 11) p-value
Polymorphonuclear zinc, mmol/1010 polymorphonuclear
  On admission – – NR
  On entry to study 1.75 ± 0.11 2.05 ± 0.18 NR
  On conclusion of study 2.59 ± 0.25a 1.60 ± 0.23 NR
Plasma zinc, μmol/l
  On admission – – NR
  On entry to study 10.8 ± 0.8 8.6 ± 0.8 NR
  On conclusion of study 14.6 ± 0.9b 12.3 ± 0.9c NR
Plasma protein, g/dl
  On admission 5.3 ± 0.3 5.1 ± 0.2 NR
  On entry to study 6.6 ± 0.4 6.6 ± 0.3 NR
  On conclusion of study 7.6 ± 0.2(8)d 7.8 ± 0.1(7)c NR
Comments: packed cell volume, ferritin, vitamin A and vitamin E levels were reported but have not been extracted
Overall, plasma zinc and protein levels were weakly correlated (r = 0.56, p < 0.01); in the non-supplemented children the correlation between 
plasma zinc and protein levels was stronger (r = 0.73, p < 0.001)
Anthropometric characteristics and the results on plasma zinc, polymorphonuclear zinc, plasma vitamins A and E levels of a non-malnourished, non-
supplemented control group were reported, but have not been extracted
Secondary outcomes Zinc supplemented (n = 12)
Control (non-supplemented) 
(n = 11) p-value
Mean weight gain, g/day
  Week one 35 32 NR
  Week two 70 ± 20 40 ± 10 NR
Weight gain, g/kg/day
  Week one 4.6 ± 1.9 4.9 ± 3.3 NR/NS
  Week two 8.83 ± 1.56 5.09 ± 1.62 NR; 95% CI 0.88 to 8.36
Calorie intake, kcal/kg/day
  Week one 161 ± 8 156 ± 8 NR/NS
  Week two 180 ± 9 169 ± 9 NR/NS© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Protein intake, g/kg/day
  Week one 4.7 ± 0.2 4.6 ± 0.3 NR/NS
  Week two 5.3 ± 0.2 4.9 ± 0.3 NR/NS
Per cent who achieved 
an optimal rate 
of weight gain (at 
Children’s Nutrition Unit, 
> 10 g/kg/day)
42 9 < 0.001
Comments: the mean unsupplemented dietary zinc intake of the malnourished children was 3.7 (range 2.4–5.3) mg/d. The zinc contents of 
individual foods were reported but not extracted
Safety: taking into consideration anorexia as a common feature of severe experimental zinc deficiency in animals, there was no significant difference 
in the intake of the two groups
Tube feeding was required for a few days for one patient in each group. Two patients in each group had a blood transfusion
HIV: NR
Barriers to implementation
NR
Methodological comments
Participants were randomly selected by the nursing sisters of Children’s Nutrition Unit. During nutritional rehabilitation, the mean supplemented 
dietary in take of zinc was only 3.7 mg/d, which is < 40% the recommended daily allowance. A daily dose of 50 mg probably is unnecessarily large, 
but did not cause any side effects
Allocation to treatment groups: participants were alternately allocated to groups for a 2-week period
Blinding: no details reported. Would assume no blinding of children, investigators nor outcome assessors
Comparability of treatment groups: reports no differences in baseline characteristics (no p-values reported). The incidence of TB, pneumonia and 
vitamin A deficiency was also similar in both groups
Method of data analysis: all data were expressed as mean ± SE and were analysed by unpaired Student’s t-test. Not ITT analysis
Sample size/power calculation: NR
Attrition/dropout: one patient was excluded from the zinc group owing to being transferred to the children’s hospital with a provisional diagnosis of 
typhoid fever. One patient was excluded from the control group because two doses (100 mg) of zinc had been accidentally given
General comments
Generalisability: the criteria used to define SAM (McLaren’s criteria: < 75% W/H and W/A), differ from the current WHO criteria; however, the 
average W/H is < 70%. The age inclusion range of 1–7 years differs from SHTAC’s protocol (< 5-year-old children), though the mean age was 
39 months. It is not clear whether or not these results can be extrapolated to the general population, as the random selection of participants was not 
detailed by the authors. Many children had comorbidities, such as TB, pneumonia and vitamin A deficiency
Outcome measures: appropriate, though some key outcomes, such as mortality rate, morbidity, and time to recover were NR
Intercentre variability: not applicable
Conflict of interest: NR
IU, international units; NR, not reported; NS, not statistically significant.
a  p < 0.001, on entry to study vs on conclusion of study.
b  p < 0.01, on entry to study vs on conclusion of study.
c  p < 0.005, on entry to study vs on conclusion of study.
d  p < 0.05, on entry to study vs on conclusion of study.278 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise 
as ‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell a
 
2.  Were data collection tools shown to be reliable? Yes No  Cannot tell a
 
Summary of data collection
(Methodological strength of study)
Strong Moderate Weak b
 
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1. Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation 
status (i.e. ITT) rather than actual intervention 
received?
Yes No  Cannot tell

Global rating for studyc
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak
 (zinc status)  (weight)
N/A, not applicable.
a  ‘Yes’ for zinc status, ‘cannot tell’ for weight.
b  ‘Strong’ for zinc status, ‘weak’ for weight.
c  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.280 Appendix 12 
Vasudevan et al. 199778
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Vasudevan et 
al.78
Year: 1997
Country: India
Study design: double-
blind placebo-controlled 
trial
Setting: outpatient 
(Division of Department 
of Paediatric Medical 
College)
Number of centres: one
Funding: not stated
Intervention: zinc-supplemented 
group received 6.6 mg of 
elemental zinc, equivalent to 
20 mg of zinc sulphate, once daily
Control: placebo was provided in 
similar looking capsules to zinc 
supplement
Other comparator group: normal, 
healthy children, not malnourished 
or ill, who were siblings or 
volunteers were analysed for 
serum zinc to determine the 
normal range (outcomes NR)
Other interventions used: 
nutritional counselling to 
parents, dietary intake adjusted 
to 100–120 calories/kg/day by 
instructing the mother
Definition of SAM: protein energy 
malnutrition grades III and IV using IAP 
criteria
Number of participants: 72 children 
recruited, 62 children completed 
designated follow-up period (31 per 
group)
Sample attrition/dropout: 10 children 
(five per group)
Sample crossovers: not stated
Inclusion criteria: aged 8–24 months, 
suffering from protein–energy 
malnutrition grades III and IV
Exclusion criteria: children with other 
concurrent causes of malnutrition 
by history, physical examination and 
investigations
General characteristics of participants: 
none stated other than inclusion criteria
Outcomes: weight of the child; serum 
zinc. Primary and secondary outcomes 
were not defined
Method of assessing outcomes: serum 
zinc analysis by calorimetric methods 
using a kit obtained from Randox 
Laboratories (UK). Weight of the child 
and serum zinc was assessed at 
baseline and at 3-months follow-up. 
Serum zinc was assessed at end of 
3 months, allowing 6 days after the 
last dose of zinc prior to analysis
Adverse symptoms: none stated
Length of follow-up: 3 months
Recruitment dates: none reported
Characteristics of participants
Characteristic Zinc supplemented (n = 31) Placebo (n = 31) p-value
Mean serum zinc levels 98.4 ± 26.1 µg/dl
Comments: mean serum zinc levels for healthy group 154.4 ± 24 µg/dl significantly different to malnourished children 98.4 ± 26.1 µg/dl (p < 0.001)
Results
Outcomes Zinc supplemented (n = 31) Placebo (n = 31) p-value
Change in zinc levels 
(µg/dl) (before-and-after 
study)
+ 51.3 + 16.4 < 0.001
Rate of weight gain 
(g/kg/day)
1.4 0.98 > 0.1
Comments: states that none of the children with zinc supplementation developed any related side effects
Safety: none stated 
HIV: none stated 
Barriers to implementation
None stated 
Methodological comments
Allocation to treatment groups: not stated
Blinding: double blind
Comparability of treatment groups: matched for age (within 3 months), sex, W/A, socioeconomic status, ethnic background (data NR)
Method of data analysis: t-tests (paired and Student’s)
Sample size/power calculation: not stated
Attrition/dropout: 10 children (five per group) did not complete the designated follow-up. Reasons for dropout were NR
General comments
Generalisability: limited details are provided about the group and so it is only possible to indicate that the study is relevant to children aged 
8–24 months with PEM
Outcome measures: suitable outcomes were reported
Intercentre variability: not relevant
Conflict of interest: none stated
NR, not reported.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.   What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.   If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior 
to the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
282 Appendix 12 
E. Data collection methods
1. Were data collection tools shown to be valid? Yes No  Cannot tell
 – zinc  – weight
2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak
 – zinc  – weight
F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1. What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1. Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2. Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on 
sections A–F)
Strong Moderate Weak
 – zinc  – weight
N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Bhutta et al. 199979
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Bhutta et al.79
Year: 1999
Country: Pakistan
Study design: double-blind 
RCT
Setting: Nutrition Research 
ward at the National 
Institute of Child Health
Number of centres: one
Funding: the Applied 
Diarrhoeal Disease 
Research Program of 
the Harvard Institute for 
International Development 
via an agreement with the 
US Agency for International 
Development
Intervention: zinc supplementation 
(3 mg/kg/day of elemental zinc 
sulphate, single daily dose) during 
14 days of inpatient dietary therapy 
and continued for 14 days at home 
(with home available diets) after 
discharge
Control: placebo during 14 days 
of inpatient dietary therapy and 
continued for 14 days at home (with 
home available diets) after discharge
Other interventions used: applied to 
all children: stabilisation period of 
24 hours during which i.v. and oral 
rehydration fluids were administered 
as necessary and antibiotic therapy 
for concomitant non-enteric 
infections was initiated. Stool output 
quantified and and any coexisting 
dehydration or electrolyte imbalance 
corrected
Dietary therapy with rice-lentil KY 
diet, supplemented with vitamins 
initiated and continued under 
supervision for 14 days. Diet 
administered ad libitum, in gradually 
increasing amounts, to provide at 
least 100 kcal/kg/day by day 4 of 
therapy
Details of the diet below
Breastfeeding continued as required
Degree of dehydration, body 
temperature, vital signs and clinical 
status recorded twice daily or more 
frequently as clinically indicated. 
In cases of suspected septicaemia 
a blood culture was obtained 
before initiation of broad-spectrum 
antibiotics (usually i.v. ampicillin 
and gentamicin, or i.v. ceftriaxone in 
suspected typhoidal salmonellosis). 
Suspected bacterial lower respiratory 
infections evaluated by chest 
radiography and treated according to 
the standard WHO guidelines
Definition of SAM: not defined, 
although children were shown to 
meet W/A and MUAC criteria
Number of participants: N = 87 
(intervention, n = 43; control, n = 44)
Sample attrition/dropout: 10 
participants did not complete 
the inpatient part of the study 
and did not take supplements at 
home. Zinc group: two discharged 
prematurely, two because of 
concomitant infection precluding 
full enteral feeds, and one because 
of development of recurrent 
dehydration. Control: two discharged 
prematurely, three because of 
concomitant infection precluding full 
enteral feeds
Sample crossovers: not applicable
Inclusion criteria: children aged 
6–36 months with persistent 
diarrhoea (four or more unformed 
stools per day continuously for at 
least 14 days) and malnutrition 
(WAZ ≤ 2)
Exclusion criteria:
  ■ children with overt evidence of 
kwashiorkor and ocular or skin 
lesions suggestive of vitamin A 
or zinc deficiency
  ■ children who still needed 
i.v. fluids or were unable to 
tolerate oral feeds because of 
concomitant illness at the end of 
the 24-hour stabilisation phase 
were also excluded
General characteristics of 
participants: children aged 
6–36 months with persistent 
diarrhoea and evidence of 
malnutrition
Primary outcome: overall weight 
gain by day 14 of inpatient therapy
Secondary outcomes (> 14 days 
inpatient therapy):
  ■ overall energy intake 
(kcal/kg/day)
  ■ stool frequency (number/day)
  ■ stool volume (g/kg/day) for 
males
  ■ changes in laboratory 
parameters (included serum 
albumin, prealbumin, alkaline 
phasphatase, insulin-like growth 
factor-1, plasma copper and 
zinc)
  ■ time to weight gain
  ■ time to diarrhoeal recovery
  ■ time taken to achieve a 30% 
and 50% reduction in stool 
output
Method of assessing outcomes: 
unclothed weight obtained prior to 
feed at admission, and daily, on 
a double-beam balance sensitive 
up to 10 g. Length measured on 
an infant stadiometer, occipito-
frontal, mid-arm, and mid-thigh 
circumferences measured using 
paper tape. Anthropomorphic 
measures repeated at days 7, 14 
and 28
Laboratory measurements were 
undertaken at baseline, 7 and 
14 days
Daily amounts of food consumed 
estimated by weighing left-over 
food. Breastfed amount estimated 
by immediate test weighing
Accurate records of stool, vomitus 
and urinary output were maintained 
by quantifying stool output 
separately from urine by means of 
adhesive bags. For females, only 
stool frequency and character were 
recorded after 72 hours of therapy 
(because of high rates of urine–stool 
admixture)284 Appendix 12 
A range of laboratory investigations 
were carried out at baseline, day 
7 and day 14 on stools and blood 
(details not data extracted).Intestinal 
permeability was also assessed. 
Children were considered zinc 
deficient based on plasma zinc 
levels < 60 μg/dl (9.18 μmol/l)
Time to weight gain: time taken 
to achieve weight gain for three 
or more days consecutively after 
achieving a caloric intake of 
100 kcal/kg/day
Time to diarrhoeal recovery: time 
taken to achieve a reduction in stool 
volume to < 30 g/kg/day in males, 
stool frequency less than four per 
day in both, and achievement of a 
semisoft stool consistency
Compliance with therapy: assessed 
by estimation of remaining 
supplement volume at return 
appointment
Adverse symptoms: NR
Length of follow-up: 28 days
Recruitment dates: July 1993 to 
September 1995
Characteristics of participants
Characteristic Intervention (zinc) (n = 43) Control (placebo) (n = 44) p-value
Sex (M : F) 27 : 16 26 : 18 NS
Age, months 11.6 ± 5.6 13.1 ± 6.2 NS
WAZ –3.47 ± 0.97  –3.27 ± 1.33 NS
HAZ –1.68 ± 1.14 –1.44 ± 1.34 NS
WHZ –3.02 ± 0.90 –3.13 ± 1.19 NS
Mid-arm circumference, 
cm
11.1 ± 1.5 11.6 ± 1.9 NS
Total protein, g/l 55.0 ± 9.2 56.8 ± 8.9 NS
Serum albumin, g/l 33.7 ± 7.8 33.5 ± 6.5 NS
Serum prealbumin, mg/l  93.8 ± 40.2 77.4 ± 35.0 NS
Haemoglobin, g/l 92.3 ± 18.2 91.6 ± 19.0 NS
Haematocrit, % 29.9 ± 4.3 29.8 ± 4.9 NS
C-reactive protein, mg/l  32.9 ± 42.5 41.4 ± 67.6 NS
Plasma zinc, μg/dl 78.0 ± 32.2 70.3 ± 19.0 NS
Plasma copper, μg/dl 67.4 ± 34.2 64.1 ± 19.2 NS
Duration of diarrhoea 
14–30 days
33 (77%) 32 (73%) NS 
> 30 days 10 (23%) 12 (27%)
Stool at admission, n (%)
 Watery 32 (74) 28 (64) NS
 Bloody 3 (7) 2 (5)
 Mucoid 3 (7) 6 (14)
 Mixed 5 (12) 8 (18)© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Stool volume n (%)a
  < 40 g/kg/day 13 (30) 9 (20) NS
  40–70 g/kg/day 10 (23) 17 (39)
  > 70 g/kg/day 20 (47) 18 (41)
Stool frequency n (%)a
  1–5 per day 10 (23) 8 (18) NS
  6–10 per day 14 (33) 15 (34)
  > 10 per day 19 (44) 21 (48)
Degree of dehydration at admission n (%)
 None 23 (53) 29 (66) NS
 Mild 16 (37) 11 (25)
 Moderate 2 (5) 2 (5)
 Severe 2 (5) 2 (5)
Comments: at baseline, overall, 25 children (29%) had plasma zinc levels < 60 μg/dl (9.18 μmol/l) and were therefore considered zinc deficient. 
Stool pathogens: enteropathogenic E. coli and Campylobacter jejuni in two each, S. paratyphi and Aeromonas hydrophilia in two children in the zinc 
group, and V. cholerae ogawa in one child in the placebo group. Degree of dehydration at admission similar in both groups, amounts of i.v. fluids (not 
data extracted) and ORS (not data extracted) consumed during initial stabilisation were comparable
Results
Primary outcomes Intervention (zinc) Control (placebo) p-value
Overall weight increment, 
g/kg/day
10.3 ± 5.7 8.7 ± 6.5 NS
Weight, kg
  Day 1 6.08 ± 1.32 6.33 ± 1.56
  Day 7 6.27 ± 1.29 6.84 ± 1.41
  Day 14 6.67 ± 1.43 7.13 ± 1.42 0.27b
Comments: text indicates that rate of weight gain was slow in children with evidence of systemic infection requiring antibiotics, but numerical data 
are not presented. These patients were distributed equally between the two groups
Secondary outcomes Intervention (zinc), mean ± SD 
(n = 43)
Control (placebo), mean ± SD 
(n = 44)
p-value
Plasma zinc, μg/dlc
  Day 1 78.0 ± 32.2 70.3 ± 19.0
  Day 7 100 ± 48 64 ± 20
  Day 14  112 ± 64 68 ± 20 0.03d
Caloric intake, kcal/kg/day
  Day 1 83.1 ± 37.5 80.2 ± 28.6
  Day 7 129.6 ± 39.6 123.8 ± 36.9
  Day 14 130.7 ± 46.6 121.1 ± 49.7 0.79b
Overall increment in caloric 
intake, kcal/kg/day
39.9 ± 46.5 40.0 ± 51.3 NS
Stool frequency, n/day
  Day 1 10.2 ± 6.4 11.8 ± 7.8
  Day 7 5.9 ± 5.6 5.2 ± 3.7
  Day 14 2.9 ± 1.6 3.0 ± 2.2 0.52b
Decrease in stool 
frequency, n/day
7.4 ± 7.4 8.1 ± 8.8 NS286 Appendix 12 
Stool volume, g/kg/day (males)
  Day 1 116.8 ± 103.7 141.9 ± 171.6
  Day 7 66.7 ± 68.1 43.9 ± 40.1
  Day 14 24.9 ± 16.2 27.8 ± 31.4 0.42b
Decrease in stool volume 
(g/kg/day)
91.1 ± 103.6 98.0 ± 187.9 NS
Mid-arm circumference (cm)
  Day 1 11.4 ± 1.5 11.5 ± 1.9
  Day 7 11.7 ± 1.4 12.0 ± 1.8
  Day 14 12.0 ± 1.4 12.4 ± 1.8 0.66b
Overall increment in mid-
arm circumference
0.3 ± 0.3 0.4 ± 0.3 NS
Weight gain during 
the 14 days of 
ambulatory home based 
supplementation, g/kg/day
9.2 ± 46 7.6 ± 5.7 NS
Increment in mid-
arm circumference 
after 14 days of 
ambulatory home based 
supplementation
0.13 ± 0.28 0.19 ± 0.40 NR
Comments: data from Kaplan–Meier plots of time-to-diarrhoeal-recovery and time-to-weight-gain have not been data extracted. Although children in 
the zinc group had a faster initial reduction in stool output (log-rank test for time to 30% reduction in stool output; p < 0.03) there was no significant 
difference between the groups for the time take for a 50% reduction in stool output (p = 0.24). The overall time taken for diarrhoeal recovery 
(p = 0.713) and weight gain (p = 0.397) were comparable
The authors performed subgroup analyses on outcomes for the subgroup with low plasma zinc levels at admission (not data extracted), and for the 
subgroup of stunted children (HAZ < –2) (data not presented in paper). There were no significant differences, but the authors acknowledge that their 
study had insufficient power to detect significant differences in these subgroups
Data on the lactulose: rhamnose ratio, and the sequential breath hydrogen excretion values were not extracted
Safety: no child had a relapse of diarrhoea and the morbidity patterns were comparable during the 14-day period of home supplementation and 
follow-up
The authors point out that care is needed when supplementing with single nutrients as some may interfere with the absorption of others. In 
particular, significant interaction of zinc absorption with copper and iron has been described. Data on plasma copper have not been data extracted 
from a line figure. A significant trend in reduction of serum copper was seen in the zinc group, whereas values significantly increased in the placebo 
group by the end of the second week of therapy. Numerical values (as well as the line graph) are provided in the paper, but it is not clear what these 
correspond to as they do not appear to match expected values on the graph for plasma copper at day 14
HIV: NR
Barriers to implementation
NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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Methodological comments
Zinc dose: the authors note that zinc could have been provided at a fixed daily dose for ease of administration. However, they gave 3 mg/kg/day of 
elemental zinc in an attempt to evaluate a level of zinc intake that provided almost twice the recommended daily allowance. In addition, this level 
could also have been emulated from dietary sources subsequently. The dose was also believed to be sufficient for replenishment of plasma zinc 
levels
Allocation to treatment groups: block randomisation. The randomisation code, maintained by the Pharmacy Department at the Aga Khan University 
Hospital was not available to the investigators until the end of the study. The pharmacy department were unaware of the identity of enrolled patients
Blinding: described as double blind
Comparability of treatment groups: described as closely comparable for all admission clinical, nutritional, and laboratory parameters. Also 
comparable for the duration and severity of diarrhoea, as assessed by history as well as during the period of stabilisation. An equal number of 
children in both groups revealed stool pathogens on cultures
Method of data analysis: A mid-term analysis of morbidity and mortality among the participants was conducted independently by consultants 
from Applied Diarrhoeal Disease Research Program, and the study was allowed to proceed to conclusion. Final analysis was on an ITT basis, 
irrespective of length of stay in the study. Differences between groups evaluated for categorical data by chi-squared analysis or Fisher’s exact test 
as appropriate. Differences for continuous data compared by two-tailed Student’s t-test. Sequential data for primary and secondary outcomes at 
baseline, day 7 and 14 evaluated by analysis of variance for repeated measures, evaluating the interaction of time trend and treatment effect. Time 
to event data for the two groups compared by survival analysis using the log-rank test. A subgroup analysis was conducted for the subgroup of 
children considered zinc deficient. Significance was set at 5%
Sample size/power calculation: reported and reference provided for the formula used. The formula used was for analysis of longitudinal continuous 
data, and the calculation was based on the known pattern and rate of weight gain (5 ± 3 g/kg/day) in comparably malnourished children with 
persistent diarrhoea receiving the same KY-based diet. It was estimated that to achieve at least a 30% difference in weight gain after 14 days of 
therapy, with 80% power and a type 1 error of 0.05, 40 participants would be needed in each group. However, the authors note that although overall 
weight gain exceeded their initial estimates, the SDs were wide, which led to the possibility that the study had insufficient power to elucidate smaller 
put potentially significant differences in stool output or weight gain. The authors estimated the final power of the study to detect a 25% difference in 
rates of weight gain was < 60%
Attrition/dropout: numbers overall and by trial group were provided with reasons
General comments
Generalisability: a doctor and nurse in constant attendance on the ward, this level of supervision might not be possible in all settings. As children 
with kwashiorkor or symptoms suggestive of vitamin A or zinc deficiency were excluded from this study, the results may not be applicable to these 
groups
Outcome measures: a primary outcome measure was stated although this outcome was subsequently presented among other results. Outcomes 
were listed and defined where necessary. Outcome data were presented as mean ± SD
Intercentre variability: not applicable
Conflict of interest: not stated
Dietary therapy
Khitchri (60 g rice, 30 g lentils, 10 g dry weight cottonseed oil and 1 g salt) prepared on site daily. Fresh live yoghurt obtained from a single source. 
Zinc content estimated to be < 2.5 mg zinc per 100 g. Vitamin mixture (1.5 the daily recommended doses): vitamin A (4500 units, 1.35 mg), vitamin 
D (600 units, 15 μg), vitamin B1 (2.2 mg), vitamin B2 (1.8 mg), vitamin B6 (1.5 mg), vitamin B12 (4.5 μg), nicotinamide (15 mg), vitamin C (75 mg)
ANOVA, analysis of variance; HAZ, weight-for-age z-score; NR, not reported; NS, not statistically significant; WAZ, weight-for-age z-score; 
WHZ, weight-for-height z-score.
a  Observed during initial period of stabilisation.
b  p-values are for the repeated measures ANOVA which evaluated the interaction of time trend and therapy effect for both groups during 14 
days of therapy. All differences are non-significant.
c  Estimated by reviewer from line figure.
d  Zinc-supplemented children showed a sustained increment in plasma zinc and had significantly higher values at days 7 and 14 in comparison 
with controls (p = 0.03 for time trend, p = 0.03 for therapy effect). By day 7 of zinc supplementation only three (8%) of the zinc group had 
plasma zinc levels < 60 μg/dl.288 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1. What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot 
tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot 
tell

2.   Were the study participants aware of the research 
question?
Yes No  Cannot 
tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot 
tell

2.   Were data collection tools shown to be reliable? Yes No  Cannot 
tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot 
tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot 
tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot 
tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot 
tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot 
tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.290 Appendix 12 
Manary and Brewster 199780
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Manary and Brewster80
Year: 1997
Country: Malawi
Study design: double-blind 
RCT (judged as CCT in quality 
assessment)
Setting: inpatient (hospital-
based NRU)
Number of centres: one
Funding: none reported
Intervention: high potassium 
supplementation (additional 
3 mmol/kg potassium above 
the standard supplement given 
in corn syrup as a medication, 
total potassium dose of 
7.7 mmol/kg/day in phase one of 
diet, i.e. first 7 days)
Control: standard potassium 
supplementation (3.2 mmol/kg/
day of potassium plus placebo of 
corn syrup given as a medication, 
total potassium dose of 
4.7 mmol/kg/day in phase one of 
diet, i.e. first 7 days)
Other interventions used: initial 
routine medications were 
cotrimoxazole, albendazole, 
magnesium (2.8 mmol/kg/day), 
zinc (40 mg daily as lactate) and 
multivitamins. Oral rehydration 
solution and i.v. fluid were used 
cautiously to avoid excess sodium 
and fluid loads. Standard regime of 
mild feeds (see end of table)
Definition of SAM: only described as 
children with kwashiorkor
Number of participants: N = 116 
(intervention, n = 55; control, n = 61)
Sample attrition/dropout: n = 17 
were excluded because they 
absconded before completion of 
the 7-day potassium supplement or 
placebo (intervention n = 7, control 
n = 10)
Sample crossovers: none reported
Inclusion criteria: all children 
admitted with kwashiorkor to the 
NRU
Exclusion criteria: children with 
oedema owing to renal disease or 
malarial anaemia
General characteristics of 
participants: rural children < 3 years 
of age admitted to hospital with 
kwashiorkor, with or without 
diarrhoea or HIV infection, but 
excluding oedema owing to renal 
disease or malarial anaemia
Primary outcomes: NR
Outcomes: deaths, clinical sepsis, 
skin ulcers, per cent weight loss, 
cough, dyspnoea, duration of 
hospital stay, irritability, diarrhoea 
and oedema
Method of assessing outcomes: 
daily weight taken plus 
examination for oedema, fever, 
respiratory signs, oral ulcers, skin 
ulcers and irritability
Number of days for: cough, 
duration of hospital stay, irritability, 
diarrhoea and 2+ or 3+ oedema
Number of cases for: dyspnoea
Per cent weight loss: assessed by 
day 7 and by discharge
Clinical sepsis: days 2–7 and 
days 8–24. Diagnosis based on 
fever, shock without dehydration, 
dyspnoea or an abrupt change in 
mental status or general condition 
(no microbiological investigations 
to confirm diagnosis)
Pedal oedema was graded on 
a 0–3 scale (1+ = < 0.5 cm of 
pitting oedema of the dorsum of 
the foot; 3+ = gross oedema of 
shins and eyelids)
Deaths: defined as early if it 
occurred in the first 5 days; 
defined as late if it occurred after 
at least 5 days of NRU treatment; 
defined as unexpected if there 
were no clinical indications of a 
life-threatening complication
Adverse symptoms: mothers were 
asked daily for 7 days if child was 
irritable, anorexic, able to finish 
the feeds, had diarrhoea, vomiting, 
a cough or respiratory distress
Charts of seriously ill children 
taken home against medical 
advice were reviewed blindly if 
they had received ≥ 7 days of 
treatment, to decide whether or 
not they were likely to have died 
at home and these children were 
then added to the late deaths
Length of follow-up: unclear
Recruitment dates: 10 February 
1995 to 16 March 1995© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Characteristics of participants
Characteristic Intervention (n = 48) Control (n = 51) p-value
Mean age, months (SD) 29.3 (14) 27.9 (15) 0.62
Wasting (%) > –1 9 (19) 8 (17) NR
W/H (SD) –2 15 (32) 6 (12) 0.91
z-scores (SD) –3 12 (26) 20 (42) NR
Oedema free 
(SD)
< –3 11 (23) 14 (29) NR
Mean (SD) –2.04 (1.20) –2.40 (1.13) 0.13
Stunting (%) > –2 11 (23) 5 (10) NR
H/A (SD) –3 10 (21) 13 (27) 0.92
(z-scores) (SD) –4 11 (23) 15 (31) NR
< –4 15 (32) 15 (31) NR
Mean (SD) –3.01 (1.73) –3.44 (1.25) 0.16
Oedema on admission (%)
 1+ 9 (19) 9 (18) NR
 2+ 13 (27) 16 (31) 0.90
 3+ 26 (54)  26 (51) NR
Rash (%)
 Nil 16 (33) 22 (43) NR
 Mild 16 (33) 15 (29) 0.90
 Moderate 13 (27) 9 (18) NR
 Severe 3 (6) 5 (10) NR
Cough (%) 24 (50) 34 (67) 0.14
Clinical sepsis (%)a 4 (8) 7 (14) 0.59
Fever > 38.0 °C (%) 7 (15) 11 (22) 0.52
Haematocrit, mean % (SD) 31 (7) 30 (10) 0.49
Diarrhoea, n (%) 16 (33) 19 (37) 0.84
Mean days of diarrhoea before 
admission (SD)
4.2 (3.1) 4.6 (4.0) 0.56
Severe anorexia (%) 12 (25) 14 (27) 0.96
Irritability (%) 40 (83) 42 (82) 0.89
Skin ulcers (%) 18 (37) 19 (37) 0.86
Comments: clinical signs and symptoms on admission for whole sample: fever (39%), cough (53%), shortness of breath (12%), sore mouth (28%), 
oral thrush (24%), hair changes (58%), hepatomegaly of > 2 cm below the costal margin (28%) and splenomegaly (10%)
Baseline characteristics only provided for those followed up
Results
Outcomes Intervention (n = 37)b Control (n = 41)b p-value
Late death (%)c 3 (8) 13 (32) 0.02
Left before discharge (after 
day 7) (%)
3 (8) 8 (19.5) 0.15
Clinical sepsis (days 2–7) (%) 0 (0) 9 (22) 0.01
Clinical sepsis (days 8–24) (%) 3 (9) 9 (22) 0.05
New skin ulcers, number of 
cases (%)
4 (11) 13 (33) 0.05
Weight loss by day 7, % (SD) 5.6 (8.0) 4.0 (7.2) 0.36
Weight loss by discharge, % 
(SD)
4.9 (9.1) 3.8 (10.3) 0.61292 Appendix 12 
Cough, number of days (SD) 2.3 (2.6) 3.9 (2.7) 0.01
Dyspnoea, number of cases (%)  1 (3) 10 (24.4) 0.01
Hospital stay, number of days 
(SD)
11.6 (0.9) 13.2 (4.9) 0.21
Irritability, number of days (SD) 3.4 (1.7) 3.7 (2.1) 0.47
Diarrhoea, number of days (SD) 0.9 (2.5) 1.5 (1.7) 0.14
Oedema 2+ or 3+, number of 
days (SD) 
2.7 (2.2) 2.7 (2.1) 0.99
Number of deaths in hospital 
(%)
14 (29.2)d 20 (39.2)d 0.40
Number of death in
  First 48 hours 6 6 NR
  Days 3–5 5 4 NR
  Late deaths  3 10 NR
Adjusted late deaths (%) 3/37 (8.1) 13/41 (31.7)  0.02e
Causes of late death
 Sepsis 3 3 NR
 Anaemia 2 NR
 Unexpected 5f NR 
Comments: case-fatality rate was reduced by 33% in the intervention group (13/48) compared with the control group (21/51). Note, possible error 
in n/N, as all other information suggests 14/48 and 20/51 deaths
The intervention group had significantly fewer presumed septic episodes (3 vs 18) [OR 8.9 (95% CI 2.2 to 50.9)] respiratory symptoms and new 
skin ulcerations than controls
Safety: none stated
HIV: no enzyme-linked immunosorbent assays for HIV infection were conducted because of a refusal of consent. Paper reported prevalence figures 
from unpublished 1993–4 data (n = 519) as 6% for kwashiorkor patients and 17% for marasmic kwashiorkor patients. Also states that > 30% of 
Blantyre mothers are infected, and the transmission rate (by PCR) at birth is 27%106 with presumably an additional 14% infected via breast milk;107 
therefore, expected prevalence rates for infants are around 12% before ceasing breastfeeding
Barriers to implementation
Lack of skilled management of individual cases, owing to a variety of constraints which are not readily remediable, were responsible for a case-
fatality rate of 34% for kwashiorkor. Authors state that they are attempting the rate through feasible changes in management. Nasogastric tube 
feeding was used infrequently because of resistance from mothers, reducing the potassium intake in anorexic children
It is suggested that the blanket recommendation of a supplement of 4 mmol/kg is insufficient for phase one and might well be too much for the 
rapid growth phase when added to the diet. Authors state that although individualising doses of micronutrients as a medication has merits, the 
constraints at NRU make adding them to the diet a much more convenient option when nursing care is limited
Authors recommend that results can not be extrapolated to this setting, as there are regional differences in the prevalence of potassium depletion in 
kwashiorkor, which may be related to the mineral content of weaning diets and that additional losses of potassium can occur in stool with diarrhoea 
(present on admission to the NRU in this study in 33–37% of cases)
Methodological comments
Allocation to treatment groups: described as randomised, but no details provided
Blinding: described as double-blind, placebo-controlled trial. Investigators, health workers and mothers unaware of child’s allocation group
Comparability of treatment groups: no significant differences between treatment arms (all p-values reported)
Method of data analysis: dichotomous parameters were evaluated as ORs with 95% CI with Fisher’s exact test and Yates’ corrected p-values. 
Continuous parameters were evaluated using Student’s t-test (Epi Info version 6)
Sample size/power calculation: none reported
Attrition/dropout: numbers and reasons reported. Discontinuation rates appears to be similar between the two groups© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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General comments
Generalisability: not generalisable to children with oedema because of renal disease or malarial anaemia who were excluded and also not 
generalisable to older children. Not all the children may have met the current WHO criteria for SAM, as the sample included children with 
kwashiorkor categorised as W/H –2
Outcome measures: no primary outcome defined. Outcome measures appear suitable and appropriate
Intercentre variability: not applicable
Conflict of interest: none reported
Diet for all admissions (phase one and phase two)
Phase 1: dried skimmed milk, sugar, vegetable oil and water containing 278 kJ (66 kcal) and 1.0 g of protein per 100 ml. Daily intake per kilogram 
of body weight was approximately 332 kJ (79 kcal), 1.2 g of protein and 1.5 mmol of potassium. Once oedema, appetite and mental status had 
improved, children advanced to a phase two diet (generally in the second week of treatment, after completion of the potassium supplement or 
placebo)
Phase 2: four feeds of high-energy milk 477 kJ (114 kcal) and 4.1 g of protein per 100 ml, as well as two feeds of a local weaning porridge of maize, 
soya, sugar and oil consisting of 468 kJ (112 kcal) and 3.3 g of protein per 100 ml. Daily intake of 150 mmol/kg/day: 712 kJ (170 kcal), 5.8 g of 
protein and 7.6 mol of potassium/kg/day. The higher protein intake in phase one was necessitated by the use of a milk-oil-sugar premix for both 
phases
The protein and energy densities of these diets were similar to those recommended by Waterlow97 of 336 kJ (80 kcal) and 0.7 g of protein/kg/day in 
phase one and 735 kJ (175 kcal) and 5.75 g of protein/kg/day in phase two. States that the potassium treatment doses for children in both groups 
were within the ranges of those recommended for SAM in the scientific literature
NR, not reported; NRU, nutritional rehabilitation unit; PCR, polymerase chain reaction.
a See  Methods of assessing outcomes for definition.
b  Numbers excluded 21 early deaths (intervention, n = 11; control, n = 10).
c  Includes three controls who left hospital to die at home.
d  Thirty-four known deaths in hospital during the study (34% case fatality), of which 21 were early and 13 were late deaths (after day 5). Eleven 
children (intervention n = 3, control n = 8) were taken from hospital before discharge after completing the 7-day trial, but before resolution of 
oedema and clinical improvement. Figure includes three of these children (all control), which had been assessed blindly to have been seriously 
ill and unlikely to have survived at home.
e  OR 5.3 (95% CI 1.2 to 31.0).
f  The children who died unexpectedly had persisting diarrhoea and died between days 9 and 13.294 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study likely 
to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2. What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders that 
were controlled [either in the design (e.g. by stratification or 
matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research question? Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the study 
(If the percentage differs by groups, record the lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended intervention 
(contamination or co-intervention) that may influence the 
results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study design? Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.296 Appendix 12 
Philip et al. 198281
Data extraction table
Reference and 
design Intervention Participants  Outcome measures
Author: Philip et al.81
Year: 1982
Country: India
Study design: CCT
Setting: inpatient
Number of centres: 
one
Funding: NR
Intervention: standard diet + nicotinic 
acid, 25 mg/kg/day (three divided doses) 
for 1 month
Control: standard diet for 1 month
Standard diet contained 4 g protein 
and 200 kcal obtained from K Mix two 
(supplied by UNICEF), tapioca, sugar, 
gingelly oil and rice (no further details 
reported)
Other interventions used: none reported
Definition of SAM: no specific 
reference made to SAM, only those 
‘fulfilling the standard criteria for 
marasmas’ (no further details 
reported)
Number of participants: N = 80 
(nicotinic acid, n = 40; control, 
n = 40)
Sample attrition/dropout: none 
reported
Sample crossovers: none reported
Inclusion criteria: standard criteria 
for marasmus (no reference or 
details provided)
Exclusion criteria: none reported.
General characteristics of 
participants: marasmic children aged 
0–4 years
Primary outcomes: weight gain
Secondary outcomes: calorie 
consumption
Method of assessing outcomes: 
weight was recorded every morning 
before being given the standard 
diet. The calculated amount of food 
was given five times daily at 0700, 
1000, 1300, 1600 and 2100 hours 
in divided quantities for 1 month. No 
further details
Adverse symptoms: none reported
Length of follow-up: none beyond the 
1 month treatment period
Recruitment dates: 1974–6
Characteristics of participants
Characteristic Nicotinic acid (n = 40) Standard diet (n = 40) p-value
Age (years), n (%)
 0–1 10 (25) 7 (17.5) NR
 1–2 22 (55)a 23 (57.5) NR
 2–3 7 (17.5) 8 (20) NR
 3–4 1 (2.5) 2 (5) NR
Comments: no difference in sex distribution was noted. No other baseline characteristics were reported by the authors
Results
Primary outcomes Nicotinic acid (n = 40) Standard diet (n = 40) p-value
Weight gain in 
1 month, g/kg 
231.05 (20.05) 171.81 (22.01) 0.001b
Comments: results are reported as mean (SD)
When weight gain was calculated separately for each week, both groups showed maximum gain during week 2, followed by week 3, with the lowest 
gain in weeks 1 and 4 (no data reported)
For both groups, the rate of weight gain was slightly higher in those children with a greater initial weight deficit
Secondary 
outcomes Nicotinic acid (n = 40) Standard diet (n = 40) p-value
Calories consumed 
for 1 g gain in weight
14.2 19.3 NR
Safety: none of the children experienced any remarkable side effects of nicotinic acid
HIV: NR© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Barriers to implementation
NR
Methodological comments
Allocation to treatment groups: not randomised. No details on allocation
Blinding: NR. No details on how nicotinic acid administered and thus blinding of patients, care providers and outcome assessors is unknown
Comparability of treatment groups: age is the only baseline characteristic reported; the distribution of the age ranges from 0–4 years was similar 
between the two groups, but no comment or p-value was reported. Authors noted that there was no difference in sex distribution (no data or 
p-value)
Method of data analysis: ITT analysis as data at end of study period is for all 80 subjects. No further details reported
Sample size/power calculation: NR
Attrition/dropout: none reported. Data at 1 month is for all included subjects so assume no dropouts
General comments
Generalisability: unable to tell whether or not the included children would meet the current WHO criteria as no specific definition of SAM was given; 
majority of children < 2 years. Unable to compare these children to the general SAM population as no baseline characteristics were given and 
reporting is limited
Outcome measures: primary outcome of weight gain was appropriate although mortality was NR
Intercentre variability: N/A
Conflict of interest: no details on funding nor any conflicts of interest were reported
N/A, not applicable; NR, not reported.
a  Reported as 65%, but 22/40 = 55%.
b Reports  t = 13.05 (assume Student’s t-test value).298 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT
CCT 
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No
4.  If answer was yes, was the method appropriate? Yes No
Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell
Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.300 Appendix 12 
Vásquez-Garibay 200582
Data extraction table
Reference and design Intervention Participants  Outcome measures
Author: Vásquez-
Garibay82
Year: 2005
Country: Mexico
Study design: RCT
Setting: inpatient (Unit 
of Studies of Infantile 
Nutrition, Metabolic 
ward, Unit of Studies of 
Infantile Nutrition, Civil 
Hospital of Guadalajara)
Number of centres: one
Funding: none reported
Intervention: added NT (NT+) 
(SMA; Wyeth de México, SA 
de CV, Mexico): a milk-based 
formula with NT and corn syrup 
added to increase energy density 
to 3.35 kJ/ml (casein-dominant 
formula) (see end of table for 
details)
Control: no added NT (NT–) (S26; 
Wyeth de México, SA de CV, 
Mexico): similar formula with the 
same energy density, but no added 
NT (whey-dominant formula) (see 
end of table for details)
Feeding was through a nasogastric 
tube with infant formula 
(3.35 kJ/ml) for 2 weeks and ad 
libitum for a further 2 weeks
Other interventions used: parasites 
found in faeces were treated prior 
to acceptance into study
Definition of SAM: W/A or W/H < –3 
SD from the median using the NCHS/
WHO reference
Number of participants: N = 25 (NT+, 
n = 12; NT–, n = 13)
Sample attrition/dropout : n = 5
NT+: n = 1 (excluded owing to a non-
determined liver disease)
NT–: n = 4 (excluded owing to fever 
syndrome n = 1, emetic syndrome 
n = 1, poor nutritional progress and a 
positive HIV test n = 2)
Sample crossovers: none reported
Inclusion criteria:
  ■ full-term infants with normal birth 
weight, primary and severe PEM, 
aged 3–18 months, W/A or W/H 
< –3 SD from the median NCHS/
WHO standard
  ■ infants with severe PEM, free 
of infection and/or moderate or 
severe episodes of diarrhoea 
(infants with less than four 
liquid or semi-liquid stools) were 
accepted
  ■ only infants with the same clinical 
type of severe and primary PEM 
(marasmus) were investigated
Exclusion criteria:
  ■ infants rejecting formula feeding
  ■ genetic, congenital, chronic and/
or severe pathologies (Down’s 
syndrome, mucoviscidosis, 
congenital cardiac disease, 
cerebral palsy, kidney disease 
and others)
  ■ infant’s clinical condition might 
be detrimental to the completion 
of the study
  ■ voluntary discharge
  ■ non-compliance by parent or 
legal guardian
  ■ any other pathology 
contraindicating oral or enteral 
feeding
General characteristics of 
participants:  
Infants aged 3–18 months with 
severe PEM and who are free of 
infection and moderate or severe 
diarrhoea 
Primary outcomes: not specifically 
reported
Outcomes: weight, length, head 
circumference, arm circumference, 
triceps, subscapular, subcostal and 
suprailiac skin fold thickness
Method of assessing outcomes: 
specialised personnel took care of 
the infants for the duration of the 
study. Two observers carried out the 
measurements
Anthropometric measurements were 
taken at start of study and once a 
week for 4 weeks. Blood samples were 
obtained by antecubital venopuncture at 
the start of study (at 0700 hours prior to 
first feed), after 2 weeks and at end of 
study (see end of table for details)
Weight: taken in a calibrated scale 
without clothes (Bame model 440, 
Mexico; with a minimum of 5 g). Before 
and after each bottle feed, bottles were 
weighed on a triple-beam balance 
(Ohaus, Florhand Park, New Jersey)
Length: measured on infant-measuring 
board (read to the nearest 0.1 cm)
Age and measurements of length 
and weight, W/A, L/A and W/L, 
were calculated and expressed as 
z-scores. Head circumference, arm 
circumference, and triceps, subscapular, 
subcostal and suprailiac skin fold 
thickness were determined with a Lange 
Skinfold Caliper (Cambridge Scientific 
Industries, Inc, Cambridge, Maryland)
Definitions:
  ■ primary PEM: cause of malnutrition 
was an inadequate and insufficient 
diet commonly associated with 
repeated upper respiratory tract 
infectious disease and/or frequent 
diarrhoea
  ■ severe PEM: free of infection and/
or moderate or severe episodes of 
diarrhoea (infants with less than 
four liquid or semi-liquid stools)
Adverse symptoms: none reported
Length of follow-up: 4 weeks
Recruitment dates: March 1996 to 
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Characteristics of participants
Characteristic NT+ (n = 11) NT– (n = 9) p-value
Mean birth weight, g (SD)  2975 (387) 3021 (369) 0.81
Mean age, days (SD)  228 (138) 242 (173) 0.84
Mean age, months (SD) 7.6 (4.6) 8.1 (3.2) NR
Sex, M : F 8 : 3 5 : 4 NR
Mean weight, g (SD)  4246 (1403) 3955 (1250) 0.87
Mean length, cm (SD)  61.1 (8.0) 60.2 (7.7) 0.95
Mean head circumference, cm (SD) 39.7 (3.4) 38.9 (2.1) 0.85
Mean arm circumference, cm (SD) 7.9 (1.1) 7.6 (1.0) 0.44
Mean triceps, mm (SD)a  3.8 (1.0) 2.8 (0.6) 0.031
Mean subscapular, mm (SD)a  2.9 (0.7) 2.4 (0.6) 0.076
Mean subcostal, mm (SD)a  2.3 (0.5) 1.8 (0.3) 0.045
Mean suprailiac, mm (SD)a  2.2 (0.5) 1.7 (0.3) 0.020
Mean total upper arm area, mm2 (SD)  512 (139) 463 (114) 0.54
Mean upper arm muscle area, mm2 (SD) 369 (89) 361 (84) 0.82
Mean upper arm fat area, mm2 (SD) 143 (53) 101 (33) 0.003
Mean arm fat index, % (SD)  27 (4) 22 (2) 0.005
Mean BMI (SD) 11.0 (0.9) 10.6 (1.0) 0.33
W/H mean z-score (SD)  –2.80 (0.73) –2.99 ± 0.74 0.001
Results
Outcomes: indicatorb NT+ (n = 11) NT– (n = 9) p-valuec
Mean skin fold, mm (SD)
Triceps
 Initial  3.8 (1.0)  2.8 (0.6)  0.031
  Fourth week 9.2 (2.6)  8.5 (1.6) 0.517
Subscapular
 Initial  2.9 (0.7) 2.4 (0.6) 0.076
  Fourth week 8.1 (2.7) 6.4 (1.1) 0.112
Subcostal
 Initial  2.3 (0.5)  1.8 (0.3)  0.045
  Fourth week 5.5 (1.9)  4.0 (0.6) 0.004
Suprailiac
 Initial  2.2 (0.5) 1.7 (0.3)  0.02 
  Fourth week 5.7 (2.5)  4.2 (0.6) 0.114 
Body composition, mean (SD)
Total upper arm area, mm2
 Initial  512 (139) 463 (114) 0.54
  Fourth week 960 (199) 903 (148)  0.49
Upper arm muscle area, mm2
 Initial  369 (89)  361 (84)  0.82
  Fourth week 571 (73)  508 (112) 0.83 
Upper arm fat area, mm2
 Initial  143 (54) 101 (33) 0.003
  Fourth week 443 (154)  395 (84)  0.42
Arm fat index, %
 Initial  27 (4)  22 (2) 0.005
  Fourth week 45 (8) 44 (7) 0.76302 Appendix 12 
BMI, kg/m2
 Initial  11.0 (0.9)  10.6 (1.0) 0.33
  Fourth week 15.1 (1.0)  14.5 (1.0) 0.23
Mean weight gain, g/day (SD) 67 (15)  69 (12)
W/H mean z-score (SD), fourth week  –0.64 (0.66) –0.94 (0.47) 0.001
Comments: both NT+ and NT– showed significant improvement in W/A and W/L indices from the first week; however, p-values were reported for 
within group differences only. Mean weight gain was similar between groups (no p-value reported)
Paper talks of W/A and W/L, but only outcomes for W/L and L/A are provided (not W/A)
Typical weight gain was five times higher than that of normal infants aged around 8 months and the pace of linear growth was doubled
Other outcomes  NT+ (n = 11) NT– (n = 9) p-value
Mean urea concentration, mg/l (SD)
Mean alkaline phosphatase, U/l (SD)
136 (36)
152 (77)
214 (66)
218 (46)
0.009
0.041
Comments: both groups were integrated for initial vs final outcome comparison of creatinine, glucose, calcium and phosphorus levels, showing 
significant improvements in each for the whole group. The same was true for haemoglobin levels and mean corpuscular volume. There were no 
significant changes in white blood cell count
Safety: NR 
HIV: although not specifically part of the exclusion criteria, two infants with positive HIV tests were excluded
Barriers to implementation
None reported
Methodological comments
Allocation to treatment groups: random assignment into two groups following an arbitrary schedule precisely. When one patient was eliminated, 
another one was included, receiving the formula that corresponded to the next number in the random sample
Blinding: none reported
Comparability of treatment groups: baseline age, weight and length were similar, although fat stores were slightly higher in the NT+ group. However, 
apart from significant differences in skin fold, there were also significant baseline differences in upper-arm muscle area, upper-arm fat area and arm 
fat index between the groups
Method of data analysis: paired Student’s t-tests for the analysis of all initial vs weekly anthropometric indicators (including initial vs final means 
of the biochemical and haematological indicators). Non-paired Student t-tests were used to compare the anthropometric, biochemical and 
haematologic mean indicators of group NT+ vs group NT– at different stages in the study. Dbase-IV (Microsoft Corporation, Redmond, WA, USA), Epi 
Info 6.04 and SPSS/PC programmes were used for capturing, processing and analysing data. Null hypothesis was rejected with a p-value of ≤ 0.05
Sample size/power calculation: sample size calculated at 12 for each group (calculations reported). Authors state that the sample size was large 
enough to compare both groups, considering they had similar means and SDs in most of the anthropometric indicators at the end of the study. 
However, after exclusions, number of participants was below the sample size needed
Attrition/dropout: number of exclusions and reasons reported
General comments
Generalisability: only to full-term infants with normal birth weight, with primary and severe PEM aged 3–18 months were included. Generalisability 
might therefore not extent to older children or to children with below birth weight. Definition of SAM meets the WHO criteria
Outcome measures: outcomes appear appropriate
Intercentre variability: N/A, one centre only
Conflict of interest: none reported
Milk-based infant formulasd NT+ (SMA) NT– (S26)
Nutrients (per litre)
  Energy, kJ 2845 2800
  Fat, g  36 33.9
  Linoleate, g  –  7.99 
  Protein, g  15 14.9
  Carbohydrate, g  72 75.9
  Mineral salts (ashes), g  2.5 2.0
  Sodium, mg  150  156
  Potassium, mg  560 659
  Chloride, mg  380 429.5
  Calcium, mg  420 419.5
  Phosphorus, mg  280 210© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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  Vitamin A, IU  2000 1998 
  Vitamin D, IU 400 400
  Vitamin E, IU  19 17.9
  Vitamin K, μg  55 54.9
  Vitamin C, mg 55   53.9
  Thiamin B1, μg 670 400
  Riboflavin B2, μg  1000 899
  Niacin, μg 5000 4995
  Vitamin B6, μg 420 499.5
  Folic acid, μg 50  59.9
  Pantothenic acid, μg 2100 2992
  Vitamin B12, μg 1.3 1.3
  Biotin, μg 15  14.6
  Choline, mg  100 49.9
  Magnesium, mg  35 40
  Iron, mg  12 8
  Iodine, μg 60 33
  Copper, μg 470 413
  Zinc, mg  5 5
  Manganese, μg 100 46.9 
Commercially available formulas with NT (in milligrams per liter) cytidine monophosphate (16.5), uridine monophosphate (5.0), adenosine 
monophosphate (4.0), guanosine monophosphate (2.0) and inosine monophosphate (2.0) (SMA; 2845 kJ/L); and without NT (S26; 2800 kJ/L). 
Both formulas, belonging to the same batch, had a similar nutritional content and were within the accepted range for infant formula. The formula 
was placed in a feeding bag of 500 ml (Pisa; Guadalajara, Jalisco, Mexico), then introduced into a feeding tube (D-731 o 732; Desvar de Mexico, 
Sociedad Anónima, Mexico) and administered to infants by continuous infusion pump (Braun, Germany)
From day 1: daily oral vitamins (vitamin A 5000 IU, vitamin D 1000 IU, vitamin C 50 mg, thiamin 1 mg, riboflavin 0.8 mg, niacin 6 mg and folic acid 
0.5 mg)
During the first 5 days: energy intake = 670 kJ/kg/day, protein intake 3.2 g/kg/day
After day 5: depending on the new weight (kilograms), the energy and protein intake was adjusted to 837 kJ/kg/day and 4 g/kg/day, respectively
From day 6: elemental iron 3 mg/kg daily
Start of third week: infants were fed ad libitum by bottle. The total amount of formula, protein and energy intake was calculated daily. The formula 
included all the water, energy, proteins and other nutrients required. No other foods were offered during the 4-week nutritional period (infants were 
started with complementary foods before being discharged)
Laboratory tests: blood samples at start for total proteins, serum albumin, calcium, phosphorus, magnesium, alkaline phosphatase, urea, creatinine, 
glucose, sodium, potassium, chloride and haemoglobin, as well as urine analysis. The calcium, phosphorus, magnesium and total protein 
determinations were done by the final point colorimetric method (RA-1000 Technicon; Bayer Diagnostic, Tarrytown, NY); alkaline phosphatase, by 
an enzymatic method of zero order and a C-405 filter; and haemoglobin, by a modified haemiglobincyanide method (CELL-DYN 3500R; Abbott 
Laboratories, Diagnostics Division, North Chicago, IL, USA)
IU, international units; L/A, length-for-age; N/A, not applicable; NR, not reported.
a  Skin fold.
b Denotes  p < 0.001; initial vs fourth week within each group.
c  Denotes that some p-values are differences between group. Because of the absence of further notations, it is uncertain which p-values are for 
within group and which for between group differences. However, authors state that there were no significant differences between groups at 
week 4 for total upper arm area, upper arm muscle area, upper arm fat area or arm fat index.
d  Powder infant formula; Wyeth de México, Sociedad Anónima de Cuenta variable.304 Appendix 12 
Quality assessment for primary studies (modified for severe malnutrition)
A. Selection bias
1.  Are the individuals selected to participate in the study 
likely to be representative of the target population?
Very likely Somewhat likely Not likely Cannot tell

2.  What percentage of selected individuals participated? 80–100% 60–79% < 60% N/A Cannot 
tell

Summary of selection bias
(Methodological strength of study)
Strong Moderate Weak

B. Study design
1.  What was the study design?
(Please tick appropriate and specify design if categorise as 
‘Other’)
RCT 
CCT
Cohort analytic (two group pre + post)
Case–control
Cohort [one group pre + post (before and after)]
Interrupted time series
Other – specify
Cannot Tell
2.  Was the study described as randomised? Yes No

If answer to no. 2 is ‘no’ complete summary then go to section C. Confounders. If answer is ‘yes’, answer no. 3 and no. 4 below, before completing 
summary for this section
3.  If answer was yes, was the method of randomisation 
described?
Yes No

4.  If answer was yes, was the method appropriate? Yes No

Summary of study design
(Methodological strength of study)
Strong Moderate Weak

C. Confounders
1.  Were there important differences between groups prior to 
the intervention?
Yes No  Cannot tell

2.  If yes, indicate the percentage of relevant confounders 
that were controlled [either in the design (e.g. by 
stratification or matching) or in the analysis]?
80–100% 60–79% < 60% Cannot tell

Summary of confounders
(Methodological strength of study)
Strong Moderate Weak

D. Blinding
1.  Was the outcome assessor aware of the intervention or 
exposure status of participants?
Yes No  Cannot tell

2.  Were the study participants aware of the research 
question?
Yes No  Cannot tell

Summary of blinding
(Methodological strength of study)
Strong Moderate Weak
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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E. Data collection methods
1.  Were data collection tools shown to be valid? Yes No  Cannot tell

2.  Were data collection tools shown to be reliable? Yes No  Cannot tell

Summary of data collection
(Methodological strength of study)
Strong Moderate Weak

F. Withdrawals and dropouts
1.  Were withdrawals and dropouts reported in terms of 
numbers and reasons per group?
Yes No  Cannot tell

2.  Indicate the percentage of participants completing the 
study (If the percentage differs by groups, record the 
lowest)
80–100% 60–79% < 60% Cannot tell

Summary of withdrawals and dropouts
(Methodological strength of study)
Strong Moderate Weak

G. Intervention integrity
1.  What percentage of participants received the allocated 
intervention or exposure of interest?
80–100% 60–79% < 60% Cannot tell

2.  Was the consistency of the intervention measured? Yes No Cannot tell

3.  Is it likely that subjects received an unintended 
intervention (contamination or co-intervention) that may 
influence the results?
Yes No  Cannot tell

H. Analysis
1.  Indicate the unit of allocation Community Organisation/
institution
Practice/
office
Provider Patient

2.  Indicate the unit of analysis Community Organisation/
institution
Practice/
office
Provider Patient

3.  Are the statistical methods appropriate for the study 
design?
Yes No  Cannot tell

4.  Is the analysis performed by intervention allocation status 
(i.e. ITT) rather than actual intervention received?
Yes No  Cannot tell

Global rating for studya
(Overall methodological strength of study – based on sections 
A–F)
Strong Moderate Weak

N/A, not applicable.
a  Strong = four strong ratings with no weak ratings; moderate = one weak rating; weak = two or more weak ratings.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Picot et al. under the terms of a commissioning contract issued by the 
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